Details of Disease

General Information of Disease (ID: DISNGJLM)

Disease Name Breast neoplasm
Synonyms
tumor of the breast; breast tumour; tumour of the breast; breast neoplasm (disease); breast tumor; neoplasm of the breast; tumor of breast; neoplasm, breast; breast neoplasm; neoplasm of breast; tumour of breast
Definition A benign or malignant neoplasm of the breast parenchyma. It can originate from the ducts, lobules or the breast adipose tissue. Breast neoplasms are much more common in females than males.
Disease Hierarchy
DIS9SBJX: Neoplasm of thorax
DISTBY9Z: Tumour
DISJTGMA: Breast disorder
DISNGJLM: Breast neoplasm
Disease Identifiers
MONDO ID
MONDO_0021100
MESH ID
D001943
UMLS CUI
C1458155
MedGen ID
264172
HPO ID
HP:0100013
SNOMED CT ID
126926005

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 856 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ADAM8 TTQWYMD Limited Altered Expression [1]
ADAMTS1 TTS2TEI Limited Biomarker [2]
ADIPOQ TTXKA7D Limited Biomarker [3]
AKT3 TTO6SGY Limited Altered Expression [4]
ANO1 TTOJI4S Limited Biomarker [5]
APEX1 TTHGL48 Limited Biomarker [6]
BCL2L1 TTRE6AX Limited Altered Expression [7]
BMI1 TTIPNSR Limited Genetic Variation [8]
BRIP1 TTZV7LJ Limited Genetic Variation [9]
CAMP TTULOB6 Limited Altered Expression [10]
CCL5 TT9DWLC Limited Biomarker [11]
CCNA2 TTAMQ62 Limited Altered Expression [12]
CD46 TTMS7DF Limited Altered Expression [13]
CDC25A TTLZS4Q Limited Biomarker [14]
CDH5 TTXLCFO Limited Biomarker [15]
CDKN1C TTBSUAR Limited Biomarker [16]
CEACAM5 TTY6DTE Limited Biomarker [17]
CEBPB TTUI35N Limited Biomarker [18]
CERK TT9XRNV Limited Biomarker [19]
CLDN4 TTMTS9H Limited Altered Expression [20]
CSF3 TT5TQ2W Limited Biomarker [21]
CTSL TT36ETB Limited Biomarker [22]
CXCL1 TTLK1RW Limited Altered Expression [23]
CXCR2 TT30C9G Limited Biomarker [24]
CXCR3 TT1UCIJ Limited Altered Expression [25]
CYP11A1 TTSYVO6 Limited Genetic Variation [26]
CYP2E1 TTWVHQ5 Limited Biomarker [27]
DCN TTB3XAN Limited Biomarker [28]
DHFR TTYZVDJ Limited Biomarker [29]
DKK3 TTY2ZV6 Limited Biomarker [30]
DLL4 TTV23LH Limited Biomarker [31]
DTL TT8396I Limited Biomarker [32]
EIF4EBP1 TTKGEBL Limited Altered Expression [33]
EPHA2 TTRJB2G Limited Altered Expression [34]
F11R TT3C8EG Limited Altered Expression [35]
FABP5 TTNT2S6 Limited Altered Expression [36]
FLT4 TTDCBX5 Limited Altered Expression [37]
FOLR1 TTVC37M Limited Altered Expression [38]
FOLR2 TTT54CI Limited Altered Expression [39]
FOSL1 TTY8LZG Limited Genetic Variation [40]
FYN TT2B9KF Limited Biomarker [41]
GAPDH TTUGSWA Limited Biomarker [42]
GJB2 TTRGZX3 Limited Altered Expression [43]
GPNMB TT7315J Limited Altered Expression [44]
GRIK2 TT0K5RG Limited Biomarker [45]
GRN TT0LWE3 Limited Biomarker [46]
HDAC1 TT6R7JZ Limited Biomarker [47]
HDAC5 TTUELN5 Limited Altered Expression [48]
HMGA1 TTBA219 Limited Biomarker [49]
HPSE TTR7GJO Limited Altered Expression [50]
HRAS TT28ZON Limited Genetic Variation [51]
HSD11B2 TT9H85R Limited Altered Expression [52]
HSF1 TTN6STZ Limited Biomarker [53]
HTRA1 TT8POQR Limited Posttranslational Modification [54]
IL11 TTGUYTR Limited Altered Expression [55]
IL13RA2 TTMPZ7V Limited Biomarker [56]
IL15RA TTGN89I Limited Biomarker [57]
IRF1 TT4TU3L Limited Biomarker [58]
KAT2B TTVK7SB Limited Biomarker [59]
KCNH1 TT9XKUC Limited Altered Expression [60]
KDM4A TTZHPB8 Limited Altered Expression [61]
KDM5B TTCLI75 Limited Altered Expression [62]
KLK4 TT4319X Limited Altered Expression [63]
KLK6 TTLPF4X Limited Altered Expression [64]
KRT17 TTKV0EC Limited Altered Expression [65]
LGALS3 TTFPQV7 Limited Altered Expression [66]
LIN28A TTO50LN Limited Altered Expression [67]
LRP1 TTF2V7I Limited Altered Expression [68]
LTA TTP73TM Limited Genetic Variation [69]
MAP2K7 TT6QY3J Limited Genetic Variation [70]
MCAM TTHRE05 Limited Biomarker [71]
MIF TT6804T Limited Biomarker [72]
NECTIN4 TTPO9EG Limited Biomarker [73]
NISCH TT789FN Limited Biomarker [74]
NR5A2 TTAU3SY Limited Biomarker [75]
NTN1 TT0AH4L Limited Altered Expression [76]
PAK2 TT279WO Limited Biomarker [77]
PDE7B TTWIEY9 Limited Altered Expression [78]
PLAUR TTNOSTX Limited Altered Expression [79]
PML TTLH9NY Limited Altered Expression [80]
POSTN TT8ALTZ Limited Biomarker [81]
PPARGC1B TTKSQ3W Limited Altered Expression [82]
PRKCD TT7A1BO Limited Altered Expression [83]
PRKCI TTWJTHX Limited Biomarker [84]
PRKCQ TT1MS7X Limited Altered Expression [85]
PRMT5 TTR1D7X Limited Altered Expression [86]
PTPN13 TT405FP Limited Biomarker [87]
REL TT1ZCTH Limited Altered Expression [85]
RHOB TT6LPFO Limited Altered Expression [88]
RIPK1 TTVJHX8 Limited Biomarker [89]
ROCK1 TTZN7RP Limited Genetic Variation [90]
RPE65 TTBOH16 Limited Altered Expression [91]
RPS6KA3 TTUM2ZR Limited Altered Expression [92]
S100A6 TT716MY Limited Altered Expression [93]
SATB1 TTLFRIC Limited Biomarker [94]
SELE TT1PL7M Limited Biomarker [95]
SIRT1 TTUF2HO Limited Altered Expression [96]
SPN TTOZAX0 Limited Altered Expression [97]
SULF2 TTLQTHB Limited Biomarker [98]
TACR1 TTZPO1L Limited Altered Expression [99]
TERF1 TT1Y6J2 Limited Posttranslational Modification [100]
TFF1 TTNOJIZ Limited Altered Expression [101]
TFPI TT068JH Limited Biomarker [102]
TNFRSF10A TT5WLRX Limited Biomarker [103]
TNFRSF10B TTW20TU Limited Altered Expression [104]
TNFRSF12A TTKPS7V Limited Altered Expression [105]
TNFSF13 TTOI1RM Limited Biomarker [106]
TPT1 TT3PTB6 Limited Altered Expression [107]
UBE3A TTUZX6V Limited Altered Expression [108]
UGCG TTPHEX3 Limited Biomarker [109]
UGT1A1 TT34ZAF Limited Genetic Variation [110]
ULK1 TT4D7MJ Limited Altered Expression [111]
VEGFD TTOM5H4 Limited Altered Expression [112]
XIAP TTK3WBU Limited Biomarker [113]
XPO1 TTCJUR4 Limited Biomarker [114]
ZEB2 TTT2WK4 Limited Altered Expression [115]
ZFP36L1 TT8QVJO Limited Biomarker [116]
ZNF217 TTY3BRA Limited Altered Expression [117]
CRHR2 TTIY658 Disputed Biomarker [118]
GSTP1 TT40K12 Disputed Genetic Variation [119]
HSPB8 TTY0OJN Disputed Biomarker [120]
ACKR3 TTRQJTC moderate Altered Expression [121]
AGR2 TT9K86S moderate Altered Expression [122]
AKT1 TTWTSCV moderate Genetic Variation [123]
ANGPTL4 TTWALY5 moderate Biomarker [124]
AR TTKPW01 moderate Altered Expression [125]
AREG TT76B3W moderate Biomarker [126]
ATF3 TTCE793 moderate Altered Expression [127]
BAP1 TT47RXJ moderate Biomarker [128]
BCHE TT3MSAO moderate Biomarker [129]
BIRC5 TTTPU1G moderate Biomarker [130]
BMP7 TTKOBRA moderate Biomarker [131]
BSG TT5UJWD moderate Altered Expression [132]
BTK TTGM6VW moderate Genetic Variation [133]
CAV1 TTXUBN2 moderate Biomarker [134]
CCL20 TT2XAZY moderate Biomarker [135]
CCN1 TTPK79J moderate Biomarker [136]
CCND1 TTFCJ7S moderate Biomarker [137]
CD274 TT8ZLTI moderate Altered Expression [138]
CD40 TT1ERKL moderate Biomarker [139]
CD44 TTWFBT7 moderate Biomarker [140]
CDA TTQ12RK moderate Altered Expression [141]
CDH1 TTLAWO6 moderate Biomarker [142]
CDK4 TT0PG8F moderate Biomarker [143]
CDKN1B TTLGFVW moderate Biomarker [144]
CEL TTTRNQW moderate Altered Expression [145]
CSF1R TT7MRDV moderate Biomarker [146]
CXCL12 TT4UGTF moderate Biomarker [147]
CXCL13 TT0NIZ1 moderate Altered Expression [148]
CXCL8 TTCTE1G moderate Biomarker [149]
CYP19A1 TTSZLWK moderate Altered Expression [150]
CYP1B1 TTI84H7 moderate Altered Expression [151]
CYP24A1 TT82UI1 moderate Altered Expression [152]
CYP2B6 TTMH124 moderate Altered Expression [153]
DCK TTJOCE4 moderate Altered Expression [154]
DNMT3A TTJUALD moderate Biomarker [155]
DPYD TTZPS91 moderate Biomarker [156]
DUSP1 TTG8HIM moderate Posttranslational Modification [157]
EDNRB TT3ZTGU moderate Therapeutic [158]
EGF TTED8JB moderate Biomarker [159]
EIF4E TTZGCP6 moderate Altered Expression [160]
ENPEP TT9PBIL moderate Altered Expression [161]
EP300 TTGH73N moderate Biomarker [162]
EPCAM TTZ8WH4 moderate Biomarker [163]
EPHB4 TTI4ZX2 moderate Biomarker [129]
ETS1 TTTGPSD moderate Biomarker [164]
EYA2 TTUY9C6 moderate Biomarker [165]
FABP3 TT3TGLR moderate Biomarker [166]
FGF1 TTMY81X moderate Biomarker [167]
FHIT TTMS54D moderate Genetic Variation [168]
FLT1 TT1VAUK moderate Biomarker [169]
FN1 TTPJ921 moderate Altered Expression [170]
GJA1 TT4F7SL moderate Altered Expression [171]
GPX1 TTYAHBP moderate Biomarker [172]
GREM1 TTOUZN5 moderate Altered Expression [173]
GRPR TTC1MVT moderate Biomarker [174]
HIF1A TTSN6QU moderate Altered Expression [175]
HIPK2 TTOB49C moderate Altered Expression [176]
HP TTLC8E1 moderate Biomarker [177]
ID1 TTBXVDE moderate Biomarker [178]
IGF1R TTQFBMY moderate Biomarker [179]
IGF2 TTE8WGO moderate Altered Expression [180]
IGFBP1 TTCJTWF moderate Genetic Variation [181]
IGFBP3 TTZHNQA moderate Biomarker [182]
IGFBP7 TTUQ01B moderate Biomarker [183]
IRS1 TTAJSQ0 moderate Biomarker [184]
KDM1A TTNR0UQ moderate Altered Expression [48]
KHDRBS1 TTAT6C7 moderate Altered Expression [185]
KLK3 TTS78AZ moderate Altered Expression [186]
MAP3K8 TTGECUM moderate Biomarker [187]
MDM2 TT9TE0O moderate Biomarker [188]
MDM4 TT9OUDQ moderate Altered Expression [189]
MME TT5TKPM moderate Biomarker [129]
MMP11 TTZW4MV moderate Altered Expression [190]
MMP13 TTHY57M moderate Biomarker [191]
MMP14 TTJ4QE7 moderate Biomarker [192]
MMP7 TTMTWOS moderate Altered Expression [193]
MTAP TTDBX7N moderate Biomarker [194]
MTDH TTH6SA5 moderate Biomarker [195]
MUC1 TTBHFYQ moderate Biomarker [196]
MYB TT8V13P moderate Altered Expression [197]
MYLK TT18ETS moderate Altered Expression [198]
NCOA3 TT124R0 moderate Genetic Variation [199]
NFKB1 TTUIZKC moderate Biomarker [200]
NME1 TTDY8JH moderate Genetic Variation [201]
NOTCH4 TTXDIK2 moderate Biomarker [202]
PAK1 TTFN95D moderate Altered Expression [203]
PDCD1 TTNBFWK moderate Biomarker [204]
PDGFRA TT8FYO9 moderate Altered Expression [205]
PDPK1 TTYMGWX moderate Biomarker [206]
PDZK1 TTDTBLM moderate Altered Expression [207]
PHGDH TT8DRCK moderate Biomarker [208]
PIK3CB TT9H4P3 moderate Genetic Variation [123]
PIN1 TTJNTSI moderate Altered Expression [209]
PRL TTJ2TSA moderate Biomarker [210]
PTGS2 TTVKILB moderate Biomarker [211]
RAD51 TTC0G1L moderate Biomarker [212]
RPS6KB1 TTG0U4H moderate Biomarker [213]
RPS6KB2 TTMVQXO moderate Altered Expression [214]
SCGB2A2 TT1W3RE moderate Altered Expression [37]
SDC2 TT5H2F0 moderate Biomarker [215]
SERPINB5 TT1KW50 moderate Altered Expression [216]
SERPINE1 TTTO43N moderate Biomarker [217]
SLC19A3 TT9BTWM moderate Altered Expression [218]
SLC9A1 TTGSEFH moderate Altered Expression [219]
SOD2 TT9O4C5 moderate Biomarker [220]
SRC TT6PKBN moderate Biomarker [221]
STAT3 TTHJT3X moderate Biomarker [222]
STC2 TT4EFTR moderate Altered Expression [223]
TFRC TT8MG4S moderate Altered Expression [224]
TGFBR2 TTZE3P7 moderate Altered Expression [225]
THBS1 TTKI0H1 moderate Altered Expression [226]
TIE1 TTT4236 moderate Altered Expression [227]
TMPRSS6 TTL9KE7 moderate Biomarker [228]
TNC TTUCPMY moderate Biomarker [229]
TWIST1 TTX1MY7 moderate Biomarker [230]
USP13 TTVJIO2 moderate Altered Expression [231]
YAP1 TT8UN2D moderate Biomarker [232]
ABCA4 TTLB52K Strong Altered Expression [233]
ABCC1 TTOI92F Strong Altered Expression [234]
ABCC2 TTFLHJV Strong Altered Expression [234]
ABCG2 TTIMJ02 Strong Biomarker [235]
ABL1 TT6B75U Strong Posttranslational Modification [236]
ACHE TT1RS9F Strong Biomarker [129]
ACKR1 TTKY2NS Strong Biomarker [237]
ACLY TT0Z6Y2 Strong Biomarker [238]
ACVR1 TTJNBQA Strong Biomarker [239]
ADAM33 TTQICM2 Strong Biomarker [240]
ADAMTS5 TTXSU2Y Strong Biomarker [241]
ADCYAP1R1 TT5OREU Strong Altered Expression [242]
ADORA2B TTNE7KG Strong Biomarker [243]
ADORA3 TTJFY5U Strong Biomarker [243]
AFP TTCFEA1 Strong Therapeutic [244]
AHR TT037IE Strong Altered Expression [245]
AIF1 TT12MEP Strong Altered Expression [246]
AKR1C3 TT5ZWB6 Strong Altered Expression [247]
AKT2 TTH24WI Strong Biomarker [248]
ALCAM TT2AFT6 Strong Biomarker [249]
ALK TTPMQSO Strong Biomarker [250]
ALOX12 TT12ABZ Strong Altered Expression [251]
ALOX15 TTN9T81 Strong Biomarker [252]
ANK1 TTKFPMH Strong Genetic Variation [253]
ANTXR2 TTOD34I Strong Altered Expression [254]
ANXA1 TTUCK4B Strong Biomarker [255]
ANXA2 TT4YANI Strong Biomarker [256]
ANXA8 TTSW16P Strong Biomarker [257]
APC2 TTSMK36 Strong Biomarker [258]
APEH TTYWEDQ Strong Biomarker [259]
ARAF TT5TURO Strong Therapeutic [260]
ARF1 TT70KXY Strong Biomarker [261]
ARG2 TTV1AG6 Strong Altered Expression [262]
ASRGL1 TT4WT91 Strong Biomarker [263]
ATAD2 TT9A0HI Strong Altered Expression [264]
ATAT1 TTWUHQ1 Strong Biomarker [265]
ATP7B TTOPO51 Strong Biomarker [266]
ATRAID TTFLIKM Strong Biomarker [267]
AURKA TTPS3C0 Strong Altered Expression [268]
AURKB TT9RTBL Strong Altered Expression [269]
AZGP1 TTUPYLV Strong Biomarker [270]
BACE2 TT69DB8 Strong Altered Expression [271]
BAX TTQ57WJ Strong Altered Expression [272]
BCAT1 TTES57P Strong Altered Expression [273]
BCAT2 TTF9OQ6 Strong Biomarker [274]
BCL2A1 TTGT9C7 Strong Biomarker [275]
BDKRB1 TTG5QIA Strong Altered Expression [276]
BIRC2 TTQ5LRD Strong Biomarker [277]
BIRC7 TTHZ8TA Strong Biomarker [278]
BMP1 TT0L58T Strong Biomarker [159]
BMP4 TTD3BSX Strong Biomarker [239]
BMP6 TT07RIB Strong Biomarker [279]
BMPR2 TTGKF90 Strong Biomarker [239]
BMX TTN2I9E Strong Biomarker [280]
BPHL TTTZ3EU Strong Biomarker [281]
BRD7 TT07ZS1 Strong Genetic Variation [282]
BST2 TT90BJT Strong Altered Expression [283]
BTG1 TTL7N2W Strong Altered Expression [284]
C1QBP TTWTD7F Strong Biomarker [285]
CA12 TTSYM0R Strong Altered Expression [286]
CA9 TT2LVK8 Strong Altered Expression [287]
CACNA1H TTZPWGN Strong Altered Expression [288]
CAPN2 TTG5QB7 Strong Biomarker [289]
CARM1 TTIZQFJ Strong Altered Expression [290]
CASP2 TT12VNG Strong Altered Expression [291]
CASP7 TTM7Y45 Strong Biomarker [292]
CASP8 TT6SZNG Strong Biomarker [250]
CBR1 TTVG0SN Strong Genetic Variation [293]
CBX7 TTBN3HC Strong Biomarker [294]
CCL21 TTLZK1U Strong Altered Expression [295]
CCL22 TTBTWI1 Strong Altered Expression [296]
CCNB1 TT9P6OW Strong Altered Expression [297]
CCND3 TT1JXNR Strong Altered Expression [298]
CCNE1 TTCEJ4F Strong Biomarker [299]
CCNE2 TTLDRGX Strong Biomarker [300]
CCR4 TT7HQD0 Strong Biomarker [301]
CCR5 TTJIH8Q Strong Biomarker [302]
CCR7 TT2GIDQ Strong Altered Expression [303]
CCR9 TTIPS8B Strong Altered Expression [304]
CD1A TTBGTFN Strong Biomarker [305]
CD24 TTCTYNP Strong Biomarker [306]
CD4 TTN2JFW Strong Biomarker [307]
CD55 TT5Z9WY Strong Biomarker [308]
CD74 TTCMYP9 Strong Biomarker [309]
CD9 TTZEIBV Strong Altered Expression [310]
CDC25C TTESBNC Strong Altered Expression [311]
CDH11 TTRGWZC Strong Biomarker [312]
CDH2 TT1WS0T Strong Biomarker [313]
CDH3 TTARMD9 Strong Altered Expression [314]
CDK1 TTH6V3D Strong Biomarker [315]
CDK12 TTJ21A9 Strong Biomarker [184]
CDK2 TT7HF4W Strong Biomarker [316]
CDK5R1 TTBYM6V Strong Biomarker [317]
CDK6 TTO0FDJ Strong Biomarker [318]
CDK7 TTQYF7G Strong Altered Expression [319]
CDK9 TT1LVF2 Strong Biomarker [320]
CDKN2C TTBRUGA Strong Biomarker [267]
CEACAM3 TTPX7I5 Strong Biomarker [321]
CEACAM6 TTIGH2W Strong Biomarker [322]
CEBPA TT5LWG1 Strong Altered Expression [323]
CENPE TTZD5QR Strong Biomarker [324]
CFLAR TTJZQYH Strong Biomarker [325]
CGA TTFC29G Strong Biomarker [326]
CGB3 TTUH273 Strong Biomarker [326]
CHEK1 TTTU902 Strong Biomarker [327]
CHKA TT10AWB Strong Altered Expression [328]
CHN2 TT39YVO Strong Biomarker [329]
CHUK TT1F8OQ Strong Altered Expression [330]
CLCN2 TT30NW6 Strong Altered Expression [331]
CLIC1 TT8KZG6 Strong Biomarker [332]
CLK2 TT85TPS Strong Biomarker [333]
CMA1 TT8VUE0 Strong Biomarker [334]
CNR2 TTMSFAW Strong Biomarker [335]
COL18A1 TT63DI9 Strong Genetic Variation [336]
COL1A2 TTUABC1 Strong Altered Expression [337]
COL7A1 TTBCOKN Strong Biomarker [258]
COMT TTKWFB8 Strong Biomarker [338]
COPS5 TTSTNJR Strong Altered Expression [339]
CPB2 TTP18AY Strong Biomarker [340]
CPE TTXPWO6 Strong Altered Expression [341]
CRHR1 TT7EFHR Strong Biomarker [250]
CRTC2 TTFWETR Strong Biomarker [342]
CSE1L TTTRULD Strong Biomarker [343]
CSF1 TT0IQER Strong Biomarker [344]
CSK TTX6F0Q Strong Biomarker [289]
CSNK1A1 TTFQEMX Strong Altered Expression [345]
CSNK1D TTH30UI Strong Biomarker [346]
CSNK1E TTA8PLI Strong Altered Expression [347]
CSNK2A1 TTER6YH Strong Biomarker [348]
CSNK2A2 TT7GR5W Strong Altered Expression [330]
CTAG1A TTE5ITK Strong Altered Expression [349]
CTCFL TTY0RZT Strong Biomarker [350]
CTSD TTPT2QI Strong Biomarker [351]
CTSH TT3G406 Strong Biomarker [352]
CTSK TTDZN01 Strong Biomarker [352]
CXCL2 TTZF0K2 Strong Biomarker [353]
CXCL9 TTWE5PB Strong Biomarker [354]
CXCR5 TTIW59R Strong Altered Expression [148]
CXXC5 TTVS4C3 Strong Altered Expression [355]
CYP17A1 TTRA5BZ Strong Genetic Variation [119]
CYP1A2 TTS1DTU Strong Biomarker [356]
CYP2A6 TTAQ6ZW Strong Genetic Variation [357]
CYP2C9 TTR40YJ Strong Genetic Variation [358]
CYP2D6 TTVG215 Strong Biomarker [359]
CYP3A4 TTWP7HQ Strong Altered Expression [360]
CYP3A5 TTHS0OK Strong Altered Expression [361]
DDR1 TTI1FPZ Strong Altered Expression [362]
DDX5 TTZKPVC Strong Biomarker [363]
DDX58 TTVB0O3 Strong Biomarker [364]
DEFB4A TTIVY12 Strong Biomarker [365]
DEK TT1NMGV Strong Biomarker [313]
DHCR24 TTTK0NH Strong Biomarker [366]
DIABLO TTN74LE Strong Biomarker [367]
DIO1 TTU3X26 Strong Biomarker [368]
DKK1 TTE3RAC Strong Altered Expression [369]
DKK2 TTST5KX Strong Altered Expression [370]
DLL1 TT9CFQD Strong Biomarker [371]
DNAJB1 TTPXAWS Strong Biomarker [372]
DNMT1 TT6S2FE Strong Biomarker [373]
E2F1 TTASI04 Strong Biomarker [374]
E2F2 TT5FYX0 Strong Genetic Variation [375]
E2F3 TTWIJYH Strong Altered Expression [376]
EBP TT4VQZX Strong Biomarker [377]
EDN2 TTMR0OP Strong Biomarker [378]
EGLN1 TT9ISBX Strong Biomarker [379]
ELAVL1 TTPC9D0 Strong Biomarker [380]
ELK3 TT5OJMV Strong Biomarker [292]
ENAH TTY36UA Strong Biomarker [381]
ENG TTB30LE Strong Altered Expression [382]
ENPP2 TTSCIM2 Strong Biomarker [383]
EPHA3 TTHS2LR Strong Biomarker [384]
EPHA5 TTV9KOD Strong Posttranslational Modification [385]
EPHB6 TTZEMUY Strong Biomarker [386]
EPOR TTAUX24 Strong Altered Expression [387]
ERBB3 TTSINU2 Strong Biomarker [388]
EREG TTYSB89 Strong Altered Expression [389]
ESRRA TTPNQAC Strong Altered Expression [390]
ESRRB TTKF0XS Strong Altered Expression [391]
ETS2 TT9AH0M Strong Altered Expression [392]
EZH2 TT9MZCQ Strong Altered Expression [393]
EZR TTE47YC Strong Altered Expression [394]
F10 TTCIHJA Strong Biomarker [395]
F2RL1 TTQR74A Strong Genetic Variation [396]
F3 TT38MDJ Strong Biomarker [397]
F7 TTF0EGX Strong Altered Expression [398]
F8 TT1290U Strong Biomarker [399]
FADS2 TTT2VDU Strong Altered Expression [400]
FANCF TTNZKFJ Strong Posttranslational Modification [401]
FAP TTGPQ0F Strong Altered Expression [402]
FASN TT7AOUD Strong Altered Expression [403]
FCGR3A TTIFOC0 Strong Altered Expression [25]
FDXR TT3W4IX Strong Biomarker [404]
FFAR1 TTB8FUC Strong Biomarker [405]
FGF10 TTNPEFX Strong Genetic Variation [406]
FGF19 TTGCH11 Strong Altered Expression [407]
FGF4 TTCEKVZ Strong Biomarker [408]
FGF7 TTFY134 Strong Altered Expression [409]
FGF8 TTIUF3J Strong Altered Expression [410]
FGFR1 TTRLW2X Strong Biomarker [411]
FGFR4 TT1KX2S Strong Genetic Variation [412]
FGR TTPOGS1 Strong Biomarker [413]
FKBP1A TTMW94E Strong Biomarker [414]
FKBP4 TTHY0FT Strong Altered Expression [415]
FLNA TTSTRZY Strong Biomarker [416]
FOSL2 TT689IR Strong Altered Expression [417]
FOXC2 TTLBAP1 Strong Biomarker [418]
FOXP1 TT0MUCI Strong Altered Expression [419]
FOXP3 TT1X3QF Strong Biomarker [420]
FOXQ1 TTEJZOL Strong Biomarker [421]
FPR1 TT5Y4EM Strong Altered Expression [422]
FPR2 TTOJ1NF Strong Biomarker [423]
FSCN1 TTTRS9B Strong Biomarker [424]
FSTL3 TTWRPM8 Strong Altered Expression [425]
FTO TTFW3BT Strong Biomarker [426]
FUT3 TTUPAD7 Strong Genetic Variation [427]
G3BP1 TTG0R8Z Strong Altered Expression [428]
GATA3 TT45KOB Strong Biomarker [429]
GDF2 TTAP4T1 Strong Biomarker [430]
GH1 TTT3YKH Strong Biomarker [431]
GHR TTHJWYD Strong Biomarker [432]
GHSR TTWDC17 Strong Genetic Variation [433]
GJA3 TTFZRG0 Strong Biomarker [434]
GLO1 TTV9A7R Strong Altered Expression [435]
GMNN TT390KA Strong Biomarker [436]
GNRH1 TT0ID4A Strong Altered Expression [437]
GNRHR TT8R70G Strong Biomarker [438]
GPER1 TTDSB34 Strong Biomarker [439]
GPI TT19JIZ Strong Biomarker [275]
GRB2 TTEYRJ9 Strong Altered Expression [440]
GRM1 TTVBPDM Strong Altered Expression [441]
GSN TTUH7OM Strong Altered Expression [442]
GSR TTEP6RV Strong Biomarker [443]
GSTA1 TT4P8DE Strong Genetic Variation [444]
GSTO1 TTWO3SH Strong Genetic Variation [444]
GUSB TTHS7CM Strong Genetic Variation [445]
GZMB TTKEPHX Strong Altered Expression [446]
HBEGF TT15SL0 Strong Altered Expression [447]
HDAC6 TT5ZKDI Strong Altered Expression [448]
HDAC9 TT8M4E1 Strong Altered Expression [449]
HEXIM1 TTFOKAH Strong Altered Expression [62]
HLA-G TTLKFB3 Strong Altered Expression [450]
HMGCR TTPADOQ Strong Altered Expression [451]
HMOX1 TTI6V2A Strong Altered Expression [452]
HNRNPA1 TTPJ9XK Strong Altered Expression [453]
HOXA5 TTXSVQP Strong Altered Expression [454]
HOXA7 TTMRE4Q Strong Posttranslational Modification [455]
HOXB13 TTZ6I58 Strong Genetic Variation [456]
HRH1 TTTIBOJ Strong Altered Expression [457]
HSD17B1 TTIWB6L Strong Genetic Variation [458]
HSD17B13 TTDJYZR Strong Altered Expression [459]
HSD17B2 TT0PT1R Strong Genetic Variation [460]
HSP90B1 TTFPKXQ Strong Altered Expression [461]
HTT TTIWZ0O Strong Genetic Variation [462]
ICOS TTE5VP6 Strong Biomarker [463]
IDH1 TTV2A1R Strong Genetic Variation [51]
IDO1 TTZJYKH Strong Biomarker [354]
IFNB1 TT4TZ8J Strong Therapeutic [464]
IGF1 TTT6LOU Strong Altered Expression [465]
IGF2R TTPNE41 Strong Altered Expression [466]
IGFBP2 TTU4QSN Strong Biomarker [467]
IGFBP5 TTDWEA8 Strong Biomarker [468]
IKBKB TTJ3E9X Strong Altered Expression [469]
IL11RA TTZPLJS Strong Biomarker [470]
IL12RB2 TT4SWR8 Strong Genetic Variation [471]
IL1R1 TTWOTEA Strong Altered Expression [472]
IL25 TTVMO5W Strong Biomarker [473]
IL2RB TT9721Y Strong Altered Expression [474]
IL32 TTD4G7L Strong Biomarker [475]
IL4R TTDWHC3 Strong Biomarker [177]
ILK TT7ALZG Strong Biomarker [476]
IMP3 TTEJA2R Strong Biomarker [477]
IRS2 TTF95B8 Strong Biomarker [478]
ISG15 TTVOH3T Strong Biomarker [479]
ITCH TT5SEWD Strong Biomarker [480]
ITGA2 TTSJ542 Strong Biomarker [481]
ITGA5 TTHIZP9 Strong Altered Expression [482]
ITGA6 TT165T3 Strong Altered Expression [483]
ITGAV TTT1R2L Strong Biomarker [484]
ITGB3 TTJA1ZO Strong Biomarker [475]
ITPR1 TT5HWAT Strong Altered Expression [485]
ITPR3 TTH1769 Strong Altered Expression [485]
JAG2 TTOJY1B Strong Biomarker [371]
JUN TTS7IR5 Strong Biomarker [486]
JUP TTREN0G Strong Biomarker [487]
KAT6A TT6O1J0 Strong Altered Expression [488]
KCNJ3 TTGM19J Strong Altered Expression [489]
KCNK9 TTL4FMB Strong Biomarker [490]
KDM1B TT8VP2T Strong Altered Expression [491]
KDM4C TTV8CRH Strong Biomarker [492]
KDM5C TT94UCF Strong Biomarker [47]
KISS1 TTU2O6T Strong Altered Expression [493]
KISS1R TT3KBZY Strong Altered Expression [493]
KIT TTX41N9 Strong Posttranslational Modification [494]
KLF4 TTTI53X Strong Posttranslational Modification [495]
KLK2 TTJLNAW Strong Altered Expression [496]
KLKB1 TTN0PCX Strong Genetic Variation [497]
KMT5A TTGC95K Strong Altered Expression [498]
KMT5C TT7H3YM Strong Altered Expression [499]
KRT19 TT3JF9E Strong Biomarker [500]
L3MBTL3 TTQDMJN Strong Biomarker [250]
LAG3 TTNVXAW Strong Biomarker [501]
LALBA TTBRLU3 Strong Biomarker [502]
LAPTM4B TTEJQT0 Strong Altered Expression [503]
LATS2 TTML7FG Strong Altered Expression [504]
LCK TT860QF Strong Biomarker [505]
LCN2 TTKTLAI Strong Altered Expression [506]
LDHA TTW76JE Strong Biomarker [507]
LEP TTBJEZ5 Strong Biomarker [508]
LEPR TT0HD6V Strong Altered Expression [509]
LGMN TTPTWV5 Strong Biomarker [510]
LGR4 TTY6C71 Strong Altered Expression [511]
LHCGR TT2O4W9 Strong Genetic Variation [512]
LIFR TTID542 Strong Biomarker [513]
LIMK1 TTWL9TY Strong Biomarker [514]
LNPEP TTY2KP7 Strong Biomarker [515]
LONP1 TTM1VPZ Strong Altered Expression [516]
LOX TTQHNAM Strong Altered Expression [517]
LOXL2 TTFSUHX Strong Biomarker [518]
LPAR1 TTQ6S1K Strong Altered Expression [519]
LPAR2 TTB7Y8I Strong Biomarker [520]
LSM1 TT2KHSC Strong Biomarker [521]
LTF TTSZDQU Strong Biomarker [522]
LY6K TT5GKHN Strong Altered Expression [523]
LY75 TTG180Q Strong Biomarker [524]
LYN TT1RWNJ Strong Biomarker [525]
LYVE1 TTG8DNU Strong Biomarker [526]
MAGEC1 TT9M6NA Strong Biomarker [527]
MAP3K1 TTW8TJI Strong Biomarker [528]
MAP3K2 TTIX0ZU Strong Biomarker [529]
MAP3K20 TTTUZ3O Strong Biomarker [530]
MAP3K7 TTJQT60 Strong Biomarker [303]
MAPK14 TTQBR95 Strong Biomarker [531]
MAPK7 TTU6FSC Strong Altered Expression [532]
MAPK9 TT3IVG2 Strong Altered Expression [533]
MAPKAPK2 TTMUG9D Strong Altered Expression [534]
MAZ TT059DA Strong Altered Expression [535]
MBOAT4 TTSYOWR Strong Biomarker [433]
MCL1 TTL53M6 Strong Biomarker [536]
MELK TTBZOTY Strong Biomarker [537]
MFGE8 TT1GLAJ Strong Biomarker [538]
MGMT TTJ8DV7 Strong Altered Expression [539]
MKI67 TTB4UNG Strong Altered Expression [540]
MKNK1 TTEZAUX Strong Altered Expression [541]
MLH1 TTISG27 Strong Genetic Variation [542]
MMP1 TTMX39J Strong Biomarker [277]
MMP17 TTVSZKN Strong Altered Expression [543]
MMP2 TTLM12X Strong Biomarker [544]
MMP3 TTUZ2L5 Strong Altered Expression [545]
MMP8 TTGA1IV Strong Biomarker [546]
MPL TTIHYA4 Strong Altered Expression [547]
MSI1 TTSM4BA Strong Altered Expression [548]
MSLN TT4RXME Strong Biomarker [549]
MSMB TTYH1ZK Strong Biomarker [550]
MSR1 TT2TDH9 Strong Altered Expression [551]
MST1R TTBQ3OC Strong Biomarker [552]
MTA1 TTO4HUS Strong Altered Expression [553]
MTNR1A TT0WAIE Strong Altered Expression [554]
MTNR1B TT32JK8 Strong Altered Expression [555]
MTOR TTCJG29 Strong Biomarker [45]
MTTP TTUS1RD Strong Posttranslational Modification [236]
MUC16 TTC1PS3 Strong Biomarker [556]
MYC TTNQ5ZP Strong Altered Expression [557]
NCL TTK1V5Q Strong Biomarker [558]
NEDD4 TT1QU6G Strong Altered Expression [559]
NEDD8 TTNDC4K Strong Altered Expression [560]
NEDD9 TT1UREA Strong Altered Expression [561]
NEK8 TT8AH9I Strong Altered Expression [562]
NEK9 TTM57AW Strong Biomarker [563]
NFKB2 TTKLNRV Strong Altered Expression [564]
NFKBIA TTSHAEB Strong Biomarker [565]
NMUR2 TT2L6C5 Strong Altered Expression [566]
NOS2 TTF10I9 Strong Altered Expression [272]
NOS3 TTCM4B3 Strong Biomarker [567]
NOTCH1 TTB1STW Strong Altered Expression [568]
NOTCH3 TTVX7IA Strong Biomarker [569]
NPEPPS TT371QC Strong Altered Expression [497]
NPPB TTY63XT Strong Altered Expression [570]
NQO1 TT8XK6L Strong Biomarker [571]
NRG1 TTEH395 Strong Biomarker [572]
NRP1 TTIPJCB Strong Biomarker [573]
NRP2 TTRXUVC Strong Altered Expression [574]
NTRK3 TTXABCW Strong Biomarker [575]
NTSR1 TTTUMEP Strong Altered Expression [576]
NUAK1 TT65FL0 Strong Biomarker [577]
OLFM4 TTK1CX7 Strong Altered Expression [578]
ORAI1 TTE76YK Strong Biomarker [579]
OSM TTIVXSE Strong Biomarker [580]
P2RY6 TTNVSKA Strong Altered Expression [581]
PABPC1 TTHC8EF Strong Biomarker [582]
PAK4 TT7Y3BZ Strong Altered Expression [583]
PAOX TTNQ760 Strong Biomarker [584]
PARG TT39J16 Strong Biomarker [281]
PARP1 TTVDSZ0 Strong Genetic Variation [585]
PCSK6 TT75LN9 Strong Altered Expression [586]
PCSK7 TTD30LY Strong Altered Expression [587]
PCSK9 TTNIZ2B Strong Biomarker [588]
PDE2A TTJGW1Z Strong Biomarker [589]
PDE5A TTJ0IQB Strong Biomarker [590]
PDK1 TTCZOF2 Strong Genetic Variation [591]
PEBP1 TT1BGU8 Strong Biomarker [592]
PEMT TT735V2 Strong Genetic Variation [593]
PEPD TTLZXI0 Strong Altered Expression [594]
PFKFB3 TTTHMQJ Strong Biomarker [595]
PGC TT7K6AD Strong Genetic Variation [596]
PGF TT48I1Y Strong Biomarker [597]
PGRMC1 TTY3LAZ Strong Biomarker [598]
PHB TT6U071 Strong Genetic Variation [599]
PIM1 TTTN5QW Strong Altered Expression [600]
PIM2 TT69J2Z Strong Biomarker [53]
PKD2L1 TTAHD89 Strong Biomarker [601]
PKM TT4LOT8 Strong Biomarker [602]
PKN2 TTTHO0M Strong Genetic Variation [603]
PLA2G4A TTT1JVS Strong Biomarker [604]
PLAC1 TTM18HX Strong Biomarker [605]
PLCG1 TT6T4JI Strong Altered Expression [606]
PLD1 TT3T17P Strong Altered Expression [607]
PLD2 TTRLMKF Strong Altered Expression [608]
PLK1 TTH4IP0 Strong Biomarker [609]
PLK4 TTGPNZQ Strong Biomarker [610]
PMEL TT8MK59 Strong Altered Expression [564]
POR TTOQ9GZ Strong Genetic Variation [611]
PPARD TT2JWF6 Strong Altered Expression [612]
PPIB TT6ZFQ4 Strong Biomarker [613]
PPIF TTRFQTB Strong Biomarker [614]
PPM1D TTENJAB Strong Genetic Variation [615]
PPP1CA TTFLH0E Strong Altered Expression [616]
PPP5C TTTW7FJ Strong Altered Expression [617]
PRDX4 TTPBL9I Strong Altered Expression [618]
PRKACA TT5U49F Strong Posttranslational Modification [619]
PRKCA TTFJ8Q1 Strong Genetic Variation [603]
PRKCE TT57MT2 Strong Altered Expression [620]
PRKCZ TTBSN0L Strong Genetic Variation [603]
PRKD1 TTSLUMT Strong Altered Expression [621]
PRMT1 TTVOJAI Strong Biomarker [622]
PRMT7 TTAR2P0 Strong Altered Expression [623]
PSCA TT9T4AV Strong Biomarker [624]
PSEN2 TTWN3F4 Strong Genetic Variation [625]
PSIP1 TTH9LDP Strong Altered Expression [474]
PTGER2 TT1ZAVI Strong Biomarker [626]
PTGER4 TT79WV3 Strong Biomarker [626]
PTGS1 TT8NGED Strong Biomarker [627]
PTH1R TTFPD47 Strong Altered Expression [628]
PTK2 TTON5IT Strong Biomarker [629]
PTK6 TT6TH8V Strong Altered Expression [630]
PTN TTA9EJK Strong Biomarker [631]
PTP4A2 TT1MHKD Strong Biomarker [632]
PTP4A3 TT7YM8D Strong Biomarker [633]
PTPN1 TTELIN2 Strong Altered Expression [634]
PTPN2 TTY8PUS Strong Altered Expression [635]
PTPRB TT64I9Q Strong Altered Expression [636]
PTPRJ TTWMKXP Strong Genetic Variation [637]
PTPRZ1 TT4SEA8 Strong Altered Expression [638]
PYY TTVFJLX Strong Biomarker [639]
RAC1 TT2M9CG Strong Biomarker [640]
RAC3 TT9BQ50 Strong Biomarker [641]
RACK1 TTJ10AL Strong Biomarker [642]
RAF1 TTAN5W2 Strong Genetic Variation [643]
RARB TTISP28 Strong Biomarker [644]
RASA1 TTPNZ1F Strong Altered Expression [645]
RBPJ TT72D4Z Strong Altered Expression [646]
RECK TTRZBW7 Strong Altered Expression [647]
RGS16 TTFRES8 Strong Genetic Variation [648]
RGS2 TTKB7T3 Strong Biomarker [565]
RGS6 TTJ96M8 Strong Biomarker [649]
RHBDF2 TTH1ZOP Strong Genetic Variation [650]
RHO TTH0KSX Strong Altered Expression [651]
RHOA TTP2U16 Strong Genetic Variation [51]
RIC8A TTDFTJG Strong Biomarker [250]
RIPK2 TTCQ2E5 Strong Altered Expression [652]
ROBO1 TTND1YP Strong Genetic Variation [653]
ROCK2 TTGWKQJ Strong Biomarker [654]
ROR1 TTDEJAU Strong Biomarker [655]
ROR2 TTUDPCI Strong Biomarker [656]
RPS6KA1 TTIXKA4 Strong Altered Expression [92]
RPS6KA2 TT0ZW9O Strong Altered Expression [657]
RPS6KA6 TT3KYWB Strong Altered Expression [658]
RRM1 TTWP0NS Strong Biomarker [659]
RSF1 TTMP86V Strong Biomarker [660]
RSPO1 TTI9HL4 Strong Altered Expression [661]
RSPO3 TT7HJTF Strong Biomarker [662]
RXRA TT6PEUO Strong Biomarker [663]
RXRB TTKLV96 Strong Biomarker [664]
S1PR1 TT9JZCK Strong Biomarker [665]
SCGB1A1 TTONPVW Strong Altered Expression [666]
SCGB1D2 TT5D314 Strong Altered Expression [667]
SCUBE2 TTWREQP Strong Biomarker [668]
SDC1 TTYDSVG Strong Biomarker [669]
SEMA3A TTVKD3S Strong Biomarker [670]
SEMA4D TT5UT28 Strong Biomarker [671]
SETD2 TTPC3H4 Strong Altered Expression [175]
SETD7 TTJ0FSU Strong Biomarker [672]
SF3B1 TTL2WUI Strong Genetic Variation [51]
SGCG TTSMT9W Strong Biomarker [673]
SGK1 TTTV8EJ Strong Altered Expression [674]
SIGMAR1 TT5TPI6 Strong Biomarker [675]
SIRT2 TTLKF5M Strong Biomarker [676]
SIRT5 TTH0IOD Strong Altered Expression [677]
SKP2 TT5B2EO Strong Biomarker [678]
SLC12A6 TT8DFHE Strong Altered Expression [679]
SLC12A7 TTU2PCD Strong Altered Expression [679]
SLC16A1 TTN1J82 Strong Biomarker [334]
SLC16A3 TTG6VD5 Strong Biomarker [680]
SLC22A16 TTITAVR Strong Genetic Variation [681]
SLC23A2 TTOP832 Strong Altered Expression [682]
SLC27A4 TT20AYF Strong Altered Expression [683]
SLC2A1 TT79TKF Strong Altered Expression [554]
SLC2A9 TTIF3GB Strong Biomarker [684]
SLC39A6 TTZN1CF Strong Biomarker [685]
SLC3A2 TT5CZSM Strong Biomarker [686]
SLC5A5 TTW7HI9 Strong Altered Expression [687]
SLC7A5 TTPH2JB Strong Biomarker [686]
SLCO1A2 TTUGD21 Strong Altered Expression [688]
SLCO1B1 TTFGXEB Strong Biomarker [689]
SLCO1B3 TTU86P0 Strong Altered Expression [690]
SLIT2 TTDWK85 Strong Biomarker [691]
SMPD1 TTJTM88 Strong Biomarker [692]
SMYD2 TT7YJFO Strong Altered Expression [693]
SMYD3 TTKLJYX Strong Biomarker [47]
SNCG TT5TQNZ Strong Biomarker [694]
SOCS1 TT8COJM Strong Altered Expression [695]
SOCS3 TTI0ME6 Strong Biomarker [696]
SP1 TTZEP6S Strong Altered Expression [697]
SPARC TTBQFM7 Strong Altered Expression [698]
SPDEF TT2ZUPY Strong Altered Expression [699]
SPHK1 TTOHFIY Strong Altered Expression [700]
SQLE TTE14XG Strong Altered Expression [701]
SREBF1 TTER0UB Strong Altered Expression [702]
SREBF2 TTRQ4AP Strong Biomarker [703]
SSTR1 TTIND6G Strong Genetic Variation [704]
SSTR3 TTJX3UE Strong Biomarker [705]
ST14 TTPRO7W Strong Altered Expression [706]
ST8SIA4 TTDP8YM Strong Altered Expression [707]
STAT1 TTN7R6K Strong Biomarker [708]
STAT6 TTWOE1T Strong Altered Expression [709]
STC1 TTDLUER Strong Altered Expression [223]
STEAP1 TT9E64S Strong Altered Expression [710]
STMN1 TT7W5OT Strong Biomarker [275]
STS TTHM0R1 Strong Biomarker [711]
STXBP4 TTKS60G Strong Biomarker [250]
STYK1 TTRMCYJ Strong Biomarker [712]
SUV39H1 TTUWQTK Strong Biomarker [47]
SYK TT2HUPM Strong Biomarker [505]
TACSTD2 TTP2HE5 Strong Biomarker [713]
TCF3 TTULOD8 Strong Altered Expression [474]
TDP1 TT64IHJ Strong Altered Expression [714]
TERF2 TT5XSLT Strong Altered Expression [715]
TFAP2A TTDY4BS Strong Altered Expression [716]
TGFA TTTLQFR Strong Biomarker [717]
TGFBR1 TTP4520 Strong Genetic Variation [718]
TGM2 TT2F4OL Strong Altered Expression [719]
THRA TTTSEPU Strong Genetic Variation [720]
THRB TTGER3L Strong Biomarker [721]
TIAM1 TTNU6I5 Strong Biomarker [722]
TMBIM6 TT7QSMG Strong Biomarker [276]
TMEM97 TT9NXW4 Strong Biomarker [723]
TNF TTF8CQI Strong Biomarker [724]
TNFRSF11A TT3K9S2 Strong Altered Expression [390]
TNFRSF13B TTL9OD4 Strong Altered Expression [725]
TNFRSF17 TTZ3P4W Strong Altered Expression [725]
TNFRSF8 TT2GM5R Strong Altered Expression [726]
TNFSF10 TTA5MS9 Strong Biomarker [727]
TNFSF11 TT9E8HR Strong Biomarker [728]
TNFSF12 TTBTDM1 Strong Biomarker [729]
TNK2 TTIET93 Strong Altered Expression [730]
TOP1 TTGTQHC Strong Biomarker [731]
TP53BP1 TTX4UE9 Strong Biomarker [45]
TPBG TT70MLA Strong Altered Expression [732]
TPX2 TT0PHL4 Strong Biomarker [733]
TRIM24 TT9Q7AE Strong Altered Expression [734]
TRIM27 TTTO3QN Strong Biomarker [423]
TRIM28 TTQ2BKV Strong Biomarker [735]
TRIP10 TTKHTGE Strong Biomarker [736]
TRPM7 TTFPVZO Strong Biomarker [737]
TRPV6 TTBK14N Strong Altered Expression [738]
TSG101 TTHU7JA Strong Genetic Variation [739]
TSPO TTPTXIN Strong Biomarker [740]
TTK TTP7EGM Strong Altered Expression [741]
TXN TTZJ5U9 Strong Biomarker [742]
TXNRD1 TTR7UJ3 Strong Altered Expression [743]
TYMP TTO0IB8 Strong Altered Expression [744]
TYMS TTP1UKZ Strong Biomarker [745]
TYRP1 TTFRV98 Strong Altered Expression [746]
UBE2T TT0A1R8 Strong Biomarker [32]
UCP1 TTI12YJ Strong Altered Expression [747]
UMPS TTAFJUD Strong Biomarker [748]
USP2 TTUEQ1W Strong Biomarker [749]
USP44 TTJLTNM Strong Altered Expression [750]
VEGFB TTPJQHE Strong Biomarker [751]
VIP TTGTWLF Strong Biomarker [752]
WAS TTE8T73 Strong Biomarker [753]
WDR5 TT7OFWB Strong Biomarker [754]
WEE1 TTJFOAL Strong Altered Expression [755]
WNT5A TTKG7F8 Strong Biomarker [756]
WT1 TTZ8UT4 Strong Biomarker [757]
WWP1 TTBWMKT Strong Biomarker [758]
XRCC5 TTCB9KW Strong Altered Expression [759]
YES1 TT0SQ8J Strong Altered Expression [345]
ZNF224 TT1CDXL Strong Altered Expression [442]
AURKC TTLYXIT Definitive Altered Expression [760]
BMP2 TTP3IGX Definitive Biomarker [761]
CAT TTPS279 Definitive Altered Expression [272]
CSF2 TTNYZG2 Definitive Biomarker [762]
FOS TTOM5AU Definitive Biomarker [763]
FOXM1 TTD3KOX Definitive Altered Expression [764]
FST TTDNM9W Definitive Biomarker [765]
HSP90AA1 TT78R5H Definitive Genetic Variation [766]
IL24 TT1EPXZ Definitive Biomarker [767]
IL7 TT8FRMO Definitive Biomarker [768]
KRAS TTM8FR7 Definitive Genetic Variation [643]
MAP3K11 TTETX6Q Definitive Altered Expression [769]
NOTCH2 TT82FVD Definitive Genetic Variation [770]
PRKDC TTK3PY9 Definitive Genetic Variation [771]
PTEN TTXJ3W7 Definitive Biomarker [142]
RARA TTW38KT Definitive Biomarker [416]
RUNX3 TTKCVO7 Definitive Posttranslational Modification [772]
TERT TTQY2EJ Definitive Biomarker [773]
UTRN TTNO1VA Definitive Altered Expression [774]
UTS2 TTERU0T Definitive Genetic Variation [775]
------------------------------------------------------------------------------------
⏷ Show the Full List of 856 DTT(s)
This Disease Is Related to 23 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
ABCC11 DTWN7FC Limited Altered Expression [233]
SLC20A1 DTMULXV Limited Biomarker [147]
SLC27A2 DTXK9WA Limited Biomarker [776]
ABCC5 DTYVM24 Strong Altered Expression [777]
ATP2B1 DTJWQ1L Strong Biomarker [778]
SLC10A6 DT5A9X2 Strong Biomarker [779]
SLC16A7 DTLT3UG Strong Altered Expression [780]
SLC25A5 DTL1TRY Strong Altered Expression [781]
SLC26A1 DTJ785O Strong Altered Expression [782]
SLC28A1 DT0EQPW Strong Biomarker [783]
SLC2A10 DT3BI6S Strong Biomarker [784]
SLC2A2 DTUJPOL Strong Biomarker [785]
SLC2A3 DT9SQ3L Strong Biomarker [786]
SLC2A5 DTOR02F Strong Biomarker [684]
SLC2A6 DTS4MKQ Strong Biomarker [684]
SLC30A1 DT1BO38 Strong Biomarker [787]
SLC30A2 DTIAF6C Strong Altered Expression [788]
SLC39A10 DTK02RZ Strong Biomarker [685]
SLC39A2 DTL8VXO Strong Biomarker [787]
SLC39A7 DTDQSAM Strong Biomarker [685]
SLC4A11 DTH2J1G Strong Altered Expression [731]
SLC4A9 DTSQY0W Strong Biomarker [789]
SLC52A1 DT7NOKR Strong Genetic Variation [396]
------------------------------------------------------------------------------------
⏷ Show the Full List of 23 DTP(s)
This Disease Is Related to 48 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
ACP3 DEDW5H6 Limited Biomarker [790]
ACP5 DESITDW Limited Altered Expression [791]
ADH1B DEEN9RD Limited Genetic Variation [792]
MT1A DE5ME8A Limited Altered Expression [554]
P4HA2 DE5EGK0 Limited Biomarker [793]
SULT1E1 DESTKG6 Limited Altered Expression [794]
CYP1A1 DE6OQ3W moderate Altered Expression [795]
GSTM1 DEYZEJA moderate Altered Expression [796]
NAT2 DER7TA0 moderate Altered Expression [797]
PER1 DE9HF0I moderate Biomarker [798]
PLPP1 DE6WXTH moderate Altered Expression [799]
ACSS2 DEE76VW Strong Altered Expression [800]
ADH1C DEM1HNL Strong Genetic Variation [792]
ADHFE1 DE8RJ3F Strong Biomarker [801]
AKR1B10 DEP6GT1 Strong Biomarker [802]
AKR1C1 DE7P2FB Strong Altered Expression [803]
AKR1C2 DEOY5ZM Strong Altered Expression [803]
ALDH1A1 DE2JP1Y Strong Altered Expression [804]
APRT DE2MV1R Strong Biomarker [805]
BLMH DECH1VP Strong Biomarker [806]
CBR3 DEIVKZ8 Strong Genetic Variation [807]
CHDH DEAHED0 Strong Genetic Variation [593]
CYP27B1 DE3FYEM Strong Genetic Variation [808]
CYP2C18 DEZMWRE Strong Altered Expression [809]
CYP2C8 DES5XRU Strong Genetic Variation [810]
CYP3A43 DEO1IE3 Strong Biomarker [811]
CYP3A7 DERD86B Strong Altered Expression [361]
CYP4F3 DEFCMPI Strong Altered Expression [812]
DIO3 DET89OV Strong Biomarker [277]
GGCT DEKW6PB Strong Altered Expression [813]
GSTT1 DE3PKUG Strong Genetic Variation [814]
HPGD DEHKSC6 Strong Biomarker [815]
HSD17B7 DEDMWFX Strong Altered Expression [459]
HSD3B1 DERDQWN Strong Biomarker [816]
MT2A DEFKGT7 Strong Altered Expression [817]
MTRR DE6NIY9 Strong Genetic Variation [818]
NDUFS3 DE741FI Strong Biomarker [582]
PCYT2 DEIX1PO Strong Altered Expression [819]
PON2 DEHJU7E Strong Biomarker [820]
PSAT1 DEBS17P Strong Altered Expression [497]
PTGDS DER3H9C Strong Altered Expression [821]
SAT1 DEMWO83 Strong Biomarker [584]
SMOX DEOH5V3 Strong Biomarker [584]
SULT1A1 DEYWLRK Strong Biomarker [822]
SULT1A2 DERUZL7 Strong Genetic Variation [823]
TGM3 DEOEB3Q Strong Altered Expression [824]
UGT2B15 DENZ6B1 Strong Altered Expression [825]
GLS DE3E0VT Definitive Altered Expression [826]
------------------------------------------------------------------------------------
⏷ Show the Full List of 48 DME(s)
This Disease Is Related to 1165 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ADAR OTQNOHR8 Limited Biomarker [29]
AFF3 OTR0705Z Limited Altered Expression [827]
ANKRD30A OTJXYAE5 Limited Altered Expression [828]
ARID3B OTUP9MS4 Limited Altered Expression [829]
ATP2C2 OTGIHTYQ Limited Biomarker [830]
BARD1 OTTC0Z9Y Limited Genetic Variation [831]
BID OTOSHSHU Limited Altered Expression [620]
BIN1 OTK8O0X8 Limited Biomarker [832]
BRCC3 OTK0ZN7Y Limited Altered Expression [833]
CBFA2T3 OTOJ10S1 Limited Biomarker [834]
CBLL2 OTB4AD3V Limited Altered Expression [835]
CBX1 OT2L4XZX Limited Biomarker [294]
CCN5 OTADU8JJ Limited Biomarker [836]
CDKN2B OTAG24N1 Limited Biomarker [837]
CEBPD OTNBIPMY Limited Altered Expression [838]
CHAC1 OTJGE772 Limited Altered Expression [839]
CKAP4 OTDUC9ME Limited Altered Expression [91]
CLCA2 OTF191LZ Limited Biomarker [840]
CLDN7 OTNE0XHQ Limited Biomarker [20]
CMTM1 OTKN7E89 Limited Biomarker [841]
COL11A2 OT3BQUBH Limited Genetic Variation [585]
CSTA OT1K68KE Limited Altered Expression [842]
CTTN OTJRG4ES Limited Biomarker [843]
DACT1 OT19Z704 Limited Altered Expression [844]
DIRAS3 OT3XHLQA Limited Biomarker [845]
DYNLL1 OTR69LHT Limited Biomarker [846]
E2F6 OT2PN28R Limited Altered Expression [847]
EIF3E OTI0WG98 Limited Biomarker [848]
EMB OT67E3Q1 Limited Biomarker [849]
EPB41L3 OTS6CHG2 Limited Posttranslational Modification [850]
ETV6 OTCZMG61 Limited Biomarker [851]
EXO1 OTI87RS5 Limited Altered Expression [852]
FBLN1 OT5MHHOP Limited Genetic Variation [853]
FHL2 OT0OAYWT Limited Altered Expression [854]
FNBP1L OTH1S2P2 Limited Biomarker [855]
FOSB OTW6C05J Limited Biomarker [763]
G3BP2 OTAWW3KI Limited Biomarker [856]
GATAD2B OTJL128N Limited Biomarker [363]
GHRH OT94U6MO Limited Biomarker [857]
GPX4 OTRAFFX2 Limited Altered Expression [858]
H2BC10 OTLQH0D6 Limited Altered Expression [859]
H2BC5 OTXDTDHN Limited Altered Expression [859]
HBP1 OTDPGGDV Limited Altered Expression [860]
IGBP1 OTTHH4YE Limited Biomarker [861]
ILF3 OTKMZ5K5 Limited Altered Expression [862]
INTS2 OT2N5TCK Limited Altered Expression [863]
INTS6 OT6GDV46 Limited Biomarker [848]
JMJD6 OTILR7E4 Limited Altered Expression [864]
JUNB OTG2JXV5 Limited Biomarker [763]
JUND OTNKACJD Limited Biomarker [763]
KIF14 OTXHT4JM Limited Biomarker [865]
KPNA2 OTU7FOE6 Limited Altered Expression [866]
KRT5 OTVGI9HT Limited Altered Expression [65]
LOXL1 OTA0NEJU Limited Biomarker [867]
MACIR OTPSW8Y8 Limited Biomarker [45]
MAP1LC3B OTUYHB84 Limited Altered Expression [111]
MECOM OTP983W8 Limited Biomarker [868]
MEF2A OTV2SF6E Limited Altered Expression [869]
MEST OT8Q4U8Y Limited Altered Expression [870]
MITF OT6XJCZH Limited Biomarker [851]
MLXIPL OTR9MLLW Limited Biomarker [871]
MNX1 OTXP9FH1 Limited Altered Expression [872]
MOSPD2 OTTN4NR7 Limited Posttranslational Modification [873]
MSN OTZJ4J6G Limited Genetic Variation [874]
MT1B OTUA4FFH Limited Altered Expression [554]
MT1E OTXJKU4Y Limited Altered Expression [554]
MT1F OTZVUYG1 Limited Altered Expression [554]
MT1G OTAV1OCR Limited Altered Expression [554]
MT1H OT0MVBM6 Limited Altered Expression [554]
MT1M OTVT8PLU Limited Altered Expression [554]
MT1X OT9AKFVS Limited Altered Expression [554]
MUCL1 OT9QUFL3 Limited Altered Expression [875]
MUL1 OT2JC9YR Limited Altered Expression [835]
NCOA2 OTMQFPBB Limited Biomarker [413]
NEU1 OTH9BY8Y Limited Altered Expression [384]
NEURL1 OT2C4P70 Limited Altered Expression [384]
NMI OTYVG3NM Limited Altered Expression [876]
NOL9 OTCCIJ8I Limited Altered Expression [877]
NONO OTN36Q6U Limited Biomarker [878]
NR2F1 OTGWZWYL Limited Biomarker [879]
NR2F6 OTNVO2B6 Limited Biomarker [880]
NSD3 OT3677ZG Limited Biomarker [881]
NTS OTPGDNQS Limited Altered Expression [576]
OIP5 OTI5C2DE Limited Altered Expression [882]
OLIG2 OTMCN6D3 Limited Altered Expression [883]
PDCD4 OTZ6NXUX Limited Altered Expression [884]
PLAAT4 OTI66SAJ Limited Biomarker [364]
POLD3 OTEQEFQ2 Limited Biomarker [363]
POT1 OTNBXJCQ Limited Altered Expression [715]
POU1F1 OTXT8A5C Limited Biomarker [147]
PPP1R9B OTDCTHTT Limited Biomarker [885]
PRIM1 OTWWP8Y6 Limited Altered Expression [886]
RAD50 OTYMU9G1 Limited Altered Expression [887]
RAI2 OTR8LX4J Limited Biomarker [888]
RAP1GDS1 OTH70UHD Limited Altered Expression [889]
RASGRP3 OTEMEV3P Limited Altered Expression [890]
RASSF2 OT2JHDO4 Limited Biomarker [891]
RBBP7 OTLB56HX Limited Altered Expression [892]
RBBP8 OTRHJ3GI Limited Biomarker [893]
RBP1 OTRP1MFC Limited Altered Expression [894]
RELA OTUJP9CN Limited Altered Expression [895]
SCGB2A1 OT9L87U9 Limited Biomarker [896]
SCGB3A1 OTIR98RB Limited Biomarker [897]
SFRP2 OT8GZ0CA Limited Altered Expression [898]
SHMT1 OTIINA3J Limited Genetic Variation [899]
SIAH2 OTKED2XN Limited Altered Expression [504]
SIM2 OT0QWHK4 Limited Biomarker [900]
SIPA1 OTXY5RXC Limited Biomarker [901]
SLC22A18 OT9C3KR4 Limited Altered Expression [902]
SOX17 OT9H4WWE Limited Biomarker [903]
SOX9 OTVDJFGN Limited Biomarker [904]
SPAG9 OT45AHMB Limited Biomarker [905]
TACC2 OTW4M7HI Limited Altered Expression [906]
TAF5L OTCP6ZYD Limited Biomarker [907]
TAF7L OTPDZ6XV Limited Altered Expression [882]
TFF3 OTJJDRTU Limited Altered Expression [908]
THRSP OTKYE01L Limited Altered Expression [909]
TRAF7 OTW8Q5TF Limited Altered Expression [910]
TRMT11 OTRK0IOR Limited Biomarker [45]
BLID OT479VJV Disputed Genetic Variation [911]
CRABP1 OTISDG5X Disputed Altered Expression [912]
DLX4 OTLWVCN4 Disputed Biomarker [913]
MRPS30 OTDXIAGG Disputed Genetic Variation [406]
SRSF6 OTGLOSYE Disputed Altered Expression [118]
ACTB OT1MCP2F moderate Biomarker [914]
ALDH1A3 OT1C9NKQ moderate Biomarker [915]
ARHGDIA OTEXWJDO moderate Altered Expression [916]
BAG1 OTRQNIA4 moderate Altered Expression [917]
BCL3 OT1M5B95 moderate Biomarker [918]
BMP5 OTC0Y6E0 moderate Altered Expression [919]
BRMS1 OTV5A6LL moderate Biomarker [903]
CAV2 OT1FGRQX moderate Biomarker [215]
CLCA4 OTCRR1M9 moderate Altered Expression [920]
CPT1A OTI862QH moderate Biomarker [921]
CTCF OT8ZB70U moderate Altered Expression [350]
CTNND1 OTUMPSHR moderate Altered Expression [922]
EVL OTZ8ZDNY moderate Biomarker [923]
FADD OTV7GFHH moderate Posttranslational Modification [924]
FEN1 OT6QGG7O moderate Biomarker [925]
FLOT1 OT0JPPJZ moderate Altered Expression [926]
GADD45A OTDRV63V moderate Biomarker [315]
GDPD5 OTUM65JL moderate Altered Expression [927]
GINS2 OT974IYI moderate Altered Expression [928]
H2AX OT18UX57 moderate Biomarker [929]
H4C1 OTB71W46 moderate Posttranslational Modification [930]
HERC2 OTNQYKOB moderate CausalMutation [931]
HES1 OT8P19W2 moderate Biomarker [932]
HMMR OT4M0JTZ moderate Biomarker [733]
HOXB1 OTGC0EKI moderate Biomarker [933]
HRG OTPLUFOG moderate Biomarker [934]
IKBKE OT5VYOSM moderate Altered Expression [935]
JAG1 OT3LGT6K moderate Biomarker [936]
KBTBD11 OTBOY3WH moderate Biomarker [937]
KLHDC7B OT2H5BNX moderate Altered Expression [937]
LGR6 OTPZ1PWR moderate Biomarker [938]
MAP2K4 OTZPZX11 moderate Biomarker [563]
MED12 OTQZ4D2X moderate Genetic Variation [939]
MED28 OTEDM1L5 moderate Biomarker [940]
MTSS1 OT5DTDO2 moderate Altered Expression [941]
MVP OTJGHJRB moderate Altered Expression [68]
NBN OT73B5MD moderate Altered Expression [942]
NRIP1 OTIZOJQV moderate Biomarker [943]
OGT OT1Z1ZXE moderate Biomarker [944]
PER3 OTVKYVJA moderate Biomarker [945]
POLQ OTBHK0E6 moderate Altered Expression [946]
POU4F2 OT6SW5H0 moderate Altered Expression [947]
PPP1R1B OTSIJMQ9 moderate Biomarker [948]
PSAP OTUOEKY7 moderate Altered Expression [949]
PSD4 OTEFB87Z moderate Altered Expression [950]
PXN OTVMMUOF moderate Altered Expression [951]
QSOX1 OT4ZPK4P moderate Altered Expression [952]
RAD54L OTEGMAKG moderate Biomarker [953]
RB1 OT9VMY7B moderate Altered Expression [93]
RBM3 OTAJ7R31 moderate Biomarker [954]
SERPINB2 OT72QLZB moderate Biomarker [955]
SHBG OTPWU5IW moderate Biomarker [956]
SKA2 OTVYF4XT moderate Biomarker [957]
STIM2 OTYNXAW0 moderate Biomarker [958]
TFAP2C OTUDIW05 moderate Altered Expression [959]
TIMP2 OT8S1RRP moderate Altered Expression [226]
TLE1 OT50MRZ1 moderate Altered Expression [960]
TP73 OT0LUO47 moderate Biomarker [961]
TREX1 OTQG7K12 moderate Altered Expression [852]
TRIM22 OTJBLG5R moderate Altered Expression [962]
A2ML1 OTWNUXIS Strong Biomarker [963]
ABI1 OT5H4M62 Strong Biomarker [964]
ACACA OT5CQPZY Strong Biomarker [802]
ACKR2 OTWYY14H Strong Biomarker [965]
ACOX2 OT3VH359 Strong Biomarker [966]
ACSBG1 OTM040MW Strong Biomarker [967]
ACTA2 OTEDLG8E Strong Biomarker [277]
ADAM15 OTZ7VLTP Strong Altered Expression [968]
ADAM28 OT3GBVHL Strong Genetic Variation [969]
ADAMTS18 OTRMFI04 Strong Altered Expression [970]
ADAP1 OTM4CHU1 Strong Genetic Variation [971]
ADGRF5 OTWU7AOO Strong Altered Expression [972]
ADGRL2 OTCXD2YR Strong Genetic Variation [973]
ADIPOR1 OT65ZFZN Strong Altered Expression [3]
ADIPOR2 OT2HDTL8 Strong Biomarker [974]
ADPRS OTI1KPN6 Strong Biomarker [281]
AFAP1 OTR473H8 Strong Biomarker [975]
AFDN OTTRU341 Strong Biomarker [976]
AGFG1 OTI8ZKC4 Strong Altered Expression [977]
AGO2 OT4JY32Q Strong Altered Expression [978]
AGO3 OTNQGROH Strong Biomarker [978]
AGO4 OTKXQD70 Strong Biomarker [978]
AGR3 OTONJPDP Strong Altered Expression [979]
AIM2 OT86QUI8 Strong Biomarker [980]
AKAP12 OTCVRDDX Strong Biomarker [565]
AKAP13 OTOZAR14 Strong Biomarker [981]
AKAP9 OT7Z2YRP Strong Genetic Variation [982]
AKIP1 OT7XPG27 Strong Altered Expression [983]
ALDOA OTWRFTIB Strong Biomarker [332]
ALKBH3 OTS1CD9Z Strong Genetic Variation [984]
ALKBH8 OTXN70DV Strong Biomarker [313]
ALOX15B OTWQQ08W Strong Biomarker [252]
ANGPTL2 OTB6JG41 Strong Biomarker [985]
ANKRD34A OTI00ROL Strong Biomarker [250]
ANLN OTXJY54C Strong Biomarker [986]
ANP32B OT3SQMLU Strong Biomarker [725]
ANXA6 OT9KIQ0Y Strong Altered Expression [987]
AP1S2 OTZHJFYI Strong Biomarker [988]
AP2A1 OTEFZB21 Strong Biomarker [989]
APBB3 OTNUTR0N Strong Altered Expression [551]
APH1A OT97F1TU Strong Biomarker [183]
APOBEC3A OTYO6F5P Strong Biomarker [990]
ARAP3 OTUWZTH7 Strong Altered Expression [991]
ARFGEF1 OTPAU0L4 Strong Genetic Variation [992]
ARHGAP1 OT0H2ZBZ Strong Altered Expression [993]
ARHGEF4 OTR2VG0W Strong Genetic Variation [994]
ARHGEF5 OTUVGFT9 Strong Altered Expression [995]
ARHGEF7 OT9BPJCL Strong Altered Expression [996]
ARID1A OTRWDV3P Strong Biomarker [997]
ARID4A OT1XKBZ0 Strong Altered Expression [998]
ARID4B OTYLPILE Strong Biomarker [999]
ARNT OTMSIEZY Strong Biomarker [1000]
ARNT2 OTAQD3YV Strong Biomarker [1001]
ARRDC3 OTAKW7R9 Strong Biomarker [1002]
ARTN OTWIWGL6 Strong Biomarker [1003]
ASAH1 OT1DNGXL Strong Biomarker [1004]
ASCC1 OTH4VAP9 Strong Altered Expression [996]
ASCC2 OT3B204T Strong Altered Expression [564]
ASCL2 OT3D62WB Strong Altered Expression [1005]
ASF1A OT4S44GP Strong Altered Expression [1006]
ATF1 OT251CI0 Strong Altered Expression [1007]
ATF2 OTNIZPEA Strong Genetic Variation [1008]
ATG10 OTVRPC5X Strong Biomarker [250]
ATP1B2 OTYTBYVU Strong Biomarker [1009]
ATP2B2 OT1NPZ9T Strong Genetic Variation [1010]
ATXN1 OTQF0HNR Strong Biomarker [1011]
AXIN2 OTRMGQNU Strong Biomarker [1012]
AZIN2 OT8OB7CG Strong Biomarker [1013]
AZU1 OTHXU264 Strong Biomarker [1014]
B3GNT5 OTA0DE43 Strong Biomarker [109]
B4GALNT1 OTCY80HS Strong Altered Expression [782]
B4GAT1 OT5NH9TD Strong Biomarker [250]
BAD OT63ERYM Strong Genetic Variation [643]
BANP OT1JMTBD Strong Altered Expression [1015]
BATF3 OTI61WXQ Strong Altered Expression [372]
BCAR1 OTKT2C2N Strong Biomarker [1016]
BCAS1 OTQKJR81 Strong Altered Expression [731]
BCAS2 OTRMF2WY Strong Biomarker [1017]
BCAS4 OT596N5E Strong Altered Expression [1018]
BCCIP OTFFKG79 Strong Genetic Variation [1019]
BCL10 OT47MCLI Strong Posttranslational Modification [1020]
BCL2L11 OTNQQWFJ Strong Biomarker [1021]
BCL2L12 OTS6IFZY Strong Biomarker [1022]
BCL2L14 OT87E7HW Strong Altered Expression [1023]
BCORL1 OTPTFQN5 Strong Altered Expression [1024]
BEX2 OT4G5SIC Strong Altered Expression [1025]
BHLHE22 OTZUQY5L Strong Altered Expression [1026]
BIK OTTH1T3D Strong Biomarker [1027]
BMPR1A OTQOA4ZH Strong Biomarker [1028]
BNIP3 OT4SO7J4 Strong Biomarker [426]
BNIP3L OTJKOMXE Strong Genetic Variation [1029]
BPTF OTD1RZAD Strong Altered Expression [1030]
BRMS1L OTJIW47U Strong Posttranslational Modification [1031]
BTC OTW4B2O0 Strong Altered Expression [389]
BTG2 OTZF6K1H Strong Altered Expression [1032]
BTN3A2 OT3DIBU3 Strong Biomarker [250]
BUD31 OTN3HZYF Strong Altered Expression [1030]
C1QA OT6XKVVA Strong Genetic Variation [1033]
CADM1 OTRWG9QS Strong Posttranslational Modification [850]
CALB2 OTSNMCG9 Strong Altered Expression [1034]
CAMK2B OTS9YK3E Strong Biomarker [1035]
CAMK2G OTHD9KJG Strong Biomarker [1035]
CAP1 OTYM8A2N Strong Biomarker [515]
CAPG OTJ86KI6 Strong Biomarker [1036]
CAPNS1 OT95EBBD Strong Altered Expression [1037]
CASZ1 OTWJ2OR8 Strong Biomarker [1038]
CAV3 OTWSFDB4 Strong Biomarker [1039]
CAVIN2 OTFHHDRU Strong Altered Expression [1040]
CBX2 OTOQ5WS4 Strong Altered Expression [1041]
CBX5 OT8VYY84 Strong Biomarker [1042]
CCAR1 OTUXLQZZ Strong Altered Expression [1043]
CCAR2 OTLUDG5T Strong Biomarker [1044]
CCDC54 OTW5WCX9 Strong Altered Expression [1045]
CCL18 OT7JYSK9 Strong Biomarker [1046]
CCL25 OTLWJ8CJ Strong Altered Expression [304]
CCL28 OTY6XNQ7 Strong Altered Expression [1047]
CCN3 OTOW5YL4 Strong Biomarker [1048]
CCN4 OT69BER9 Strong Altered Expression [1048]
CCN6 OTRFHQ2Z Strong Biomarker [1049]
CCNA1 OTX4HD45 Strong Biomarker [1050]
CCNDBP1 OTBWG1M0 Strong Altered Expression [1051]
CCNH OTKDU3SR Strong Biomarker [45]
CCT5 OTPZ38BT Strong Biomarker [275]
CD109 OTDADBM4 Strong Biomarker [258]
CD151 OTF3UZS7 Strong Altered Expression [877]
CD1D OT3ROU4J Strong Biomarker [1052]
CD226 OT4UG0KB Strong Biomarker [1053]
CD63 OT2UGZA9 Strong Altered Expression [310]
CD68 OTOYEY3J Strong Biomarker [420]
CD79A OTOJC8DV Strong Biomarker [1054]
CD8A OTDWQJXK Strong Biomarker [285]
CD99 OTPUZ5DE Strong Altered Expression [1055]
CDC42 OT5QBC5M Strong Altered Expression [532]
CDC6 OTX93FE7 Strong Biomarker [1056]
CDCP1 OTD7RRWK Strong Altered Expression [1057]
CDK10 OTKP7TTR Strong Genetic Variation [1058]
CDK15 OT8S67QS Strong Biomarker [1059]
CDK2AP2 OTR99SJ8 Strong Biomarker [1060]
CDR2 OTD3ZJST Strong Biomarker [1061]
CDSN OTQW4HV6 Strong Biomarker [1062]
CDT1 OTVY53VG Strong Genetic Variation [1063]
CEACAM7 OTKFDTZY Strong Biomarker [321]
CELF2 OTLJJ4VT Strong Biomarker [1064]
CELSR2 OTON6JSZ Strong Altered Expression [1065]
CEMIP OTK80FYN Strong Altered Expression [1066]
CEMIP2 OT9I1XUO Strong Altered Expression [1067]
CENPF OT7AG0SW Strong Biomarker [275]
CEP55 OTGSG2PA Strong Biomarker [1068]
CFL1 OTT6D5MH Strong Biomarker [332]
CGB7 OTBJO30D Strong Altered Expression [1069]
CHAF1A OTXSSY4H Strong Biomarker [59]
CHFR OTRAD2TT Strong Biomarker [1070]
CHGB OT7SAQT2 Strong Genetic Variation [1069]
CHI3L1 OT2Z7VJH Strong Biomarker [1071]
CHL1 OT6E6E8P Strong Posttranslational Modification [1072]
CHPT1 OT4FJ0K3 Strong Altered Expression [1073]
CHRDL2 OTJU2I5H Strong Altered Expression [1074]
CIB2 OT9ZJX1I Strong Biomarker [16]
CILK1 OTWOYEYP Strong Biomarker [530]
CITED1 OTUJQ3VL Strong Biomarker [1075]
CITED2 OT812TV7 Strong Biomarker [1076]
CITED4 OTR6NHI2 Strong Altered Expression [1077]
CIZ1 OT3UKHPI Strong Biomarker [1078]
CKS1B OTNUPLUJ Strong Biomarker [61]
CLDN1 OT27KV99 Strong Genetic Variation [1079]
CLDN3 OT71MN9S Strong Altered Expression [20]
CLIC4 OT6KTPKD Strong Biomarker [1080]
CLIP1 OTTGAEJE Strong Altered Expression [1081]
CLUL1 OTYIXQ36 Strong Biomarker [582]
CMC2 OTRYIO1J Strong Biomarker [275]
CNTN3 OTC1274J Strong Genetic Variation [992]
COL10A1 OTC4G2YC Strong Biomarker [1082]
COL4A1 OTL6D1YE Strong Altered Expression [1083]
COL4A2 OTJK1LKN Strong Biomarker [1084]
COP1 OT6J2K12 Strong Altered Expression [1085]
CORO1A OTVAZOHC Strong Biomarker [16]
COTL1 OT6YCNLF Strong Biomarker [332]
CPD OT2CS64Y Strong Altered Expression [1086]
CRABP2 OTY01V9G Strong Biomarker [1087]
CREB3L1 OT2JHIHM Strong Biomarker [1088]
CRISP2 OT8HLTV5 Strong Altered Expression [226]
CRKL OTOYSD1R Strong Altered Expression [1089]
CSHL1 OTQKU2F5 Strong Altered Expression [646]
CSMD1 OTIVDSC4 Strong Altered Expression [1090]
CTAG1B OTIQGW6U Strong Altered Expression [349]
CTBP1 OTVYH2DH Strong Biomarker [1091]
CTBP2 OTGZGT87 Strong Biomarker [1092]
CTU1 OTNTM9D1 Strong Biomarker [313]
CTU2 OT323X9J Strong Biomarker [313]
CUEDC2 OTWMOLAJ Strong Altered Expression [1093]
CUL5 OTMTZD47 Strong Therapeutic [1094]
CUX1 OTU1LCNJ Strong Altered Expression [564]
CUZD1 OTDQJVZ8 Strong Biomarker [1095]
CXCL17 OTRCEVIZ Strong Altered Expression [1096]
CXCL3 OTSL94KH Strong Altered Expression [1097]
CXCL5 OTZOUPCA Strong Biomarker [1098]
CYTH3 OTBXAT3Z Strong Biomarker [1099]
DAB2IP OTF456VC Strong Posttranslational Modification [1100]
DACH1 OTMKNAGG Strong Biomarker [1101]
DACT2 OTNLCC0K Strong Altered Expression [1102]
DAP OT5YLL7E Strong Posttranslational Modification [1103]
DAP3 OTNPEZYM Strong Biomarker [582]
DCAF1 OT3ZDVOE Strong Altered Expression [977]
DCLRE1C OTW3KB1I Strong Genetic Variation [1104]
DDB2 OTO8HVVB Strong Biomarker [1105]
DDIT3 OTI8YKKE Strong Biomarker [1106]
DDX17 OTXRMMBP Strong Biomarker [1107]
DDX53 OTHK3EGZ Strong Biomarker [1108]
DEPP1 OTB36PHJ Strong Biomarker [565]
DERL1 OTJUS74N Strong Altered Expression [1109]
DES OTI09KBW Strong Biomarker [277]
DHRS11 OTU3J0ZL Strong Altered Expression [459]
DHX9 OT5AAOQI Strong Biomarker [1110]
DLC1 OTP8LMCR Strong Altered Expression [1111]
DLEC1 OTMKKBUW Strong Posttranslational Modification [1112]
DLG2 OTQ3BD8U Strong Genetic Variation [1113]
DLK2 OT56Y83S Strong Altered Expression [1114]
DMBT1 OTVNU9D9 Strong Genetic Variation [1115]
DMP1 OTBWBWW7 Strong Biomarker [1116]
DNAH8 OTGES2OU Strong Biomarker [1117]
DNAJA3 OT61924T Strong Altered Expression [1118]
DNAJB6 OTMHIIAN Strong Biomarker [1119]
DNAJC12 OTNU59PT Strong Altered Expression [372]
DNAJC2 OT3JDA0R Strong Biomarker [1120]
DOCK3 OTF3YS2W Strong Biomarker [1121]
DRG1 OTIFYMI3 Strong Altered Expression [1122]
DSC2 OTODVH8K Strong Altered Expression [1123]
DSC3 OTYG47F8 Strong Biomarker [1124]
DTX3 OTSUUV9N Strong Biomarker [784]
DUSP2 OTH54FMR Strong Posttranslational Modification [1009]
DUSP22 OTEZ3U85 Strong Biomarker [1125]
DUSP6 OT4H6RKW Strong Altered Expression [1126]
DYNC2H1 OTLC8K6B Strong Biomarker [277]
E2F4 OTB3JFH4 Strong Altered Expression [1127]
E2F5 OT1XWING Strong Altered Expression [1128]
EBAG9 OTTQLQCP Strong Biomarker [1129]
EEF1A2 OT9Z23K5 Strong Altered Expression [1130]
EEF1B2 OTW64NPU Strong Biomarker [332]
EEF1D OTM5ZD8Y Strong Altered Expression [1131]
EEF1E1 OTRA6XOB Strong Biomarker [267]
EEF2 OTZ7SZ39 Strong Biomarker [332]
EFEMP1 OTZVUOOB Strong Biomarker [1132]
EFNA1 OTU2NUA2 Strong Biomarker [1133]
EIF2S2 OTXF0B09 Strong Biomarker [784]
EIF3A OTFABY9G Strong Altered Expression [1134]
EIF3H OT61RBF5 Strong Biomarker [1135]
EIF4A1 OTMTBX6N Strong Altered Expression [1136]
EIF6 OTEXMUED Strong Biomarker [784]
ELF3 OTUTLEQO Strong Biomarker [1137]
ELK1 OTH9MXD6 Strong Biomarker [1138]
ELP1 OTYEWBF7 Strong Biomarker [313]
ELP3 OTT5UKSZ Strong Biomarker [313]
EMILIN2 OTOYK5A8 Strong Altered Expression [1139]
EN2 OT7EZCM2 Strong Altered Expression [1140]
ENC1 OTJEUB6U Strong Biomarker [1141]
ENDOG OT5IM7B3 Strong Biomarker [1142]
ENO1 OTB1KWJS Strong Biomarker [544]
ENTPD5 OTFH05B9 Strong Biomarker [1143]
EPRS1 OTXK0FLB Strong Altered Expression [1144]
EPS8 OTZ6ES6V Strong Altered Expression [1145]
ERAS OT528IZO Strong Altered Expression [1146]
ERCC2 OT1C8HQ4 Strong Genetic Variation [1147]
ERCC4 OTFIOPG1 Strong Altered Expression [1148]
ERP29 OTNKANMH Strong Altered Expression [1149]
ERRFI1 OT7VZ2IZ Strong Altered Expression [1150]
ERVW-1 OTWV8DXJ Strong Biomarker [1151]
ESRP2 OTVTKJ4I Strong Biomarker [1152]
ETFA OTXX61VZ Strong Biomarker [1153]
ETV1 OT6PMJIK Strong Biomarker [1154]
ETV4 OT8C98UZ Strong Altered Expression [1155]
ETV5 OTE2OBM4 Strong Biomarker [1156]
EYA1 OTHU807A Strong Biomarker [1157]
EYA3 OTHLP1J3 Strong Biomarker [1158]
FABP7 OTRE2H4G Strong Biomarker [664]
FANCB OTMZTXB5 Strong Biomarker [1159]
FANCD2 OTVEB5LF Strong Biomarker [1160]
FASTK OTTHFZMP Strong Altered Expression [1161]
FAT4 OT7QONNV Strong Biomarker [1162]
FBL OTRODIE5 Strong Biomarker [582]
FBLN2 OTEHR7N7 Strong Biomarker [241]
FBXL17 OT8R6KYN Strong Biomarker [1163]
FBXO31 OTF96IC2 Strong Altered Expression [1164]
FERMT1 OT626PBA Strong Biomarker [1165]
FERMT3 OTFQOT3C Strong Altered Expression [1166]
FEV OTYEC4IR Strong Biomarker [1167]
FGD5 OT5VIRP2 Strong Biomarker [784]
FGF13 OTHNNVSG Strong Biomarker [1168]
FGF3 OT9PK2SI Strong Biomarker [408]
FKBPL OTR9ND6K Strong Therapeutic [1169]
FLACC1 OTZN9TZV Strong Biomarker [250]
FLG OTE9QDV6 Strong Biomarker [1170]
FLOT2 OTZ0QR5L Strong Altered Expression [926]
FOXF1 OT2CJZ5K Strong Biomarker [1171]
FOXF2 OTV20NGX Strong Biomarker [1172]
FOXJ1 OT7LLBZ7 Strong Biomarker [1009]
FOXL1 OT89XFPN Strong Biomarker [1173]
FOXN1 OTE80D6I Strong Biomarker [1174]
FOXO3 OTHXQG4P Strong Biomarker [1175]
FRK OTEKV1SC Strong Biomarker [1176]
FSIP1 OTYLL6GM Strong Altered Expression [1177]
FXYD3 OT9PPRHE Strong Altered Expression [1178]
FXYD5 OT81DIOD Strong Biomarker [1179]
FZR1 OT0WGWZS Strong Biomarker [678]
GAB1 OTQKE6V4 Strong Altered Expression [1180]
GAB2 OTBFN705 Strong Biomarker [1181]
GABARAP OTAQUX6E Strong Altered Expression [1182]
GABARAPL1 OT4U7SBG Strong Altered Expression [1183]
GALNT16 OTUBTPGE Strong Biomarker [250]
GALNT6 OTOQQVH1 Strong Biomarker [1184]
GATA1 OTX1R7O1 Strong Biomarker [672]
GCNT2 OTRUIMC4 Strong Altered Expression [1185]
GDE1 OTU6FSBF Strong Biomarker [1186]
GDF10 OTEVXGJ7 Strong Biomarker [239]
GDF9 OTNTVKVU Strong Biomarker [1187]
GEMIN2 OT4L6TLL Strong Biomarker [1188]
GIPC1 OTXLVCPJ Strong Biomarker [1189]
GIT2 OTQ2EQJ1 Strong Biomarker [1099]
GLS2 OT08MSHL Strong Altered Expression [1190]
GNA12 OT3IRZH3 Strong Biomarker [1191]
GNAI2 OTTLGRGH Strong Biomarker [354]
GNAS OTMH8BKJ Strong Genetic Variation [51]
GNB3 OTA6HYBA Strong Genetic Variation [1192]
GNL2 OTURD1GV Strong Biomarker [1193]
GNL3 OTILGYO4 Strong Biomarker [1194]
GPC1 OTQKRSSV Strong Biomarker [1195]
GPLD1 OTUUQOVY Strong Biomarker [1196]
GPR161 OT80FYA3 Strong Biomarker [1197]
GPX2 OTXI2NTI Strong Biomarker [1198]
GPX7 OTINT9Z4 Strong Biomarker [1199]
GRB7 OTF8Y9XY Strong Biomarker [248]
GREB1 OTU6ZA26 Strong Biomarker [1200]
GRP OT8JDFNI Strong Biomarker [1201]
GSDME OT1ZWY32 Strong Altered Expression [1202]
GSTM3 OTLA2WJT Strong Altered Expression [357]
GTF2IRD1 OTEG9KU1 Strong Altered Expression [1203]
GUCY1A2 OTR6DVAA Strong Biomarker [258]
H1-2 OT0AVI4M Strong Biomarker [275]
H2AJ OTVA4XTW Strong Altered Expression [1145]
H2AZ1 OT3KJJNQ Strong Genetic Variation [1204]
H2BC12 OTQ8V0KG Strong Biomarker [275]
H6PD OTO7TNDD Strong Biomarker [1205]
HACD1 OTEC7EP7 Strong Biomarker [515]
HADHB OT4Y1I62 Strong Biomarker [582]
HAP1 OT6SG0JQ Strong Altered Expression [1206]
HAPLN4 OTZQOG9A Strong Biomarker [250]
HAS2 OTTD3PAL Strong Biomarker [1207]
HAVCR2 OTOL603T Strong Altered Expression [1208]
HCLS1 OTX7WGYN Strong Altered Expression [474]
HES6 OTWO5SCF Strong Altered Expression [1209]
HEY1 OTJQL0I3 Strong Biomarker [371]
HEY2 OTU4J3ZI Strong Biomarker [371]
HEYL OTN7BH79 Strong Biomarker [371]
HGS OTCYYCAC Strong Altered Expression [1210]
HHEX OTLIUVYX Strong Biomarker [1211]
HIC1 OTI9TWY4 Strong Biomarker [1133]
HIP1 OT7AKCFQ Strong Biomarker [1212]
HM13 OTGEO1LP Strong Altered Expression [306]
HNRNPK OTNPRM8U Strong Biomarker [582]
HNRNPL OT0DJX74 Strong Biomarker [582]
HNRNPR OT3FITK2 Strong Biomarker [582]
HOXA1 OTMSOJ7D Strong Altered Expression [1213]
HOXB9 OTMVHQOU Strong Biomarker [1214]
HOXC10 OT5WF17M Strong Biomarker [1215]
HOXC8 OTJUYU8J Strong Altered Expression [1216]
HOXD10 OT0NOWU2 Strong Altered Expression [1217]
HOXD11 OT9XGA4G Strong Biomarker [1218]
HOXD13 OTWSC8TF Strong Posttranslational Modification [1219]
HPR OTXSC9UB Strong Biomarker [1220]
HSBP1 OTHZRMOF Strong Altered Expression [1221]
HSD17B8 OTX1DWEF Strong Altered Expression [1222]
HSPA14 OTZCA5LK Strong Altered Expression [1223]
HSPA4 OT5HR0AR Strong Altered Expression [1224]
HSPB2 OTS01646 Strong Biomarker [1225]
HSPBP1 OTRS37HK Strong Altered Expression [1226]
HSPH1 OTVRR73T Strong Biomarker [1227]
HUNK OTZR4GBH Strong Biomarker [1228]
IBSP OT29944Y Strong Biomarker [1229]
ICAM5 OTDGGAFH Strong Biomarker [258]
ID4 OTPMJ39I Strong Altered Expression [1230]
IFIT3 OTPGHZB9 Strong Altered Expression [1231]
IFITM1 OTECO1G8 Strong Altered Expression [1232]
IGF2BP3 OTB97VIK Strong Posttranslational Modification [971]
IGFALS OTTWCZYM Strong Genetic Variation [1233]
IGFBPL1 OTY4HVN8 Strong Posttranslational Modification [1234]
IL17B OTS86H50 Strong Biomarker [1235]
IL17RB OT0KDNSF Strong Biomarker [1235]
IL1RAPL1 OTW3T4B2 Strong Altered Expression [1236]
IMMP1L OTA6LOLR Strong Altered Expression [306]
IMPA1 OTBUVW1Z Strong Altered Expression [306]
INCENP OT9HFRYK Strong Genetic Variation [1237]
ING2 OT6H0EWF Strong Biomarker [285]
ING4 OT0VVG4V Strong Altered Expression [1065]
INHBB OT2QLD11 Strong Altered Expression [1238]
INPPL1 OTCDAVBQ Strong Biomarker [1239]
INSL4 OTK9F0LX Strong Biomarker [1240]
IQSEC1 OTK1PBFD Strong Biomarker [1241]
IRF5 OT8SIIAP Strong Biomarker [1242]
IRF6 OTKJ44EV Strong Biomarker [1243]
ISYNA1 OT49ONSE Strong Altered Expression [272]
ITFG1 OTX0PCR3 Strong Altered Expression [1244]
ITGA9 OTHN1IKA Strong Altered Expression [1245]
ITGB3BP OT6Q7GR3 Strong Biomarker [1246]
ITGB4 OT28UK84 Strong Altered Expression [483]
ITIH1 OTSXJGQF Strong Genetic Variation [1247]
ITIH5 OTP46PZM Strong Altered Expression [382]
ITSN2 OT8S0OO8 Strong Biomarker [354]
JTB OT314JB6 Strong Altered Expression [1248]
KAT5 OTL7257A Strong Altered Expression [1249]
KAT7 OTUN98IC Strong Biomarker [316]
KAT8 OT5LPQTR Strong Biomarker [47]
KCNH4 OTHJ8WTU Strong Biomarker [1138]
KCNH8 OT3I5FLB Strong Biomarker [1138]
KDM4B OT5P1UPY Strong Altered Expression [1250]
KDM6A OTZM3MJJ Strong Biomarker [47]
KHSRP OTDHZARB Strong Altered Expression [474]
KIF15 OTJRJEXL Strong Biomarker [1251]
KIFC1 OTNQDS00 Strong Biomarker [1251]
KIN OTB2DNQU Strong Altered Expression [1252]
KL OTD4VWU6 Strong Biomarker [1253]
KLF10 OT4F4UGS Strong Altered Expression [1254]
KLF17 OT5NWVP7 Strong Biomarker [834]
KLF2 OTIP1UFX Strong Altered Expression [1255]
KLF6 OTQY9S7F Strong Genetic Variation [1256]
KLF8 OTUC5CDB Strong Altered Expression [1257]
KLHDC10 OTLDF1OX Strong Biomarker [250]
KLHDC2 OTBHH882 Strong Biomarker [1258]
KLHDC7A OTZAAF38 Strong Biomarker [250]
KLK11 OT5PKX7Y Strong Altered Expression [1259]
KLK12 OTNYK59J Strong Genetic Variation [1260]
KLK13 OT8LOD2U Strong Altered Expression [1261]
KLK15 OT7BVG17 Strong Altered Expression [1262]
KMT2C OTC59BCO Strong Altered Expression [1263]
KMT2D OTTVHCLY Strong Biomarker [1264]
KRR1 OTCMJ3K3 Strong Biomarker [1120]
KRT14 OTUVZ1DW Strong Biomarker [277]
KRT18 OTVLQFIP Strong Biomarker [277]
KRT8 OTTM4X11 Strong Biomarker [1265]
LACRT OTROSU7Z Strong Altered Expression [1266]
LAD1 OT6YGTVX Strong Biomarker [1267]
LAMA3 OTFME7HT Strong Posttranslational Modification [1268]
LAMA5 OTIIXE4M Strong Biomarker [1269]
LAMP3 OTN0XL3W Strong Altered Expression [1270]
LAMP5 OTC672RM Strong Altered Expression [1271]
LAMTOR1 OTIBJBW9 Strong Biomarker [267]
LAMTOR2 OTHEDISB Strong Biomarker [1060]
LAMTOR5 OTER0U8L Strong Biomarker [162]
LARP6 OTUQ9QS9 Strong Biomarker [1272]
LATS1 OTOOCG4R Strong Altered Expression [1273]
LBX1 OTQJHICM Strong Biomarker [1274]
LCOR OT1K7DKB Strong Altered Expression [1275]
LDHAL6B OT3T9D1S Strong Biomarker [332]
LDHB OT9B1CT3 Strong Biomarker [1276]
LEF1 OTWS5I5H Strong Biomarker [313]
LEFTY1 OT51HVC4 Strong Altered Expression [1277]
LETMD1 OTZTZ4RD Strong Biomarker [1278]
LFNG OTPSUBN2 Strong Altered Expression [1279]
LGALS4 OTKQCG0H Strong Altered Expression [1280]
LGALS7 OTMSVI7R Strong Biomarker [1281]
LHB OT5GBOVJ Strong Altered Expression [1069]
LIG4 OT40DNXU Strong Genetic Variation [1282]
LIMA1 OTONPC9R Strong Altered Expression [1283]
LIMD1 OTN1CG6R Strong Altered Expression [1284]
LIMD2 OTSIFTD8 Strong Biomarker [354]
LIN28B OTVWP0FN Strong Altered Expression [1285]
LLGL1 OTAIQSXZ Strong Biomarker [565]
LLGL2 OTU8ZDC4 Strong Biomarker [655]
LMLN OTQF0JPY Strong Biomarker [550]
LMNB1 OT100T3P Strong Biomarker [1286]
LOXL4 OT6XY2JL Strong Altered Expression [1287]
LRIG1 OTY5HZN5 Strong Genetic Variation [1288]
LRRC37A OT41U0KO Strong Biomarker [250]
LRRC37A2 OT9UI93T Strong Biomarker [250]
LRRC3B OT9VDGPR Strong Biomarker [250]
LRRC49 OT9SOV66 Strong Altered Expression [1289]
LSP1 OTSPSIFO Strong Biomarker [1290]
LTBP1 OTR7Q75L Strong Biomarker [1291]
LTBP4 OTC8WL2V Strong Biomarker [1292]
LUM OTSRC874 Strong Altered Expression [1293]
LYNX1 OTK4103B Strong Biomarker [523]
LYPD5 OTGP7UKA Strong Biomarker [1294]
MACC1 OTV3DLX0 Strong Biomarker [1295]
MAD2L1 OTXNGZCG Strong Biomarker [1296]
MAFK OTZJUE4P Strong Biomarker [267]
MAGI3 OTDJ5QUH Strong Altered Expression [1297]
MAL OTBM30SW Strong Altered Expression [1298]
MAMSTR OT4J6Z7G Strong Biomarker [1299]
MAN2C1 OT17VT8D Strong Biomarker [250]
MAP2K3 OTI2OREX Strong Altered Expression [534]
MAPK13 OT0W9GE7 Strong Altered Expression [1300]
MAPK15 OT8SW0L7 Strong Biomarker [1301]
MAPRE1 OTCVQD60 Strong Altered Expression [1302]
MARK4 OT6Z2TGV Strong Biomarker [1303]
MATK OTVOJJLJ Strong Biomarker [1304]
MB OTYWYL2D Strong Genetic Variation [1305]
MBD2 OTUQPP0R Strong Biomarker [426]
MBNL1 OTOV7J85 Strong Altered Expression [1306]
MCAT OTH07FIW Strong Biomarker [334]
MCM3AP OT895FEC Strong Biomarker [1307]
MCPH1 OTYT3TT5 Strong Genetic Variation [1308]
MCTS1 OT7SAOJP Strong Biomarker [334]
MED1 OTOO24C4 Strong Biomarker [1121]
MED14 OTMD20XN Strong Biomarker [1309]
MEIS1 OTH9DKAD Strong Biomarker [1310]
MEPE OTXJRUW0 Strong Biomarker [1311]
METTL6 OTYAOD1Q Strong Biomarker [784]
METTL8 OT7E09Y4 Strong Altered Expression [1244]
MIA3 OTBVIZQD Strong Biomarker [1000]
MIB2 OTJCC3HS Strong Biomarker [834]
MIEN1 OTCQ8DAD Strong Biomarker [1312]
MLLT11 OTG5RVHC Strong Altered Expression [1313]
MMP26 OT9O89KU Strong Biomarker [1314]
MNT OTPC4ANL Strong Genetic Variation [1315]
MOS OTNMQPFJ Strong Genetic Variation [1316]
MRE11 OTGU8TZM Strong Genetic Variation [1317]
MRPL13 OT6D8Y9G Strong Biomarker [582]
MRPL19 OTRBKF6R Strong Biomarker [582]
MRPL9 OT3I6W77 Strong Biomarker [582]
MRPS22 OTIVNAJL Strong Biomarker [582]
MRPS23 OTDVWT5V Strong Biomarker [784]
MRPS28 OT8CLJ6M Strong Biomarker [582]
MRPS7 OT57AX7G Strong Biomarker [582]
MSH6 OT46FP09 Strong Biomarker [1318]
MST1 OTOC4UNG Strong Biomarker [550]
MSX1 OT5U41ZP Strong Posttranslational Modification [1319]
MSX2 OT1WDKE1 Strong Altered Expression [1320]
MT3 OTVCZ7HI Strong Biomarker [1321]
MTA2 OTCCYIQJ Strong Altered Expression [1294]
MTA3 OTIA6C79 Strong Altered Expression [1322]
MTUS1 OTBPALMU Strong Biomarker [1323]
MUC5B OTPW6K5C Strong Biomarker [1324]
MYBBP1A OTIVEMIU Strong Biomarker [413]
MYBL2 OTZ3JX8Q Strong Biomarker [1325]
MYEOV OTDC7UHL Strong Biomarker [1326]
MYH9 OT94Z706 Strong Biomarker [1327]
MYOD1 OTV2S79X Strong Genetic Variation [1328]
MYOF OTRFC3IJ Strong Biomarker [1329]
MZF1 OTMVZCPW Strong Altered Expression [1330]
NAIP OTLA925F Strong Altered Expression [1331]
NANOG OTUEY1FM Strong Altered Expression [856]
NBPF1 OTAZ55UQ Strong Biomarker [1332]
NCOA6 OTOMIGTV Strong Genetic Variation [1333]
NCOR1 OT04XNOU Strong Biomarker [1334]
NDC80 OTS7D306 Strong Altered Expression [1335]
NDE1 OT2N8Q17 Strong Biomarker [1336]
NDRG1 OTVO66BO Strong Biomarker [1337]
NDRG2 OT5L6KD7 Strong Altered Expression [1338]
NDUFAF3 OT4MCB6W Strong Altered Expression [1339]
NDUFAF4 OTWJ5B9M Strong Biomarker [1340]
NECTIN2 OTIE0W6O Strong Therapeutic [1341]
NEDD4L OT1B19RU Strong Altered Expression [568]
NELFB OTCFH88S Strong Biomarker [1342]
NET1 OTZHNMJV Strong Altered Expression [483]
NFATC1 OT4TMERS Strong Altered Expression [345]
NFATC2 OTK5T6HZ Strong Biomarker [958]
NFATC4 OTTDCUAO Strong Biomarker [1343]
NFIC OTLMCUIB Strong Biomarker [1171]
NLRP2 OTJA81JU Strong Genetic Variation [1344]
NMBR OTBJEGPN Strong Biomarker [1345]
NME2 OTCYGLHV Strong Biomarker [1346]
NMU OTW9X7BQ Strong Altered Expression [566]
NOC2L OTNT7R33 Strong Biomarker [1347]
NOCT OTVSYP2D Strong Biomarker [1348]
NOP16 OT2829ZC Strong Altered Expression [1349]
NOP53 OTA2YKO6 Strong Altered Expression [1231]
NOP9 OTA3O9QW Strong Biomarker [258]
NOX1 OTZPJQCC Strong Biomarker [1350]
NPAS2 OTMRT2TS Strong Genetic Variation [1351]
NPNT OTFZAO1G Strong Biomarker [1352]
NPTN OTAQKSAU Strong Biomarker [1353]
NR2C2 OTDZWVOJ Strong Biomarker [303]
NR2F2 OTJFS67N Strong Biomarker [1354]
NRCAM OT80HHQ2 Strong Biomarker [258]
NRF1 OTOXWNV8 Strong Biomarker [1355]
NRG2 OTMDE844 Strong Altered Expression [389]
NRG3 OTIFZ5CT Strong Altered Expression [389]
NSD2 OTQ6SW4R Strong Biomarker [1356]
NSUN6 OTPBRUH6 Strong Biomarker [655]
NT5C3A OT67KZJA Strong Biomarker [1357]
NTN4 OTDRRMP3 Strong Biomarker [1358]
NUCB2 OTHO6JWN Strong Altered Expression [1359]
NUDT1 OTZSES3W Strong Altered Expression [1360]
NUDT17 OTE8FOEW Strong Biomarker [250]
NUDT2 OTMHM1DH Strong Biomarker [1361]
NUMA1 OTTKAVG4 Strong Genetic Variation [1362]
NUMB OTMB586Q Strong Biomarker [1363]
NUP43 OTDF5K8Y Strong Altered Expression [1364]
NUPR1 OT4FU8C0 Strong Altered Expression [1365]
NUS1 OT4DQ82L Strong Biomarker [1366]
OAS3 OT6E5FYS Strong Altered Expression [564]
OCLN OTSUTVWL Strong Biomarker [518]
OMA1 OT0JRVY7 Strong Biomarker [1367]
OSGIN1 OT9KIVZW Strong Biomarker [1368]
OTUD4 OT7U62SW Strong Biomarker [897]
OVOL2 OTFM1GKF Strong Biomarker [1369]
P2RX5 OTLBR20R Strong Biomarker [75]
P4HB OTTYNYPF Strong Altered Expression [1370]
PA2G4 OT7IG7HT Strong Biomarker [1371]
PADI2 OTT40K94 Strong Altered Expression [1372]
PAEP OTQA0NV4 Strong Genetic Variation [874]
PALB2 OT6DNDBG Strong Genetic Variation [1373]
PARVB OT9OGVWX Strong Biomarker [320]
PAX2 OTKP1N8F Strong Altered Expression [1374]
PAX7 OTDMQRPO Strong Altered Expression [1375]
PCBP1 OTHN0TD7 Strong Altered Expression [1376]
PCDH17 OTRK0M05 Strong Biomarker [1377]
PCDHGB6 OT1Y20JS Strong Biomarker [1218]
PCGF2 OTIY1J5L Strong Altered Expression [1378]
PCLAF OTMVIOUU Strong Altered Expression [1379]
PDCD6 OT2YA5M8 Strong Altered Expression [1380]
PDHX OTG7O271 Strong Altered Expression [1381]
PDPN OTBUV19I Strong Biomarker [1382]
PDZK1IP1 OTWA6M5K Strong Altered Expression [1383]
PEA15 OTKCKTSX Strong Biomarker [1384]
PES1 OTMZK7XE Strong Biomarker [1385]
PFDN4 OT5NRHER Strong Altered Expression [1386]
PFKFB4 OTQYEXL2 Strong Genetic Variation [199]
PFN1 OTHTGA1H Strong Altered Expression [1387]
PGK1 OT6V1ICH Strong Biomarker [1370]
PGP OT6QQ7OR Strong Biomarker [1388]
PHB2 OTCAX3AW Strong Altered Expression [1389]
PHF20 OTCBVH5P Strong Biomarker [834]
PHLDA1 OTFTWMIQ Strong Altered Expression [1390]
PI3 OT47MTC3 Strong Biomarker [1391]
PIAS1 OTZVAHZI Strong Altered Expression [1392]
PIBF1 OTCBT1A1 Strong Altered Expression [1393]
PIK3C2B OTY2PROB Strong Biomarker [1394]
PIK3C3 OTLUM9L7 Strong Biomarker [1395]
PIK3R1 OT5BZ1J9 Strong Biomarker [1396]
PIP OTH719AH Strong Biomarker [1397]
PIP4K2B OTF1VGJ9 Strong Altered Expression [1398]
PITX2 OTWMXAOY Strong Posttranslational Modification [1399]
PKD1 OT5ALRZ5 Strong Biomarker [1400]
PLAG1 OTT9AJQY Strong Altered Expression [497]
PLAGL1 OTZAO900 Strong Altered Expression [1401]
PLCB2 OTPAHDGO Strong Altered Expression [1402]
PLCD1 OT6WFVXZ Strong Altered Expression [1403]
PLEKHD1 OTGYUZKM Strong Biomarker [250]
PLPP5 OTHT51D6 Strong Biomarker [1404]
PLXNB1 OTCA7JIT Strong Altered Expression [1405]
PMEPA1 OTY8Z9UF Strong Biomarker [1406]
PODXL OTPNQXF3 Strong Biomarker [1407]
POLD1 OTWO4UCJ Strong Genetic Variation [1408]
POLE OTFM3MMU Strong Genetic Variation [51]
POLI OTBA4DCE Strong Genetic Variation [1409]
POTEF OTV3WXYE Strong Altered Expression [1410]
POU5F1 OTDHHN7O Strong Altered Expression [1411]
PPBP OT1FHGQS Strong Biomarker [1121]
PPFIA1 OTYYFA9C Strong Altered Expression [1412]
PPIG OTZ8BTTM Strong Biomarker [1413]
PPP1R10 OT7GE3BN Strong Altered Expression [1414]
PPP1R12B OTONIS87 Strong Biomarker [1327]
PPP2R1A OTYA3GB4 Strong Genetic Variation [51]
PPP2R1B OTFIHQGD Strong Genetic Variation [1415]
PPP2R5B OTW2QIX9 Strong Genetic Variation [1415]
PPP6R3 OTIXD60Q Strong Biomarker [1416]
PRAP1 OT48QD82 Strong Biomarker [1417]
PRC1 OTHD0XS0 Strong Biomarker [1002]
PRDM1 OTQLSVBS Strong Altered Expression [919]
PRDX6 OTS8KC8A Strong Altered Expression [1418]
PREX1 OTUTPVA9 Strong Altered Expression [1419]
PRIMA1 OT9ITT3P Strong Biomarker [1420]
PRKN OTJBN41W Strong Altered Expression [835]
PRLH OTJBP360 Strong Biomarker [1211]
PRMT2 OT63JZCI Strong Altered Expression [1421]
PRMT6 OT5V3XIN Strong Altered Expression [1422]
PROX1 OT68R6IO Strong Posttranslational Modification [1423]
PRPF19 OTQ1STV3 Strong Altered Expression [1424]
PRR5 OTYHSGJL Strong Altered Expression [1425]
PRSS50 OTC5JAVO Strong Altered Expression [1426]
PRSS55 OTXXWI5Y Strong Altered Expression [226]
PRUNE1 OTQ3UHWQ Strong Biomarker [1427]
PSG2 OT2EIXAI Strong Biomarker [321]
PSMC3IP OT9UB5UO Strong Biomarker [1428]
PSMC4 OTS3XN41 Strong Altered Expression [1429]
PSMC5 OTJOORMR Strong Altered Expression [1430]
PSMD8 OTY6X27P Strong Altered Expression [1431]
PSMG1 OTZ5I6UM Strong Altered Expression [242]
PSORS1C2 OTK43GE4 Strong Altered Expression [1432]
PTBP2 OTF4S7NE Strong Biomarker [1433]
PTGES3 OTPPQWI0 Strong Biomarker [317]
PTPN23 OT5WDPXB Strong Biomarker [41]
PTPRA OTZA82J1 Strong Altered Expression [68]
PTPRD OTZPJ3GX Strong Biomarker [258]
PTPRO OTFLKWOY Strong Altered Expression [1434]
PTTG1 OTIMYS4W Strong Biomarker [1435]
PUM1 OTTMWP8L Strong Altered Expression [1429]
PVR OT3N91T7 Strong Biomarker [1436]
PYCARD OT67RON3 Strong Altered Expression [1437]
PYGO2 OTZHB2OI Strong Biomarker [1438]
PYHIN1 OT30GD05 Strong Altered Expression [216]
QRSL1 OTJDU2UG Strong Altered Expression [1439]
RAB11A OTC4FW0J Strong Biomarker [732]
RAB27A OT9SQRWY Strong Altered Expression [1440]
RAB27B OTPF9D0K Strong Altered Expression [1441]
RAB31 OTMLXQZ0 Strong Biomarker [1442]
RAB3D OTGKRR3C Strong Biomarker [1440]
RAB5A OTFR2KM4 Strong Altered Expression [1443]
RAB6C OTA66R5E Strong Posttranslational Modification [1444]
RABEP1 OTQROTGT Strong Altered Expression [1445]
RABEP2 OTO61X27 Strong Genetic Variation [1446]
RABL6 OTJLVIQ1 Strong Altered Expression [1447]
RACGAP1 OTQE8IEH Strong Biomarker [329]
RAD23B OT0PGOG3 Strong Biomarker [1448]
RAD51B OTCJVRMY Strong Biomarker [1449]
RAD51C OTUD6SY5 Strong Biomarker [1450]
RAD51D OTKOU5XN Strong Genetic Variation [1451]
RAD52 OT0OTDHI Strong Genetic Variation [1452]
RAD54B OTMWB2P2 Strong Genetic Variation [1453]
RAD9A OTJ3AJQU Strong Altered Expression [1454]
RALGAPB OTY8CGA3 Strong Biomarker [963]
RALYL OT232N7Q Strong Biomarker [582]
RANBP9 OTM8COM5 Strong Biomarker [1455]
RAP1A OT5RH6TI Strong Altered Expression [1456]
RAPH1 OTMQXW7S Strong Biomarker [967]
RASAL2 OTGMMX6W Strong Biomarker [1457]
RASEF OTGSAM2E Strong Altered Expression [1458]
RASGRF2 OT67DAGF Strong Altered Expression [987]
RASSF3 OT4V9SRK Strong Biomarker [1459]
RB1CC1 OTZK8PFX Strong Biomarker [582]
RBBP4 OTG3BT3M Strong Altered Expression [892]
RBL1 OTDEBFYC Strong Biomarker [1460]
RBL2 OTBQSOE6 Strong Altered Expression [1461]
RBM10 OTES2MES Strong Biomarker [1462]
RBM38 OTPO8EXU Strong Altered Expression [1463]
RBM5 OTCBWHHV Strong Altered Expression [1464]
RBMX OTFZN66E Strong Biomarker [1465]
RCC1 OT25AGMB Strong Genetic Variation [1466]
RCCD1 OT60N06L Strong Biomarker [250]
RECQL OTPCH3JH Strong Biomarker [1467]
REPS1 OTX4ERRK Strong Biomarker [1468]
REPS2 OTSE3TRP Strong Biomarker [1310]
RERG OTF6MMLV Strong Altered Expression [1469]
REST OTLL92LQ Strong Biomarker [1470]
RFC4 OTWALD2R Strong Biomarker [925]
RHBDD2 OTX54ILM Strong Altered Expression [1471]
RHOBTB2 OT2DATFX Strong Posttranslational Modification [1472]
RHOC OTOLE1FT Strong Altered Expression [1473]
RHOU OTERIAD4 Strong Altered Expression [1474]
RIBC2 OTDB4FM2 Strong Biomarker [582]
RIN1 OTPBROUD Strong Biomarker [1475]
RIOX1 OTN41QXP Strong Genetic Variation [1315]
RIOX2 OT2YFPI2 Strong Genetic Variation [1315]
RMDN1 OTE1NB6U Strong Altered Expression [1476]
RMDN2 OTK5WSFI Strong Altered Expression [1476]
RMDN3 OTKO7AUM Strong Altered Expression [1476]
RMND1 OT7I6RBT Strong Biomarker [250]
RNASEH2C OTJL9ZRN Strong Posttranslational Modification [1477]
RNF11 OTFBJSKQ Strong Altered Expression [1478]
RNF115 OT35B6L5 Strong Altered Expression [835]
RNF144A OTCG27CT Strong Altered Expression [1479]
RNF182 OT08FLHZ Strong Biomarker [258]
RNF20 OT9NK6ZT Strong Altered Expression [750]
RNF31 OT4BZONL Strong Altered Expression [1480]
RNF40 OTC8SDA3 Strong Altered Expression [750]
RNF41 OTN1DQOY Strong Biomarker [1481]
RNF5 OTDQGI37 Strong Genetic Variation [1482]
RNPS1 OT7G4COD Strong Altered Expression [1483]
ROBO3 OTPVG40S Strong Biomarker [364]
RPA1 OT76POLP Strong Altered Expression [1484]
RPA2 OTZ54WAF Strong Altered Expression [1485]
RPAIN OTBMXAYK Strong Altered Expression [977]
RPL13 OTFKNTD6 Strong Biomarker [1486]
RPL19 OT33LM66 Strong Altered Expression [1487]
RPL23A OTPYLCCX Strong Biomarker [582]
RPL31 OTV9E1OE Strong Biomarker [582]
RPL7A OT6E6UKF Strong Genetic Variation [1488]
RPLP2 OT2YBK3W Strong Biomarker [250]
RPN2 OTJ1SKOA Strong Biomarker [1489]
RPP14 OT4OYFSK Strong Biomarker [1060]
RPS14 OTB90KV5 Strong Altered Expression [1431]
RPS4X OTIH80EK Strong Biomarker [582]
RPS6 OTT4D1LN Strong Biomarker [932]
RPS7 OTIK25WI Strong Biomarker [582]
RPS8 OTEBS4HZ Strong Biomarker [582]
RRAD OTW2O4GD Strong Biomarker [1490]
RRAS OTBBF28C Strong Biomarker [317]
RRAS2 OT83NCEB Strong Altered Expression [1491]
RRM2B OTE8GBUR Strong Altered Expression [659]
RRP1B OTHDRVML Strong Biomarker [1492]
RRP8 OTGZHVVW Strong Altered Expression [1493]
RUVBL2 OTGWJ4T4 Strong Altered Expression [1494]
S100A2 OTTGHJ1H Strong Biomarker [1495]
S100A7 OTJFVJRF Strong Biomarker [1496]
SAFB OTGRV2LW Strong Biomarker [1497]
SALL4 OTC08PR5 Strong Altered Expression [1498]
SART3 OTC1AM7S Strong Altered Expression [564]
SASH1 OTQA8BD4 Strong Altered Expression [1499]
SAT2 OT28QL7H Strong Altered Expression [782]
SCAF11 OTX59D0X Strong Biomarker [1188]
SCARA5 OTOVA96E Strong Altered Expression [1500]
SCO2 OTJQQDRS Strong Altered Expression [744]
SCRIB OTW4N3FV Strong Biomarker [1501]
SDC4 OTKUVUGZ Strong Altered Expression [1502]
SDHA OTOJ8QFF Strong Biomarker [442]
SEL1L OTC0FB7T Strong Altered Expression [1503]
SEMA3C OTEGUY7F Strong Altered Expression [1504]
SEMA7A OT0ZJK64 Strong Biomarker [1505]
SEPTIN9 OT1VMRFQ Strong Biomarker [1506]
SERPINA4 OTBK0GG7 Strong Biomarker [1507]
SERPINA5 OTTZXPGD Strong Biomarker [1508]
SERPINB6 OT7G55IK Strong Biomarker [515]
SERPINE2 OTYF5340 Strong Altered Expression [1509]
SETBP1 OTKGCOSR Strong Biomarker [1510]
SETD1A OTVVWRIC Strong Altered Expression [1511]
SETDB1 OTWVUA1B Strong Biomarker [91]
SF3A1 OTI733D7 Strong Altered Expression [1429]
SF3B2 OTNW2U4Y Strong Genetic Variation [51]
SF3B6 OTPRKS6S Strong Biomarker [1060]
SFN OTLJCZ1U Strong Posttranslational Modification [1512]
SFPQ OTLCIAPJ Strong Biomarker [183]
SFRP1 OT0U9G41 Strong Genetic Variation [1513]
SFRP5 OTLCVVSH Strong Posttranslational Modification [1514]
SGTA OTKOJ3JB Strong Biomarker [1515]
SH2D3A OTVJBSRC Strong Altered Expression [1516]
SH2D3C OTAGXO0N Strong Altered Expression [1516]
SH3GL2 OTOE443G Strong Genetic Variation [1517]
SH3KBP1 OTIUA60B Strong Biomarker [1518]
SH3RF1 OT7MYGYO Strong Genetic Variation [1519]
SHC1 OT1J5IRN Strong Biomarker [708]
SIAH1 OT29A838 Strong Altered Expression [1520]
SIGIRR OTNC3XFD Strong Altered Expression [1236]
SIGLEC7 OTNDLURR Strong Altered Expression [474]
SIL1 OTDI85I5 Strong Biomarker [1521]
SIM1 OTYKFPKZ Strong Biomarker [1218]
SIN3B OTFB59FK Strong Altered Expression [1522]
SIRT7 OT5M4OT4 Strong Altered Expression [1523]
SIX1 OT70YYWM Strong Biomarker [1524]
SIX6 OTD1RD9D Strong Biomarker [1525]
SLC25A43 OTY6MWVD Strong Genetic Variation [1526]
SLIT1 OT35RBNT Strong Biomarker [1527]
SLIT3 OTU8MKEU Strong Biomarker [1527]
SLN OTERIU75 Strong Biomarker [1528]
SMAD4 OTWQWCKG Strong Genetic Variation [51]
SMARCA2 OTSGJ8SV Strong Biomarker [1529]
SMARCE1 OTAX4ITH Strong Biomarker [629]
SMIM22 OTTX8AH1 Strong Altered Expression [1530]
SMPD3 OTHQBETH Strong Biomarker [1009]
SMPX OTLSHGBF Strong Altered Expression [646]
SMUG1 OT2YIOCQ Strong Biomarker [1531]
SMURF2 OT3TRVL7 Strong Altered Expression [1532]
SNAI1 OTDPYAMC Strong Biomarker [1533]
SNAI2 OT7Y8EJ2 Strong Biomarker [1534]
SND1 OTT734JN Strong Altered Expression [564]
SNRK OTX0OPHO Strong Biomarker [1535]
SNX32 OTIXXIHF Strong Biomarker [250]
SNX9 OTLNQ0ZM Strong Altered Expression [1536]
SOCS2 OTBPNKJQ Strong Biomarker [1537]
SORBS1 OTWH8762 Strong Biomarker [515]
SOS1 OTTCWXC3 Strong Biomarker [1538]
SOSTDC1 OTAKDNSM Strong Biomarker [1539]
SPA17 OT8J7T7U Strong Altered Expression [1045]
SPATA13 OTQ8NPAW Strong Biomarker [971]
SPATA18 OTOEHTHU Strong Biomarker [250]
SPC25 OTCAS0OH Strong Altered Expression [1540]
SPEN OT37A2MD Strong Altered Expression [1541]
SPINT1 OT1CLR5L Strong Biomarker [1542]
SPINT2 OTQV7BKQ Strong Biomarker [1543]
SPZ1 OTQH8HJ5 Strong Altered Expression [226]
SRA1 OTYOGMTG Strong Biomarker [1544]
SRARP OTR3TNTJ Strong Altered Expression [1545]
SRCIN1 OTQZNQQ5 Strong Altered Expression [1546]
SRP72 OTPV73W7 Strong Biomarker [1357]
SRSF5 OTC5WP98 Strong Altered Expression [1547]
ST18 OTPRIMTA Strong Altered Expression [1548]
ST6GALNAC1 OT3JQD99 Strong Biomarker [1549]
ST6GALNAC2 OT9PBQVT Strong Biomarker [1550]
ST7 OTZG8RC6 Strong Genetic Variation [1551]
ST8SIA1 OTGND2YZ Strong Biomarker [1552]
STAP2 OTEB1VVI Strong Biomarker [1553]
STARD3 OTSTC5B5 Strong Altered Expression [1554]
STARD8 OTY9IAKW Strong Biomarker [258]
STAT5A OTBSJGN3 Strong Biomarker [1555]
STAT5B OTZVPEBT Strong Altered Expression [1556]
STATH OTQHBHM9 Strong Biomarker [1557]
STIM1 OT8CLQ1W Strong Biomarker [579]
STING1 OTDAP4G0 Strong Biomarker [1558]
STIP1 OT7TXLOX Strong Altered Expression [1231]
STK17B OT4NYNO8 Strong Altered Expression [1559]
STK24 OTGUHOIL Strong Altered Expression [1560]
STK3 OTLNSCQD Strong Altered Expression [1561]
STUB1 OTSUYI9A Strong Altered Expression [1411]
SULF1 OTJCNCO0 Strong Altered Expression [1562]
SUPV3L1 OT416O2G Strong Altered Expression [1563]
SUSD2 OTSJTAZP Strong Biomarker [1564]
SUSD3 OTERJTUL Strong Altered Expression [1565]
SUZ12 OT655XF8 Strong Altered Expression [1566]
SYBU OT3FQV7N Strong Altered Expression [1476]
SYNE1 OTSBSLUH Strong Biomarker [258]
SYNJ2 OTLRHXP1 Strong Biomarker [1567]
SYNJ2BP OT2Q677P Strong Biomarker [1568]
SYNM OTOI8TRJ Strong Biomarker [1569]
TAB1 OTPM6F85 Strong Biomarker [1570]
TADA3 OTNUAIO9 Strong Biomarker [1571]
TAFA4 OT0RHMNG Strong Biomarker [1218]
TANK OTZSGFIK Strong Biomarker [565]
TAP2 OTWSYFI7 Strong Altered Expression [1572]
TARBP2 OT1QQ8H3 Strong Altered Expression [1573]
TBC1D9 OTSSCTB5 Strong Altered Expression [1574]
TBPL1 OT4I143E Strong Altered Expression [715]
TBX2 OTTOT7A9 Strong Altered Expression [1575]
TCHP OTVDMHSY Strong Altered Expression [1576]
TCIM OTARUXQF Strong Altered Expression [1577]
TCL1B OT4CSO39 Strong Biomarker [1578]
TET1 OTZDHT1D Strong Biomarker [1579]
TET3 OT76U3YF Strong Biomarker [1579]
TFAP2B OTR1T8E9 Strong Altered Expression [1580]
TFEB OTJUJJQY Strong Altered Expression [1581]
TFF2 OTRXB19X Strong Altered Expression [1582]
TFPI2 OTZCRWOR Strong Posttranslational Modification [1583]
TGFB1I1 OTIK337D Strong Biomarker [1584]
THAP10 OTCMT4L7 Strong Posttranslational Modification [1289]
THBS2 OTXET551 Strong Biomarker [1585]
THEMIS2 OTI1OBLN Strong Therapeutic [1586]
THOC1 OTVABJ4Z Strong Altered Expression [1587]
TIAL1 OTV2KFZH Strong Genetic Variation [1588]
TIMELESS OTD8DCBJ Strong Biomarker [1589]
TIMP1 OTOXC51H Strong Biomarker [1590]
TIMP3 OTDGQAD1 Strong Genetic Variation [1591]
TIMP4 OT8A68SW Strong Altered Expression [1592]
TINF2 OT861N2N Strong Altered Expression [715]
TIPRL OTS2FZ8O Strong Altered Expression [1244]
TJP1 OTBDCUPK Strong Biomarker [1593]
TLE3 OTR9PH95 Strong Biomarker [248]
TLK1 OTICTXI8 Strong Biomarker [1594]
TLK2 OTZ09CG8 Strong Biomarker [1595]
TM4SF1 OTY0ECQN Strong Altered Expression [1596]
TM9SF4 OT85D4H9 Strong Altered Expression [1597]
TMED10 OTUXSHH7 Strong Biomarker [317]
TMEM158 OT0KUBBI Strong Altered Expression [1598]
TMEM25 OTIMMWZ6 Strong Biomarker [1310]
TMPRSS13 OTMAOAP3 Strong Biomarker [550]
TMSB10 OTLVZ13T Strong Altered Expression [1599]
TNFAIP6 OT1SLUZH Strong Biomarker [1600]
TNFRSF10C OTVHOL9B Strong Biomarker [1601]
TNFRSF10D OTOSRDJT Strong Biomarker [1601]
TNFSF18 OT3ANRX1 Strong Altered Expression [1602]
TNIP1 OTRAOTEW Strong Biomarker [565]
TNN OTQK2AMX Strong Altered Expression [1603]
TOB1 OTNW949D Strong Altered Expression [1604]
TOPBP1 OT6UPZPD Strong Altered Expression [1605]
TP53BP2 OTOWJ2Y4 Strong Altered Expression [1606]
TP63 OT0WOOKQ Strong Altered Expression [91]
TPD52 OTPKSK43 Strong Altered Expression [1607]
TPD52L1 OTSA6U0I Strong Biomarker [1608]
TPI1 OT14KP4B Strong Biomarker [1370]
TPM1 OTD73X6R Strong Biomarker [1609]
TPPP2 OTI3WA6X Strong Biomarker [267]
TPSG1 OTDESHKT Strong Biomarker [1610]
TRADD OTBOSJHO Strong Altered Expression [1611]
TRAF4 OTJLRVMC Strong Altered Expression [1612]
TRAM1 OT3I0H8E Strong Biomarker [1613]
TRAP1 OTNG0L8J Strong Altered Expression [1614]
TRERF1 OTA7UQF1 Strong Biomarker [248]
TRIB3 OTG5OS7X Strong Altered Expression [1615]
TRIM25 OT35SG1R Strong Biomarker [1616]
TRIM29 OT2DNESG Strong Altered Expression [1617]
TRIM62 OT15YO6N Strong Biomarker [1618]
TRMT12 OTCN4IQZ Strong Altered Expression [1619]
TRPS1 OT7XPPEL Strong Biomarker [1620]
TSC22D1 OTN4GFWD Strong Altered Expression [1621]
TSPAN13 OTCS9BZY Strong Altered Expression [877]
TTC4 OTAPMYXU Strong Genetic Variation [1622]
ADAM23 OTVWT6JZ Definitive Biomarker [1623]
BCAR3 OTPJ17M8 Definitive Biomarker [1624]
CD82 OTH8MC64 Definitive Altered Expression [1625]
CLDN2 OTRF3D6Y Definitive Biomarker [1626]
DAB2 OTRMQTMZ Definitive Biomarker [1627]
EMSY OTBQ3KQE Definitive Genetic Variation [1628]
ESRP1 OTNCS4SL Definitive Altered Expression [1152]
FBXO22 OTEJ5MO0 Definitive Biomarker [1629]
HOXB7 OTC7WYU8 Definitive Biomarker [1630]
HOXC11 OT8NMHM6 Definitive Altered Expression [949]
IRX2 OTBHXXQ2 Definitive Altered Expression [1631]
KLK10 OTD573EL Definitive Biomarker [1632]
LGALS9 OT7MF91K Definitive Altered Expression [1633]
NDN OTYBYJ82 Definitive Biomarker [1634]
RASSF1 OTEZIPB7 Definitive Posttranslational Modification [1635]
REV3L OT0OP8EJ Definitive Altered Expression [1636]
RND1 OTOC223Z Definitive Altered Expression [1637]
SRSF1 OTF61HOV Definitive Altered Expression [1638]
TBX3 OTM64N7K Definitive Biomarker [1639]
------------------------------------------------------------------------------------
⏷ Show the Full List of 1165 DOT(s)

References

1 ADAM8 expression in breast cancer derived brain metastases: Functional implications on MMP-9 expression and transendothelial migration in breast cancer cells.Int J Cancer. 2018 Feb 15;142(4):779-791. doi: 10.1002/ijc.31090. Epub 2017 Oct 31.
2 Decreased expression of ADAMTS-1 in human breast tumors stimulates migration and invasion.Mol Cancer. 2013 Jan 5;12:2. doi: 10.1186/1476-4598-12-2.
3 Effects of two types of energy restriction on methylation levels of adiponectin receptor 1 and leptin receptor overlapping transcript in a mouse mammary tumour virus-transforming growth factor- breast cancer mouse model.Br J Nutr. 2021 Jan 14;125(1):1-9. doi: 10.1017/S0007114519002757. Epub 2019 Nov 5.
4 AKT3 regulates ErbB2, ErbB3 and estrogen receptor expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.Cell Signal. 2014 May;26(5):1021-9. doi: 10.1016/j.cellsig.2014.01.018. Epub 2014 Jan 24.
5 Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling.Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):E1026-34. doi: 10.1073/pnas.1217072110. Epub 2013 Feb 19.
6 Prevalence of BER gene polymorphisms in sporadic breast cancer.Oncol Rep. 2008 Apr;19(4):1033-8.
7 Underexpression of transcriptional regulators is common in metastatic breast cancer cells overexpressing Bcl-xL.Carcinogenesis. 2006 Jun;27(6):1169-79. doi: 10.1093/carcin/bgi363. Epub 2006 Feb 20.
8 Lower expression of miR-218 in human breast cancer is associated with lymph node metastases, higher grades, and poorer prognosis.Tumour Biol. 2017 Aug;39(8):1010428317698362. doi: 10.1177/1010428317698362.
9 Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk.Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3482-9. doi: 10.1158/1055-9965.EPI-08-0594.
10 Overexpression of CXCR4 synergizes with LL-37 in the metastasis of breast cancer cells.Biochim Biophys Acta Mol Basis Dis. 2018 Nov;1864(11):3837-3846. doi: 10.1016/j.bbadis.2018.09.008. Epub 2018 Sep 9.
11 Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.J Natl Cancer Inst. 2016 Oct 5;109(1):djw199. doi: 10.1093/jnci/djw199. Print 2017 Jan.
12 Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides.Br J Cancer. 2006 Jun 5;94(11):1697-702. doi: 10.1038/sj.bjc.6603147.
13 The utility of a tissue slice model system to determine breast cancer infectivity by oncolytic adenoviruses.J Surg Res. 2010 Oct;163(2):270-5. doi: 10.1016/j.jss.2010.03.072. Epub 2010 Apr 24.
14 17beta-estradiol (E2) induces cdc25A gene expression in breast cancer cells by genomic and non-genomic pathways.J Cell Biochem. 2006 Sep 1;99(1):209-20. doi: 10.1002/jcb.20902.
15 Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling.Cancer Res. 2008 Mar 1;68(5):1388-97. doi: 10.1158/0008-5472.CAN-07-2706.
16 CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity.Cell Cycle. 2013 Mar 15;12(6):935-43. doi: 10.4161/cc.23883. Epub 2013 Feb 19.
17 Growth factors and breast tumors, comparison of selected growth factors with traditional tumor markers.Anticancer Res. 2011 Dec;31(12):4653-6.
18 C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells.Cancer Cell. 2006 Sep;10(3):203-14. doi: 10.1016/j.ccr.2006.07.019.
19 Ceramide kinase promotes tumor cell survival and mammary tumor recurrence.Cancer Res. 2014 Nov 1;74(21):6352-63. doi: 10.1158/0008-5472.CAN-14-1292. Epub 2014 Aug 27.
20 Claudin expression in breast cancer: high or low, what to expect?.Histol Histopathol. 2012 Oct;27(10):1283-95. doi: 10.14670/HH-27.1283.
21 Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines.Breast Cancer Res. 2018 Oct 22;20(1):126. doi: 10.1186/s13058-018-1054-3.
22 Novel roles of 1,25(OH)2D3 on DNA repair provide new strategies for breast cancer treatment.J Steroid Biochem Mol Biol. 2014 Oct;144 Pt A:59-64. doi: 10.1016/j.jsbmb.2013.09.009. Epub 2013 Sep 27.
23 Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF- signaling proteins.BMC Cancer. 2014 Oct 24;14:781. doi: 10.1186/1471-2407-14-781.
24 CXCR2: A Novel Mediator of Mammary Tumor Bone Metastasis.Int J Mol Sci. 2019 Mar 12;20(5):1237. doi: 10.3390/ijms20051237.
25 High Numbers of Circulating CD57(+) NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2(+) Primary Breast Cancer.Cancer Immunol Res. 2019 Aug;7(8):1280-1292. doi: 10.1158/2326-6066.CIR-18-0896. Epub 2019 Jun 12.
26 Haplotype analysis of CYP11A1 identifies promoter variants associated with breast cancer risk.Cancer Res. 2007 Jun 15;67(12):5673-82. doi: 10.1158/0008-5472.CAN-07-0467.
27 Interaction of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferase M1 to breast cancer in Taiwanese woman without smoking and drinking habits.Breast Cancer Res Treat. 2006 Nov;100(1):93-8. doi: 10.1007/s10549-006-9226-8. Epub 2006 Jun 7.
28 Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases.Hum Gene Ther. 2015 Dec;26(12):813-25. doi: 10.1089/hum.2015.098. Epub 2015 Nov 10.
29 A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer. J Biol Chem. 2017 Mar 24;292(12):4873-4884.
30 Epigenetic silencing of the WNT antagonist Dickkopf 3 disrupts normal Wnt/-catenin signalling and apoptosis regulation in breast cancer cells.J Cell Mol Med. 2013 Oct;17(10):1236-46. doi: 10.1111/jcmm.12099. Epub 2013 Jul 24.
31 A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth.Sci Rep. 2016 Jun 15;6:27985. doi: 10.1038/srep27985.
32 Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.Sci Rep. 2017 Dec 13;7(1):17530. doi: 10.1038/s41598-017-17836-7.
33 Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer.BMC Cancer. 2019 May 23;19(1):491. doi: 10.1186/s12885-019-5667-4.
34 ProNGF increases breast tumor aggressiveness through functional association of TrkA with EphA2.Cancer Lett. 2019 May 1;449:196-206. doi: 10.1016/j.canlet.2019.02.019. Epub 2019 Feb 13.
35 Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.Breast Cancer Res. 2018 Nov 20;20(1):140. doi: 10.1186/s13058-018-1064-1.
36 Utilization of adipocyte-derived lipids and enhanced intracellular trafficking of fatty acids contribute to breast cancer progression.Cell Commun Signal. 2018 Jun 18;16(1):32. doi: 10.1186/s12964-018-0221-6.
37 Mammaglobin-A, VEGFR3, and Ki67 in Human Breast Cancer Pathology and Five Year Survival.Breast Cancer (Auckl). 2019 Jun 26;13:1178223419858957. doi: 10.1177/1178223419858957. eCollection 2019.
38 High folic acid diet enhances tumour growth in PyMT-induced breast cancer.Br J Cancer. 2017 Mar 14;116(6):752-761. doi: 10.1038/bjc.2017.11. Epub 2017 Feb 2.
39 Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer.PLoS One. 2015 Aug 6;10(8):e0135012. doi: 10.1371/journal.pone.0135012. eCollection 2015.
40 Association of FOSL1 copy number alteration and triple negative breast tumors.Genet Mol Biol. 2019 Feb 28;42(1):26-31. doi: 10.1590/1678-4685-gmb-2017-0267. Print 2019 Jan-Mar.
41 Suppression of protein tyrosine phosphatase N23 predisposes to breast tumorigenesis via activation of FYN kinase.Genes Dev. 2017 Oct 1;31(19):1939-1957. doi: 10.1101/gad.304261.117. Epub 2017 Oct 24.
42 Parallel assessment of circulatory cell-free DNA by PCR and nucleosomes by ELISA in breast tumors.Int J Biol Markers. 2008 Apr-Jun;23(2):69-73. doi: 10.1177/172460080802300202.
43 Cx26 inhibits breast MDA-MB-435 cell tumorigenic properties by a gap junctional intercellular communication-independent mechanism.Carcinogenesis. 2006 Dec;27(12):2528-37. doi: 10.1093/carcin/bgl110. Epub 2006 Jun 15.
44 GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin 51 for efficient breast cancer metastasis.Oncogene. 2015 Oct;34(43):5494-504. doi: 10.1038/onc.2015.8. Epub 2015 Mar 16.
45 Identification of recurrent fusion genes across multiple cancer types.Sci Rep. 2019 Jan 31;9(1):1074. doi: 10.1038/s41598-019-38550-6.
46 PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4192-9. doi: 10.1158/1078-0432.CCR-05-2663.
47 Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer.Anticancer Res. 2011 Dec;31(12):4115-25.
48 Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.Oncogene. 2017 Jan 5;36(1):133-145. doi: 10.1038/onc.2016.186. Epub 2016 May 23.
49 High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer.Breast Cancer Res Treat. 2020 Jan;179(1):25-35. doi: 10.1007/s10549-019-05419-1. Epub 2019 Sep 17.
50 Heparanase Accelerates Obesity-Associated Breast Cancer Progression.Cancer Res. 2019 Oct 15;79(20):5342-5354. doi: 10.1158/0008-5472.CAN-18-4058. Epub 2019 Sep 3.
51 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
52 Chemistry, biochemistry, metabolic fate and mechanism of action of 6-oxo-cholestan-3,5-diol (OCDO), a tumor promoter and cholesterol metabolite.Biochimie. 2018 Oct;153:139-149. doi: 10.1016/j.biochi.2018.04.008. Epub 2018 Apr 12.
53 Phosphorylation of HSF1 by PIM2 Induces PD-L1 Expression and Promotes Tumor Growth in Breast Cancer.Cancer Res. 2019 Oct 15;79(20):5233-5244. doi: 10.1158/0008-5472.CAN-19-0063. Epub 2019 Aug 13.
54 Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer.PLoS One. 2013 Apr 8;8(4):e60359. doi: 10.1371/journal.pone.0060359. Print 2013.
55 MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11.Nat Commun. 2013;4:1393. doi: 10.1038/ncomms2393.
56 Activin A Signaling Regulates IL13R2 Expression to Promote Breast Cancer Metastasis.Front Oncol. 2019 Feb 5;9:32. doi: 10.3389/fonc.2019.00032. eCollection 2019.
57 Vaccination with tumor cells expressing IL-15 and IL-15R inhibits murine breast and prostate cancer.Gene Ther. 2014 Apr;21(4):393-401. doi: 10.1038/gt.2014.10. Epub 2014 Feb 27.
58 Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer.Breast Cancer Res Treat. 2010 May;121(1):227-31. doi: 10.1007/s10549-009-0509-8. Epub 2009 Aug 21.
59 Nano-Strategies to Target Breast Cancer-Associated Fibroblasts: Rearranging the Tumor Microenvironment to Achieve Antitumor Efficacy.Int J Mol Sci. 2019 Mar 13;20(6):1263. doi: 10.3390/ijms20061263.
60 In vivo dual targeting of the oncogenic Ether--go-go-1 potassium channel by calcitriol and astemizole results in enhanced antineoplastic effects in breast tumors.BMC Cancer. 2014 Oct 3;14:745. doi: 10.1186/1471-2407-14-745.
61 Regulation of Transient Site-specific Copy Gain by MicroRNA.J Biol Chem. 2016 Mar 4;291(10):4862-71. doi: 10.1074/jbc.M115.711648. Epub 2016 Jan 11.
62 Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells.Breast Cancer Res. 2019 Dec 5;21(1):138. doi: 10.1186/s13058-019-1228-7.
63 Expression analysis and study of KLK4 in benign and malignant breast tumours.Thromb Haemost. 2009 Feb;101(2):381-7.
64 Biochemical pathways mediated by KLK6 protease in breast cancer.Mol Oncol. 2019 Nov;13(11):2329-2343. doi: 10.1002/1878-0261.12493. Epub 2019 Sep 30.
65 CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer.Int J Oncol. 2016 Oct;49(4):1343-50. doi: 10.3892/ijo.2016.3639. Epub 2016 Jul 29.
66 The expression of galectin-3 in breast cancer and its association with chemoresistance: a systematic review of the literature.Arch Gynecol Obstet. 2019 Nov;300(5):1113-1120. doi: 10.1007/s00404-019-05292-9. Epub 2019 Sep 9.
67 Induction of the RNA regulator LIN28A is required for the growth and pathogenesis of RESTless breast tumors.Cancer Res. 2012 Jul 1;72(13):3207-16. doi: 10.1158/0008-5472.CAN-11-1639. Epub 2012 Apr 24.
68 Both LRP5 and LRP6 receptors are required to respond to physiological Wnt ligands in mammary epithelial cells and fibroblasts.J Biol Chem. 2012 May 11;287(20):16454-66. doi: 10.1074/jbc.M112.362137. Epub 2012 Mar 20.
69 Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk.Hum Genet. 2007 May;121(3-4):483-90. doi: 10.1007/s00439-006-0315-x. Epub 2007 Jan 11.
70 Hypoxia/HIF1 induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.Oncotarget. 2015 Feb 10;6(4):1967-80. doi: 10.18632/oncotarget.2806.
71 CD146, a novel target of CD44-signaling, suppresses breast tumor cell invasion.Cell Commun Signal. 2017 Nov 9;15(1):45. doi: 10.1186/s12964-017-0200-3.
72 Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.J Exp Med. 2012 Feb 13;209(2):275-89. doi: 10.1084/jem.20111117. Epub 2012 Jan 23.
73 Nectin-4 is a breast cancer stem cell marker that induces WNT/-catenin signaling via Pi3k/Akt axis.Int J Biochem Cell Biol. 2017 Aug;89:85-94. doi: 10.1016/j.biocel.2017.06.007. Epub 2017 Jun 7.
74 Expression of long noncoding RNA MALAT1 correlates with increased levels of Nischarin and inhibits oncogenic cell functions in breast cancer.PLoS One. 2018 Jun 18;13(6):e0198945. doi: 10.1371/journal.pone.0198945. eCollection 2018.
75 LRH-1 controls proliferation in breast tumor cells by regulating CDKN1A gene expression.Oncogene. 2015 Aug 20;34(34):4509-18. doi: 10.1038/onc.2014.382. Epub 2014 Dec 1.
76 Ultrasound molecular imaging as a non-invasive companion diagnostic for netrin-1 interference therapy in breast cancer.Theranostics. 2018 Oct 6;8(18):5126-5142. doi: 10.7150/thno.27221. eCollection 2018.
77 Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):7869-7878. doi: 10.1073/pnas.1722617115. Epub 2018 Jul 9.
78 Phosphodiesterase 7B/microRNA-200c relationship regulates triple-negative breast cancer cell growth.Oncogene. 2019 Feb;38(7):1106-1120. doi: 10.1038/s41388-018-0499-2. Epub 2018 Sep 12.
79 Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor.Breast Cancer Res Treat. 2008 Sep;111(2):229-40. doi: 10.1007/s10549-007-9782-6. Epub 2007 Oct 20.
80 Stratification and therapeutic potential of PML in metastatic breast cancer.Nat Commun. 2016 Aug 24;7:12595. doi: 10.1038/ncomms12595.
81 Epithelial periostin expression is correlated with poor survival in patients with invasive breast carcinoma.PLoS One. 2017 Nov 21;12(11):e0187635. doi: 10.1371/journal.pone.0187635. eCollection 2017.
82 PGC-1 regulates HER2-overexpressing breast cancer cells proliferation by metabolic and redox pathways.Tumour Biol. 2016 May;37(5):6035-44. doi: 10.1007/s13277-015-4449-0. Epub 2015 Nov 24.
83 Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA.Br J Cancer. 2008 Nov 18;99(10):1644-50. doi: 10.1038/sj.bjc.6604728. Epub 2008 Oct 28.
84 Control of MT1-MMP transport by atypical PKC during breast-cancer progression.Proc Natl Acad Sci U S A. 2014 May 6;111(18):E1872-9. doi: 10.1073/pnas.1400749111. Epub 2014 Apr 21.
85 PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis.J Clin Invest. 2007 Dec;117(12):4009-21. doi: 10.1172/JCI32424.
86 Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.Cancer Med. 2019 May;8(5):2414-2428. doi: 10.1002/cam4.2114. Epub 2019 Apr 8.
87 PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.Cancer Res. 2010 Jun 15;70(12):5116-26. doi: 10.1158/0008-5472.CAN-09-4368. Epub 2010 May 25.
88 Atorvastatin Inhibits Breast Cancer Cells by Downregulating PTEN/AKT Pathway via Promoting Ras Homolog Family Member B (RhoB).Biomed Res Int. 2019 Mar 18;2019:3235021. doi: 10.1155/2019/3235021. eCollection 2019.
89 High-Throughput Assessment of Kinome-wide Activation States.Cell Syst. 2019 Oct 23;9(4):366-374.e5. doi: 10.1016/j.cels.2019.08.005. Epub 2019 Sep 11.
90 Activating ROCK1 somatic mutations in human cancer.Oncogene. 2010 Apr 29;29(17):2591-8. doi: 10.1038/onc.2010.3. Epub 2010 Feb 8.
91 Setdb1, a novel interactor of Np63, is involved in breast tumorigenesis.Oncotarget. 2016 May 17;7(20):28836-48. doi: 10.18632/oncotarget.7089.
92 The Clinical Implications of RSK1-3 in Human Breast Cancer.Anticancer Res. 2016 Mar;36(3):1267-74.
93 Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial.Breast Cancer Res Treat. 2015 Jun;151(2):309-18. doi: 10.1007/s10549-015-3397-0. Epub 2015 Apr 28.
94 Overexpression and involvement of special AT-rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells.Cancer Sci. 2010 Jan;101(1):80-6. doi: 10.1111/j.1349-7006.2009.01372.x. Epub 2009 Sep 26.
95 The effect of soluble E-selectin on tumor progression and metastasis.BMC Cancer. 2016 May 24;16:331. doi: 10.1186/s12885-016-2366-2.
96 Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer.J Pineal Res. 2019 Sep;67(2):e12586. doi: 10.1111/jpi.12586. Epub 2019 Jun 9.
97 Intracellular patterns of sialophorin expression define a new molecular classification of breast cancer and represent new targets for therapy.Br J Cancer. 2014 Jan 7;110(1):146-55. doi: 10.1038/bjc.2013.526. Epub 2013 Nov 26.
98 Matrix detachment and proteasomal inhibitors diminish Sulf-2 expression in breast cancer cell lines and mouse xenografts.Clin Exp Metastasis. 2013 Apr;30(4):407-15. doi: 10.1007/s10585-012-9546-5. Epub 2013 Feb 15.
99 Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer.Cancer Res. 2013 Nov 1;73(21):6424-34. doi: 10.1158/0008-5472.CAN-12-4573. Epub 2013 Sep 12.
100 Integrated analysis of promoter methylation and expression of telomere related genes in breast cancer.Oncotarget. 2017 Apr 11;8(15):25442-25454. doi: 10.18632/oncotarget.16036.
101 Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mammary tumor development in TFF1-knockout mice.Oncogene. 2011 Jul 21;30(29):3261-73. doi: 10.1038/onc.2011.41. Epub 2011 Feb 28.
102 Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer.Oncotarget. 2017 Aug 14;8(45):78870-78881. doi: 10.18632/oncotarget.20239. eCollection 2017 Oct 3.
103 TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.Mol Cancer Res. 2008 Dec;6(12):1861-71. doi: 10.1158/1541-7786.MCR-08-0313.
104 RRR-gamma-tocopherol induces human breast cancer cells to undergo apoptosis via death receptor 5 (DR5)-mediated apoptotic signaling.Cancer Lett. 2008 Feb 8;259(2):165-76. doi: 10.1016/j.canlet.2007.10.008. Epub 2007 Nov 19.
105 The HER2- and heregulin 1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.Mol Cancer Res. 2013 Apr;11(4):393-404. doi: 10.1158/1541-7786.MCR-12-0542. Epub 2013 Feb 1.
106 Neutrophil TLR4 and PKR are targets of breast cancer cell glycosaminoglycans and effectors of glycosaminoglycan-induced APRIL secretion.Oncogenesis. 2018 Jun 15;7(6):45. doi: 10.1038/s41389-018-0058-2.
107 Phospho-TCTP as a therapeutic target of Dihydroartemisinin for aggressive breast cancer cells.Oncotarget. 2015 Mar 10;6(7):5275-91. doi: 10.18632/oncotarget.2971.
108 Overexpression of ligase defective E6-associated protein, E6-AP, results in mammary tumorigenesis.Breast Cancer Res Treat. 2012 Feb;132(1):97-108. doi: 10.1007/s10549-011-1567-2. Epub 2011 May 8.
109 Glycan-related gene expression signatures in breast cancer subtypes; relation to survival.Mol Oncol. 2015 Apr;9(4):861-76. doi: 10.1016/j.molonc.2014.12.013. Epub 2015 Jan 14.
110 Genetic polymorphisms in the UGT1A1 gene and breast cancer risk in Greek women.Genet Test. 2007 Fall;11(3):303-6. doi: 10.1089/gte.2007.0020.
111 USP1 (ubiquitin specific peptidase 1) targets ULK1 and regulates its cellular compartmentalization and autophagy.Autophagy. 2019 Apr;15(4):613-630. doi: 10.1080/15548627.2018.1535291. Epub 2018 Oct 29.
112 Tumor-derived VEGF-C, but not VEGF-D, promotes sentinel lymph node lymphangiogenesis prior to metastasis in breast cancer patients.Med Oncol. 2012 Dec;29(4):2594-600. doi: 10.1007/s12032-012-0205-0. Epub 2012 May 6.
113 Thymoquinone inhibits tumor growth and induces apoptosis in a breast cancer xenograft mouse model: the role of p38 MAPK and ROS.PLoS One. 2013 Oct 2;8(10):e75356. doi: 10.1371/journal.pone.0075356. eCollection 2013.
114 Combined Targeting of Estrogen Receptor Alpha and XPO1 Prevent Akt Activation, Remodel Metabolic Pathways and Induce Autophagy to Overcome Tamoxifen Resistance.Cancers (Basel). 2019 Apr 4;11(4):479. doi: 10.3390/cancers11040479.
115 AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNF-induced epithelial-mesenchymal transition in triple-negative breast cancer.Oncotarget. 2015 Apr 10;6(10):7804-14. doi: 10.18632/oncotarget.3158.
116 Targeting AU-rich element-mediated mRNA decay with a truncated active form of the zinc-finger protein TIS11b/BRF1 impairs major hallmarks of mammary tumorigenesis.Oncogene. 2019 Jun;38(26):5174-5190. doi: 10.1038/s41388-019-0784-8. Epub 2019 Mar 26.
117 The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone.J Pathol. 2017 May;242(1):73-89. doi: 10.1002/path.4882. Epub 2017 Mar 27.
118 Estrogen alters the splicing of type 1 corticotropin-releasing hormone receptor in breast cancer cells.Sci Signal. 2013 Jul 2;6(282):ra53. doi: 10.1126/scisignal.2003926.
119 Steroid metabolism gene polymorphisms and their implications on breast and ovarian cancer prognosis.Genet Mol Res. 2017 Jul 6;16(3). doi: 10.4238/gmr16039691.
120 Induction of Hsp22 (HspB8) by estrogen and the metalloestrogen cadmium in estrogen receptor-positive breast cancer cells.Cell Stress Chaperones. 2007 Winter;12(4):307-19. doi: 10.1379/csc-276.1.
121 Assessment of CXC ligand 12-mediated calcium signalling and its regulators in basal-like breast cancer cells.Oncol Lett. 2018 Apr;15(4):4289-4295. doi: 10.3892/ol.2018.7827. Epub 2018 Jan 19.
122 AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients.Exp Mol Pathol. 2017 Apr;102(2):280-283. doi: 10.1016/j.yexmp.2017.02.016. Epub 2017 Feb 24.
123 Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors.Med Mol Morphol. 2020 Mar;53(1):15-20. doi: 10.1007/s00795-019-00226-5. Epub 2019 May 28.
124 The cancer gene WWOX behaves as an inhibitor of SMAD3 transcriptional activity via direct binding.BMC Cancer. 2013 Dec 11;13:593. doi: 10.1186/1471-2407-13-593.
125 Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.J Clin Pathol. 2019 Jan;72(1):7-11. doi: 10.1136/jclinpath-2018-205485. Epub 2018 Nov 13.
126 Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth.Breast Cancer Res. 2018 Oct 26;20(1):131. doi: 10.1186/s13058-018-1057-0.
127 Activation of the canonical Wnt/-catenin pathway in ATF3-induced mammary tumors.PLoS One. 2011 Jan 31;6(1):e16515. doi: 10.1371/journal.pone.0016515.
128 Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.Cancer Res. 2016 Jan 15;76(2):206-15. doi: 10.1158/0008-5472.CAN-15-0295. Epub 2015 Dec 30.
129 Copy number variation in ACHE/EPHB4 (7q22) and in BCHE/MME (3q26) genes in sporadic breast cancer.Chem Biol Interact. 2013 Mar 25;203(1):344-7. doi: 10.1016/j.cbi.2012.09.020. Epub 2012 Oct 9.
130 Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.Clin Cancer Res. 2008 May 1;14(9):2681-9. doi: 10.1158/1078-0432.CCR-07-1760.
131 BMP7 influences proliferation, migration, and invasion of breast cancer cells.Cancer Lett. 2009 Mar 8;275(1):35-43. doi: 10.1016/j.canlet.2008.09.028. Epub 2008 Nov 5.
132 Lentivirus mediated RNA interference of EMMPRIN (CD147) gene inhibits the proliferation, matrigel invasion and tumor formation of breast cancer cells.Cancer Biomark. 2016 Jul 8;17(2):237-47. doi: 10.3233/CBM-160636.
133 Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.N Engl J Med. 2014 Jun 12;370(24):2286-94. doi: 10.1056/NEJMoa1400029. Epub 2014 May 28.
134 Loss of caveolin-1 alters extracellular matrix protein expression and ductal architecture in murine mammary glands.PLoS One. 2017 Feb 10;12(2):e0172067. doi: 10.1371/journal.pone.0172067. eCollection 2017.
135 CCL20 promotes migration and invasiveness of human cancerous breast epithelial cells in primary culture.Mol Carcinog. 2017 Nov;56(11):2461-2473. doi: 10.1002/mc.22693. Epub 2017 Jul 4.
136 A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway.Oncogene. 2005 Jan 27;24(5):761-79. doi: 10.1038/sj.onc.1208238.
137 The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.Breast Cancer Res. 2019 Feb 28;21(1):34. doi: 10.1186/s13058-019-1121-4.
138 Atezolizumab Combo Approved for PD-L1-positive TNBC.Cancer Discov. 2019 May;9(5):OF2. doi: 10.1158/2159-8290.CD-NB2019-038. Epub 2019 Mar 20.
139 Triggering CD40 on endothelial cells contributes to tumor growth.J Exp Med. 2006 Oct 30;203(11):2441-50. doi: 10.1084/jem.20060844. Epub 2006 Oct 16.
140 CD44-Targeted Multifunctional Nanomedicines Based on a Single-Component Hyaluronic Acid Conjugate with All-Natural Precursors: Construction and Treatment of Metastatic Breast Tumors in Vivo.Biomacromolecules. 2020 Jan 13;21(1):104-113. doi: 10.1021/acs.biomac.9b01012. Epub 2019 Sep 18.
141 APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer.Oncotarget. 2018 Jul 17;9(55):30513-30526. doi: 10.18632/oncotarget.25495. eCollection 2018 Jul 17.
142 Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis.Nat Commun. 2019 Aug 16;10(1):3716. doi: 10.1038/s41467-019-11618-7.
143 CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1.Nat Commun. 2017 Jan 9;8:13923. doi: 10.1038/ncomms13923.
144 HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.PLoS Comput Biol. 2016 Apr 1;12(4):e1004827. doi: 10.1371/journal.pcbi.1004827. eCollection 2016 Apr.
145 A new prognostic factor of breast cancer: High carboxyl ester lipase expression related to poor survival.Cancer Genet. 2019 Nov;239:54-61. doi: 10.1016/j.cancergen.2019.09.005. Epub 2019 Sep 18.
146 Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals.Int J Cancer. 2009 Jan 1;124(1):215-22. doi: 10.1002/ijc.23903.
147 Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis.Oncogene. 2018 Mar;37(11):1430-1444. doi: 10.1038/s41388-017-0036-8. Epub 2018 Jan 11.
148 RelA driven co-expression of CXCL13 and CXCR5 is governed by a multifaceted transcriptional program regulating breast cancer progression.Biochim Biophys Acta Mol Basis Dis. 2019 Feb 1;1865(2):502-511. doi: 10.1016/j.bbadis.2018.12.002. Epub 2018 Dec 12.
149 Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis.Blood Adv. 2019 Jan 22;3(2):198-211. doi: 10.1182/bloodadvances.2018026161.
150 Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression.J Steroid Biochem Mol Biol. 2019 May;189:161-170. doi: 10.1016/j.jsbmb.2019.03.002. Epub 2019 Mar 6.
151 Aromatase, CYP1B1 and fatty acid synthase expression in breast tumors of BRCA1 mutation carriers.Pathol Oncol Res. 2009 Sep;15(3):407-9. doi: 10.1007/s12253-008-9137-6.
152 QW-1624F2-2, a synthetic analogue of 1,25-dihydroxyvitamin D3, enhances the response to other deltanoids and suppresses the invasiveness of human metastatic breast tumor cells.Mol Cancer Ther. 2006 Nov;5(11):2806-14. doi: 10.1158/1535-7163.MCT-06-0092.
153 Regulation of aromatase induction by nuclear receptor coregulator PELP1.J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):211-8. doi: 10.1016/j.jsbmb.2009.09.009. Epub 2009 Sep 30.
154 Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs.Breast Cancer Res Treat. 2012 Feb;131(3):809-18. doi: 10.1007/s10549-011-1477-3. Epub 2011 Apr 5.
155 Altered DNA methyltransferases promoter methylation and mRNA expression are associated with tamoxifen response in breast tumors.J Cell Physiol. 2018 Sep;233(9):7305-7319. doi: 10.1002/jcp.26562. Epub 2018 Mar 25.
156 [Significance of pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase levels to predict postoperative recurrence in primary breast cancer].Gan To Kagaku Ryoho. 2008 Mar;35(3):431-6.
157 DUSP1 promoter methylation in peripheral blood leukocyte is associated with triple-negative breast cancer risk.Sci Rep. 2017 Feb 21;7:43011. doi: 10.1038/srep43011.
158 Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats.Breast Cancer Res Treat. 2005 Dec;94(3):237-47. doi: 10.1007/s10549-005-9000-3.
159 The Inhibitory Effect of (-)-Epigallocatechin-3-Gallate on Breast Cancer Progression via Reducing SCUBE2 Methylation and DNMT Activity.Molecules. 2019 Aug 9;24(16):2899. doi: 10.3390/molecules24162899.
160 Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.Breast Cancer Res Treat. 2013 Aug;141(1):79-88. doi: 10.1007/s10549-013-2671-2. Epub 2013 Aug 24.
161 miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-, CCNJ, and MEGF9.PLoS One. 2013 Oct 3;8(10):e76247. doi: 10.1371/journal.pone.0076247. eCollection 2013.
162 The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.J Biol Chem. 2015 Sep 11;290(37):22649-61. doi: 10.1074/jbc.M115.658468. Epub 2015 Jul 30.
163 Plasticity and intratumoural heterogeneity of cell surface antigen expression in breast cancer.Br J Cancer. 2018 Mar 20;118(6):813-819. doi: 10.1038/bjc.2017.497. Epub 2018 Feb 20.
164 Ets-1 controls breast cancer cell balance between invasion and growth.Int J Cancer. 2014 Nov 15;135(10):2317-28. doi: 10.1002/ijc.28881. Epub 2014 May 5.
165 The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis.Cell Death Dis. 2017 Jul 13;8(7):e2928. doi: 10.1038/cddis.2017.325.
166 Suppression of mammary-derived growth inhibitor gene expression by growth hormone and insulin-like growth factor I.Int J Oncol. 1998 Sep;13(3):577-82. doi: 10.3892/ijo.13.3.577.
167 Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer.Oncogene. 2008 Nov 27;27(56):7094-105. doi: 10.1038/onc.2008.292. Epub 2008 Sep 1.
168 Concomitant loss of heterozygosity at the BRCA1 and FHIT genes as a prognostic factor in sporadic breast cancer.Cancer Genet Cytogenet. 2010 May;199(1):24-30. doi: 10.1016/j.cancergencyto.2010.01.019.
169 Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.Anticancer Res. 2015 Jul;35(7):4023-36.
170 iRGD-guided tamoxifen polymersomes inhibit estrogen receptor transcriptional activity and decrease the number of breast cancer cells with self-renewing capacity.J Nanobiotechnology. 2019 Dec 7;17(1):120. doi: 10.1186/s12951-019-0553-4.
171 Cx43 Expression Correlates with Breast Cancer Metastasis in MDA-MB-231 Cells In Vitro, In a Mouse Xenograft Model and in Human Breast Cancer Tissues.Cancers (Basel). 2019 Apr 1;11(4):460. doi: 10.3390/cancers11040460.
172 Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response.Free Radic Biol Med. 2008 Apr 1;44(7):1483-91. doi: 10.1016/j.freeradbiomed.2008.01.009. Epub 2008 Jan 26.
173 Latent transforming growth factor binding protein 4 (LTBP4) is downregulated in mouse and human DCIS and mammary carcinomas.Cell Oncol (Dordr). 2011 Oct;34(5):419-34. doi: 10.1007/s13402-011-0023-y. Epub 2011 Apr 6.
174 Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples.PLoS One. 2019 Jan 15;14(1):e0210905. doi: 10.1371/journal.pone.0210905. eCollection 2019.
175 ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis.J Clin Invest. 2018 May 1;128(5):1937-1955. doi: 10.1172/JCI95089. Epub 2018 Apr 9.
176 HIPK2 downregulates vimentin and inhibits breast cancer cell invasion.Cancer Biol Ther. 2012 Feb 15;13(4):198-205. doi: 10.4161/cbt.13.4.18694. Epub 2012 Feb 15.
177 IL4 Receptor-Targeted Proapoptotic Peptide Blocks Tumor Growth and Metastasis by Enhancing Antitumor Immunity.Mol Cancer Ther. 2017 Dec;16(12):2803-2816. doi: 10.1158/1535-7163.MCT-17-0339. Epub 2017 Sep 6.
178 The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini.Cancer Res. 2008 Apr 15;68(8):3026-36. doi: 10.1158/0008-5472.CAN-07-3079.
179 Inhibition of insulin-like growth factor 1 signaling synergistically enhances the tumor suppressive role of triptolide in triple-negative breast cancer cells.Oncol Lett. 2019 Jul;18(1):822-829. doi: 10.3892/ol.2019.10356. Epub 2019 May 14.
180 The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications.Cancer Lett. 2017 Jan 28;385:198-206. doi: 10.1016/j.canlet.2016.10.023. Epub 2016 Oct 22.
181 IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).PLoS One. 2008 Jul 2;3(7):e2578. doi: 10.1371/journal.pone.0002578.
182 Enhancement of mammary tumour growth by IGFBP-3 involves impaired T cell accumulation.Endocr Relat Cancer. 2018 Feb;25(2):111-122. doi: 10.1530/ERC-17-0384. Epub 2017 Dec 7.
183 Implications of reconstruction protocol for histo-biological characterisation of breast cancers using FDG-PET radiomics.EJNMMI Res. 2018 Dec 29;8(1):114. doi: 10.1186/s13550-018-0466-5.
184 CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.EMBO Rep. 2019 Oct 4;20(10):e48058. doi: 10.15252/embr.201948058. Epub 2019 Aug 30.
185 p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA.Oncogene. 2017 Jan 19;36(3):304-317. doi: 10.1038/onc.2016.202. Epub 2016 Jun 27.
186 Prostate-specific antigen gene expression and telomerase activity in breast cancer patients: possible relationship to steroid hormone receptors.Oncol Res. 2011;19(8-9):375-80. doi: 10.3727/096504011x13123323849636.
187 Tpl-2/Cot and COX-2 in breast cancer.Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008 Jun;152(1):21-5. doi: 10.5507/bp.2008.003.
188 MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population.Breast Cancer Res Treat. 2019 Feb;174(1):257-269. doi: 10.1007/s10549-018-5065-7. Epub 2018 Nov 23.
189 MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability.Mol Cancer. 2017 Mar 7;16(1):55. doi: 10.1186/s12943-017-0626-7.
190 The clinical implications of MMP-11 and CK-20 expression in human breast cancer.Clin Chim Acta. 2010 Feb;411(3-4):234-41. doi: 10.1016/j.cca.2009.11.009. Epub 2009 Nov 13.
191 Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications.Mol Oncol. 2017 Dec;11(12):1788-1805. doi: 10.1002/1878-0261.12145. Epub 2017 Oct 31.
192 p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer.Oncogene. 2016 Jan 21;35(3):344-57. doi: 10.1038/onc.2015.87. Epub 2015 Apr 20.
193 Constitutive activation of STAT3 in breast cancer cells: A review.Int J Cancer. 2016 Jun 1;138(11):2570-8. doi: 10.1002/ijc.29923. Epub 2015 Nov 28.
194 Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.PLoS One. 2016 Jan 11;11(1):e0145647. doi: 10.1371/journal.pone.0145647. eCollection 2016.
195 Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro.Breast Cancer Res. 2018 Sep 18;20(1):113. doi: 10.1186/s13058-018-1042-7.
196 Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid.Cancer Immunol Res. 2019 Jan;7(1):113-122. doi: 10.1158/2326-6066.CIR-18-0256. Epub 2018 Nov 9.
197 Estrogen receptor- recruits P-TEFb to overcome transcriptional pausing in intron 1 of the MYB gene.Nucleic Acids Res. 2012 Jul;40(13):5988-6000. doi: 10.1093/nar/gks286. Epub 2012 Apr 5.
198 Loss of MLCK leads to disruption of cell-cell adhesion and invasive behavior of breast epithelial cells via increased expression of EGFR and ERK/JNK signaling.Oncogene. 2016 Aug 25;35(34):4495-508. doi: 10.1038/onc.2015.508. Epub 2016 Feb 15.
199 Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer.Nature. 2018 Apr;556(7700):249-254. doi: 10.1038/s41586-018-0018-1. Epub 2018 Apr 3.
200 Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition.Cancer Lett. 2009 Jan 18;273(2):243-9. doi: 10.1016/j.canlet.2008.08.015. Epub 2008 Sep 19.
201 Genetic polymorphisms of metastasis suppressor gene NME1 and breast cancer survival.Clin Cancer Res. 2008 Aug 1;14(15):4787-93. doi: 10.1158/1078-0432.CCR-08-0083.
202 NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.Breast Cancer Res. 2011 Jun 14;13(3):R63. doi: 10.1186/bcr2900.
203 Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.Breast Cancer Res Treat. 2019 Sep;177(2):369-382. doi: 10.1007/s10549-019-05329-2. Epub 2019 Jun 28.
204 Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis.Mol Cancer Ther. 2020 Mar;19(3):802-811. doi: 10.1158/1535-7163.MCT-19-0495. Epub 2019 Dec 3.
205 Bone marrow-derived fibroblasts are a functionally distinct stromal cell population in breast cancer.J Exp Med. 2018 Dec 3;215(12):3075-3093. doi: 10.1084/jem.20180818. Epub 2018 Nov 23.
206 Immunohistochemical analysis of PDK1 expression in breast cancer.Diagn Pathol. 2014 Apr 16;9:82. doi: 10.1186/1746-1596-9-82.
207 Association of rs1801157 single nucleotide polymorphism of CXCL12 gene in breast cancer in Pakistan and in-silico expression analysis of CXCL12-CXCR4 associated biological regulatory network.PeerJ. 2017 Sep 15;5:e3822. doi: 10.7717/peerj.3822. eCollection 2017.
208 Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth.Oncotarget. 2013 Dec;4(12):2502-11. doi: 10.18632/oncotarget.1540.
209 Mixed-lineage kinase 3 phosphorylates prolyl-isomerase Pin1 to regulate its nuclear translocation and cellular function.Proc Natl Acad Sci U S A. 2012 May 22;109(21):8149-54. doi: 10.1073/pnas.1200804109. Epub 2012 May 7.
210 What Is Breast in the Bone?.Int J Mol Sci. 2016 Oct 22;17(10):1764. doi: 10.3390/ijms17101764.
211 Euterpe oleracea extract inhibits tumorigenesis effect of the chemical carcinogen DMBA in breast experimental cancer.BMC Complement Altern Med. 2018 Apr 2;18(1):116. doi: 10.1186/s12906-018-2183-z.
212 Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T.Breast Cancer Res Treat. 2019 Apr;174(2):543-550. doi: 10.1007/s10549-018-05094-8. Epub 2018 Dec 14.
213 Trastuzumab stimulation of ribosomal protein S6 kinase 1 (S6K1) predicts de novo trastuzumab resistance.Biochem Biophys Res Commun. 2017 Jan 29;483(1):739-744. doi: 10.1016/j.bbrc.2016.12.072. Epub 2016 Dec 18.
214 Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.Breast Cancer Res Treat. 2011 Aug;128(3):713-23. doi: 10.1007/s10549-010-1058-x. Epub 2010 Oct 16.
215 Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells.Mol Cancer. 2015 Jan 27;14(1):15. doi: 10.1186/s12943-014-0279-8.
216 Interferon-inducible protein IFIXalpha inhibits cell invasion by upregulating the metastasis suppressor maspin.Mol Carcinog. 2008 Oct;47(10):739-43. doi: 10.1002/mc.20423.
217 Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer.Breast. 2019 Aug;46:101-107. doi: 10.1016/j.breast.2019.05.007. Epub 2019 May 3.
218 Quantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patients. PLoS One. 2011;6(7):e22233.
219 Defining the Na(+)/H(+) exchanger NHE1 interactome in triple-negative breast cancer cells.Cell Signal. 2017 Jan;29:69-77. doi: 10.1016/j.cellsig.2016.10.005. Epub 2016 Oct 15.
220 Manganese superoxide dismutase: effect of the ala16val polymorphism on protein, activity, and mRNA levels in human breast cancer cell lines and stably transfected mouse embryonic fibroblasts.Mol Cell Biochem. 2010 Feb;335(1-2):107-18. doi: 10.1007/s11010-009-0247-6. Epub 2009 Sep 13.
221 Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion.Curr Biol. 2015 Dec 7;25(23):3019-34. doi: 10.1016/j.cub.2015.09.072. Epub 2015 Nov 5.
222 STAT3 Activation-Induced Fatty Acid Oxidation in CD8(+) T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth.Cell Metab. 2020 Jan 7;31(1):148-161.e5. doi: 10.1016/j.cmet.2019.10.013. Epub 2019 Nov 21.
223 Stanniocalcin Expression as a Predictor of Late Breast Cancer Recurrence.Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):653-659. doi: 10.1158/1055-9965.EPI-17-0905. Epub 2018 Mar 28.
224 Tissue-specific selection of optimal reference genes for expression analysis of anti-cancer drug-related genes in tumor samples using quantitative real-time RT-PCR.Exp Mol Pathol. 2015 Jun;98(3):375-81. doi: 10.1016/j.yexmp.2014.10.014. Epub 2014 Nov 3.
225 TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells.Breast Cancer Res Treat. 2008 Jan;107(1):15-24. doi: 10.1007/s10549-007-9526-7. Epub 2007 Feb 15.
226 ADAM12 Is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling.Mol Cancer Res. 2017 Nov;15(11):1608-1622. doi: 10.1158/1541-7786.MCR-17-0188. Epub 2017 Aug 1.
227 Overexpression of the receptor tyrosine kinase Tie-1 intracellular domain in breast cancer.Tumour Biol. 2003 Mar-Apr;24(2):61-9. doi: 10.1159/000071078.
228 Matriptase-2 inhibits HECV motility and tubule formation in vitro and tumour angiogenesis in vivo.Mol Cell Biochem. 2013 Mar;375(1-2):207-17. doi: 10.1007/s11010-012-1544-z. Epub 2012 Dec 13.
229 Quantitative analysis of three-dimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function.Am J Pathol. 2010 Feb;176(2):827-38. doi: 10.2353/ajpath.2010.090006. Epub 2009 Dec 30.
230 Consequences of EMT-Driven Changes in the Immune Microenvironment of Breast Cancer and Therapeutic Response of Cancer Cells.J Clin Med. 2019 May 9;8(5):642. doi: 10.3390/jcm8050642.
231 Deubiquitylation and stabilization of PTEN by USP13.Nat Cell Biol. 2013 Dec;15(12):1486-1494. doi: 10.1038/ncb2874. Epub 2013 Nov 24.
232 YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation.Cancer Lett. 2019 Oct 10;462:51-60. doi: 10.1016/j.canlet.2019.07.015. Epub 2019 Jul 25.
233 High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival.Breast Cancer Res Treat. 2013 Feb;137(3):773-82. doi: 10.1007/s10549-012-2398-5. Epub 2013 Jan 4.
234 Genetic variability in the regulation of the expression cluster of MDR genes in patients with breast cancer.Cancer Chemother Pharmacol. 2017 Aug;80(2):251-260. doi: 10.1007/s00280-017-3354-1. Epub 2017 Jun 10.
235 FBLN-4 and BCRP genes as two prognostic markers are downregulated in breast cancer tissue.Cancer Biomark. 2017;19(1):51-55. doi: 10.3233/CBM-160335.
236 HER2 Signaling Hijacks the Creatine Shuttle to Fuel Breast Cancer Cell Growth.Cell Metab. 2018 Dec 4;28(6):805-807. doi: 10.1016/j.cmet.2018.11.009.
237 Atypical Chemokine Receptor 1 (DARC/ACKR1) in Breast Tumors Is Associated with Survival, Circulating Chemokines, Tumor-Infiltrating Immune Cells, and African Ancestry.Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):690-700. doi: 10.1158/1055-9965.EPI-18-0955.
238 mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer.Oncotarget. 2016 May 3;7(18):25224-40. doi: 10.18632/oncotarget.8279.
239 Genetic variation in bone morphogenetic proteins and breast cancer risk in hispanic and non-hispanic white women: The breast cancer health disparities study.Int J Cancer. 2013 Jun 15;132(12):2928-39. doi: 10.1002/ijc.27960. Epub 2012 Dec 13.
240 Breast cancer is associated with methylation and expression of the a disintegrin and metalloproteinase domain33 (ADAM33) gene affected by endocrinedisrupting chemicals.Oncol Rep. 2018 Nov;40(5):2766-2777. doi: 10.3892/or.2018.6675. Epub 2018 Aug 30.
241 Cleavage of Fibulin-2 by the aggrecanases ADAMTS-4 and ADAMTS-5 contributes to the tumorigenic potential of breast cancer cells.Oncotarget. 2017 Feb 21;8(8):13716-13729. doi: 10.18632/oncotarget.14627.
242 Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.Gynecol Endocrinol. 2005 Jun;20(6):327-33. doi: 10.1080/09513590500098240.
243 Adenosine modulates cell growth in the human breast cancer cells via adenosine receptors.Oncol Res. 2007;16(12):575-85. doi: 10.3727/000000007783629981.
244 Hormones of pregnancy, alpha-feto protein, and reduction of breast cancer risk. Adv Exp Med Biol. 2008;617:477-84. doi: 10.1007/978-0-387-69080-3_47.
245 High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism.PLoS One. 2018 Jan 10;13(1):e0190619. doi: 10.1371/journal.pone.0190619. eCollection 2018.
246 Daintain/AIF-1 promotes breast cancer proliferation via activation of the NF-kappaB/cyclin D1 pathway and facilitates tumor growth.Cancer Sci. 2008 May;99(5):952-7. doi: 10.1111/j.1349-7006.2008.00787.x. Epub 2007 Mar 12.
247 Expression of 17beta-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters.J Steroid Biochem Mol Biol. 2008 Dec;112(4-5):194-200. doi: 10.1016/j.jsbmb.2008.10.004. Epub 2008 Oct 19.
248 Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.J Clin Oncol. 2009 Feb 1;27(4):542-9. doi: 10.1200/JCO.2008.17.1462. Epub 2008 Dec 15.
249 Gold nanoprobe-based method for sensing activated leukocyte cell adhesion molecule (ALCAM) gene expression, as a breast cancer biomarker.Artif Cells Nanomed Biotechnol. 2017 Mar;45(2):277-282. doi: 10.3109/21691401.2016.1146732. Epub 2016 Feb 28.
250 A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer.Nat Genet. 2018 Jul;50(7):968-978. doi: 10.1038/s41588-018-0132-x. Epub 2018 Jun 18.
251 Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy.Indian J Cancer. 2006 Oct-Dec;43(4):163-8. doi: 10.4103/0019-509x.29421.
252 Reduction of isoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer.Prostaglandins Leukot Essent Fatty Acids. 2006 Apr;74(4):235-45. doi: 10.1016/j.plefa.2006.01.009. Epub 2006 Mar 23.
253 Microsatellite instabilities at five chromosomes in primary breast tumors.Oncogene. 1994 Dec;9(12):3695-700.
254 Anthrax toxin receptor 2 is expressed in murine and tumor vasculature and functions in endothelial proliferation and morphogenesis.Oncogene. 2010 Feb 11;29(6):789-801. doi: 10.1038/onc.2009.383. Epub 2009 Nov 9.
255 Annexin A1 influences in breast cancer: Controversies on contributions to tumour, host and immunoediting processes.Pharmacol Res. 2017 May;119:278-288. doi: 10.1016/j.phrs.2017.02.011. Epub 2017 Feb 14.
256 MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression.Mol Cancer. 2015 Aug 15;14:156. doi: 10.1186/s12943-015-0428-8.
257 Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer.Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6872-9. doi: 10.1158/1078-0432.CCR-05-0547.
258 Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis.PLoS Med. 2008 May 27;5(5):e114. doi: 10.1371/journal.pmed.0050114.
259 Presence of two members of c-erbA receptor gene family (c-erbA beta and c-erbA2) in smallest region of somatic homozygosity on chromosome 3p21-p25 in human breast carcinoma.J Natl Cancer Inst. 1989 Dec 6;81(23):1815-20. doi: 10.1093/jnci/81.23.1815.
260 The effects of beta-estradiol on Raf activity, cell cycle progression and growth factor synthesis in the MCF-7 breast cancer cell line. Cancer Biol Ther. 2002 May-Jun;1(3):256-62. doi: 10.4161/cbt.77.
261 Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1. Oncotarget. 2016 Sep 6;7(36):58111-58120.
262 Mapping Metabolic Events in the Cancer Cell Cycle Reveals Arginine Catabolism in the Committed SG(2)M Phase.Cell Rep. 2019 Feb 12;26(7):1691-1700.e5. doi: 10.1016/j.celrep.2019.01.059.
263 Optimizing the dosing schedule of l-asparaginase improves its anti-tumor activity in breast tumor-bearing mice.J Pharmacol Sci. 2018 Apr;136(4):228-233. doi: 10.1016/j.jphs.2018.01.008. Epub 2018 Mar 12.
264 ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2.Cancer Res. 2010 Nov 15;70(22):9402-12. doi: 10.1158/0008-5472.CAN-10-1199. Epub 2010 Sep 23.
265 ATAT1/MEC-17 acetyltransferase and HDAC6 deacetylase control a balance of acetylation of alpha-tubulin and cortactin and regulate MT1-MMP trafficking and breast tumor cell invasion.Eur J Cell Biol. 2012 Nov-Dec;91(11-12):950-60. doi: 10.1016/j.ejcb.2012.07.001. Epub 2012 Aug 16.
266 Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma.Jpn J Cancer Res. 2002 Jan;93(1):70-7. doi: 10.1111/j.1349-7006.2002.tb01202.x.
267 A p18 mutant defective in CDK6 binding in human breast cancer cells.Cancer Res. 1996 Oct 15;56(20):4586-9.
268 Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.PLoS One. 2015 Apr 1;10(4):e0120020. doi: 10.1371/journal.pone.0120020. eCollection 2015.
269 Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3, FOXM1, and a gene signature associated with mitosis.Breast Cancer Res. 2011 Jun 29;13(3):R70. doi: 10.1186/bcr2913.
270 Zinc-2-glycoprotein: a proliferative factor for breast cancer? In vitro study and molecular mechanisms.Oncol Rep. 2013 May;29(5):2025-9. doi: 10.3892/or.2013.2311. Epub 2013 Feb 27.
271 A novel aspartic protease gene, ALP56, is up-regulated in human breast cancer independently from the cathepsin D gene.Breast Cancer Res Treat. 2003 Mar;78(1):37-44. doi: 10.1023/a:1022149226430.
272 Therapeutic Effect of Camel Milk and Its Exosomes on MCF7 Cells In Vitro and In Vivo.Integr Cancer Ther. 2018 Dec;17(4):1235-1246. doi: 10.1177/1534735418786000. Epub 2018 Jul 10.
273 The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ER-negative breast cancer.Oncogene. 2017 Jul 20;36(29):4124-4134. doi: 10.1038/onc.2017.32. Epub 2017 Mar 20.
274 Transcriptional hallmarks of cancer cell lines reveal an emerging role of branched chain amino acid catabolism.Sci Rep. 2017 Aug 10;7(1):7820. doi: 10.1038/s41598-017-08329-8.
275 Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen.Breast Cancer Res Treat. 2008 Jun;109(3):491-501. doi: 10.1007/s10549-007-9673-x. Epub 2007 Jul 21.
276 Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts.J Pathol. 2006 Dec;210(4):420-30. doi: 10.1002/path.2071.
277 Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.EMBO Mol Med. 2014 Dec;6(12):1542-60. doi: 10.15252/emmm.201404402.
278 Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol. 2007 Jan;71(1):101-11. doi: 10.1124/mol.106.027367. Epub 2006 Oct 11.
279 Bone morphogenetic protein 6 inhibit stress-induced breast cancer cells apoptosis via both Smad and p38 pathways.J Cell Biochem. 2008 Apr 1;103(5):1584-97. doi: 10.1002/jcb.21547.
280 The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells.Oncogene. 2004 Mar 11;23(10):1854-62. doi: 10.1038/sj.onc.1207308.
281 Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome.Int J Cancer. 2013 Dec 15;133(12):2791-800. doi: 10.1002/ijc.28304. Epub 2013 Aug 9.
282 BRD7 is a candidate tumour suppressor gene required for p53 function.Nat Cell Biol. 2010 Apr;12(4):380-9. doi: 10.1038/ncb2038. Epub 2010 Mar 14.
283 Cysteine-linked dimerization of BST-2 confers anoikis resistance to breast cancer cells by negating proapoptotic activities to promote tumor cell survival and growth.Cell Death Dis. 2017 Mar 16;8(3):e2687. doi: 10.1038/cddis.2017.68.
284 Bcell translocation 1 gene inhibits cellular metastasisassociated behavior in breast cancer.Mol Med Rep. 2014 Jun;9(6):2374-80. doi: 10.3892/mmr.2014.2118. Epub 2014 Apr 4.
285 Application of polymersomes engineered to target p32 protein for detection of small breast tumors in mice.Oncotarget. 2018 Apr 10;9(27):18682-18697. doi: 10.18632/oncotarget.24588. eCollection 2018 Apr 10.
286 Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer.Cancer Res. 2008 May 1;68(9):3505-15. doi: 10.1158/0008-5472.CAN-07-6151.
287 Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.Endocr Relat Cancer. 2006 Sep;13(3):921-30. doi: 10.1677/erc.1.01216.
288 Identification of a new breast cancer-related gene by restriction landmark genomic scanning.Anticancer Res. 2006 Jan-Feb;26(1A):35-42.
289 Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion.J Cell Biol. 2008 Mar 10;180(5):957-71. doi: 10.1083/jcb.200708048.
290 PELP1 oncogenic functions involve CARM1 regulation.Carcinogenesis. 2013 Jul;34(7):1468-75. doi: 10.1093/carcin/bgt091. Epub 2013 Mar 13.
291 HOXA5-induced apoptosis in breast cancer cells is mediated by caspases 2 and 8.Mol Cell Biol. 2004 Jan;24(2):924-35. doi: 10.1128/MCB.24.2.924-935.2004.
292 Capsaicin-induced inactivation of sensory neurons promotes a more aggressive gene expression phenotype in breast cancer cells.Breast Cancer Res Treat. 2006 Oct;99(3):351-64. doi: 10.1007/s10549-006-9219-7. Epub 2006 Apr 1.
293 CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.Cancer Sci. 2008 Oct;99(10):2045-54. doi: 10.1111/j.1349-7006.2008.00903.x.
294 Prognostic values of distinct CBX family members in breast cancer.Oncotarget. 2017 Sep 28;8(54):92375-92387. doi: 10.18632/oncotarget.21325. eCollection 2017 Nov 3.
295 Cathepsin D specifically cleaves the chemokines macrophage inflammatory protein-1 alpha, macrophage inflammatory protein-1 beta, and SLC that are expressed in human breast cancer.Am J Pathol. 2003 Apr;162(4):1183-90. doi: 10.1016/s0002-9440(10)63914-4.
296 Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.Cancer Res. 2009 Mar 1;69(5):2000-9. doi: 10.1158/0008-5472.CAN-08-2360. Epub 2009 Feb 24.
297 miR-379 regulates cyclin B1 expression and is decreased in breast cancer.PLoS One. 2013 Jul 10;8(7):e68753. doi: 10.1371/journal.pone.0068753. Print 2013.
298 Nicotine-induced human breast cancer cell proliferation attenuated by garcinol through down-regulation of the nicotinic receptor and cyclin D3 proteins.Breast Cancer Res Treat. 2011 Jan;125(1):73-87. doi: 10.1007/s10549-010-0821-3. Epub 2010 Mar 13.
299 4-Hydroxytamoxifen-stimulated processing of cyclin E is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells. Toxicology. 2013 Jul 5;309:61-5. doi: 10.1016/j.tox.2013.04.012. Epub 2013 Apr 25.
300 Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3319-28. doi: 10.1158/1078-0432.CCR-06-0225.
301 The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer.Breast Cancer Res Treat. 2012 Feb;131(3):837-48. doi: 10.1007/s10549-011-1502-6. Epub 2011 Apr 9.
302 CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis.BMC Cancer. 2017 Dec 8;17(1):834. doi: 10.1186/s12885-017-3817-0.
303 Targeting of TGF--activated protein kinase 1 inhibits chemokine (C-C motif) receptor 7 expression, tumor growth and metastasis in breast cancer.Oncotarget. 2015 Jan 20;6(2):995-1007. doi: 10.18632/oncotarget.2739.
304 CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion.Int J Oncol. 2011 May;38(5):1279-85. doi: 10.3892/ijo.2011.953. Epub 2011 Feb 23.
305 CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome.Histopathology. 2008 Jan;52(2):203-12. doi: 10.1111/j.1365-2559.2007.02919.x.
306 IMP3 promotes TNBC stem cell property through miRNA-34a regulation.Eur Rev Med Pharmacol Sci. 2018 May;22(9):2688-2696. doi: 10.26355/eurrev_201805_14965.
307 Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.Breast Cancer Res Treat. 2006 Jul;98(1):17-29. doi: 10.1007/s10549-005-9108-5. Epub 2006 Jun 7.
308 Prognostic significance of CD55 expression in breast cancer.Clin Cancer Res. 2008 Aug 1;14(15):4780-6. doi: 10.1158/1078-0432.CCR-07-1844.
309 Measurements of heterotypic associations between cluster of differentiation CD74 and CD44 in human breast cancer-derived cells.Oncotarget. 2017 Sep 14;8(54):92143-92156. doi: 10.18632/oncotarget.20922. eCollection 2017 Nov 3.
310 Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells.Oncol Rep. 2003 Mar-Apr;10(2):405-10.
311 Anti-tumor activity of SL4 against breast cancer cells: induction of G(2)/M arrest through modulation of the MAPK-dependent p21 signaling pathway.Sci Rep. 2016 Nov 7;6:36486. doi: 10.1038/srep36486.
312 Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.Oncotarget. 2014 Mar 30;5(6):1458-74. doi: 10.18632/oncotarget.1538.
313 Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer.J Exp Med. 2016 Oct 17;213(11):2503-2523. doi: 10.1084/jem.20160397. Epub 2016 Oct 10.
314 Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin.BMC Cancer. 2008 Jan 29;8:28. doi: 10.1186/1471-2407-8-28.
315 Estrogen receptor causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2.Breast Cancer Res Treat. 2011 Oct;129(3):777-84. doi: 10.1007/s10549-010-1273-5. Epub 2010 Dec 1.
316 Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.Cancer Res. 2013 Sep 1;73(17):5556-68. doi: 10.1158/0008-5472.CAN-13-0013. Epub 2013 Aug 16.
317 High levels of Hsp90 cochaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistance.Cancer Res. 2010 Nov 1;70(21):8446-56. doi: 10.1158/0008-5472.CAN-10-1590. Epub 2010 Sep 16.
318 Recent progress in carcinogenesis, progression and therapy of breast cancer: the 20th Hiroshima Cancer Seminar--the 4th Three Universities' Consortium International Symposium, October 2010: 31 October 2010, International Conference Center Hiroshima.Jpn J Clin Oncol. 2011 Jul;41(7):924-30. doi: 10.1093/jjco/hyr054. Epub 2011 May 12.
319 Identification of two isoforms of the Cak receptor kinase that are coexpressed in breast tumor cell lines.Oncogene. 1996 Apr 4;12(7):1469-77.
320 Parvin-beta inhibits breast cancer tumorigenicity and promotes CDK9-mediated peroxisome proliferator-activated receptor gamma 1 phosphorylation.Mol Cell Biol. 2008 Jan;28(2):687-704. doi: 10.1128/MCB.01617-06. Epub 2007 Nov 12.
321 Combining mammaglobin and carcinoembryonic mRNA markers for early detection of micrometastases from breast cancers--a molecular study of 59 patients.Asian Pac J Cancer Prev. 2006 Jul-Sep;7(3):396-8.
322 Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen.Clin Cancer Res. 2008 Jan 15;14(2):405-11. doi: 10.1158/1078-0432.CCR-07-1363.
323 Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer.Clin Cancer Res. 2005 May 1;11(9):3184-90. doi: 10.1158/1078-0432.CCR-04-2625.
324 Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.Breast Cancer Res. 2016 Jul 1;18(1):70. doi: 10.1186/s13058-016-0728-y.
325 Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.Invest New Drugs. 2012 Apr;30(2):541-7. doi: 10.1007/s10637-010-9597-x. Epub 2010 Nov 25.
326 Beta-hCG/LH receptor (b-HCG/LH-R) expression is increased in invasive versus preinvasive breast cancer: implications for breast carcinogenesis?.J Cancer Res Clin Oncol. 2009 Feb;135(2):191-5. doi: 10.1007/s00432-008-0458-3. Epub 2008 Aug 29.
327 Inhibiting checkpoint kinase 1 protects bone from bone resorption by mammary tumor in a mouse model.Oncotarget. 2018 Jan 19;9(10):9364-9378. doi: 10.18632/oncotarget.24286. eCollection 2018 Feb 6.
328 Near infrared fluorescent imaging of choline kinase alpha expression and inhibition in breast tumors.Oncotarget. 2017 Mar 7;8(10):16518-16530. doi: 10.18632/oncotarget.14965.
329 Rac-GAP-dependent inhibition of breast cancer cell proliferation by {beta}2-chimerin.J Biol Chem. 2005 Jul 1;280(26):24363-70. doi: 10.1074/jbc.M411629200. Epub 2005 Apr 29.
330 Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells.Cancer Res. 2005 Dec 15;65(24):11375-83. doi: 10.1158/0008-5472.CAN-05-1602.
331 Tumorigenicity of human breast cancer is associated with loss of the Ca2+-activated chloride channel CLCA2.Cancer Res. 1999 Nov 1;59(21):5488-91.
332 Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling.Cell Cycle. 2010 Jun 15;9(12):2412-22. doi: 10.4161/cc.9.12.11989. Epub 2010 Jun 15.
333 CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer.Cancer Res. 2015 Apr 1;75(7):1516-26. doi: 10.1158/0008-5472.CAN-14-2443. Epub 2015 Feb 10.
334 Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells.AAPS J. 2019 Jan 7;21(2):13. doi: 10.1208/s12248-018-0279-5.
335 Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006 Jul 1;66(13):6615-21. doi: 10.1158/0008-5472.CAN-05-4566.
336 Endostatin gene variation and protein levels in breast cancer susceptibility and severity.BMC Cancer. 2007 Jun 22;7:107. doi: 10.1186/1471-2407-7-107.
337 Procollagen I COOH-terminal fragment induces VEGF-A and CXCR4 expression in breast carcinoma cells.Exp Cell Res. 2008 Jul 1;314(11-12):2289-98. doi: 10.1016/j.yexcr.2008.04.016. Epub 2008 May 10.
338 Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms.Cancer Res. 2008 Jul 15;68(14):5997-6005. doi: 10.1158/0008-5472.CAN-08-0043.
339 CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression.Cancer Res. 2008 Jan 15;68(2):506-15. doi: 10.1158/0008-5472.CAN-07-3060.
340 Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment.Clin Exp Metastasis. 2017 Feb;34(2):155-169. doi: 10.1007/s10585-017-9837-y. Epub 2017 Jan 25.
341 Differential processing of neuropeptide proprotein in human breast adenocarcinoma.J Endocrinol Invest. 2013 Oct;36(9):745-52. doi: 10.3275/8935. Epub 2013 Apr 12.
342 TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells.BMC Cancer. 2008 Oct 3;8:282. doi: 10.1186/1471-2407-8-282.
343 Next-generation RNA sequencing of FFPE subsections reveals highly conserved stromal reprogramming between canine and human mammary carcinoma.Dis Model Mech. 2019 Aug 8;12(8):dmm040444. doi: 10.1242/dmm.040444.
344 miR-21 is targeted by omega-3 polyunsaturated fatty acid to regulate breast tumor CSF-1 expression.Carcinogenesis. 2012 Oct;33(10):1897-908. doi: 10.1093/carcin/bgs198. Epub 2012 Jun 7.
345 Wnt-5a/Ca2+-induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1alpha signaling in human mammary epithelial cells.Mol Cell Biol. 2006 Aug;26(16):6024-36. doi: 10.1128/MCB.02354-05.
346 Therapeutic targeting of casein kinase 1 in breast cancer.Sci Transl Med. 2015 Dec 16;7(318):318ra202. doi: 10.1126/scitranslmed.aac8773.
347 Casein kinase 1 promotes cell proliferation by regulating mRNA translation.Cancer Res. 2014 Jan 1;74(1):201-11. doi: 10.1158/0008-5472.CAN-13-1175. Epub 2013 Nov 18.
348 Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT.Cancer Lett. 2007 Oct 28;256(2):229-37. doi: 10.1016/j.canlet.2007.06.010. Epub 2007 Jul 16.
349 Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers.Histopathology. 2018 Jul;73(1):68-80. doi: 10.1111/his.13498. Epub 2018 Apr 14.
350 BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours.Br J Cancer. 2008 Feb 12;98(3):571-9. doi: 10.1038/sj.bjc.6604181. Epub 2008 Jan 15.
351 Alteration of cathepsin D trafficking induced by hypoxia and extracellular acidification in MCF-7 breast cancer cells.Biochimie. 2016 Feb;121:123-30. doi: 10.1016/j.biochi.2015.11.007. Epub 2015 Nov 12.
352 Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer.Int J Biol Markers. 2008 Jul-Sep;23(3):161-8. doi: 10.1177/172460080802300305.
353 Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB. Carcinogenesis. 2008 Apr;29(4):779-89.
354 Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.Breast Cancer Res Treat. 2009 Nov;118(1):45-56. doi: 10.1007/s10549-008-0207-y. Epub 2008 Oct 17.
355 CXXC5 expression in prostate cancer: implications for cancer progression.Int J Exp Pathol. 2017 Aug;98(4):234-243. doi: 10.1111/iep.12241.
356 Coffee consumption and CYP1A2*1F genotype modify age at breast cancer diagnosis and estrogen receptor status.Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):895-901. doi: 10.1158/1055-9965.EPI-07-0555.
357 Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.Breast Cancer Res. 2004;6(3):R252-63. doi: 10.1186/bcr784. Epub 2004 Mar 26.
358 CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
359 Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.Breast Cancer Res Treat. 2009 Dec;118(3):531-8. doi: 10.1007/s10549-009-0463-5. Epub 2009 Jul 12.
360 Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.Cell Chem Biol. 2017 Oct 19;24(10):1259-1275.e6. doi: 10.1016/j.chembiol.2017.08.009. Epub 2017 Sep 14.
361 The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue.Breast Cancer Res Treat. 2001 Nov;70(1):47-54. doi: 10.1023/a:1012526406741.
362 DDR1 promotes breast tumor growth by suppressing antitumor immunity.Oncol Rep. 2019 Dec;42(6):2844-2854. doi: 10.3892/or.2019.7338. Epub 2019 Sep 27.
363 DEAD-box protein p68 is regulated by -catenin/transcription factor 4 to maintain a positive feedback loop in control of breast cancer progression.Breast Cancer Res. 2014 Dec 12;16(6):496. doi: 10.1186/s13058-014-0496-5.
364 Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers.Cancer Res. 2018 Nov 1;78(21):6183-6195. doi: 10.1158/0008-5472.CAN-18-0730. Epub 2018 Sep 17.
365 Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity.Mol Ther. 2009 Sep;17(9):1626-36. doi: 10.1038/mt.2009.111. Epub 2009 Jun 16.
366 Hierarchical Convolutional Neural Networks for Segmentation of Breast Tumors in MRI With Application to Radiogenomics.IEEE Trans Med Imaging. 2019 Feb;38(2):435-447. doi: 10.1109/TMI.2018.2865671. Epub 2018 Aug 16.
367 Impaired kinetics of Bax-GFP and Smac/DIABLO-GFP in caspase-8- and bid-silenced and Bcl-2 overexpressed breast cancer MCF-7 cells exposed to camptothecin.Cell Mol Biol (Noisy-le-grand). 2007 Jan 21;52 Suppl:OL915-22.
368 Human breast cancer tissue expresses high level of type 1 5'-deiodinase.Thyroid. 2007 Jan;17(1):3-10. doi: 10.1089/thy.2006.0012.
369 Dickkopf-1 (Dkk1) protein expression in breast cancer with special reference to bone metastases.Clin Exp Metastasis. 2018 Dec;35(8):763-775. doi: 10.1007/s10585-018-9937-3. Epub 2018 Sep 20.
370 Dickkopf-related protein 2 induces G0/G1 arrest and apoptosis through suppressing Wnt/-catenin signaling and is frequently methylated in breast cancer.Oncotarget. 2017 Jun 13;8(24):39443-39459. doi: 10.18632/oncotarget.17055.
371 Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation.Anticancer Res. 2010 Oct;30(10):3853-67.
372 JDP1 (DNAJC12/Hsp40) expression in breast cancer and its association with estrogen receptor status.Int J Mol Med. 2006 Feb;17(2):363-7.
373 Expression and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in tamoxifen-treated breast cancer patients.Gene. 2019 Feb 15;685:24-31. doi: 10.1016/j.gene.2018.10.060. Epub 2018 Oct 23.
374 Unraveling a tumor type-specific regulatory core underlying E2F1-mediated epithelial-mesenchymal transition to predict receptor protein signatures.Nat Commun. 2017 Aug 4;8(1):198. doi: 10.1038/s41467-017-00268-2.
375 Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors.Int J Cancer. 2009 May 1;124(9):2077-81. doi: 10.1002/ijc.24198.
376 Curtailing overexpression of E2F3 in breast cancer using siRNA (E2F3)-based gene silencing.Arch Med Res. 2012 Aug;43(6):415-22. doi: 10.1016/j.arcmed.2012.08.009. Epub 2012 Sep 7.
377 Ectopic expression of hC/EBPs in breast tumor cells induces apoptosis.Mol Cell Biochem. 2010 Apr;337(1-2):111-8. doi: 10.1007/s11010-009-0290-3. Epub 2009 Oct 23.
378 A role for endothelin-2 and its receptors in breast tumor cell invasion.Cancer Res. 2004 Apr 1;64(7):2461-8. doi: 10.1158/0008-5472.can-03-1069.
379 Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis.Oncogene. 2011 Feb 3;30(5):548-60. doi: 10.1038/onc.2010.433. Epub 2010 Sep 20.
380 Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells.Cancer Biol Ther. 2008 Sep;7(9):1496-506. doi: 10.4161/cbt.7.9.6490. Epub 2008 Sep 23.
381 Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression.Cancer Discov. 2016 May;6(5):516-31. doi: 10.1158/2159-8290.CD-15-1183. Epub 2016 Jan 25.
382 ITIH5 induces a shift in TGF- superfamily signaling involving Endoglin and reduces risk for breast cancer metastasis and tumor death.Mol Carcinog. 2018 Feb;57(2):167-181. doi: 10.1002/mc.22742. Epub 2017 Oct 30.
383 The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin.Biochem Biophys Res Commun. 2006 Feb 3;340(1):175-82. doi: 10.1016/j.bbrc.2005.11.171. Epub 2005 Dec 9.
384 Designing a HER2/neu promoter to drive alpha1,3galactosyltransferase expression for targeted anti-alphaGal antibody-mediated tumor cell killing.Breast Cancer Res. 2005;7(4):R487-94. doi: 10.1186/bcr1034. Epub 2005 May 3.
385 Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer.Hum Pathol. 2010 Jan;41(1):48-58. doi: 10.1016/j.humpath.2009.06.007. Epub 2009 Sep 5.
386 EphB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells.Oncogene. 2009 Apr 9;28(14):1706-13. doi: 10.1038/onc.2009.18. Epub 2009 Feb 23.
387 Quantitative comparison of erythropoietin receptor levels in the epithelial versus endothelial fractions of primary breast tumors.Anticancer Res. 2011 Apr;31(4):1189-95.
388 Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.BMC Cancer. 2018 Oct 26;18(1):1045. doi: 10.1186/s12885-018-4917-1.
389 ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis.Ann Oncol. 2008 Jan;19(1):73-80. doi: 10.1093/annonc/mdm431. Epub 2007 Oct 24.
390 ERR promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors.Oncogene. 2019 Feb;38(7):950-964. doi: 10.1038/s41388-018-0579-3. Epub 2018 Nov 26.
391 The orphan nuclear receptor estrogen-related receptor beta (ERR) in triple-negative breast cancer.Breast Cancer Res Treat. 2020 Feb;179(3):585-604. doi: 10.1007/s10549-019-05485-5. Epub 2019 Nov 19.
392 Ets2 in tumor fibroblasts promotes angiogenesis in breast cancer.PLoS One. 2013 Aug 16;8(8):e71533. doi: 10.1371/journal.pone.0071533. eCollection 2013.
393 Genome-wide expression analysis reveals six contravened targets of EZH2 associated with breast cancer patient survival.Sci Rep. 2019 Feb 13;9(1):1974. doi: 10.1038/s41598-019-39122-4.
394 1 integrin binding phosphorylates ezrin at T567 to activate a lipid raft signalsome driving invadopodia activity and invasion.PLoS One. 2013 Sep 24;8(9):e75113. doi: 10.1371/journal.pone.0075113. eCollection 2013.
395 Simvastatin induces apoptosis in human breast cancer cells in a NFkappaB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa. Thromb Res. 2008;122(2):191-202. doi: 10.1016/j.thromres.2007.09.017. Epub 2007 Nov 26.
396 PH motifs in PAR1&2 endow breast cancer growth.Nat Commun. 2015 Nov 24;6:8853. doi: 10.1038/ncomms9853.
397 Inhibition of tissue factor signaling in breast tumour xenografts induces widespread changes in the microRNA expression profile.Biochem Biophys Res Commun. 2017 Dec 16;494(3-4):700-705. doi: 10.1016/j.bbrc.2017.10.139. Epub 2017 Oct 28.
398 Coagulation factor VII is regulated by androgen receptor in breast cancer.Exp Cell Res. 2015 Feb 1;331(1):239-250. doi: 10.1016/j.yexcr.2014.10.002. Epub 2014 Oct 14.
399 Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells.Thromb Haemost. 2006 Aug;96(2):196-201.
400 Expression of human delta-6-desaturase is associated with aggressiveness of human breast cancer.Int J Mol Med. 2003 Aug;12(2):253-7.
401 Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers.Breast Cancer Res Treat. 2008 Sep;111(1):113-20. doi: 10.1007/s10549-007-9766-6. Epub 2007 Oct 12.
402 Serum DPPIV activity and CD26 expression on lymphocytes in patients with benign or malignant breast tumors.Immunobiology. 2011 Aug;216(8):942-6. doi: 10.1016/j.imbio.2011.01.005. Epub 2011 Jan 12.
403 Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.Histol Histopathol. 2017 Jul;32(7):687-698. doi: 10.14670/HH-11-830. Epub 2016 Oct 7.
404 A drug-delivery strategy for overcoming drug resistance in breast cancer through targeting of oncofetal fibronectin.Nanomedicine. 2017 Feb;13(2):713-722. doi: 10.1016/j.nano.2016.10.005. Epub 2016 Oct 19.
405 Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40.J Biol Chem. 2005 Apr 8;280(14):13285-91. doi: 10.1074/jbc.M410922200. Epub 2005 Feb 4.
406 Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation.Am J Hum Genet. 2016 Oct 6;99(4):903-911. doi: 10.1016/j.ajhg.2016.07.017. Epub 2016 Sep 15.
407 FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression.Mol Carcinog. 2018 Nov;57(11):1616-1625. doi: 10.1002/mc.22884. Epub 2018 Aug 22.
408 Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011 Oct 27;54(20):7066-83. doi: 10.1021/jm2006222. Epub 2011 Sep 21.
409 Expression of keratinocyte growth factor and its receptor in human breast cancer: its inhibitory role in the induction of apoptosis possibly through the overexpression of Bcl-2.Arch Histol Cytol. 2004 Dec;67(5):455-64. doi: 10.1679/aohc.67.455.
410 Identification of fibroblast growth factor-8b target genes associated with early and late cell cycle events in breast cancer cells.Mol Cell Endocrinol. 2012 Jul 6;358(1):104-15. doi: 10.1016/j.mce.2012.03.009. Epub 2012 Mar 23.
411 GPER Mediates a Feedforward FGF2/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells toward Breast Tumor Progression.Cells. 2019 Mar 7;8(3):223. doi: 10.3390/cells8030223.
412 The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells.Oncogene. 2010 Mar 11;29(10):1543-52. doi: 10.1038/onc.2009.432. Epub 2009 Nov 30.
413 Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.Endocr Relat Cancer. 2010 Dec 21;18(1):113-27. doi: 10.1677/ERC-09-0285. Print 2011 Feb.
414 The role of calcineurin/NFAT in SFRP2 induced angiogenesis--a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus.PLoS One. 2011;6(6):e20412. doi: 10.1371/journal.pone.0020412. Epub 2011 Jun 3.
415 Elevated FKBP52 expression indicates a poor outcome in patients with breast cancer.Oncol Lett. 2017 Nov;14(5):5379-5385. doi: 10.3892/ol.2017.6828. Epub 2017 Aug 25.
416 Genomic landscapes of breast fibroepithelial tumors.Nat Genet. 2015 Nov;47(11):1341-5. doi: 10.1038/ng.3409. Epub 2015 Oct 5.
417 Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility.Breast Cancer Res Treat. 2008 Feb;107(3):337-47. doi: 10.1007/s10549-007-9559-y. Epub 2007 Mar 28.
418 Prognostic significance of epithelial-mesenchymal transition proteins Twist and Foxc2 in phyllodes tumours of the breast.Breast Cancer Res Treat. 2015 Feb;150(1):19-29. doi: 10.1007/s10549-015-3296-4. Epub 2015 Feb 13.
419 FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer.EBioMedicine. 2019 Jan;39:226-238. doi: 10.1016/j.ebiom.2018.11.066. Epub 2018 Dec 20.
420 Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.Oncoimmunology. 2018 Sep 11;7(12):e1509820. doi: 10.1080/2162402X.2018.1509820. eCollection 2018.
421 Forkhead Box Q1 Is a Novel Target of Breast Cancer Stem Cell Inhibition by Diallyl Trisulfide.J Biol Chem. 2016 Jun 24;291(26):13495-508. doi: 10.1074/jbc.M116.715219. Epub 2016 Apr 29.
422 Annexin-1 signals mitogen-stimulated breast tumor cell proliferation by activation of the formyl peptide receptors (FPRs) 1 and 2.FASEB J. 2011 Feb;25(2):483-96. doi: 10.1096/fj.09-154096. Epub 2010 Oct 7.
423 Tumor cell escape from therapy-induced senescence.Biochem Pharmacol. 2019 Apr;162:202-212. doi: 10.1016/j.bcp.2018.12.013. Epub 2018 Dec 19.
424 Expression of the actin-binding proteins indicates that cofilin and fascin are related to breast tumour size.J Int Med Res. 2010 May-Jun;38(3):1042-8. doi: 10.1177/147323001003800331.
425 Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth.Cancer Res. 2007 Aug 1;67(15):7223-9. doi: 10.1158/0008-5472.CAN-07-0805.
426 RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.Mol Cancer. 2019 Mar 28;18(1):46. doi: 10.1186/s12943-019-1004-4.
427 The challenge of determining the impact of FUT3 tumor-associated polymorphism rs2306969 (-6951 C> T) in invasive breast cancer cells.Mol Biol Rep. 2019 Jun;46(3):3531-3536. doi: 10.1007/s11033-019-04780-0. Epub 2019 Mar 30.
428 Heregulin induces expression, ATPase activity, and nuclear localization of G3BP, a Ras signaling component, in human breast tumors.Cancer Res. 2002 Mar 1;62(5):1251-5.
429 Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance.BMC Cancer. 2019 Nov 12;19(1):1085. doi: 10.1186/s12885-019-6295-8.
430 Inhibitory effects of BMP9 on breast cancer cells by regulating their interaction with pre-adipocytes/adipocytes.Oncotarget. 2017 May 30;8(22):35890-35901. doi: 10.18632/oncotarget.16271.
431 Elevated GH/IGF-I promotes mammary tumors in high-fat, but not low-fat, fed mice.Carcinogenesis. 2014 Nov;35(11):2467-73. doi: 10.1093/carcin/bgu161. Epub 2014 Aug 1.
432 Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer.Eur J Endocrinol. 2007 Feb;156(2):187-94. doi: 10.1530/EJE-06-0611.
433 A novel human ghrelin variant (In1-ghrelin) and ghrelin-O-acyltransferase are overexpressed in breast cancer: potential pathophysiological relevance.PLoS One. 2011;6(8):e23302. doi: 10.1371/journal.pone.0023302. Epub 2011 Aug 4.
434 A novel role of gap junction connexin46 protein to protect breast tumors from hypoxia.Int J Cancer. 2010 Aug 15;127(4):839-48. doi: 10.1002/ijc.25107.
435 Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade.Int J Oncol. 2012 Aug;41(2):670-80. doi: 10.3892/ijo.2012.1478. Epub 2012 May 14.
436 Geminin overexpression induces mammary tumors via suppressing cytokinesis.Oncotarget. 2011 Dec;2(12):1011-27. doi: 10.18632/oncotarget.363.
437 Gonadotropin-releasing hormone gene expression in MDA-MB-231 and ZR-75-1 breast carcinoma cell lines.Cancer Res. 1991 May 15;51(10):2577-81.
438 The human gonadotropin-releasing hormone receptor gene (GNRHR) maps to chromosome band 4q13.Cytogenet Cell Genet. 1995;70(3-4):211-4. doi: 10.1159/000134035.
439 GPER1 influences cellular homeostasis and cytostatic drug resistance via influencing long chain ceramide synthesis in breast cancer cells.Int J Biochem Cell Biol. 2019 Jul;112:95-106. doi: 10.1016/j.biocel.2019.05.002. Epub 2019 May 11.
440 Accelerated mammary tumor development in mutant polyomavirus middle T transgenic mice expressing elevated levels of either the Shc or Grb2 adapter protein.Mol Cell Biol. 1999 Dec;19(12):8169-79. doi: 10.1128/MCB.19.12.8169.
441 Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells.Breast Cancer Res Treat. 2015 May;151(1):57-73. doi: 10.1007/s10549-015-3365-8. Epub 2015 Apr 10.
442 Identification of endogenous reference genes for qRT-PCR analysis in normal matched breast tumor tissues.Oncol Res. 2009;17(8):353-65. doi: 10.3727/096504009788428460.
443 Elevation of glutathione, glutathione-reductase and nucleic acids in both normal tissues and tumour of breast cancer patients.Cancer Lett. 1993 Aug 16;72(1-2):11-5. doi: 10.1016/0304-3835(93)90004-s.
444 Polymorphisms of glutathione S-transferase A1 and O1 and breast cancer among postmenopausal Danish women.Eur J Cancer Prev. 2008 Jun;17(3):225-9. doi: 10.1097/CEJ.0b013e3282b6fe1e.
445 Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.Cancer Res. 2007 Oct 15;67(20):10038-46. doi: 10.1158/0008-5472.CAN-07-0146.
446 An Oncolytic Adenovirus Targeting Transforming Growth Factor Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.Hum Gene Ther. 2019 Sep;30(9):1117-1132. doi: 10.1089/hum.2019.059. Epub 2019 Jul 1.
447 Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.PLoS One. 2014 May 14;9(5):e97771. doi: 10.1371/journal.pone.0097771. eCollection 2014.
448 Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway.Oncogene. 2018 Nov;37(45):5952-5966. doi: 10.1038/s41388-018-0379-9. Epub 2018 Jul 6.
449 Cabazitaxel and thymoquinone co-loaded lipospheres as a synergistic combination for breast cancer.Chem Phys Lipids. 2019 Nov;224:104707. doi: 10.1016/j.chemphyslip.2018.11.009. Epub 2018 Dec 4.
450 Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer.J Pathol. 2002 Mar;196(3):266-74. doi: 10.1002/path.1039.
451 Pre-diagnostic statin use, lymph node status and mortality in women with stages I-III breast cancer.Br J Cancer. 2017 Aug 8;117(4):588-596. doi: 10.1038/bjc.2017.227. Epub 2017 Jul 18.
452 Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer.Clin Cancer Res. 2018 Apr 1;24(7):1617-1628. doi: 10.1158/1078-0432.CCR-17-2587. Epub 2018 Jan 16.
453 hnRNP A1-mediated translational regulation of the G quadruplex-containing RON receptor tyrosine kinase mRNA linked to tumor progression.Oncotarget. 2016 Mar 29;7(13):16793-805. doi: 10.18632/oncotarget.7589.
454 HOXA5 regulates hMLH1 expression in breast cancer cells.Neoplasia. 2006 Apr;8(4):250-8. doi: 10.1593/neo.05766.
455 DNA methylation changes in murine breast adenocarcinomas allow the identification of candidate genes for human breast carcinogenesis.Mamm Genome. 2011 Apr;22(3-4):249-59. doi: 10.1007/s00335-011-9318-6. Epub 2011 Mar 4.
456 Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk.Sci Rep. 2016 Jul 18;6:30026. doi: 10.1038/srep30026.
457 Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer.Cancer Lett. 2018 Jun 28;424:70-83. doi: 10.1016/j.canlet.2018.03.014. Epub 2018 Mar 14.
458 Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):115-28. doi: 10.1016/j.jsbmb.2007.10.004. Epub 2007 Nov 17.
459 Breast adipose tissue estrogen metabolism in postmenopausal women with or without breast cancer.J Clin Endocrinol Metab. 2014 Dec;99(12):E2661-7. doi: 10.1210/jc.2014-2550.
460 Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.J Mol Endocrinol. 2008 Apr;40(4):161-72. doi: 10.1677/JME-07-0101.
461 Cell membrane gp96 facilitates HER2 dimerization and serves as a novel target in breast cancer.Int J Cancer. 2015 Aug 1;137(3):512-24. doi: 10.1002/ijc.29405. Epub 2015 Jan 8.
462 CAG repeat size in Huntingtin alleles is associated with cancer prognosis.Eur J Hum Genet. 2016 Aug;24(9):1310-5. doi: 10.1038/ejhg.2016.13. Epub 2016 Mar 16.
463 CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer.JCI Insight. 2017 Jun 2;2(11):e91487. doi: 10.1172/jci.insight.91487. eCollection 2017 Jun 2.
464 Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs.Cancer Invest. 2008 Aug;26(7):662-70. doi: 10.1080/07357900701871134.
465 The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer.Oncogene. 2019 May;38(21):4015-4027. doi: 10.1038/s41388-019-0694-9. Epub 2019 Jan 28.
466 Differential expression of the mannose 6-phosphate/ insulin-like growth factor-II receptor in human breast cancer cell lines of different invasive potential.Med Sci Monit. 2002 Aug;8(8):BR293-300.
467 Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer.Br J Cancer. 2014 Jun 10;110(12):2855-64. doi: 10.1038/bjc.2014.232. Epub 2014 May 22.
468 Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer.Cancer Res. 2010 Apr 15;70(8):3013-9. doi: 10.1158/0008-5472.CAN-09-3108. Epub 2010 Mar 30.
469 Regulation of breast cancer induced bone disease by cancer-specific IKK.Oncotarget. 2018 Mar 23;9(22):16134-16148. doi: 10.18632/oncotarget.24743. eCollection 2018 Mar 23.
470 Expression of interleukin 11 and its receptor and their prognostic value in human breast cancer.Ann Surg Oncol. 2006 Jun;13(6):802-8. doi: 10.1245/ASO.2006.05.028. Epub 2006 Apr 14.
471 IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis.Clin Cancer Res. 2008 Oct 15;14(20):6683-9. doi: 10.1158/1078-0432.CCR-07-4389.
472 Alteration on the expression of IL-1, PDGF, TGF-beta, EGF, and FGF receptors and c-Fos and c-Myc proteins in bone marrow mesenchymal stroma cells from advanced untreated lung and breast cancer patients.Stem Cells Dev. 2005 Oct;14(5):587-94. doi: 10.1089/scd.2005.14.587.
473 IL-25 blockade inhibits metastasis in breast cancer.Protein Cell. 2017 Mar;8(3):191-201. doi: 10.1007/s13238-016-0345-7. Epub 2016 Dec 1.
474 Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types.Cancer Res. 2009 Sep 15;69(18):7188-97. doi: 10.1158/0008-5472.CAN-08-4899. Epub 2009 Sep 8.
475 Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin 3-p38 MAPK signalling.Cancer Lett. 2019 Feb 1;442:320-332. doi: 10.1016/j.canlet.2018.10.015. Epub 2018 Oct 27.
476 Expression of EMT inducers integrin-linked kinase (ILK) and ZEB1 in phyllodes breast tumors is associated with aggressive phenotype.Histol Histopathol. 2018 Sep;33(9):937-949. doi: 10.14670/HH-11-987. Epub 2018 Apr 2.
477 IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG.Oncogene. 2016 Mar 3;35(9):1111-21. doi: 10.1038/onc.2015.164. Epub 2015 May 18.
478 Insulin receptor substrate 2-mediated phosphatidylinositol 3-kinase signaling selectively inhibits glycogen synthase kinase 3 to regulate aerobic glycolysis.J Biol Chem. 2014 Jun 27;289(26):18603-13. doi: 10.1074/jbc.M114.564070. Epub 2014 May 8.
479 The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer.Breast Cancer Res. 2008;10(4):R58. doi: 10.1186/bcr2117. Epub 2008 Jul 15.
480 The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway.Oncotarget. 2014 Nov 15;5(21):10886-900. doi: 10.18632/oncotarget.2540.
481 Chemical modulation of VLA integrin affinity in human breast cancer cells.Exp Cell Res. 2007 Apr 1;313(6):1121-34. doi: 10.1016/j.yexcr.2007.01.015. Epub 2007 Feb 3.
482 Steroid receptor coactivator-1 upregulates integrin ?expression to promote breast cancer cell adhesion and migration.Cancer Res. 2011 Mar 1;71(5):1742-51. doi: 10.1158/0008-5472.CAN-10-3453. Epub 2011 Feb 22.
483 Coexpression of alpha6beta4 integrin and guanine nucleotide exchange factor Net1 identifies node-positive breast cancer patients at high risk for distant metastasis.Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):80-6. doi: 10.1158/1055-9965.EPI-08-0842.
484 CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells.Clin Exp Metastasis. 2008;25(2):139-48. doi: 10.1007/s10585-007-9132-4. Epub 2007 Dec 5.
485 1H NMR Metabolomics Reveals Association of High Expression of Inositol 1, 4, 5 Trisphosphate Receptor and Metabolites in Breast Cancer Patients.PLoS One. 2017 Jan 10;12(1):e0169330. doi: 10.1371/journal.pone.0169330. eCollection 2017.
486 Alternative Polyadenylation in Triple-Negative Breast Tumors Allows NRAS and c-JUN to Bypass PUMILIO Posttranscriptional Regulation.Cancer Res. 2016 Dec 15;76(24):7231-7241. doi: 10.1158/0008-5472.CAN-16-0844. Epub 2016 Oct 10.
487 Candidate target genes for loss of heterozygosity on human chromosome 17q21.Br J Cancer. 2004 Jun 14;90(12):2384-9. doi: 10.1038/sj.bjc.6601848.
488 Identification of MYST3 as a novel epigenetic activator of ER frequently amplified in breast cancer.Oncogene. 2017 May 18;36(20):2910-2918. doi: 10.1038/onc.2016.433. Epub 2016 Nov 28.
489 GIRK1 triggers multiple cancer-related pathways in the benign mammary epithelial cell line MCF10A.Sci Rep. 2019 Dec 17;9(1):19277. doi: 10.1038/s41598-019-55683-w.
490 Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene.Cancer Cell. 2003 Mar;3(3):297-302. doi: 10.1016/s1535-6108(03)00054-0.
491 Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression.Oncotarget. 2017 Jul 19;8(47):81737-81753. doi: 10.18632/oncotarget.19387. eCollection 2017 Oct 10.
492 Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression.Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):E3367-76. doi: 10.1073/pnas.1217394109. Epub 2012 Nov 5.
493 KISS1R induces invasiveness of estrogen receptor-negative human mammary epithelial and breast cancer cells.Endocrinology. 2013 Jun;154(6):1999-2014. doi: 10.1210/en.2012-2164. Epub 2013 Mar 24.
494 Loss of c-KIT expression in breast cancer correlates with malignant transformation of breast epithelium and is mediated by KIT gene promoter DNA hypermethylation.Exp Mol Pathol. 2018 Aug;105(1):41-49. doi: 10.1016/j.yexmp.2018.05.011. Epub 2018 May 28.
495 Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis.Nat Commun. 2015 Sep 30;6:8419. doi: 10.1038/ncomms9419.
496 Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3.Int J Cancer. 2002 Aug 10;100(5):507-14. doi: 10.1002/ijc.10520.
497 The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines.Br J Cancer. 1999 Mar;79(9-10):1594-602. doi: 10.1038/sj.bjc.6690254.
498 A functional single nucleotide polymorphism of SET8 is prognostic for breast cancer.Oncotarget. 2016 Jun 7;7(23):34277-87. doi: 10.18632/oncotarget.9099.
499 Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins.Cancer Biol Ther. 2006 Jan;5(1):65-70. doi: 10.4161/cbt.5.1.2288.
500 Isolation and characterization of adult mammary stem cells from breast cancer-adjacent tissues.Oncol Lett. 2017 Sep;14(3):2894-2902. doi: 10.3892/ol.2017.6485. Epub 2017 Jun 28.
501 DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.Clin Epigenetics. 2018 Jun 15;10:78. doi: 10.1186/s13148-018-0512-1. eCollection 2018.
502 Immunotherapeutic target expression on breast tumors can be amplified by hormone receptor antagonism: a novel strategy for enhancing efficacy of targeted immunotherapy.Oncotarget. 2017 May 16;8(20):32536-32549. doi: 10.18632/oncotarget.15812.
503 In Vitro and In Vivo Study on the Effect of Lysosome-associated Protein Transmembrane 4 Beta on the Progression of Breast Cancer.J Breast Cancer. 2019 Sep;22(3):375-386. doi: 10.4048/jbc.2019.22.e43.
504 Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase.Nat Cell Biol. 2015 Jan;17(1):95-103. doi: 10.1038/ncb3073. Epub 2014 Dec 1.
505 Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis.J Biol Chem. 2006 Apr 21;281(16):11322-31. doi: 10.1074/jbc.M512546200. Epub 2006 Feb 10.
506 Macrophage-derived lipocalin-2 transports iron in the tumor microenvironment.Oncoimmunology. 2017 Dec 22;7(3):e1408751. doi: 10.1080/2162402X.2017.1408751. eCollection 2018.
507 LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response.PLoS One. 2018 Sep 24;13(9):e0203965. doi: 10.1371/journal.pone.0203965. eCollection 2018.
508 JAK/STAT3-Regulated Fatty Acid -Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance.Cell Metab. 2018 Jan 9;27(1):136-150.e5. doi: 10.1016/j.cmet.2017.11.001. Epub 2017 Dec 14.
509 Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway.Breast Cancer Res. 2014 Oct 25;16(5):426. doi: 10.1186/s13058-014-0426-6.
510 Suppression of Asparaginyl Endopeptidase Inhibits Polyomavirus Middle T Antigen-Induced Tumor Formation and Metastasis.Oncol Res. 2017 Mar 13;25(3):407-415. doi: 10.3727/096504016X14743350548249. Epub 2016 Sep 22.
511 LGR4 modulates breast cancer initiation, metastasis, and cancer stem cells.FASEB J. 2018 May;32(5):2422-2437. doi: 10.1096/fj.201700897R. Epub 2017 Dec 21.
512 Luteinizing hormone signaling and breast cancer: polymorphisms and age of onset.J Clin Endocrinol Metab. 2003 Apr;88(4):1653-7. doi: 10.1210/jc.2002-021585.
513 YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: implications for breast cancer.Breast Cancer Res. 2012 Dec 5;14(6):326. doi: 10.1186/bcr3349.
514 LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system.Int J Cancer. 2006 Jun 1;118(11):2703-10. doi: 10.1002/ijc.21650.
515 Antineoplastic effect of pectic polysaccharides from green sweet pepper (Capsicum annuum) on mammary tumor cells in vivo and in vitro.Carbohydr Polym. 2018 Dec 1;201:280-292. doi: 10.1016/j.carbpol.2018.08.071. Epub 2018 Aug 20.
516 Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breast tumors.Mol Cell Endocrinol. 2013 Jan 30;365(2):270-6. doi: 10.1016/j.mce.2012.10.028. Epub 2012 Nov 6.
517 The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase.Nature. 2015 Jun 4;522(7554):106-110. doi: 10.1038/nature14492. Epub 2015 May 27.
518 MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro. J Biol Chem. 2013 Oct 18;288(42):30000-30008. doi: 10.1074/jbc.C113.502310. Epub 2013 Sep 6.
519 The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer.Oncotarget. 2015 Aug 21;6(24):20604-20. doi: 10.18632/oncotarget.3774.
520 LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells.Am J Physiol Cell Physiol. 2007 May;292(5):C1927-33. doi: 10.1152/ajpcell.00400.2006.
521 Transforming function of the LSM1 oncogene in human breast cancers with the 8p11-12 amplicon.Oncogene. 2007 Mar 29;26(14):2104-14. doi: 10.1038/sj.onc.1210002. Epub 2006 Sep 25.
522 Expression and prognostic value of lactoferrin mRNA isoforms in human breast cancer.Int J Cancer. 2005 Mar 20;114(2):299-306. doi: 10.1002/ijc.20728.
523 LY-6K gene: a novel molecular marker for human breast cancer.Oncol Rep. 2006 Dec;16(6):1211-4.
524 Diagnostic utility of CD205 in breast cancer: Simultaneous detection of myoepithelial cells and dendritic cells in breast tissue by CD205.Histol Histopathol. 2020 May;35(5):481-488. doi: 10.14670/HH-18-164. Epub 2019 Sep 16.
525 Lyn tyrosine kinase inhibits nuclear export of the p53 tumor suppressor.Cancer Biol Ther. 2002 Nov-Dec;1(6):703-8. doi: 10.4161/cbt.323.
526 The nuclear corepressor 1 and the thyroid hormone receptor suppress breast tumor lymphangiogenesis.Oncotarget. 2016 Nov 29;7(48):78971-78984. doi: 10.18632/oncotarget.12978.
527 Expression of cancer-testis antigen CT7 (MAGE-C1) in breast cancer: an immunohistochemical study with emphasis on prognostic utility.Pathol Oncol Res. 2007;13(2):91-6. doi: 10.1007/BF02893483. Epub 2007 Jul 3.
528 Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.Carcinogenesis. 2009 Feb;30(2):269-74. doi: 10.1093/carcin/bgn247. Epub 2008 Nov 20.
529 MEKK2 regulates focal adhesion stability and motility in invasive breast cancer cells.Biochim Biophys Acta. 2014 May;1843(5):945-54. doi: 10.1016/j.bbamcr.2014.01.029. Epub 2014 Jan 31.
530 Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.Br J Cancer. 2011 Sep 6;105(6):796-806. doi: 10.1038/bjc.2011.321. Epub 2011 Aug 16.
531 P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer.Curr Med Chem. 2014;21(4):501-10. doi: 10.2174/0929867320666131119155023.
532 Modulation of ERK5 is a novel mechanism by which Cdc42 regulates migration of breast cancer cells.J Cell Biochem. 2015 Jan;116(1):124-32. doi: 10.1002/jcb.24950.
533 Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells.Oncogene. 2004 Jan 15;23(2):596-604. doi: 10.1038/sj.onc.1207147.
534 Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells.J Biol Chem. 2002 Dec 13;277(50):48379-85. doi: 10.1074/jbc.M209542200. Epub 2002 Oct 10.
535 MAZ drives tumor-specific expression of PPAR gamma 1 in breast cancer cells.Breast Cancer Res Treat. 2008 Sep;111(1):103-11. doi: 10.1007/s10549-007-9765-7. Epub 2007 Sep 28.
536 Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers.Oncogene. 2019 Apr;38(17):3261-3273. doi: 10.1038/s41388-018-0635-z. Epub 2019 Jan 10.
537 Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo.Cancer Res. 2010 Nov 1;70(21):8863-73. doi: 10.1158/0008-5472.CAN-10-1295. Epub 2010 Sep 22.
538 The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers. Cancer Res. 2011 Feb 1;71(3):937-45. doi: 10.1158/0008-5472.CAN-10-1471. Epub 2010 Dec 2.
539 Epigenetic modulation of BRCA-1 and MGMT genes, and histones H4 and H3 are associated with breast tumors.J Cell Biochem. 2019 Aug;120(8):13726-13736. doi: 10.1002/jcb.28645. Epub 2019 Apr 2.
540 Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.BMC Cancer. 2016 Jul 7;16:398. doi: 10.1186/s12885-016-2476-x.
541 Increased expression of MNK1b, the spliced isoform of MNK1, predicts poor prognosis and is associated with triple-negative breast cancer.Oncotarget. 2018 Feb 5;9(17):13501-13516. doi: 10.18632/oncotarget.24417. eCollection 2018 Mar 2.
542 Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors.Tech Coloproctol. 2014 Mar;18(3):285-9. doi: 10.1007/s10151-013-1030-y. Epub 2013 May 22.
543 Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma.Cancer Res. 1996 Mar 1;56(5):944-9.
544 Expression of Alpha-Enolase (ENO1), Myc Promoter-Binding Protein-1 (MBP-1) and Matrix Metalloproteinases (MMP-2 and MMP-9) Reflect the Nature and Aggressiveness of Breast Tumors.Int J Mol Sci. 2019 Aug 14;20(16):3952. doi: 10.3390/ijms20163952.
545 Matrix metalloproteinase localisation by in situ-RT-PCR in archival human breast biopsy material.Mol Cell Probes. 2008 Apr;22(2):83-9. doi: 10.1016/j.mcp.2007.06.009. Epub 2007 Jul 4.
546 SPIONs embedded in polyamino acid nanogels to synergistically treat tumor microenvironment and breast cancer cells.Int J Pharm. 2019 Jan 30;555:207-219. doi: 10.1016/j.ijpharm.2018.11.046. Epub 2018 Nov 17.
547 Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors.BMC Cancer. 2012 Sep 11;12:405. doi: 10.1186/1471-2407-12-405.
548 Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival.Mol Cancer. 2010 Aug 21;9:221. doi: 10.1186/1476-4598-9-221.
549 Mesothelin expression is associated with poor outcomes in breast cancer.Breast Cancer Res Treat. 2014 Oct;147(3):675-84. doi: 10.1007/s10549-014-3077-5. Epub 2014 Sep 6.
550 ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment.Clin Cancer Res. 2018 Mar 15;24(6):1500-1510. doi: 10.1158/1078-0432.CCR-17-1181. Epub 2017 Dec 28.
551 Altered expression of estrogen receptor coregulators during human breast tumorigenesis.Cancer Res. 2000 Nov 15;60(22):6266-71.
552 Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth.Oncoimmunology. 2018 Jul 11;7(9):e1480286. doi: 10.1080/2162402X.2018.1480286. eCollection 2018.
553 Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1--catenin signaling axis in a microRNA-34a dependent manner.Oncotarget. 2015 Jun 30;6(18):16396-410. doi: 10.18632/oncotarget.3844.
554 Immunohistochemical Expression of Melatonin Receptor MT1 and Glucose Transporter GLUT1 in Human Breast Cancer.Anticancer Agents Med Chem. 2018;18(15):2110-2116. doi: 10.2174/1871520618666181025125532.
555 Involvement of the mt1 melatonin receptor in human breast cancer.Cancer Lett. 2002 May 28;179(2):141-50. doi: 10.1016/s0304-3835(01)00873-4.
556 Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease.Med Chem. 2017;13(8):796-804. doi: 10.2174/1573406413666170424155452.
557 Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.Breast Cancer Res Treat. 2019 May;175(1):105-115. doi: 10.1007/s10549-018-05113-8. Epub 2019 Feb 12.
558 In Vivo Targeting and Positron Emission Tomography Imaging of Tumor with Intrinsically Radioactive Metal-Organic Frameworks Nanomaterials.ACS Nano. 2017 Apr 25;11(4):4315-4327. doi: 10.1021/acsnano.7b01530. Epub 2017 Mar 28.
559 PTEN and NEDD4 in Human Breast Carcinoma.Pathol Oncol Res. 2016 Jan;22(1):41-7. doi: 10.1007/s12253-015-9971-2. Epub 2015 Aug 15.
560 The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells.Mol Endocrinol. 2003 Mar;17(3):356-65. doi: 10.1210/me.2002-0323. Epub 2002 Dec 18.
561 NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer.PLoS One. 2011;6(7):e22666. doi: 10.1371/journal.pone.0022666. Epub 2011 Jul 28.
562 Nek8, a NIMA family kinase member, is overexpressed in primary human breast tumors. Gene. 2004 Mar 17;328:135-42.
563 Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.Cancer Res. 2018 May 15;78(10):2732-2746. doi: 10.1158/0008-5472.CAN-17-1990. Epub 2018 Feb 22.
564 Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells. Breast Cancer Res Treat. 2017 Apr;162(3):465-477. doi: 10.1007/s10549-017-4149-0. Epub 2017 Feb 11.
565 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
566 Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of the WNT signaling pathway.Oncotarget. 2017 May 30;8(22):36246-36265. doi: 10.18632/oncotarget.16121.
567 Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.Clin Cancer Res. 2009 Aug 15;15(16):5258-66. doi: 10.1158/1078-0432.CCR-09-0685. Epub 2009 Aug 11.
568 The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L.Oncogene. 2018 Jul;37(28):3879-3893. doi: 10.1038/s41388-018-0239-7. Epub 2018 Apr 17.
569 IL6 blockade potentiates the anti-tumor effects of -secretase inhibitors in Notch3-expressing breast cancer.Cell Death Differ. 2018 Feb;25(2):330-339. doi: 10.1038/cdd.2017.162. Epub 2017 Oct 13.
570 Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography.In Vivo. 2005 May-Jun;19(3):567-76.
571 Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance.Sci Rep. 2016 Feb 17;6:21164. doi: 10.1038/srep21164.
572 Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation.Cancer Res. 2014 Jan 1;74(1):341-52. doi: 10.1158/0008-5472.CAN-13-1055. Epub 2013 Oct 31.
573 Neuropilin-1 Associated Molecules in the Blood Distinguish Poor Prognosis Breast Cancer: A Cross-Sectional Study.Sci Rep. 2017 Jun 12;7(1):3301. doi: 10.1038/s41598-017-03280-0.
574 Transforming growth factor-1 promotes breast cancer metastasis by downregulating miR-196a-3p expression.Oncotarget. 2017 Jul 25;8(30):49110-49122. doi: 10.18632/oncotarget.16308.
575 A zwitterionic near-infrared dye linked TrkC targeting agent for imaging metastatic breast cancer.Medchemcomm. 2018 Aug 3;9(10):1754-1760. doi: 10.1039/c8md00190a. eCollection 2018 Oct 1.
576 Neurotensin receptor 1 facilitates intracellular and transepithelial delivery of macromolecules.Eur J Pharm Biopharm. 2017 Oct;119:300-309. doi: 10.1016/j.ejpb.2017.06.027. Epub 2017 Jul 6.
577 Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.Breast Cancer Res. 2018 Mar 22;20(1):22. doi: 10.1186/s13058-018-0949-3.
578 OLFM4 Expression in Ductal Carcinoma In Situ and in Invasive Breast Cancer Cohorts by a SWATH-Based Proteomic Approach.Proteomics. 2019 Nov;19(21-22):e1800446. doi: 10.1002/pmic.201800446. Epub 2019 Aug 8.
579 sp(2) -Iminosugar -glucosidase inhibitor 1-C-octyl-2-oxa-3-oxocastanospermine specifically affected breast cancer cell migration through Stim1, 1-integrin, and FAK signaling pathways.J Cell Physiol. 2017 Dec;232(12):3631-3640. doi: 10.1002/jcp.25832. Epub 2017 Apr 25.
580 Oncostatin M upregulates HIF-1 in breast tumor associated macrophages independent of intracellular oxygen concentration.Life Sci. 2018 Feb 1;194:59-66. doi: 10.1016/j.lfs.2017.12.017. Epub 2017 Dec 12.
581 Altered purinergic receptor-Ca?signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells.Mol Oncol. 2016 Jan;10(1):166-78. doi: 10.1016/j.molonc.2015.09.006. Epub 2015 Sep 25.
582 An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells. Cancer Sci. 2011 Jul;102(7):1410-7. doi: 10.1111/j.1349-7006.2011.01948.x. Epub 2011 May 5.
583 A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.Sci Rep. 2017 Feb 15;7:42555. doi: 10.1038/srep42555.
584 Spermine oxidase SMO(PAOh1), Not N1-acetylpolyamine oxidase PAO, is the primary source of cytotoxic H2O2 in polyamine analogue-treated human breast cancer cell lines.J Biol Chem. 2005 Dec 2;280(48):39843-51. doi: 10.1074/jbc.M508177200. Epub 2005 Oct 5.
585 The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.Mol Cell. 2019 Jan 17;73(2):224-237.e6. doi: 10.1016/j.molcel.2018.11.003. Epub 2018 Dec 13.
586 Opposing function of the proprotein convertases furin and PACE4 on breast cancer cells' malignant phenotypes: role of tissue inhibitors of metalloproteinase-1.Cancer Res. 2007 Oct 1;67(19):9030-4. doi: 10.1158/0008-5472.CAN-07-0807.
587 Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer.Eur J Pharm Sci. 2016 Sep 20;92:39-48. doi: 10.1016/j.ejps.2016.06.020. Epub 2016 Jun 26.
588 Effects of immunization against PCSK9 in an experimental model of breast cancer.Arch Med Sci. 2019 May;15(3):570-579. doi: 10.5114/aoms.2019.84734. Epub 2019 Apr 30.
589 Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.J Clin Oncol. 2003 Sep 15;21(18):3454-61. doi: 10.1200/JCO.2003.02.114.
590 Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression.Cancers (Basel). 2019 Nov 6;11(11):1740. doi: 10.3390/cancers11111740.
591 PDK1 promotes tumor growth and metastasis in a spontaneous breast cancer model.Oncogene. 2016 Jun 23;35(25):3314-23. doi: 10.1038/onc.2015.393. Epub 2015 Oct 12.
592 MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells.Biochem Biophys Res Commun. 2012 Aug 24;425(2):127-33. doi: 10.1016/j.bbrc.2012.07.025. Epub 2012 Jul 15.
593 Choline metabolism and risk of breast cancer in a population-based study.FASEB J. 2008 Jun;22(6):2045-52. doi: 10.1096/fj.07-101279. Epub 2008 Jan 29.
594 Extracellular matrix and HIF-1 signaling: the role of prolidase.Int J Cancer. 2008 Mar 15;122(6):1435-40. doi: 10.1002/ijc.23263.
595 Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.Breast Cancer Res Treat. 2016 Nov;160(1):29-40. doi: 10.1007/s10549-016-3968-8. Epub 2016 Sep 9.
596 Overall survival in women with breast cancer: the influence of pepsinogen C gene polymorphism.DNA Cell Biol. 2008 Jun;27(6):333-6. doi: 10.1089/dna.2007.0713.
597 Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.Biomaterials. 2018 Dec;185:117-132. doi: 10.1016/j.biomaterials.2018.09.017. Epub 2018 Sep 11.
598 High Level of Progesteron Receptor Membrane Component 1 (PGRMC 1) in Tissue of Breast Cancer Patients is Associated with Worse Response to Anthracycline-Based Neoadjuvant Therapy.Horm Metab Res. 2017 Aug;49(8):595-603. doi: 10.1055/s-0043-113635. Epub 2017 Jul 12.
599 The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation.Breast Cancer Res Treat. 2007 Jul;104(1):67-74. doi: 10.1007/s10549-006-9389-3. Epub 2006 Sep 27.
600 PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.Nat Med. 2016 Nov;22(11):1321-1329. doi: 10.1038/nm.4213. Epub 2016 Oct 24.
601 Modulation of oxidative stress and subsequent induction of apoptosis and endoplasmic reticulum stress allows citral to decrease cancer cell proliferation.Sci Rep. 2016 Jun 8;6:27530. doi: 10.1038/srep27530.
602 Oncogenic Kinase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-like Cells.Cancer Res. 2018 May 1;78(9):2248-2261. doi: 10.1158/0008-5472.CAN-17-2726. Epub 2018 Feb 12.
603 Quantification of PKC family genes in sporadic breast cancer by qRT-PCR: evidence that PKC/ overexpression is an independent prognostic factor.Int J Cancer. 2012 Dec 15;131(12):2852-62. doi: 10.1002/ijc.27600. Epub 2012 May 21.
604 Cytosolic phospholipase A2- expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours.Br J Cancer. 2011 Jan 18;104(2):338-44. doi: 10.1038/sj.bjc.6606025. Epub 2010 Nov 30.
605 A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes.Cancer Res. 2007 Oct 1;67(19):9528-34. doi: 10.1158/0008-5472.CAN-07-1350.
606 Expression of phospholipase C isozymes in human breast cancer and their clinical significance.Oncol Rep. 2017 Mar;37(3):1707-1715. doi: 10.3892/or.2017.5394. Epub 2017 Jan 20.
607 PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas.Br J Cancer. 2007 Sep 17;97(6):809-17. doi: 10.1038/sj.bjc.6603926. Epub 2007 Aug 28.
608 The transcription factors Slug (SNAI2) and Snail (SNAI1) regulate phospholipase D (PLD) promoter in opposite ways towards cancer cell invasion.Mol Oncol. 2016 May;10(5):663-76. doi: 10.1016/j.molonc.2015.12.006. Epub 2015 Dec 19.
609 Evaluation of in vitro and in vivo therapeutic antitumor efficacy of transduction of polo-like kinase 1 and heat shock transcription factor 1 small interfering RNA.Exp Ther Med. 2017 Nov;14(5):4300-4306. doi: 10.3892/etm.2017.5060. Epub 2017 Aug 28.
610 Stat3 regulates centrosome clustering in cancer cells via Stathmin/PLK1.Nat Commun. 2017 May 5;8:15289. doi: 10.1038/ncomms15289.
611 A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in African Americans.Cancer Res. 2007 Apr 15;67(8):3565-8. doi: 10.1158/0008-5472.CAN-06-4801.
612 PPAR mRNA expression, reduced by n-3 PUFA diet in mammary tumor, controls breast cancer cell growth.Biochim Biophys Acta. 2013 Nov;1831(11):1618-25. doi: 10.1016/j.bbalip.2013.07.010. Epub 2013 Jul 30.
613 Multiparametric duplex real-time nucleic acid sequence-based amplification assay for mRNA profiling.Biotechniques. 2004 Sep;37(3):476-81. doi: 10.2144/04373PF01.
614 ERR target genes are poor prognostic factors in Tamoxifen-treated breast cancer.J Exp Clin Cancer Res. 2015 May 15;34(1):45. doi: 10.1186/s13046-015-0150-9.
615 Wip1 phosphatase in breast cancer.Oncogene. 2015 Aug 20;34(34):4429-38. doi: 10.1038/onc.2014.375. Epub 2014 Nov 10.
616 The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors.BMC Cancer. 2007 May 19;7:85. doi: 10.1186/1471-2407-7-85.
617 Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer.Biochim Biophys Acta. 2008 Apr;1782(4):259-70. doi: 10.1016/j.bbadis.2008.01.004. Epub 2008 Jan 26.
618 Peroxiredoxin 4: a novel secreted mediator of cancer induced osteoclastogenesis.Cancer Lett. 2015 Jun 1;361(2):262-70. doi: 10.1016/j.canlet.2015.03.012. Epub 2015 Mar 14.
619 Growth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathway.Mol Cancer Res. 2008 May;6(5):851-61. doi: 10.1158/1541-7786.MCR-07-2030.
620 Protein kinase C epsilon confers resistance of MCF-7 cells to TRAIL by Akt-dependent activation of Hdm2 and downregulation of p53.Oncogene. 2008 Jun 26;27(28):3957-66. doi: 10.1038/onc.2008.39. Epub 2008 Mar 3.
621 The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.Cell Physiol Biochem. 2019;52(3):382-396. doi: 10.33594/000000027. Epub 2019 Mar 8.
622 Alternative splicing yields protein arginine methyltransferase 1 isoforms with distinct activity, substrate specificity, and subcellular localization.J Biol Chem. 2007 Nov 9;282(45):33009-21. doi: 10.1074/jbc.M704349200. Epub 2007 Sep 11.
623 Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression.Oncotarget. 2015 Feb 20;6(5):3013-32. doi: 10.18632/oncotarget.3072.
624 Selective detection of membrane proteins without antibodies: a mass spectrometric version of the Western blot.Mol Cell Proteomics. 2002 Feb;1(2):148-56. doi: 10.1074/mcp.m100027-mcp200.
625 Functional characterization of novel presenilin-2 variants identified in human breast cancers.Oncogene. 2006 Jun 15;25(25):3557-64. doi: 10.1038/sj.onc.1209397. Epub 2006 Feb 13.
626 Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells.J Biol Chem. 2008 Apr 25;283(17):11155-63. doi: 10.1074/jbc.M710038200. Epub 2008 Mar 4.
627 Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo.Med Oncol. 2008;25(2):172-7. doi: 10.1007/s12032-007-9016-0. Epub 2007 Oct 6.
628 The parathyroid hormone-related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cells.Br J Cancer. 2003 Feb 24;88(4):567-73. doi: 10.1038/sj.bjc.6600757.
629 SMARCE1 regulates metastatic potential of breast cancer cells through the HIF1A/PTK2 pathway.Breast Cancer Res. 2016 Aug 5;18(1):81. doi: 10.1186/s13058-016-0738-9.
630 Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.BMC Cancer. 2019 Jan 16;19(1):78. doi: 10.1186/s12885-018-5186-8.
631 Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment.Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10888-93. doi: 10.1073/pnas.0704366104. Epub 2007 Jun 19.
632 Overexpression of the protein tyrosine phosphatase PRL-2 correlates with breast tumor formation and progression.Cancer Res. 2010 Nov 1;70(21):8959-67. doi: 10.1158/0008-5472.CAN-10-2041. Epub 2010 Sep 14.
633 Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome.Ann Oncol. 2006 Oct;17(10):1517-22. doi: 10.1093/annonc/mdl159. Epub 2006 Jul 27.
634 Long non-coding RNA UCA1 promotes breast cancer by upregulating PTP1B expression via inhibiting miR-206.Cancer Cell Int. 2019 Nov 1;19:275. doi: 10.1186/s12935-019-0958-z. eCollection 2019.
635 PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer.J Cancer Res Clin Oncol. 2019 Mar;145(3):599-607. doi: 10.1007/s00432-018-2810-6. Epub 2018 Dec 4.
636 Protein tyrosine phosphatases and their inhibitors.Curr Med Chem. 2005;12(1):1-22. doi: 10.2174/0929867053363504.
637 Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer.Hum Mol Genet. 2005 Aug 15;14(16):2349-56. doi: 10.1093/hmg/ddi237. Epub 2005 Jul 6.
638 The receptor protein tyrosine phosphatase (RPTP)beta/zeta is expressed in different subtypes of human breast cancer.Biochem Biophys Res Commun. 2007 Oct 12;362(1):5-10. doi: 10.1016/j.bbrc.2007.06.050. Epub 2007 Jun 18.
639 Peptide YY and cancer: current findings and potential clinical applications.Peptides. 2002 Feb;23(2):389-95. doi: 10.1016/s0196-9781(01)00616-7.
640 Targeting of Rac GTPases blocks the spread of intact human breast cancer.Oncotarget. 2012 Jun;3(6):608-19. doi: 10.18632/oncotarget.520.
641 Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells.Breast Cancer Res. 2005;7(6):R965-74. doi: 10.1186/bcr1329. Epub 2005 Sep 30.
642 mrtl-A translation/localization regulatory protein encoded within the human c-myc locus and distributed throughout the endoplasmic and nucleoplasmic reticular network.J Cell Biochem. 2008 Nov 1;105(4):1092-108. doi: 10.1002/jcb.21909.
643 Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes.Genome Med. 2017 Apr 26;9(1):40. doi: 10.1186/s13073-017-0429-x.
644 Truncated RAR beta isoform enhances proliferation and retinoid resistance.J Cell Physiol. 2006 Dec;209(3):718-25. doi: 10.1002/jcp.20788.
645 A Transposon-based Analysis Reveals RASA1 Is Involved in Triple-Negative Breast Cancer.Cancer Res. 2017 Mar 15;77(6):1357-1368. doi: 10.1158/0008-5472.CAN-16-1586. Epub 2017 Jan 20.
646 NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells.Cancer Res. 2008 Mar 15;68(6):1881-8. doi: 10.1158/0008-5472.CAN-07-1597.
647 Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.BMC Cancer. 2009 Jan 14;9:20. doi: 10.1186/1471-2407-9-20.
648 A fragile site within the HPC1 region at 1q25.3 affecting RGS16, RGSL1, and RGSL2 in human breast carcinomas.Genes Chromosomes Cancer. 2008 Sep;47(9):766-80. doi: 10.1002/gcc.20578.
649 Regulator of G protein signaling 6 is a novel suppressor of breast tumor initiation and progression.Carcinogenesis. 2013 Aug;34(8):1747-55. doi: 10.1093/carcin/bgt128. Epub 2013 Apr 18.
650 Frequent allelic loss at the TOC locus on 17q25.1 in primary breast cancers.Genes Chromosomes Cancer. 1999 Apr;24(4):345-50. doi: 10.1002/(sici)1098-2264(199904)24:4<345::aid-gcc8>3.0.co;2-q.
651 Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters.Br J Cancer. 2002 Sep 9;87(6):635-44. doi: 10.1038/sj.bjc.6600510.
652 RIP2 enhances cell survival by activation of NF-B in triple negative breast cancer cells.Biochem Biophys Res Commun. 2018 Feb 26;497(1):115-121. doi: 10.1016/j.bbrc.2018.02.034. Epub 2018 Feb 6.
653 Multipoint interphase FISH in childhood T-acute lymphoblastic leukemia detects subpopulations that carry different chromosome 3 aberrations.Cancer Genet Cytogenet. 2007 Jan 1;172(1):54-60. doi: 10.1016/j.cancergencyto.2006.08.004.
654 The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer.Int J Oncol. 2008 Sep;33(3):585-93.
655 A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis.Nat Cell Biol. 2017 Feb;19(2):106-119. doi: 10.1038/ncb3464. Epub 2017 Jan 23.
656 Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression.Oncogene. 2017 Oct 26;36(43):5958-5968. doi: 10.1038/onc.2017.206. Epub 2017 Jun 26.
657 Immunohistochemical analysis of S6K1 and S6K2 expression in human breast tumors.Eksp Onkol. 2004 Mar;26(1):24-30.
658 Anti-invasive and antimetastatic activities of ribosomal protein S6 kinase 4 in breast cancer cells.Clin Cancer Res. 2008 Jul 15;14(14):4427-36. doi: 10.1158/1078-0432.CCR-08-0458.
659 Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.BMC Cancer. 2013 Nov 12;13:541. doi: 10.1186/1471-2407-13-541.
660 RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial.PLoS One. 2013 Dec 19;8(12):e81740. doi: 10.1371/journal.pone.0081740. eCollection 2013.
661 Clinical value of R-spondins in triple-negative and metaplastic breast cancers.Br J Cancer. 2017 Jun 6;116(12):1595-1603. doi: 10.1038/bjc.2017.131. Epub 2017 May 4.
662 MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer.Nat Genet. 2007 Jun;39(6):759-69. doi: 10.1038/ng2034. Epub 2007 Apr 29.
663 Altered localization of retinoid X receptor alpha coincides with loss of retinoid responsiveness in human breast cancer MDA-MB-231 cells.Mol Cell Biol. 2004 May;24(9):3972-82. doi: 10.1128/MCB.24.9.3972-3982.2004.
664 A fatty acid-binding protein 7/RXR pathway enhances survival and proliferation in triple-negative breast cancer. J Pathol. 2012 Nov;228(3):310-21. doi: 10.1002/path.4001. Epub 2012 Apr 18.
665 Targeting the SphK1/S1P/S1PR1 Axis That Links Obesity, Chronic Inflammation, and Breast Cancer Metastasis.Cancer Res. 2018 Apr 1;78(7):1713-1725. doi: 10.1158/0008-5472.CAN-17-1423. Epub 2018 Jan 19.
666 Mammaglobin, a potential marker of breast cancer nodal metastasis.J Pathol. 1999 Sep;189(1):28-33. doi: 10.1002/(SICI)1096-9896(199909)189:1<28::AID-PATH389>3.0.CO;2-H.
667 Mammaglobin and lipophilin B expression in breast tumors and their lack of effect on breast cancer cell proliferation.Anticancer Res. 2008 May-Jun;28(3A):1493-8.
668 Domain and functional analysis of a novel breast tumor suppressor protein, SCUBE2.J Biol Chem. 2011 Jul 29;286(30):27039-47. doi: 10.1074/jbc.M111.244418. Epub 2011 Jun 7.
669 Syndecan-1 induction in lung microenvironment supports the establishment of breast tumor metastases.Breast Cancer Res. 2018 Jul 5;20(1):66. doi: 10.1186/s13058-018-0995-x.
670 Autocrine semaphorin3A stimulates alpha2 beta1 integrin expression/function in breast tumor cells.Breast Cancer Res Treat. 2009 Nov;118(1):197-205. doi: 10.1007/s10549-008-0179-y. Epub 2008 Sep 12.
671 Semaphorin-plexin signalling genes associated with human breast tumourigenesis.Gene. 2011 Dec 10;489(2):63-9. doi: 10.1016/j.gene.2011.08.024. Epub 2011 Sep 2.
672 The transcription factor GATA1 and the histone methyltransferase SET7 interact to promote VEGF-mediated angiogenesis and tumor growth and predict clinical outcome of breast cancer.Oncotarget. 2016 Mar 1;7(9):9859-75. doi: 10.18632/oncotarget.7126.
673 The concurrent effects of azurin and Mammaglobin-A genes in inhibition of breast cancer progression and immune system stimulation in cancerous BALB/c mice.3 Biotech. 2019 Jul;9(7):271. doi: 10.1007/s13205-019-1804-7. Epub 2019 Jun 18.
674 Antiapoptotic effect of serum and glucocorticoid-inducible protein kinase is mediated by novel mechanism activating I{kappa}B kinase.Cancer Res. 2005 Jan 15;65(2):457-64.
675 The expression and functional characterization of sigma (sigma) 1 receptors in breast cancer cell lines.Cancer Lett. 2006 Oct 28;242(2):245-57. doi: 10.1016/j.canlet.2005.11.011. Epub 2006 Jan 4.
676 SIRT2: tumour suppressor or tumour promoter in operable breast cancer?.Eur J Cancer. 2014 Jan;50(2):290-301. doi: 10.1016/j.ejca.2013.10.005. Epub 2013 Oct 29.
677 SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis.Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):26625-26632. doi: 10.1073/pnas.1911954116. Epub 2019 Dec 16.
678 Dissection of the APCCdh1-Skp2 cascade in breast cancer.Clin Cancer Res. 2008 Apr 1;14(7):1966-75. doi: 10.1158/1078-0432.CCR-07-1585.
679 IGF-1 upregulates electroneutral K-Cl cotransporter KCC3 and KCC4 which are differentially required for breast cancer cell proliferation and invasiveness.J Cell Physiol. 2007 Mar;210(3):626-36. doi: 10.1002/jcp.20859.
680 Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers.Cell Cycle. 2012 Mar 15;11(6):1108-17. doi: 10.4161/cc.11.6.19530. Epub 2012 Mar 15.
681 Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics. 2007 Jun;8(6):567-75.
682 Increased expression of mitochondrial sodium-coupled ascorbic acid transporter-2 (mitSVCT2) as a central feature in breast cancer.Free Radic Biol Med. 2019 May 1;135:283-292. doi: 10.1016/j.freeradbiomed.2019.03.015. Epub 2019 Mar 19.
683 Solute Carrier Family 27 Member 4 (SLC27A4) Enhances Cell Growth, Migration, and Invasion in Breast Cancer Cells.Int J Mol Sci. 2018 Nov 1;19(11):3434. doi: 10.3390/ijms19113434.
684 Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues.J Cell Physiol. 2006 Jun;207(3):614-27. doi: 10.1002/jcp.20606.
685 Zinc Transporters and the Progression of Breast Cancers.Biol Pharm Bull. 2018;41(10):1517-1522. doi: 10.1248/bpb.b18-00086.
686 Inhibition of system L (LAT1/CD98hc) reduces the growth of cultured human breast cancer cells.Oncol Rep. 2008 Oct;20(4):885-9.
687 MEK inhibition leads to lysosome-mediated Na+/I- symporter protein degradation in human breast cancer cells.Endocr Relat Cancer. 2013 Mar 22;20(2):241-50. doi: 10.1530/ERC-12-0342. Print 2013 Apr.
688 Differential role of organic anion-transporting polypeptides in estrone-3-sulphate uptake by breast epithelial cells and breast cancer cells.J Pharmacol Exp Ther. 2012 Aug;342(2):510-9. doi: 10.1124/jpet.112.192344. Epub 2012 May 15.
689 The association of polymorphisms in hormone metabolism pathway genes, menopausal hormone therapy, and breast cancer risk: a nested case-control study in the California Teachers Study cohort.Breast Cancer Res. 2011 Apr 1;13(2):R37. doi: 10.1186/bcr2859.
690 Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma.Cancer Sci. 2007 Oct;98(10):1570-6. doi: 10.1111/j.1349-7006.2007.00570.x.
691 Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium.Cancer Res. 2011 Feb 1;71(3):976-87. doi: 10.1158/0008-5472.CAN-10-3396. Epub 2010 Dec 8.
692 Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway.J Cell Biol. 2008 Apr 21;181(2):335-50. doi: 10.1083/jcb.200705060.
693 Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.Cell Death Dis. 2018 Feb 27;9(3):326. doi: 10.1038/s41419-018-0347-x.
694 Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha.Am J Pathol. 2010 Aug;177(2):964-73. doi: 10.2353/ajpath.2010.100061. Epub 2010 Jul 1.
695 SOCS1 induced by NDRG2 expression negatively regulates STAT3 activation in breast cancer cells.Biochem Biophys Res Commun. 2007 Nov 16;363(2):361-7. doi: 10.1016/j.bbrc.2007.08.195. Epub 2007 Sep 14.
696 SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL.Int J Cancer. 2009 Apr 15;124(8):1756-66. doi: 10.1002/ijc.24172.
697 Selective estrogen receptor modulators and betulinic acid act synergistically to target ER and SP1 transcription factor dependent Pygopus expression in breast cancer.J Clin Pathol. 2016 Jun;69(6):518-26. doi: 10.1136/jclinpath-2015-203395. Epub 2015 Dec 8.
698 SPARC inhibits breast cancer bone metastasis and may be a clinical therapeutic target.Oncol Lett. 2017 Nov;14(5):5876-5882. doi: 10.3892/ol.2017.6925. Epub 2017 Sep 14.
699 Prostate-derived Ets factor, an oncogenic driver in breast cancer.Tumour Biol. 2017 May;39(5):1010428317691688. doi: 10.1177/1010428317691688.
700 Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis.Med Sci Monit. 2018 Apr 1;24:1912-1923. doi: 10.12659/msm.905833.
701 Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease.Br J Cancer. 2008 Sep 2;99(5):774-80. doi: 10.1038/sj.bjc.6604556. Epub 2008 Aug 12.
702 Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1.Cancer Res. 2008 Feb 15;68(4):1003-11. doi: 10.1158/0008-5472.CAN-07-2489.
703 SREBP-2 aggravates breast cancer associated osteolysis by promoting osteoclastogenesis and breast cancer metastasis.Biochim Biophys Acta Mol Basis Dis. 2019 Jan;1865(1):115-125. doi: 10.1016/j.bbadis.2018.10.026. Epub 2018 Oct 28.
704 Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology.Breast Cancer Res Treat. 2005 Jul;92(2):175-86. doi: 10.1007/s10549-005-2414-0.
705 Human somatostatin receptor-3 distinctively induces apoptosis in MCF-7 and cell cycle arrest in MDA-MB-231 breast cancer cells.Mol Cell Endocrinol. 2015 Sep 15;413:129-44. doi: 10.1016/j.mce.2015.06.019. Epub 2015 Jun 23.
706 ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival.Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2133-42. doi: 10.1158/1055-9965.EPI-10-0418. Epub 2010 Aug 17.
707 Progesterone receptor gene restriction fragment length polymorphisms in human breast tumors.J Natl Cancer Inst. 1991 Aug 21;83(16):1157-60. doi: 10.1093/jnci/83.16.1157.
708 The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression.Nat Commun. 2017 Mar 9;8:14638. doi: 10.1038/ncomms14638.
709 IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells.Cytokine. 2008 Apr;42(1):39-47. doi: 10.1016/j.cyto.2008.01.016. Epub 2008 Mar 14.
710 STEAP1 is over-expressed in breast cancer and down-regulated by 17beta-estradiol in MCF-7 cells and in the rat mammary gland.Endocrine. 2008 Aug-Dec;34(1-3):108-16. doi: 10.1007/s12020-008-9113-7. Epub 2008 Oct 29.
711 Shu-Gan-Liang-Xue Decoction, a Chinese herbal formula, down-regulates the expression of steroid sulfatase genes in human breast carcinoma MCF-7 cells.J Ethnopharmacol. 2010 Feb 17;127(3):620-4. doi: 10.1016/j.jep.2009.12.014. Epub 2009 Dec 16.
712 A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment.Mol Biol Rep. 2008 Mar;35(1):23-7. doi: 10.1007/s11033-006-9047-1. Epub 2007 Apr 6.
713 TROP2 methylation and expression in tamoxifen-resistant breast cancer.Cancer Cell Int. 2018 Jul 6;18:94. doi: 10.1186/s12935-018-0589-9. eCollection 2018.
714 Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based assays.J Biomol Screen. 2014 Dec;19(10):1372-82. doi: 10.1177/1087057114546551. Epub 2014 Aug 12.
715 Coordinate regulation between expression levels of telomere-binding proteins and telomere length in breast carcinomas.Cancer Med. 2012 Oct;1(2):165-75. doi: 10.1002/cam4.14. Epub 2012 Jul 24.
716 Alternative TFAP2A isoforms have distinct activities in breast cancer.Breast Cancer Res. 2011 Mar 4;13(2):R23. doi: 10.1186/bcr2838.
717 Tagging staphylococcal enterotoxin B (SEB) with TGFaL3 for breast cancer therapy.Tumour Biol. 2016 Apr;37(4):5305-16. doi: 10.1007/s13277-015-4334-x. Epub 2015 Nov 11.
718 TGFBR1(*)6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancer.Br J Cancer. 2007 Oct 22;97(8):1175-9. doi: 10.1038/sj.bjc.6603961. Epub 2007 Sep 11.
719 Increase in transglutaminase 2 expression is associated with NF-kappaB activation in breast cancer tissues.Front Biosci (Landmark Ed). 2009 Jan 1;14(5):1945-51. doi: 10.2741/3354.
720 Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer.Oncogene. 2002 Jun 20;21(27):4307-16. doi: 10.1038/sj.onc.1205534.
721 Thyroid Hormone Receptor Inhibits Self-Renewal Capacity of Breast Cancer Stem Cells.Thyroid. 2020 Jan;30(1):116-132. doi: 10.1089/thy.2019.0175. Epub 2019 Dec 30.
722 Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice.J Cancer Res Clin Oncol. 2009 Jan;135(1):69-80. doi: 10.1007/s00432-008-0437-8. Epub 2008 Jul 1.
723 Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines.Cancer Res. 2002 Jan 1;62(1):313-22.
724 Whole Transcriptomic Analysis of Apigenin on TNF Immuno-activated MDA-MB-231 Breast Cancer Cells.Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):421-431. doi: 10.21873/cgp.20146.
725 APRIL promotes breast tumor growth and metastasis and is associated with aggressive basal breast cancer.Carcinogenesis. 2015 May;36(5):574-84. doi: 10.1093/carcin/bgv020. Epub 2015 Mar 6.
726 Serum neopterin levels in patients with breast cancer.Med Oncol. 2008;25(4):403-7. doi: 10.1007/s12032-008-9054-2. Epub 2008 Mar 5.
727 Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.Clin Cancer Res. 2018 May 15;24(10):2452-2463. doi: 10.1158/1078-0432.CCR-17-1381. Epub 2018 Jan 23.
728 Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level.Int J Mol Sci. 2018 Jun 22;19(7):1848. doi: 10.3390/ijms19071848.
729 Tweak induces mammary epithelial branching morphogenesis.Oncogene. 2005 Apr 14;24(16):2613-24. doi: 10.1038/sj.onc.1208208.
730 TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells.Breast Cancer Res. 2008;10(2):R36. doi: 10.1186/bcr2087. Epub 2008 Apr 24.
731 Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis.Cancer. 2003 Jul 1;98(1):18-23. doi: 10.1002/cncr.11482.
732 The breast cancer antigen 5T4 interacts with Rab11, and is a target and regulator of Rab11 mediated trafficking.Int J Biochem Cell Biol. 2018 Jun;99:28-37. doi: 10.1016/j.biocel.2018.03.002. Epub 2018 Mar 13.
733 Cell Cycle-Dependent Tumor Engraftment and Migration Are Enabled by Aurora-A.Mol Cancer Res. 2018 Jan;16(1):16-31. doi: 10.1158/1541-7786.MCR-17-0417. Epub 2017 Oct 9.
734 Prognostic significance of TRIM24/TIF-1 gene expression in breast cancer.Am J Pathol. 2011 Apr;178(4):1461-9. doi: 10.1016/j.ajpath.2010.12.026.
735 TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development.Oncotarget. 2017 Jan 3;8(1):863-882. doi: 10.18632/oncotarget.13273.
736 Cdc42-interacting protein 4 is a Src substrate that regulates invadopodia and invasiveness of breast tumors by promoting MT1-MMP endocytosis.J Cell Sci. 2011 May 15;124(Pt 10):1739-51. doi: 10.1242/jcs.078014. Epub 2011 Apr 26.
737 TRPM7 is required for breast tumor cell metastasis.Cancer Res. 2012 Aug 15;72(16):4250-61. doi: 10.1158/0008-5472.CAN-11-3863. Epub 2012 Aug 7.
738 Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer.Mol Cancer Ther. 2012 Oct;11(10):2158-68. doi: 10.1158/1535-7163.MCT-11-0965. Epub 2012 Jul 17.
739 An upstream regulatory element confers orientation-independent enhancement of the TSG101 promoter activity in transformed cells.Mol Biol Rep. 2012 Jan;39(1):517-25. doi: 10.1007/s11033-011-0766-6. Epub 2011 May 10.
740 DAPI fluorescence in nuclei isolated from tumors.J Histochem Cytochem. 2005 Aug;53(8):1033-6. doi: 10.1369/jhc.4B6563.2005.
741 The E2F activators control multiple mitotic regulators and maintain genomic integrity through Sgo1 and BubR1.Oncotarget. 2017 Sep 8;8(44):77649-77672. doi: 10.18632/oncotarget.20765. eCollection 2017 Sep 29.
742 Targeting Thioredoxin System with an Organosulfur Compound, Diallyl Trisulfide (DATS), Attenuates Progression and Metastasis of Triple-Negative Breast Cancer (TNBC). Cell Physiol Biochem. 2018;50(5):1945-1963. doi: 10.1159/000494874. Epub 2018 Nov 5.
743 Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors.Breast Cancer Res. 2012 Dec 5;14(6):R153. doi: 10.1186/bcr3366.
744 Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.Br J Cancer. 1995 Sep;72(3):669-75. doi: 10.1038/bjc.1995.392.
745 Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.BMC Cancer. 2011 Apr 18;11:143. doi: 10.1186/1471-2407-11-143.
746 Expression of NgBR is highly associated with estrogen receptor alpha and survivin in breast cancer.PLoS One. 2013 Nov 4;8(11):e78083. doi: 10.1371/journal.pone.0078083. eCollection 2013.
747 E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis.Nat Med. 2006 Jul;12(7):809-16. doi: 10.1038/nm1440. Epub 2006 Jul 2.
748 [Evaluation of 5-fluorouracil-related genes in breast cancer to predict the effect of adjuvant therapy with CMF].Gan To Kagaku Ryoho. 2009 Jan;36(1):51-5.
749 USP2 promotes cell migration and invasion in triple negative breast cancer cell lines.Tumour Biol. 2015 Jul;36(7):5415-23. doi: 10.1007/s13277-015-3207-7. Epub 2015 Feb 17.
750 RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer.Cell Death Differ. 2017 Apr;24(4):694-704. doi: 10.1038/cdd.2016.126. Epub 2017 Feb 3.
751 The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.Breast Cancer Res. 2012 Nov 12;14(6):R145. doi: 10.1186/bcr3354.
752 Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.Regul Pept. 2007 Dec 4;144(1-3):101-8. doi: 10.1016/j.regpep.2007.06.006. Epub 2007 Jun 28.
753 Wiskott-Aldrich syndrome protein regulates leukocyte-dependent breast cancer metastasis.Cell Rep. 2013 Aug 15;4(3):429-36. doi: 10.1016/j.celrep.2013.07.007. Epub 2013 Aug 1.
754 Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers.Cell Rep. 2013 Oct 31;5(2):302-13. doi: 10.1016/j.celrep.2013.09.009. Epub 2013 Oct 10.
755 Integrated functional, gene expression and genomic analysis for the identification of cancer targets.PLoS One. 2009;4(4):e5120. doi: 10.1371/journal.pone.0005120. Epub 2009 Apr 9.
756 Reduced production and uptake of lactate are essential for the ability of WNT5A signaling to inhibit breast cancer cell migration and invasion.Oncotarget. 2017 Apr 20;8(42):71471-71488. doi: 10.18632/oncotarget.17277. eCollection 2017 Sep 22.
757 Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation.Oncogene. 2008 Jan 3;27(1):126-38. doi: 10.1038/sj.onc.1210622. Epub 2007 Jun 25.
758 Tumour-promoting activity of altered WWP1 expression in breast cancer and its utility as a prognostic indicator.J Pathol. 2008 Sep;216(1):93-102. doi: 10.1002/path.2385.
759 Immunohistochemical analysis of Ku70/86 expression of breast cancer tissues.Oncol Rep. 2007 Dec;18(6):1483-7.
760 Transcriptome analysis of the cancer/testis genes, DAZ1, AURKC, and TEX101, in breast tumors and six breast cancer cell lines.Tumour Biol. 2015 Sep;36(10):8201-6. doi: 10.1007/s13277-015-3546-4. Epub 2015 May 21.
761 Breast Tumor Microcalcification Induced by Bone Morphogenetic Protein-2: A New Murine Model for Human Breast Tumor Diagnosis.Contrast Media Mol Imaging. 2018 Nov 11;2018:2082154. doi: 10.1155/2018/2082154. eCollection 2018.
762 SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4(+) T Lymphocytes.Front Immunol. 2018 May 15;9:776. doi: 10.3389/fimmu.2018.00776. eCollection 2018.
763 Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy.Breast Cancer Res. 2013 Dec 17;15(6):R118. doi: 10.1186/bcr3587.
764 FoxM1 is a promising candidate target in the treatment of breast cancer.Oncotarget. 2017 Dec 12;9(1):842-852. doi: 10.18632/oncotarget.23182. eCollection 2018 Jan 2.
765 Follistatin Expression in Human Invasive Breast Tumors: Pathologic and Clinical Associations.Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):108-112. doi: 10.1097/PAI.0000000000000385.
766 -hCG-induced mutant BRCA1 ignites drug resistance in susceptible breast tissue.Carcinogenesis. 2019 Nov 25;40(11):1415-1426. doi: 10.1093/carcin/bgz070.
767 Suppression of Her2/Neu mammary tumor development in mda-7/IL-24 transgenic mice.Oncotarget. 2015 Nov 10;6(35):36943-54. doi: 10.18632/oncotarget.6046.
768 Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of tumor cell stemness.Oncoimmunology. 2018 Jan 3;7(4):e1414129. doi: 10.1080/2162402X.2017.1414129. eCollection 2018.
769 Transcriptional regulation of mixed lineage kinase 3 by estrogen and its implication in ER-positive breast cancer pathogenesis.Oncotarget. 2017 May 16;8(20):33172-33184. doi: 10.18632/oncotarget.16566.
770 Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression.Breast Cancer Res Treat. 2014 Jan;143(1):181-7. doi: 10.1007/s10549-013-2771-z. Epub 2013 Nov 30.
771 Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers.Cancer Res. 2008 Feb 15;68(4):971-5. doi: 10.1158/0008-5472.CAN-07-6272.
772 RUNX3 Epigenetic Inactivation Is Associated With Estrogen Receptor Positive Breast Cancer.J Histochem Cytochem. 2018 Oct;66(10):709-721. doi: 10.1369/0022155418797315. Epub 2018 Aug 22.
773 Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.Nat Genet. 2013 Apr;45(4):371-84, 384e1-2. doi: 10.1038/ng.2566.
774 Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients.Int J Cancer. 2006 Jan 15;118(2):412-21. doi: 10.1002/ijc.21332.
775 The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer.Tumour Biol. 2015 Jun;36(6):4427-32. doi: 10.1007/s13277-015-3082-2. Epub 2015 Jan 22.
776 Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome.BMC Cancer. 2013 Jan 2;13:1. doi: 10.1186/1471-2407-13-1.
777 ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone.Breast Cancer Res. 2012 Nov 22;14(6):R149. doi: 10.1186/bcr3361.
778 Antisense-mediated Inhibition of the plasma membrane calcium-ATPase suppresses proliferation of MCF-7 cells.J Biol Chem. 2005 Jul 22;280(29):27076-84. doi: 10.1074/jbc.M414142200. Epub 2005 May 23.
779 Estrone-3-Sulfate Stimulates the Proliferation of T47D Breast Cancer Cells Stably Transfected With the Sodium-Dependent Organic Anion Transporter SOAT (SLC10A6). Front Pharmacol. 2018 Aug 21;9:941. doi: 10.3389/fphar.2018.00941. eCollection 2018.
780 Adipocytes promote malignant growth of breast tumours with monocarboxylate transporter 2 expression via beta-hydroxybutyrate. Nat Commun. 2017 Mar 10;8:14706.
781 Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo.Breast Cancer Res. 2008;10(1):R11. doi: 10.1186/bcr1857. Epub 2008 Feb 12.
782 Evaluation of SAT-1, SAT-2 and GalNAcT-1 mRNA in colon cancer by real-time PCR.Mol Cell Biochem. 2007 Apr;298(1-2):59-68. doi: 10.1007/s11010-006-9350-0. Epub 2006 Nov 21.
783 Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer.Oncology. 2006;70(3):238-44. doi: 10.1159/000094541. Epub 2006 Jul 12.
784 An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer.Nat Genet. 2014 Oct;46(10):1051-9. doi: 10.1038/ng.3073. Epub 2014 Aug 24.
785 Increased transglutaminase 2 and GLUT-1 expression in breast tumors not susceptible to chemoprevention with antioxidants.Tumori. 2009 Mar-Apr;95(2):227-32. doi: 10.1177/030089160909500215.
786 Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers.Pathol Oncol Res. 2012 Jul;18(3):721-8. doi: 10.1007/s12253-012-9500-5. Epub 2012 Jan 21.
787 Regulation of zinc transporters by dietary flaxseed lignan in human breast cancer xenografts.Mol Biol Rep. 2008 Dec;35(4):595-600. doi: 10.1007/s11033-007-9129-8. Epub 2007 Sep 5.
788 ZnT2-overexpression represses the cytotoxic effects of zinc hyper-accumulation in malignant metallothionein-null T47D breast tumor cells.Cancer Lett. 2011 May 1;304(1):41-51. doi: 10.1016/j.canlet.2011.01.027. Epub 2011 Feb 25.
789 Disrupting Hypoxia-Induced Bicarbonate Transport Acidifies Tumor Cells and Suppresses Tumor Growth. Cancer Res. 2016 Jul 1;76(13):3744-55.
790 Prostatic acid phosphatase in breast cyst fluid.Malays J Pathol. 2007 Dec;29(2):95-9.
791 Human breast cancer cell lines and tissues express tartrate-resistant acid phosphatase (TRAP).Cell Biol Int. 2007 Feb;31(2):191-5. doi: 10.1016/j.cellbi.2006.09.022. Epub 2006 Oct 4.
792 Alcohol metabolism, alcohol intake, and breast cancer risk: a sister-set analysis using the Breast Cancer Family Registry.Breast Cancer Res Treat. 2007 Dec;106(2):281-8. doi: 10.1007/s10549-007-9498-7. Epub 2007 Feb 1.
793 Prolyl-4-hydroxylase subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition.BMC Cancer. 2014 Jan 2;14:1. doi: 10.1186/1471-2407-14-1.
794 Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer.J Cancer Res Clin Oncol. 2008 Jan;134(1):67-73. doi: 10.1007/s00432-007-0249-2. Epub 2007 Jul 28.
795 Macrophages attenuate the transcription of CYP1A1 in breast tumor cells and enhance their proliferation.PLoS One. 2019 Jan 7;14(1):e0209694. doi: 10.1371/journal.pone.0209694. eCollection 2019.
796 Non-coding single nucleotide variants affecting estrogen receptor binding and activity.Genome Med. 2016 Dec 13;8(1):128. doi: 10.1186/s13073-016-0382-0.
797 Retrospective analysis of estrogen receptor1 and Nacetyltransferase gene expression in normal breast tissue, primary breast tumors, and established breast cancer cell lines.Int J Oncol. 2018 Aug;53(2):694-702. doi: 10.3892/ijo.2018.4436. Epub 2018 Jun 11.
798 Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors.Neoplasia. 2007 Oct;9(10):797-800. doi: 10.1593/neo.07595.
799 Increasing the low lipid phosphate phosphatase 1 activity in breast cancer cells decreases transcription by AP-1 and expressions of matrix metalloproteinases and cyclin D1/D3.Theranostics. 2019 Aug 14;9(21):6129-6142. doi: 10.7150/thno.37094. eCollection 2019.
800 Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress.Cancer Cell. 2015 Jan 12;27(1):57-71. doi: 10.1016/j.ccell.2014.12.002.
801 ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming.J Clin Invest. 2018 Jan 2;128(1):323-340. doi: 10.1172/JCI93815. Epub 2017 Nov 27.
802 Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.J Biol Chem. 2008 Feb 8;283(6):3418-3423. doi: 10.1074/jbc.M707650200. Epub 2007 Dec 1.
803 Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling.Cancer Res. 2004 Oct 15;64(20):7610-7. doi: 10.1158/0008-5472.CAN-04-1608.
804 Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid/HIF-1/VEGF signalling in MCF-7 breast cancer cells.J Exp Clin Cancer Res. 2018 Dec 12;37(1):311. doi: 10.1186/s13046-018-0975-0.
805 Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women.Cancer Res. 2009 Jul 1;69(13):5392-9. doi: 10.1158/0008-5472.CAN-09-0108. Epub 2009 Jun 9.
806 Gene characterization, promoter analysis, and chromosomal localization of human bleomycin hydrolase.J Biol Chem. 1997 Dec 26;272(52):33298-304. doi: 10.1074/jbc.272.52.33298.
807 Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.Pharmacogenet Genomics. 2008 Jul;18(7):621-31. doi: 10.1097/FPC.0b013e328301a869.
808 25-Hydroxyvitamin D3 1alpha-hydroxylase splice variants in breast cell lines MCF-7 and MCF-10.Cancer Genomics Proteomics. 2007 Jul-Aug;4(4):295-300.
809 CYP2C and IL-6 expression in breast cancer.Breast. 2004 Feb;13(1):28-34. doi: 10.1016/j.breast.2003.07.002.
810 CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients.Br J Cancer. 2009 Dec 1;101(11):1817-23. doi: 10.1038/sj.bjc.6605428.
811 The frameshift polymorphism CYP3A43_74_delA is associated with poor differentiation of breast tumors.Cancer. 2010 Dec 1;116(23):5358-64. doi: 10.1002/cncr.25508. Epub 2010 Aug 16.
812 Detection of aromatase and keratinocyte growth factor expression in breast tumors using reverse transcription-polymerase chain reaction.J Steroid Biochem Mol Biol. 1993 Apr;45(4):217-25. doi: 10.1016/0960-0760(93)90335-t.
813 Proteomic profiling of mammary carcinomas identifies C7orf24, a gamma-glutamyl cyclotransferase, as a potential cancer biomarker.J Proteome Res. 2010 Aug 6;9(8):3941-53. doi: 10.1021/pr100160u.
814 Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer.Oncol Rep. 2008 May;19(5):1311-21.
815 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.Cancer Res. 2006 Aug 1;66(15):7818-23. doi: 10.1158/0008-5472.CAN-05-4368.
816 Expression of 3-Hydroxysteroid Dehydrogenase Type 1 in Breast Cancer is Associated with Poor Prognosis Independent of Estrogen Receptor Status.Ann Surg Oncol. 2017 Dec;24(13):4033-4041. doi: 10.1245/s10434-017-6000-6. Epub 2017 Jul 25.
817 Metallothionein-2A overexpression increases the expression of matrix metalloproteinase-9 and invasion of breast cancer cells.FEBS Lett. 2011 Jan 21;585(2):421-8. doi: 10.1016/j.febslet.2010.12.030. Epub 2010 Dec 25.
818 One-carbon metabolism-related gene polymorphisms and risk of breast cancer.Carcinogenesis. 2008 Feb;29(2):356-62. doi: 10.1093/carcin/bgm295. Epub 2008 Jan 3.
819 Phosphoethanolamine Accumulation Protects Cancer Cells under Glutamine Starvation through Downregulation of PCYT2.Cell Rep. 2019 Oct 1;29(1):89-103.e7. doi: 10.1016/j.celrep.2019.08.087.
820 Liver X Receptor (LXR)-regulated Genes of Cholesterol Trafficking and Breast Cancer Severity.Anticancer Res. 2017 Oct;37(10):5495-5498. doi: 10.21873/anticanres.11979.
821 Expression of prostaglandin D synthase in ovarian cancer.Clin Chem Lab Med. 2001 Dec;39(12):1198-203. doi: 10.1515/CCLM.2001.190.
822 Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy. Breast Cancer Res Treat. 2018 Nov;172(2):401-411. doi: 10.1007/s10549-018-4923-7. Epub 2018 Aug 17.
823 Sulfotransferase 1A2*2 is a risk factor for early-onset breast cancer.Int J Mol Med. 2002 Nov;10(5):609-12.
824 Expression of breast cancer specific gene-1 (BCSG-1/gamma-synuclein) is associated with tumour grade but not with clinical outcome of patients with breast cancer.Oncol Rep. 2006 Jul;16(1):207-12.
825 Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. Endocrinology. 2006 Aug;147(8):3843-50.
826 Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer.Front Oncol. 2019 Aug 2;9:686. doi: 10.3389/fonc.2019.00686. eCollection 2019.
827 AFF3 upregulation mediates tamoxifen resistance in breast cancers.J Exp Clin Cancer Res. 2018 Oct 16;37(1):254. doi: 10.1186/s13046-018-0928-7.
828 In silico SNP analysis of the breast cancer antigen NY-BR-1.BMC Cancer. 2016 Nov 18;16(1):901. doi: 10.1186/s12885-016-2924-7.
829 ARID3B expression in primary breast cancers and breast cancer-derived cell lines.Cell Oncol (Dordr). 2014 Aug;37(4):289-96. doi: 10.1007/s13402-014-0185-5. Epub 2014 Aug 14.
830 A Ca(2+)-ATPase Regulates E-cadherin Biogenesis and Epithelial-Mesenchymal Transition in Breast Cancer Cells.Mol Cancer Res. 2019 Aug;17(8):1735-1747. doi: 10.1158/1541-7786.MCR-19-0070. Epub 2019 May 10.
831 BARD1 and breast cancer in Poland.Breast Cancer Res Treat. 2008 Jan;107(1):119-22. doi: 10.1007/s10549-007-9537-4. Epub 2007 Feb 27.
832 Bin1 attenuation in breast cancer is correlated to nodal metastasis and reduced survival.Cancer Biol Ther. 2007 Feb;6(2):192-4. doi: 10.4161/cbt.6.2.3587. Epub 2007 Feb 7.
833 BRCC3 acts as a prognostic marker in nasopharyngeal carcinoma patients treated with radiotherapy and mediates radiation resistance in vitro.Radiat Oncol. 2015 May 30;10:123. doi: 10.1186/s13014-015-0427-3.
834 ZNF652, a novel zinc finger protein, interacts with the putative breast tumor suppressor CBFA2T3 to repress transcription.Mol Cancer Res. 2006 Sep;4(9):655-65. doi: 10.1158/1541-7786.MCR-05-0249.
835 Deubiquitinase ubiquitin-specific protease 9X regulates the stability and function of E3 ubiquitin ligase ring finger protein 115 in breast cancer cells.Cancer Sci. 2019 Apr;110(4):1268-1278. doi: 10.1111/cas.13953. Epub 2019 Feb 21.
836 CCN5, a novel transcriptional repressor of the transforming growth factor signaling pathway.Mol Cell Biol. 2011 Apr;31(7):1459-69. doi: 10.1128/MCB.01316-10. Epub 2011 Jan 24.
837 Genome analysis identifies the p15ink4b tumor suppressor as a direct target of the ZNF217/CoREST complex.Mol Cell Biol. 2008 Oct;28(19):6066-77. doi: 10.1128/MCB.00246-08. Epub 2008 Jul 14.
838 Promoter methylation reduces C/EBPdelta (CEBPD) gene expression in the SUM-52PE human breast cancer cell line and in primary breast tumors.Breast Cancer Res Treat. 2006 Jan;95(2):161-70. doi: 10.1007/s10549-005-9061-3. Epub 2005 Dec 2.
839 Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients.Br J Cancer. 2012 Jan 3;106(1):189-98. doi: 10.1038/bjc.2011.510. Epub 2011 Nov 22.
840 CLCA2, a novel RUNX1 partner gene in a therapy-related leukemia with t(1;21)(p22;q22).Cancer Genet Cytogenet. 2010 Oct 15;202(2):94-100. doi: 10.1016/j.cancergencyto.2010.07.116.
841 CMTM1_v17 is a novel potential therapeutic target in breast cancer.Oncol Rep. 2014 Nov;32(5):1829-36. doi: 10.3892/or.2014.3429. Epub 2014 Aug 20.
842 Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer.J Pathol. 2008 Feb;214(3):337-46. doi: 10.1002/path.2265.
843 ATM-Mediated Phosphorylation of Cortactin Involved in Actin Polymerization Promotes Breast Cancer Cells Migration and Invasion.Cell Physiol Biochem. 2018;51(6):2972-2988. doi: 10.1159/000496048. Epub 2018 Dec 14.
844 DACT1, an antagonist to Wnt/-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer.Breast Cancer Res. 2013 Mar 12;15(2):R23. doi: 10.1186/bcr3399.
845 Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel.BMC Cancer. 2011 Jan 19;11:22. doi: 10.1186/1471-2407-11-22.
846 Essential role of KIBRA in co-activator function of dynein light chain 1 in mammalian cells.J Biol Chem. 2006 Jul 14;281(28):19092-9. doi: 10.1074/jbc.M600021200. Epub 2006 May 9.
847 E2F6 is essential for cell viability in breast cancer cells during replication stress.Turk J Biol. 2019 Oct 14;43(5):293-304. doi: 10.3906/biy-1905-6. eCollection 2019.
848 Mammalian tumor suppressor Int6 specifically targets hypoxia inducible factor 2 alpha for degradation by hypoxia- and pVHL-independent regulation.J Biol Chem. 2007 Apr 27;282(17):12707-16. doi: 10.1074/jbc.M700423200. Epub 2007 Feb 26.
849 Embigin, regulated by HOXC8, plays a suppressive role in breast tumorigenesis.Oncotarget. 2015 Sep 15;6(27):23496-509. doi: 10.18632/oncotarget.4360.
850 Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat. 2007 Jul;103(3):283-91. doi: 10.1007/s10549-006-9377-7. Epub 2007 Jan 27.
851 Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers.Nat Commun. 2019 Sep 25;10(1):4369. doi: 10.1038/s41467-019-12291-6.
852 A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1.Genes Dev. 2017 Feb 15;31(4):353-369. doi: 10.1101/gad.289769.116. Epub 2017 Mar 9.
853 Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells.Endocrinology. 2005 Feb;146(2):760-8. doi: 10.1210/en.2004-1239. Epub 2004 Nov 4.
854 FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells.Cell Cycle. 2007 Jul 15;6(14):1779-88. doi: 10.4161/cc.6.14.4448.
855 Toca-1 is suppressed by p53 to limit breast cancer cell invasion and tumor metastasis.Breast Cancer Res. 2014 Dec 30;16(6):3413. doi: 10.1186/s13058-014-0503-x.
856 Stress granule-associated protein G3BP2 regulates breast tumor initiation.Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1033-1038. doi: 10.1073/pnas.1525387114. Epub 2017 Jan 17.
857 Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor.Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5575-9. doi: 10.1073/pnas.0700407104. Epub 2007 Mar 19.
858 Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer.J Clin Oncol. 2007 Jul 20;25(21):3015-23. doi: 10.1200/JCO.2006.10.0099.
859 A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer.Horm Cancer. 2015 Dec;6(5-6):214-24. doi: 10.1007/s12672-015-0230-5. Epub 2015 Jun 26.
860 Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer.Cancer Res. 2007 Jul 1;67(13):6136-45. doi: 10.1158/0008-5472.CAN-07-0567.
861 4 is highly expressed in carcinogen-transformed human cells and primary human cancers.Oncogene. 2011 Jun 30;30(26):2943-53. doi: 10.1038/onc.2011.20. Epub 2011 Feb 21.
862 LincIN, a novel NF90-binding long non-coding RNA, is overexpressed in advanced breast tumors and involved in metastasis.Breast Cancer Res. 2017 May 30;19(1):62. doi: 10.1186/s13058-017-0853-2.
863 INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes.Breast Cancer Res Treat. 1996;37(1):65-76. doi: 10.1007/BF01806633.
864 JMJD6 induces HOTAIR, an oncogenic lincRNA, by physically interacting with its proximal promoter.Biochem J. 2018 Jan 15;475(1):355-371. doi: 10.1042/BCJ20170664.
865 High expression of KIF14 in retinoblastoma: association with older age at diagnosis.Invest Ophthalmol Vis Sci. 2007 Nov;48(11):4901-6. doi: 10.1167/iovs.07-0063.
866 Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity.Int J Cancer. 2008 Sep 15;123(6):1433-8. doi: 10.1002/ijc.23628.
867 Lysyl oxidase-like protein localizes to sites of de novo fibrinogenesis in fibrosis and in the early stromal reaction of ductal breast carcinomas.Lab Invest. 1998 Feb;78(2):143-51.
868 SUMO1 negatively regulates the transcriptional activity of EVI1 and significantly increases its co-localization with EVI1 after treatment with arsenic trioxide.Biochim Biophys Acta. 2013 Oct;1833(10):2357-68. doi: 10.1016/j.bbamcr.2013.06.003. Epub 2013 Jun 13.
869 Class IIa HDACs repressive activities on MEF2-depedent transcription are associated with poor prognosis of ER?breast tumors.FASEB J. 2013 Mar;27(3):942-54. doi: 10.1096/fj.12-209346. Epub 2012 Nov 16.
870 Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancer.Hum Mol Genet. 2002 Jun 1;11(12):1449-53. doi: 10.1093/hmg/11.12.1449.
871 Role of carbohydrate response element-binding protein (ChREBP) in generating an aerobic metabolic phenotype and in breast cancer progression.Br J Cancer. 2014 Feb 4;110(3):715-23. doi: 10.1038/bjc.2013.765. Epub 2013 Dec 24.
872 MNX1-AS1 is a functional oncogene that induces EMT and activates the AKT/mTOR pathway and MNX1 in breast cancer.Cancer Manag Res. 2019 Jan 17;11:803-812. doi: 10.2147/CMAR.S188007. eCollection 2019.
873 Newly characterized motile sperm domain-containing protein 2 promotes human breast cancer metastasis.Int J Cancer. 2019 Jan 1;144(1):125-135. doi: 10.1002/ijc.31665. Epub 2018 Oct 29.
874 Microwave-Synthesized Platinum-Embedded Mesoporous Silica Nanoparticles as Dual-Modality Contrast Agents: Computed Tomography and Optical Imaging.Int J Mol Sci. 2019 Mar 28;20(7):1560. doi: 10.3390/ijms20071560.
875 HER2 drives Mucin-like 1 to control proliferation in breast cancer cells.Oncogene. 2016 Aug 11;35(32):4225-34. doi: 10.1038/onc.2015.487. Epub 2016 Jan 4.
876 microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer.Mol Cancer. 2014 Aug 29;13:200. doi: 10.1186/1476-4598-13-200.
877 Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker.Clin Exp Med. 2019 Aug;19(3):377-384. doi: 10.1007/s10238-019-00554-x. Epub 2019 Apr 20.
878 p54(nrb)/NONO regulates lipid metabolism and breast cancer growth through SREBP-1A.Oncogene. 2016 Mar 17;35(11):1399-410. doi: 10.1038/onc.2015.197. Epub 2015 Jul 6.
879 COUP-TFI modifies CXCL12 and CXCR4 expression by activating EGF signaling and stimulates breast cancer cell migration.BMC Cancer. 2014 Jun 6;14:407. doi: 10.1186/1471-2407-14-407.
880 Modulation of aromatase expression in human breast tissue. J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):35-40.
881 PPAPDC1B and WHSC1L1 are common drivers of the 8p11-12 amplicon, not only in breast tumors but also in pancreatic adenocarcinomas and lung tumors.Am J Pathol. 2013 Nov;183(5):1634-1644. doi: 10.1016/j.ajpath.2013.07.028. Epub 2013 Sep 17.
882 Cancer/Testis OIP5 and TAF7L Genes are Up-Regulated in Breast Cancer.Asian Pac J Cancer Prev. 2015;16(11):4623-8. doi: 10.7314/apjcp.2015.16.11.4623.
883 OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1.Cancer Res. 2005 Aug 15;65(16):7151-8. doi: 10.1158/0008-5472.CAN-05-1400.
884 Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.Breast Cancer Res Treat. 2015 Jul;152(1):29-39. doi: 10.1007/s10549-015-3446-8. Epub 2015 May 31.
885 Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors.Oncogene. 2016 May;35(21):2777-88. doi: 10.1038/onc.2015.341. Epub 2015 Sep 21.
886 DNA primase polypeptide 1 (PRIM1) involves in estrogen-induced breast cancer formation through activation of the G2/M cell cycle checkpoint.Int J Cancer. 2019 Feb 1;144(3):615-630. doi: 10.1002/ijc.31788. Epub 2018 Nov 21.
887 RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy.Cancer Biol Ther. 2014 Jun 1;15(6):777-88. doi: 10.4161/cbt.28551. Epub 2014 Mar 18.
888 Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2.Cancer Discov. 2015 May;5(5):506-19. doi: 10.1158/2159-8290.CD-14-1042. Epub 2015 Feb 25.
889 The SmgGDS splice variant SmgGDS-558 is a key promoter of tumor growth and RhoA signaling in breast cancer.Mol Cancer Res. 2014 Jan;12(1):130-42. doi: 10.1158/1541-7786.MCR-13-0362. Epub 2013 Nov 6.
890 Function of RasGRP3 in the formation and progression of human breast cancer.Mol Cancer. 2014 Apr 29;13:96. doi: 10.1186/1476-4598-13-96.
891 Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis.Oncotarget. 2015 Sep 15;6(27):23944-58. doi: 10.18632/oncotarget.4062.
892 The role of retinoblastoma-associated proteins 46 and 48 in estrogen receptor alpha mediated gene expression.Mol Cell Endocrinol. 2008 Sep 10;291(1-2):79-86. doi: 10.1016/j.mce.2008.05.016. Epub 2008 Jun 5.
893 Breast cancer risk and the BRCA1 interacting protein CTIP.Breast Cancer Res Treat. 2008 Nov;112(2):351-2. doi: 10.1007/s10549-007-9862-7. Epub 2007 Dec 20.
894 Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer.Cancer Res. 2002 Oct 15;62(20):5902-5.
895 Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer.Oncotarget. 2014 Jul 15;5(13):5087-99. doi: 10.18632/oncotarget.2086.
896 Identification of mammaglobin as a novel serum marker for breast cancer.Clin Cancer Res. 2005 Sep 15;11(18):6528-35. doi: 10.1158/1078-0432.CCR-05-0415.
897 Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors.Cancer Biol Ther. 2003 Sep-Oct;2(5):559-63. doi: 10.4161/cbt.2.5.511.
898 Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway.Cancer Res. 2009 Jun 1;69(11):4621-8. doi: 10.1158/0008-5472.CAN-08-3402. Epub 2009 May 19.
899 Polymorphism of cytosolic serine hydroxymethyltransferase, estrogen and breast cancer risk among Chinese women in Taiwan.Breast Cancer Res Treat. 2008 Sep;111(1):145-55. doi: 10.1007/s10549-007-9754-x. Epub 2007 Sep 22.
900 Regulation of DCIS to invasive breast cancer progression by Singleminded-2s (SIM2s).Oncogene. 2013 May 23;32(21):2631-9. doi: 10.1038/onc.2012.286. Epub 2012 Jul 9.
901 Case-only analyses of the associations between polymorphisms in the metastasis-modifying genes BRMS1 and SIPA1 and breast tumor characteristics, lymph node metastasis, and survival.Breast Cancer Res Treat. 2013 Jun;139(3):873-85. doi: 10.1007/s10549-013-2601-3. Epub 2013 Jun 16.
902 Low expression of SLC22A18 predicts poor survival outcome in patients with breast cancer after surgery.Cancer Epidemiol. 2011 Jun;35(3):279-85. doi: 10.1016/j.canep.2010.09.006. Epub 2010 Dec 7.
903 Development and validation of a multiplex methylation specific PCR-coupled liquid bead array for liquid biopsy analysis.Clin Chim Acta. 2016 Oct 1;461:156-64. doi: 10.1016/j.cca.2016.08.003. Epub 2016 Aug 7.
904 A Sox2-Sox9 signalling axis maintains human breast luminal progenitor and breast cancer stem cells.Oncogene. 2019 Apr;38(17):3151-3169. doi: 10.1038/s41388-018-0656-7. Epub 2019 Jan 8.
905 ARF6-JIP3/4 regulate endosomal tubules for MT1-MMP exocytosis in cancer invasion.J Cell Biol. 2015 Oct 26;211(2):339-58. doi: 10.1083/jcb.201506002.
906 Molecular cloning, genomic structure and interactions of the putative breast tumor suppressor TACC2.Genomics. 2003 Feb;81(2):192-201. doi: 10.1016/s0888-7543(02)00039-3.
907 High levels of -glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.BMC Cancer. 2013 Feb 1;13:47. doi: 10.1186/1471-2407-13-47.
908 TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer.Endocr Relat Cancer. 2015 Jun;22(3):465-79. doi: 10.1530/ERC-15-0129. Epub 2015 Apr 21.
909 Modulation of tumor fatty acids, through overexpression or loss of thyroid hormone responsive protein spot 14 is associated with altered growth and metastasis.Breast Cancer Res. 2014 Dec 4;16(6):481. doi: 10.1186/s13058-014-0481-z.
910 Downregulation of ubiquitin E3 ligase TNF receptor-associated factor 7 leads to stabilization of p53 in breast cancer.Oncol Rep. 2013 Jan;29(1):283-7. doi: 10.3892/or.2012.2121. Epub 2012 Nov 1.
911 Frequent loss of the BLID gene in early-onset breast cancer.Cytogenet Genome Res. 2011;135(1):19-24. doi: 10.1159/000330265. Epub 2011 Aug 12.
912 CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid.Mol Cancer. 2015 Jul 5;14:129. doi: 10.1186/s12943-015-0380-7.
913 Beta protein 1 homeoprotein induces cell growth and estrogen-independent tumorigenesis by binding to the estrogen receptor in breast cancer.Oncotarget. 2016 Aug 16;7(33):53204-53216. doi: 10.18632/oncotarget.10633.
914 Carcinoma associated fibroblasts (CAFs) promote breast cancer motility by suppressing mammalian Diaphanous-related formin-2 (mDia2).PLoS One. 2018 Mar 29;13(3):e0195278. doi: 10.1371/journal.pone.0195278. eCollection 2018.
915 ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells.Cell Death Differ. 2020 Jan;27(1):363-378. doi: 10.1038/s41418-019-0362-1. Epub 2019 Jun 13.
916 RhoGDI deficiency induces constitutive activation of Rho GTPases and COX-2 pathways in association with breast cancer progression.Oncotarget. 2015 Oct 20;6(32):32723-36. doi: 10.18632/oncotarget.5416.
917 A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.Oncotarget. 2016 Apr 5;7(14):18851-64. doi: 10.18632/oncotarget.7944.
918 Bcl-3 regulates TGF signaling by stabilizing Smad3 during breast cancer pulmonary metastasis.Cell Death Dis. 2016 Dec 1;7(12):e2508. doi: 10.1038/cddis.2016.405.
919 Epithelial-to-mesenchymal transition induced by TGF-1 is mediated by Blimp-1-dependent repression of BMP-5.Cancer Res. 2012 Dec 1;72(23):6268-78. doi: 10.1158/0008-5472.CAN-12-2270. Epub 2012 Oct 10.
920 Loss of CLCA4 promotes epithelial-to-mesenchymal transition in breast cancer cells.PLoS One. 2013 Dec 26;8(12):e83943. doi: 10.1371/journal.pone.0083943. eCollection 2013.
921 CPT1A regulates breast cancer-associated lymphangiogenesis via VEGF signaling.Biomed Pharmacother. 2018 Oct;106:1-7. doi: 10.1016/j.biopha.2018.05.112. Epub 2018 Jun 23.
922 P120 Catenin Isoforms Differentially Associate with Breast Cancer Invasion and Metastasis.Cancers (Basel). 2019 Sep 29;11(10):1459. doi: 10.3390/cancers11101459.
923 EVL (Ena/VASP-like) expression is up-regulated in human breast cancer and its relative expression level is correlated with clinical stages.Oncol Rep. 2008 Apr;19(4):1015-20.
924 FADD phosphorylation is critical for cell cycle regulation in breast cancer cells. Br J Cancer. 2006 Feb 27;94(4):532-9. doi: 10.1038/sj.bjc.6602955.
925 Understanding the functional impact of copy number alterations in breast cancer using a network modeling approach.Mol Biosyst. 2016 Mar;12(3):963-72. doi: 10.1039/c5mb00655d.
926 Increase in fatty acids and flotillins upon resveratrol treatment of human breast cancer cells.Sci Rep. 2019 Sep 27;9(1):13960. doi: 10.1038/s41598-019-50416-5.
927 Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.NMR Biomed. 2012 Sep;25(9):1033-42. doi: 10.1002/nbm.2766. Epub 2012 Jan 26.
928 High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients.Breast Cancer Res Treat. 2014 Nov;148(2):423-36. doi: 10.1007/s10549-014-3172-7. Epub 2014 Oct 28.
929 miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting antiapoptotic gene BCL-2: a potential for therapeutic intervention.Breast Cancer Res. 2011 Apr 4;13(2):R39. doi: 10.1186/bcr2861.
930 SUV420H2 suppresses breast cancer cell invasion through down regulation of the SH2 domain-containing focal adhesion protein tensin-3.Exp Cell Res. 2015 May 15;334(1):90-9. doi: 10.1016/j.yexcr.2015.03.010. Epub 2015 Mar 23.
931 Activating HER2 mutations in HER2 gene amplification negative breast cancer.Cancer Discov. 2013 Feb;3(2):224-37. doi: 10.1158/2159-8290.CD-12-0349. Epub 2012 Dec 7.
932 Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.Cancer Res. 2010 Mar 15;70(6):2476-84. doi: 10.1158/0008-5472.CAN-09-3114. Epub 2010 Mar 2.
933 Targeting the HOX/PBX dimer in breast cancer.Breast Cancer Res Treat. 2012 Nov;136(2):389-98. doi: 10.1007/s10549-012-2259-2. Epub 2012 Sep 30.
934 Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer.BMC Med Genomics. 2009 Jun 24;2:37. doi: 10.1186/1755-8794-2-37.
935 IKK regulates the breast cancer stem cell phenotype.Biochim Biophys Acta Mol Cell Res. 2019 Apr;1866(4):598-611. doi: 10.1016/j.bbamcr.2019.01.002. Epub 2019 Jan 5.
936 Endothelial cells provide a notch-dependent pro-tumoral niche for enhancing breast cancer survival, stemness and pro-metastatic properties.PLoS One. 2014 Nov 7;9(11):e112424. doi: 10.1371/journal.pone.0112424. eCollection 2014.
937 Characterization of Kelch domain-containing protein 7B in breast tumours and breast cancer cell lines.Oncol Lett. 2019 Sep;18(3):2853-2860. doi: 10.3892/ol.2019.10672. Epub 2019 Jul 26.
938 Genome-wide association studies identify four ER negative-specific breast cancer risk loci.Nat Genet. 2013 Apr;45(4):392-8, 398e1-2. doi: 10.1038/ng.2561.
939 Mutational analysis of MED12 exon 2 in a spectrum of fibroepithelial tumours of the breast: implications for pathogenesis and histogenesis.Histopathology. 2016 Feb;68(3):433-41. doi: 10.1111/his.12764. Epub 2015 Aug 7.
940 Resveratrol modulates MED28 (Magicin/EG-1) expression and inhibits epidermal growth factor (EGF)-induced migration in MDA-MB-231 human breast cancer cells.J Agric Food Chem. 2011 Nov 9;59(21):11853-61. doi: 10.1021/jf202426k. Epub 2011 Oct 17.
941 p63 controls cell migration and invasion by transcriptional regulation of MTSS1.Oncogene. 2016 Mar 24;35(12):1602-8. doi: 10.1038/onc.2015.230. Epub 2015 Jun 29.
942 p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial.Clin Cancer Res. 2018 Jul 1;24(13):3046-3052. doi: 10.1158/1078-0432.CCR-17-3250. Epub 2018 Mar 13.
943 Genome-wide association analysis identifies three new breast cancer susceptibility loci.Nat Genet. 2012 Jan 22;44(3):312-8. doi: 10.1038/ng.1049.
944 Gene expression of O-GlcNAc cycling enzymes in human breast cancers.Clin Exp Med. 2012 Mar;12(1):61-5. doi: 10.1007/s10238-011-0138-5. Epub 2011 May 13.
945 Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer.J Clin Oncol. 2010 Aug 10;28(23):3770-8. doi: 10.1200/JCO.2009.27.0215. Epub 2010 Jul 12.
946 A DNA repair variant in POLQ (c.-1060A > G) is associated to hereditary breast cancer patients: a case-control study.BMC Cancer. 2014 Nov 19;14:850. doi: 10.1186/1471-2407-14-850.
947 Proliferation-associated Brn-3b transcription factor can activate cyclin D1 expression in neuroblastoma and breast cancer cells.Oncogene. 2008 Jan 3;27(1):145-54. doi: 10.1038/sj.onc.1210621. Epub 2007 Jul 16.
948 Darpp-32 and t-Darpp are differentially expressed in normal and malignant mouse mammary tissue.Mol Cancer. 2014 Aug 15;13:192. doi: 10.1186/1476-4598-13-192.
949 Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer.Breast Cancer Res. 2015 Sep 4;17(1):123. doi: 10.1186/s13058-015-0636-6.
950 EFA6B antagonizes breast cancer.Cancer Res. 2014 Oct 1;74(19):5493-506. doi: 10.1158/0008-5472.CAN-14-0298. Epub 2014 Aug 12.
951 Prognostic value of EZH2, paxillin expression and DNA ploidy of breast adenocarcinoma: correlation to pathologic predictors.J BUON. 2013 Oct-Dec;18(4):879-85.
952 Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in Luminal B breast cancer.Breast Cancer Res. 2013 Mar 28;15(2):R28. doi: 10.1186/bcr3407.
953 Characterization of the human homologue of RAD54: a gene located on chromosome 1p32 at a region of high loss of heterozygosity in breast tumors.Cancer Res. 1997 Jun 15;57(12):2378-83.
954 Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.Mod Pathol. 2009 Dec;22(12):1564-74. doi: 10.1038/modpathol.2009.124. Epub 2009 Sep 4.
955 microRNA-200c/141 upregulates SerpinB2 to promote breast cancer cell metastasis and reduce patient survival.Oncotarget. 2017 May 16;8(20):32769-32782. doi: 10.18632/oncotarget.15680.
956 Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women.Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3490-8. doi: 10.1158/1055-9965.EPI-08-0734.
957 Identification and functional analysis of SKA2 interaction with the glucocorticoid receptor.J Endocrinol. 2008 Sep;198(3):499-509. doi: 10.1677/JOE-08-0019. Epub 2008 Jun 26.
958 Calcium-sensing stromal interaction molecule 2 upregulates nuclear factor of activated T cells 1 and transforming growth factor- signaling to promote breast cancer metastasis.Breast Cancer Res. 2019 Aug 29;21(1):99. doi: 10.1186/s13058-019-1185-1.
959 TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis.Breast Cancer Res Treat. 2015 Aug;152(3):519-31. doi: 10.1007/s10549-015-3492-2. Epub 2015 Jul 10.
960 TLE1 is an anoikis regulator and is downregulated by Bit1 in breast cancer cells.Mol Cancer Res. 2012 Nov;10(11):1482-95. doi: 10.1158/1541-7786.MCR-12-0144. Epub 2012 Sep 4.
961 TAp73 upregulates IL-1 in cancer cells: Potential biomarker in lung and breast cancer?.Biochem Biophys Res Commun. 2017 Jan 15;482(3):498-505. doi: 10.1016/j.bbrc.2016.10.085. Epub 2017 Feb 3.
962 Down-regulation of tripartite-motif containing 22 expression in breast cancer is associated with a lack of p53-mediated induction.Biochem Biophys Res Commun. 2013 Nov 22;441(3):600-6. doi: 10.1016/j.bbrc.2013.10.110. Epub 2013 Oct 29.
963 Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines.Mol Pharmacol. 1994 Oct;46(4):677-84.
964 Abelson interactor protein-1 positively regulates breast cancer cell proliferation, migration, and invasion.Mol Cancer Res. 2007 Oct;5(10):1031-9. doi: 10.1158/1541-7786.MCR-06-0391.
965 Chemokine decoy receptor d6 plays a negative role in human breast cancer.Mol Cancer Res. 2008 Aug;6(8):1276-88. doi: 10.1158/1541-7786.MCR-07-2108.
966 Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas.BMC Cancer. 2015 Jul 17;15:524. doi: 10.1186/s12885-015-1510-8.
967 In vivo efficacy of folate-targeted lipid-protamine-DNA (LPD-PEG-Folate) complexes in an immunocompetent syngeneic model for breast adenocarcinoma.Cancer Gene Ther. 2004 Feb;11(2):128-34. doi: 10.1038/sj.cgt.7700662.
968 Distinct functions of natural ADAM-15 cytoplasmic domain variants in human mammary carcinoma.Mol Cancer Res. 2008 Mar;6(3):383-94. doi: 10.1158/1541-7786.MCR-07-2028. Epub 2008 Feb 22.
969 Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors.Oncogene. 2004 Feb 19;23(7):1481-8. doi: 10.1038/sj.onc.1207263.
970 Epigenetic silencing of ADAMTS18 promotes cell migration and invasion of breast cancer through AKT and NF-B signaling.Cancer Med. 2017 Jun;6(6):1399-1408. doi: 10.1002/cam4.1076. Epub 2017 May 15.
971 Genome-wide DNA methylation assessment of 'BRCA1-like' early-onset breast cancer: Data from the Australian Breast Cancer Family Registry.Exp Mol Pathol. 2018 Dec;105(3):404-410. doi: 10.1016/j.yexmp.2018.11.006. Epub 2018 Nov 10.
972 GPR116, an adhesion G-protein-coupled receptor, promotes breast cancer metastasis via the Gq-p63RhoGEF-Rho GTPase pathway.Cancer Res. 2013 Oct 15;73(20):6206-18. doi: 10.1158/0008-5472.CAN-13-1049. Epub 2013 Sep 5.
973 Genomic structure and expression profile of LPHH1, a 7TM gene variably expressed in breast cancer cell lines.Biochim Biophys Acta. 2000 Apr 25;1491(1-3):75-92. doi: 10.1016/s0167-4781(00)00020-8.
974 Demonstration of adiponectin receptors 1 and 2 mRNA expression in human breast cancer cells.Cancer Lett. 2007 Jun 8;250(2):229-36. doi: 10.1016/j.canlet.2006.10.006. Epub 2006 Nov 22.
975 AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells.J Cell Physiol. 2007 Dec;213(3):740-9. doi: 10.1002/jcp.21143.
976 Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer.Oncogene. 2007 Jan 11;26(2):298-307. doi: 10.1038/sj.onc.1209772. Epub 2006 Jul 3.
977 Down-regulation of RIP expression by 17-dimethylaminoethylamino-17-demethoxygeldanamycin promotes TRAIL-induced apoptosis in breast tumor cells.Cancer Lett. 2010 Jan 28;287(2):207-15. doi: 10.1016/j.canlet.2009.06.012. Epub 2009 Jul 25.
978 Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells.Endocrinology. 2009 Jan;150(1):14-23. doi: 10.1210/en.2008-0984. Epub 2008 Sep 11.
979 AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection.PLoS One. 2015 Apr 15;10(4):e0122106. doi: 10.1371/journal.pone.0122106. eCollection 2015.
980 AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model.Mol Cancer Ther. 2006 Jan;5(1):1-7. doi: 10.1158/1535-7163.MCT-05-0310.
981 Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13.BMC Cancer. 2015 Aug 14;15:588. doi: 10.1186/s12885-015-1591-4.
982 Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis.J Natl Cancer Inst. 2008 Mar 19;100(6):437-42. doi: 10.1093/jnci/djn037. Epub 2008 Mar 11.
983 Characterization of a novel human breast cancer associated gene (BCA3) encoding an alternatively spliced proline-rich protein.Biochim Biophys Acta. 2003 Jan 3;1625(1):116-21. doi: 10.1016/s0167-4781(02)00562-6.
984 CpG promoter methylation of the ALKBH3 alkylation repair gene in breast cancer.BMC Cancer. 2017 Jul 5;17(1):469. doi: 10.1186/s12885-017-3453-8.
985 ANGPTL2 increases bone metastasis of breast cancer cells through enhancing CXCR4 signaling.Sci Rep. 2015 Mar 16;5:9170. doi: 10.1038/srep09170.
986 ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.BMC Cancer. 2016 Nov 18;16(1):904. doi: 10.1186/s12885-016-2923-8.
987 Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility.Oncotarget. 2019 Jan 4;10(2):133-151. doi: 10.18632/oncotarget.26512. eCollection 2019 Jan 4.
988 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes.Cancer Res. 2000 Oct 1;60(19):5371-5.
989 Protein-binding microarray analysis of tumor suppressor AP2 target gene specificity.PLoS One. 2011;6(8):e22895. doi: 10.1371/journal.pone.0022895. Epub 2011 Aug 18.
990 Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.Nat Genet. 2014 May;46(5):487-91. doi: 10.1038/ng.2955. Epub 2014 Apr 13.
991 Bioinformatic analysis of prognostic value of ARAP3 in breast cancer and the associated signaling pathways.Eur Rev Med Pharmacol Sci. 2017 May;21(10):2405-2412.
992 Validation of a yeast functional assay for p53 mutations using clonal sequencing.J Pathol. 2013 Dec;231(4):441-8. doi: 10.1002/path.4243.
993 Chromosome 13q12 encoded Rho GTPase activating protein suppresses growth of breast carcinoma cells, and yeast two-hybrid screen shows its interaction with several proteins.Biochem Biophys Res Commun. 2004 Jan 16;313(3):654-65. doi: 10.1016/j.bbrc.2003.12.001.
994 Hormone therapy use and breast tissue DNA methylation: analysis of epigenome wide data from the normal breast study.Epigenetics. 2019 Feb;14(2):146-157. doi: 10.1080/15592294.2019.1580111. Epub 2019 Mar 1.
995 Expression and molecular characterization of alternative transcripts of the ARHGEF5/TIM oncogene specific for human breast cancer.Hum Mol Genet. 2004 Feb 1;13(3):323-34. doi: 10.1093/hmg/ddh024. Epub 2003 Dec 8.
996 Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3.Oncogene. 2000 Feb 24;19(9):1123-31. doi: 10.1038/sj.onc.1203412.
997 The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice.Genetics. 2016 Aug;203(4):1601-11. doi: 10.1534/genetics.115.184879. Epub 2016 Jun 8.
998 Alterations of BRMS1-ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells.J Biol Chem. 2008 Mar 21;283(12):7438-44. doi: 10.1074/jbc.M709446200. Epub 2008 Jan 22.
999 Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis.PLoS Genet. 2012 May;8(5):e1002735. doi: 10.1371/journal.pgen.1002735. Epub 2012 May 31.
1000 Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.Breast Cancer Res. 2016 Feb 16;18(1):21. doi: 10.1186/s13058-016-0682-8.
1001 Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue.Breast Cancer Res Treat. 2008 Aug;110(3):521-30. doi: 10.1007/s10549-007-9739-9. Epub 2007 Sep 27.
1002 Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1.Nat Genet. 2014 Aug;46(8):886-90. doi: 10.1038/ng.3041. Epub 2014 Jul 20.
1003 Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma. Oncogene. 2010 Jun 3;29(22):3228-40. doi: 10.1038/onc.2010.71. Epub 2010 Mar 22.
1004 Anticancer effect of acid ceramidase inhibitor ceranib-2 in human breast cancer cell lines MCF-7, MDA MB-231 by the activation of SAPK/JNK, p38 MAPK apoptotic pathways, inhibition of the Akt pathway, downregulation of ER.Anticancer Drugs. 2018 Jan;29(1):50-60. doi: 10.1097/CAD.0000000000000566.
1005 Elevated ASCL2 expression in breast cancer is associated with the poor prognosis of patients.Am J Cancer Res. 2017 Apr 1;7(4):955-961. eCollection 2017.
1006 Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer.EMBO J. 2011 Feb 2;30(3):480-93. doi: 10.1038/emboj.2010.335. Epub 2010 Dec 21.
1007 Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line.J Biol Chem. 2003 Aug 1;278(31):28668-76. doi: 10.1074/jbc.M301695200. Epub 2003 May 6.
1008 Infrequent mutations of the activating transcription factor-2 gene in human lung cancer, neuroblastoma and breast cancer.Int J Oncol. 2002 Mar;20(3):527-31.
1009 Comparative epigenomics of human and mouse mammary tumors.Genes Chromosomes Cancer. 2009 Jan;48(1):83-97. doi: 10.1002/gcc.20620.
1010 Differential expression of PMCA2 mRNA isoforms in a cohort of Spanish patients with breast tumor types.Oncol Lett. 2018 Dec;16(6):6950-6959. doi: 10.3892/ol.2018.9540. Epub 2018 Oct 2.
1011 Emerging Role of Novel Biomarkers of Ly6 Gene Family in Pan Cancer.Adv Exp Med Biol. 2019;1164:47-61. doi: 10.1007/978-3-030-22254-3_4.
1012 Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer.Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2101-8. doi: 10.1158/1055-9965.EPI-08-0134.
1013 Role of ornithine decarboxylase in breast cancer.Acta Biochim Biophys Sin (Shanghai). 2008 Mar;40(3):235-43. doi: 10.1111/j.1745-7270.2008.00397.x.
1014 AZU-1: a candidate breast tumor suppressor and biomarker for tumor progression.Mol Biol Cell. 2000 Apr;11(4):1357-67. doi: 10.1091/mbc.11.4.1357.
1015 Carbon nanospheres mediated nuclear delivery of SMAR1 protein (DNA binding domain) controls breast tumor in mice model.Nanomedicine (Lond). 2018 Feb;13(4):353-372. doi: 10.2217/nnm-2017-0298. Epub 2018 Jan 17.
1016 Modeling ErbB2-p130Cas interaction to design new potential anticancer agents.Sci Rep. 2019 Feb 28;9(1):3089. doi: 10.1038/s41598-019-39510-w.
1017 Potentiation of estrogen receptor transcriptional activity by breast cancer amplified sequence 2.Biochem Biophys Res Commun. 2005 Mar 11;328(2):393-8. doi: 10.1016/j.bbrc.2004.12.187.
1018 Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer.Genes Chromosomes Cancer. 2002 Dec;35(4):311-7. doi: 10.1002/gcc.10121.
1019 BRCA2 gene mutations in Greek patients with familial breast cancer.Hum Mutat. 2002 Jan;19(1):81-2. doi: 10.1002/humu.9003.
1020 A pathway for tumor necrosis factor-alpha-induced Bcl10 nuclear translocation. Bcl10 is up-regulated by NF-kappaB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus.J Biol Chem. 2006 Jan 6;281(1):167-75. doi: 10.1074/jbc.M511014200. Epub 2005 Nov 8.
1021 Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor.PLoS One. 2013;8(4):e60685. doi: 10.1371/journal.pone.0060685. Epub 2013 Apr 5.
1022 Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors.Thromb Haemost. 2003 Jun;89(6):1081-8.
1023 Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression.Am J Pathol. 2018 Oct;188(10):2378-2391. doi: 10.1016/j.ajpath.2018.06.021. Epub 2018 Aug 1.
1024 BCoR-L1 variation and breast cancer.Breast Cancer Res. 2007;9(4):R54. doi: 10.1186/bcr1759.
1025 A feedback loop between BEX2 and ErbB2 mediated by c-Jun signaling in breast cancer.Int J Cancer. 2012 Jan 1;130(1):71-82. doi: 10.1002/ijc.25977. Epub 2011 Apr 20.
1026 Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the III isotype of tubulin.Invest New Drugs. 2016 Feb;34(1):129-37. doi: 10.1007/s10637-015-0315-6. Epub 2015 Dec 21.
1027 Low BIK outside-inside-out interactive inflammation immune-induced transcription-dependent apoptosis through FUT3-PMM2-SQSTM1-SFN-ZNF384.Immunol Res. 2016 Apr;64(2):461-9. doi: 10.1007/s12026-015-8701-x.
1028 Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis.Oncotarget. 2015 Sep 8;6(26):22890-904. doi: 10.18632/oncotarget.4413.
1029 Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.Br J Cancer. 2003 Jan 27;88(2):270-6. doi: 10.1038/sj.bjc.6600674.
1030 Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes.Nat Commun. 2019 Jul 5;10(1):2983. doi: 10.1038/s41467-019-11020-3.
1031 Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells.Mol Cancer Res. 2013 Oct;11(10):1248-57. doi: 10.1158/1541-7786.MCR-13-0096. Epub 2013 Jun 6.
1032 Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib.Oncogene. 2011 Jul 7;30(27):3084-95. doi: 10.1038/onc.2011.24. Epub 2011 Feb 21.
1033 The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement.Immunogenetics. 2006 Feb;58(1):1-8. doi: 10.1007/s00251-005-0077-y. Epub 2006 Feb 8.
1034 Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases.Mod Pathol. 2018 Sep;31(9):1367-1380. doi: 10.1038/s41379-018-0047-1. Epub 2018 May 21.
1035 Identification of novel human tumor cell-specific CaMK-II variants.Biochim Biophys Acta. 1997 Mar 1;1355(3):281-92. doi: 10.1016/s0167-4889(96)00141-3.
1036 Dynamics of the CapG actin-binding protein in the cell nucleus studied by FRAP and FCS.Chromosome Res. 2008;16(3):427-37. doi: 10.1007/s10577-008-1234-6.
1037 The oncoprotein HBXIP enhances migration of breast cancer cells through increasing filopodia formation involving MEKK2/ERK1/2/Capn4 signaling.Cancer Lett. 2014 Dec 28;355(2):288-96. doi: 10.1016/j.canlet.2014.09.047. Epub 2014 Oct 7.
1038 The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor Types.PLoS One. 2015 Sep 23;10(9):e0138726. doi: 10.1371/journal.pone.0138726. eCollection 2015.
1039 Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation.Am J Pathol. 2009 Feb;174(2):613-29. doi: 10.2353/ajpath.2009.080653.
1040 Down-regulation of the cavin family proteins in breast cancer.J Cell Biochem. 2012 Jan;113(1):322-8. doi: 10.1002/jcb.23358.
1041 A novel approach to modelling transcriptional heterogeneity identifies the oncogene candidate CBX2 in invasive breast carcinoma.Br J Cancer. 2019 Apr;120(7):746-753. doi: 10.1038/s41416-019-0387-8. Epub 2019 Mar 1.
1042 A requirement for dimerization of HP1Hsalpha in suppression of breast cancer invasion.J Biol Chem. 2006 Jul 7;281(27):18668-76. doi: 10.1074/jbc.M512454200. Epub 2006 Apr 28.
1043 Transactivator of transcription-tagged cell cycle and apoptosis regulatory protein-1 peptides suppress the growth of human breast cancer cells in vitro and in vivo.Mol Cancer Ther. 2007 May;6(5):1661-72. doi: 10.1158/1535-7163.MCT-06-0653.
1044 Negative regulation of the deacetylase SIRT1 by DBC1.Nature. 2008 Jan 31;451(7178):587-90. doi: 10.1038/nature06515.
1045 Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.Oncotarget. 2017 Aug 10;8(43):74378-74390. doi: 10.18632/oncotarget.20102. eCollection 2017 Sep 26.
1046 Acetylation of ACAP4 regulates CCL18-elicited breast cancer cell migration and invasion.J Mol Cell Biol. 2018 Dec 1;10(6):559-572. doi: 10.1093/jmcb/mjy058.
1047 Identification of a novel beta-chemokine, MEC, down-regulated in primary breast tumors.Int J Oncol. 2001 May;18(5):939-44. doi: 10.3892/ijo.18.5.939.
1048 Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features.Cancer Res. 2001 Dec 15;61(24):8917-23.
1049 Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1.Am J Pathol. 2008 Apr;172(4):893-904. doi: 10.2353/ajpath.2008.070899. Epub 2008 Mar 5.
1050 DNA methylation status of key cell-cycle regulators such as CDKNA2/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors.Clin Cancer Res. 2014 Dec 15;20(24):6357-66. doi: 10.1158/1078-0432.CCR-14-0297. Epub 2014 Oct 7.
1051 GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis.J Cell Biochem. 2007 Apr 15;100(6):1376-86. doi: 10.1002/jcb.21140.
1052 CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis.PLoS One. 2011;6(6):e20702. doi: 10.1371/journal.pone.0020702. Epub 2011 Jun 13.
1053 E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.Cancer Discov. 2018 Apr;8(4):498-515. doi: 10.1158/2159-8290.CD-17-0603.
1054 Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects.PLoS One. 2013 Oct 16;8(10):e76115. doi: 10.1371/journal.pone.0076115. eCollection 2013.
1055 A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways.J Biol Chem. 2006 Nov 17;281(46):34833-47. doi: 10.1074/jbc.M605483200. Epub 2006 Sep 19.
1056 Vaccinia virus GLV-1h237 carrying a Walker A motif mutation of mouse Cdc6 protein enhances human breast tumor therapy in mouse xenografts.Int J Oncol. 2011 Mar;38(3):871-8. doi: 10.3892/ijo.2011.910. Epub 2011 Jan 18.
1057 Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer.Cell Rep. 2015 Apr 28;11(4):564-76. doi: 10.1016/j.celrep.2015.03.044. Epub 2015 Apr 16.
1058 The PISSLRE gene: structure, exon skipping, and exclusion as tumor suppressor in breast cancer.Genomics. 1999 Feb 15;56(1):90-7. doi: 10.1006/geno.1998.5676.
1059 PA28/ Promote Breast Cancer Cell Invasion and Metastasis via Down-Regulation of CDK15.Front Oncol. 2019 Nov 22;9:1283. doi: 10.3389/fonc.2019.01283. eCollection 2019.
1060 Association of Mouse Mammary Tumor Virus With Human Breast Cancer: Histology, Immunohistochemistry and Polymerase Chain Reaction Analyses.Front Oncol. 2018 May 7;8:141. doi: 10.3389/fonc.2018.00141. eCollection 2018.
1061 Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo--associated paraneoplastic cerebellar degeneration.Neuro Oncol. 2012 Apr;14(4):506-10. doi: 10.1093/neuonc/nos006. Epub 2012 Feb 20.
1062 ADAM12 transmembrane and secreted isoforms promote breast tumor growth: a distinct role for ADAM12-S protein in tumor metastasis.J Biol Chem. 2011 Jun 10;286(23):20758-68. doi: 10.1074/jbc.M110.216036. Epub 2011 Apr 14.
1063 The association of polymorphisms of CDT1 and GMNN gene with the risk of breast cancer in Chinese women: a case-control analysis.Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006 Oct;23(5):544-7.
1064 CUGBP2 plays a critical role in apoptosis of breast cancer cells in response to genotoxic injury.Ann N Y Acad Sci. 2003 Dec;1010:504-9. doi: 10.1196/annals.1299.093.
1065 Differential cellular localization of CELSR2 and ING4 and correlations with hormone receptor status in breast cancer.Histol Histopathol. 2018 Aug;33(8):835-842. doi: 10.14670/HH-11-979. Epub 2018 Feb 28.
1066 Functional proteomic analysis reveals the involvement of KIAA1199 in breast cancer growth, motility and invasiveness.BMC Cancer. 2014 Mar 15;14:194. doi: 10.1186/1471-2407-14-194.
1067 TMEM2 Is a SOX4-Regulated Gene That Mediates Metastatic Migration and Invasion in Breast Cancer.Cancer Res. 2016 Sep 1;76(17):4994-5005. doi: 10.1158/0008-5472.CAN-15-2322. Epub 2016 Jun 21.
1068 MiR-144 suppresses proliferation, invasion, and migration of breast cancer cells through inhibiting CEP55.Cancer Biol Ther. 2018 Apr 3;19(4):306-315. doi: 10.1080/15384047.2017.1416934. Epub 2018 Mar 26.
1069 Analysis of the human CGB/LHB gene cluster in breast tumors by real-time quantitative RT-PCR assays.Cancer Lett. 2001 Jul 10;168(1):93-100. doi: 10.1016/s0304-3835(01)00496-7.
1070 Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression.Cancer Res. 2007 Jul 1;67(13):6064-74. doi: 10.1158/0008-5472.CAN-06-4109. Epub 2007 Jun 27.
1071 Increased expression of the inflammatory protein YKL-40 in precancers of the breast.Int J Cancer. 2007 Oct 1;121(7):1536-42. doi: 10.1002/ijc.22881.
1072 CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer.Oncotarget. 2017 Feb 28;8(9):15789-15801. doi: 10.18632/oncotarget.15004.
1073 Modulation of cholinephosphotransferase activity in breast cancer cell lines by Ro5-4864, a peripheral benzodiazepine receptor agonist.Biochem Biophys Res Commun. 2005 Jul 22;333(1):35-41. doi: 10.1016/j.bbrc.2005.05.071.
1074 BNF-1, a novel gene encoding a putative extracellular matrix protein, is overexpressed in tumor tissues.Gene. 2003 Jun 5;311:105-10. doi: 10.1016/s0378-1119(03)00563-8.
1075 ERalpha-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis.Oncogene. 2007 Sep 27;26(44):6406-19. doi: 10.1038/sj.onc.1210468. Epub 2007 May 7.
1076 CITED2 attenuates macrophage recruitment concordant with the downregulation of CCL20 in breast cancer cells.Oncol Lett. 2018 Jan;15(1):871-878. doi: 10.3892/ol.2017.7420. Epub 2017 Nov 15.
1077 Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer.Breast Cancer Res Treat. 2011 Nov;130(1):319-29. doi: 10.1007/s10549-011-1657-1. Epub 2011 Jul 14.
1078 Ciz1, a Novel DNA-binding coactivator of the estrogen receptor alpha, confers hypersensitivity to estrogen action.Cancer Res. 2006 Nov 15;66(22):11021-9. doi: 10.1158/0008-5472.CAN-06-2336.
1079 Identification of Claudin 1 Transcript Variants in Human Invasive Breast Cancer.PLoS One. 2016 Sep 20;11(9):e0163387. doi: 10.1371/journal.pone.0163387. eCollection 2016.
1080 Reciprocal modifications of CLIC4 in tumor epithelium and stroma mark malignant progression of multiple human cancers.Clin Cancer Res. 2007 Jan 1;13(1):121-31. doi: 10.1158/1078-0432.CCR-06-1562.
1081 Regulation of tumor angiogenesis by the microtubule-binding protein CLIP-170.Protein Cell. 2013 Apr;4(4):266-76. doi: 10.1007/s13238-013-3007-z. Epub 2013 Apr 3.
1082 COL10A1 expression is elevated in diverse solid tumor types and is associated with tumor vasculature.Future Oncol. 2012 Aug;8(8):1031-40. doi: 10.2217/fon.12.79.
1083 Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers.Br J Cancer. 2008 Jul 8;99(1):68-71. doi: 10.1038/sj.bjc.6604443. Epub 2008 Jun 17.
1084 Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice.Breast Cancer Res Treat. 2008 Jul;110(2):283-95. doi: 10.1007/s10549-007-9731-4. Epub 2007 Sep 26.
1085 COP1 and GSK3 cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis.Neoplasia. 2013 Sep;15(9):1075-85. doi: 10.1593/neo.13966.
1086 Prolactin and estrogen up-regulate carboxypeptidase-d to promote nitric oxide production and survival of mcf-7 breast cancer cells.Endocrinology. 2008 Oct;149(10):4821-8. doi: 10.1210/en.2008-0145. Epub 2008 Jun 5.
1087 CRABP2 regulates invasion and metastasis of breast cancer through hippo pathway dependent on ER status.J Exp Clin Cancer Res. 2019 Aug 16;38(1):361. doi: 10.1186/s13046-019-1345-2.
1088 Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.Breast Cancer Res. 2016 Jan 25;18(1):12. doi: 10.1186/s13058-016-0672-x.
1089 Increased Soluble CrkL in Serum of Breast Cancer Patients Is Associated with Advanced Disease.Cancers (Basel). 2019 Jul 9;11(7):961. doi: 10.3390/cancers11070961.
1090 Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer.Oncotarget. 2016 Nov 22;7(47):76920-76933. doi: 10.18632/oncotarget.12729.
1091 CtBP1 associates metabolic syndrome and breast carcinogenesis targeting multiple miRNAs.Oncotarget. 2016 Apr 5;7(14):18798-811. doi: 10.18632/oncotarget.7711.
1092 Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha.BMC Genomics. 2014 Jun 24;15(1):520. doi: 10.1186/1471-2164-15-520.
1093 CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome.EMBO J. 2007 Apr 4;26(7):1831-42. doi: 10.1038/sj.emboj.7601602. Epub 2007 Mar 8.
1094 Resveratrol enhances anti-proliferative effect of VACM-1/cul5 in T47D cancer cells. Cell Biol Toxicol. 2011 Apr;27(2):95-105. doi: 10.1007/s10565-010-9173-3. Epub 2010 Oct 15.
1095 Aberrantly high expression of the CUB and zona pellucida-like domain-containing protein 1 (CUZD1) in mammary epithelium leads to breast tumorigenesis.J Biol Chem. 2018 Feb 23;293(8):2850-2864. doi: 10.1074/jbc.RA117.000162. Epub 2018 Jan 10.
1096 VCC-1, a novel chemokine, promotes tumor growth.Biochem Biophys Res Commun. 2006 Nov 10;350(1):74-81. doi: 10.1016/j.bbrc.2006.08.194. Epub 2006 Sep 12.
1097 CXCL3 is a potential target for breast cancer metastasis.Curr Cancer Drug Targets. 2014;14(3):294-309. doi: 10.2174/1568009614666140305222328.
1098 CXCL5 secreted from adipose tissue-derived stem cells promotes cancer cell proliferation.Oncol Lett. 2018 Feb;15(2):1403-1410. doi: 10.3892/ol.2017.7522. Epub 2017 Dec 5.
1099 The lncRNA H19 mediates breast cancer cell plasticity during EMT and MET plasticity by differentially sponging miR-200b/c and let-7b.Sci Signal. 2017 Jun 13;10(483):eaak9557. doi: 10.1126/scisignal.aak9557.
1100 Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer.Clin Cancer Res. 2004 Mar 15;10(6):2082-9. doi: 10.1158/1078-0432.ccr-03-0236.
1101 DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth.Mol Cell Biol. 2006 Oct;26(19):7116-29. doi: 10.1128/MCB.00268-06.
1102 DACT2 silencing by promoter CpG methylation disrupts its regulation of epithelial-to-mesenchymal transition and cytoskeleton reorganization in breast cancer cells.Oncotarget. 2016 Oct 25;7(43):70924-70935. doi: 10.18632/oncotarget.12341.
1103 Dual promoter regulation of death-associated protein kinase gene leads to differentially silenced transcripts by methylation in cancer.Carcinogenesis. 2009 Dec;30(12):2023-30. doi: 10.1093/carcin/bgp276.
1104 Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents.Medchemcomm. 2018 Aug 24;9(10):1649-1662. doi: 10.1039/c8md00322j. eCollection 2018 Oct 1.
1105 DDB2: a novel regulator of NF-B and breast tumor invasion.Cancer Res. 2013 Aug 15;73(16):5040-52. doi: 10.1158/0008-5472.CAN-12-3655. Epub 2013 Jun 17.
1106 Anoxic induction of ATF-4 through HIF-1-independent pathways of protein stabilization in human cancer cells.Blood. 2004 Mar 1;103(5):1876-82. doi: 10.1182/blood-2003-06-1859. Epub 2003 Nov 6.
1107 Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential.Biochemistry. 2010 Jan 12;49(1):1-10. doi: 10.1021/bi901263m.
1108 Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin.J Exp Clin Cancer Res. 2019 Oct 28;38(1):427. doi: 10.1186/s13046-019-1366-x.
1109 Derlin-1 is overexpressed in human breast carcinoma and protects cancer cells from endoplasmic reticulum stress-induced apoptosis.Breast Cancer Res. 2008;10(1):R7. doi: 10.1186/bcr1849. Epub 2008 Jan 20.
1110 LncRNA AK023948 is a positive regulator of AKT.Nat Commun. 2017 Feb 8;8:14422. doi: 10.1038/ncomms14422.
1111 DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis.J Clin Invest. 2014 Apr;124(4):1646-59. doi: 10.1172/JCI71812. Epub 2014 Mar 3.
1112 Less frequent promoter hypermethylation of DLC-1 gene in primary breast cancers.Oncol Rep. 2004 Jul;12(1):141-4.
1113 A gene (DLG2) located at 17q12-q21 encodes a new homologue of the Drosophila tumor suppressor dIg-A.Genomics. 1995 Jul 1;28(1):25-31. doi: 10.1006/geno.1995.1101.
1114 EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming.Nat Commun. 2019 Nov 6;10(1):5033. doi: 10.1038/s41467-019-13034-3.
1115 Genetic mapping in mice identifies DMBT1 as a candidate modifier of mammary tumors and breast cancer risk.Am J Pathol. 2007 Jun;170(6):2030-41. doi: 10.2353/ajpath.2007.060512.
1116 Low dentin matrix protein 1 expression correlates with skeletal metastases development in breast cancer patients and enhances cell migratory capacity in vitro.Breast Cancer Res Treat. 2007 Sep;105(1):95-104. doi: 10.1007/s10549-006-9436-0. Epub 2006 Nov 30.
1117 Hematopoietic stem cell specific V-ATPase controls breast cancer progression and metastasis via cytotoxic T cells.Oncotarget. 2018 Sep 4;9(69):33215-33231. doi: 10.18632/oncotarget.26061. eCollection 2018 Sep 4.
1118 Tid1 negatively regulates the migratory potential of cancer cells by inhibiting the production of interleukin-8.Cancer Res. 2005 Oct 1;65(19):8784-91. doi: 10.1158/0008-5472.CAN-04-4422.
1119 Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer.Breast Cancer Res. 2008;10(2):R22. doi: 10.1186/bcr1874. Epub 2008 Mar 7.
1120 Autoantibody Response to ZRF1 and KRR1 SEREX Antigens in Patients with Breast Tumors of Different Histological Types and Grades.Dis Markers. 2016;2016:5128720. doi: 10.1155/2016/5128720. Epub 2016 Oct 25.
1121 Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer.Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10848-53. doi: 10.1073/pnas.96.19.10848.
1122 Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression.Oncogene. 2004 Jul 22;23(33):5675-81. doi: 10.1038/sj.onc.1207734.
1123 Down-regulation of the desmosomal cadherin desmocollin 3 in human breast cancer.Int J Oncol. 2001 Jul;19(1):169-74. doi: 10.3892/ijo.19.1.169.
1124 5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene. 2007 Jan 4;26(1):77-90. doi: 10.1038/sj.onc.1209763. Epub 2006 Jun 26.
1125 DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118.Oncogene. 2007 Sep 6;26(41):6038-49. doi: 10.1038/sj.onc.1210426. Epub 2007 Mar 26.
1126 Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance.Cancer Res. 2006 Jun 1;66(11):5950-9. doi: 10.1158/0008-5472.CAN-05-3243.
1127 Aberrant promoter methylation status is associated with upregulation of the E2F4 gene in breast cancer.Oncol Lett. 2018 Jun;15(6):8461-8469. doi: 10.3892/ol.2018.8382. Epub 2018 Mar 29.
1128 Human E2F5 gene is oncogenic in primary rodent cells and is amplified in human breast tumors.Genes Chromosomes Cancer. 2000 May;28(1):126-30.
1129 RCAS1 is associated with ductal breast cancer progression.Biochem Biophys Res Commun. 2002 May 24;293(5):1544-9. doi: 10.1016/S0006-291X(02)00401-1.
1130 Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer.Breast Cancer Res Treat. 2007 Mar;102(1):31-41. doi: 10.1007/s10549-006-9315-8. Epub 2006 Aug 9.
1131 BMP-6 promotes E-cadherin expression through repressing deltaEF1 in breast cancer cells.BMC Cancer. 2007 Nov 13;7:211. doi: 10.1186/1471-2407-7-211.
1132 Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer. 2009 Apr 1;124(7):1727-35. doi: 10.1002/ijc.24108.
1133 A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1.Oncogene. 2010 Apr 29;29(17):2467-76. doi: 10.1038/onc.2010.12. Epub 2010 Feb 15.
1134 Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues.Int J Cancer. 1990 Mar 15;45(3):457-61. doi: 10.1002/ijc.2910450314.
1135 Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer.Am J Pathol. 1999 Jun;154(6):1777-83. doi: 10.1016/S0002-9440(10)65433-8.
1136 The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape.Cell Death Dis. 2015 Jan 22;6(1):e1603. doi: 10.1038/cddis.2014.542.
1137 Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis.J Mammary Gland Biol Neoplasia. 2003 Apr;8(2):177-90. doi: 10.1023/a:1025948823955.
1138 A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer.Neoplasia. 2011 Feb;13(2):154-66. doi: 10.1593/neo.101324.
1139 Identification of 5 novel genes methylated in breast and other epithelial cancers.Mol Cancer. 2010 Mar 5;9:51. doi: 10.1186/1476-4598-9-51.
1140 EN2 is a candidate oncogene in human breast cancer.Oncogene. 2005 Oct 20;24(46):6890-901. doi: 10.1038/sj.onc.1208840.
1141 The nuclear matrix protein, NRP/B, enhances Nrf2-mediated oxidative stress responses in breast cancer cells.Cancer Res. 2007 Sep 15;67(18):8596-604. doi: 10.1158/0008-5472.CAN-06-3785.
1142 Endonuclease G promotes cell death of non-invasive human breast cancer cells.Exp Cell Res. 2006 Dec 10;312(20):4139-49. doi: 10.1016/j.yexcr.2006.09.012. Epub 2006 Sep 20.
1143 Deregulated expression of the PCPH proto-oncogene in rat mammary tumors induced with 7,12-dimethylbenz[a]anthracene.Mol Carcinog. 2002 Apr;33(4):219-27. doi: 10.1002/mc.10039.
1144 EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer.Oncotarget. 2016 Oct 25;7(43):69592-69605. doi: 10.18632/oncotarget.11870.
1145 Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression.Cancer Res. 2006 Apr 15;66(8):4065-78. doi: 10.1158/0008-5472.CAN-05-4083.
1146 The Ras-related gene ERAS is involved in human and murine breast cancer.Sci Rep. 2018 Aug 29;8(1):13038. doi: 10.1038/s41598-018-31326-4.
1147 DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk.Mol Cancer. 2008 May 2;7:36. doi: 10.1186/1476-4598-7-36.
1148 Functional profiling of nucleotide Excision repair in breast cancer.DNA Repair (Amst). 2019 Oct;82:102697. doi: 10.1016/j.dnarep.2019.102697. Epub 2019 Aug 30.
1149 ERp29, an endoplasmic reticulum secretion factor is involved in the growth of breast tumor xenografts.Mol Carcinog. 2008 Nov;47(11):886-92. doi: 10.1002/mc.20444.
1150 Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.Oncogene. 2005 Jun 30;24(28):4540-8. doi: 10.1038/sj.onc.1208658.
1151 No evidence of mammary tumor virus env gene-like sequences among Iranian women with breast cancer.Intervirology. 2014;57(6):353-6. doi: 10.1159/000366280. Epub 2014 Oct 15.
1152 Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways.EMBO Rep. 2019 Feb;20(2):e46078. doi: 10.15252/embr.201846078. Epub 2019 Jan 21.
1153 CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib.EMBO Mol Med. 2017 Aug;9(8):1052-1066. doi: 10.15252/emmm.201607084.
1154 Rcl is a novel ETV1/ER81 target gene upregulated in breast tumors.J Cell Biochem. 2008 Oct 15;105(3):866-74. doi: 10.1002/jcb.21884.
1155 ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis.Breast Cancer Res. 2018 Jul 11;20(1):73. doi: 10.1186/s13058-018-0992-0.
1156 Prognostic value of ERM gene expression in human primary breast cancers.Clin Cancer Res. 2004 Nov 1;10(21):7297-303. doi: 10.1158/1078-0432.CCR-04-0593.
1157 EYA1 phosphatase function is essential to drive breast cancer cell proliferation through cyclin D1.Cancer Res. 2013 Jul 15;73(14):4488-99. doi: 10.1158/0008-5472.CAN-12-4078. Epub 2013 May 1.
1158 Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.J Clin Invest. 2018 Jun 1;128(6):2535-2550. doi: 10.1172/JCI96784. Epub 2018 May 14.
1159 Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.Breast Cancer Res Treat. 2009 Feb;113(3):545-51. doi: 10.1007/s10549-008-9945-0. Epub 2008 Feb 27.
1160 Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.Transl Res. 2013 Mar;161(3):156-64. doi: 10.1016/j.trsl.2012.09.003. Epub 2012 Oct 11.
1161 Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models.Mol Ther Oncolytics. 2017 Aug 4;6:80-89. doi: 10.1016/j.omto.2017.08.001. eCollection 2017 Sep 15.
1162 Identification of Fat4 as a candidate tumor suppressor gene in breast cancers.Int J Cancer. 2009 Feb 15;124(4):793-8. doi: 10.1002/ijc.23775.
1163 Identification of F-box/LLR-repeated protein 17 as potential useful biomarker for breast cancer therapy.Cancer Genomics Proteomics. 2008 May-Aug;5(3-4):151-60.
1164 FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex.Cancer Res. 2005 Dec 15;65(24):11304-13. doi: 10.1158/0008-5472.CAN-05-0936.
1165 Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis.J Natl Cancer Inst. 2011 Sep 7;103(17):1323-37. doi: 10.1093/jnci/djr290. Epub 2011 Aug 10.
1166 Distinct expression profiles and functions of Kindlins in breast cancer.J Exp Clin Cancer Res. 2018 Nov 26;37(1):281. doi: 10.1186/s13046-018-0955-4.
1167 Molecular subtypes of breast cancer: metabolic correlation with F-FDG PET/CT.Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1304-11. doi: 10.1007/s00259-013-2418-7. Epub 2013 Apr 30.
1168 Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis.Int J Cancer. 2008 Dec 1;123(11):2518-31. doi: 10.1002/ijc.23802.
1169 FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy. Cancer Res. 2010 Feb 1;70(3):1090-100. doi: 10.1158/0008-5472.CAN-09-2515. Epub 2010 Jan 26.
1170 BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers.Oncogene. 1991 Apr;6(4):659-63.
1171 Forkhead Box F1 promotes breast cancer cell migration by upregulating lysyl oxidase and suppressing Smad2/3 signaling.BMC Cancer. 2016 Feb 23;16:142. doi: 10.1186/s12885-016-2196-2.
1172 The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.Cell Signal. 2016 Oct;28(10):1502-19. doi: 10.1016/j.cellsig.2016.06.021. Epub 2016 Jul 1.
1173 Overexpression of Forkhead Box L1 (FOXL1) Inhibits the Proliferation and Invasion of Breast Cancer Cells.Oncol Res. 2017 Jul 5;25(6):959-965. doi: 10.3727/096504016X14803482769179. Epub 2016 Nov 29.
1174 Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts.Anticancer Res. 2007 Mar-Apr;27(2):719-27.
1175 Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1 and FOXO3a by AMPK signaling.Int J Oncol. 2015 Nov;47(5):1874-80. doi: 10.3892/ijo.2015.3153. Epub 2015 Sep 10.
1176 Breast cancer cell line proliferation blocked by the Src-related Rak tyrosine kinase.Int J Cancer. 2003 Mar 20;104(2):139-46. doi: 10.1002/ijc.10925.
1177 Elevated expression of cancer/testis antigen FSIP1 in ER-positive breast tumors.Biomark Med. 2013 Aug;7(4):601-11. doi: 10.2217/bmm.13.58.
1178 Down-regulation of FXYD3 expression in human lung cancers: its mechanism and potential role in carcinogenesis.Am J Pathol. 2009 Dec;175(6):2646-56. doi: 10.2353/ajpath.2009.080571. Epub 2009 Nov 5.
1179 In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin.Br J Cancer. 2007 May 7;96(9):1404-8. doi: 10.1038/sj.bjc.6603743. Epub 2007 Apr 17.
1180 Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression.J Biol Chem. 2003 Aug 8;278(32):29420-34. doi: 10.1074/jbc.M301885200. Epub 2003 May 14.
1181 A role for the scaffolding adapter GAB2 in breast cancer.Nat Med. 2006 Jan;12(1):114-21. doi: 10.1038/nm1341. Epub 2005 Dec 20.
1182 Characterization of {gamma}-aminobutyric acid type A receptor-associated protein, a novel tumor suppressor, showing reduced expression in breast cancer.Cancer Res. 2005 Jan 15;65(2):394-400.
1183 High expression of gabarapl1 is associated with a better outcome for patients with lymph node-positive breast cancer.Br J Cancer. 2010 Mar 16;102(6):1024-31. doi: 10.1038/sj.bjc.6605568. Epub 2010 Mar 2.
1184 UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells.Int J Cancer. 2006 Sep 15;119(6):1383-8. doi: 10.1002/ijc.21959.
1185 Engagement of I-branching {beta}-1, 6-N-acetylglucosaminyltransferase 2 in breast cancer metastasis and TGF-{beta} signaling.Cancer Res. 2011 Jul 15;71(14):4846-56. doi: 10.1158/0008-5472.CAN-11-0414. Epub 2011 Jul 12.
1186 Suppressive effect of exogenous miR-16 and miR-34a on tumorigenesis of breast cancer cells.J Cell Biochem. 2019 Aug;120(8):13342-13353. doi: 10.1002/jcb.28608. Epub 2019 Mar 27.
1187 The role of growth differentiation factor-9 (GDF-9) and its analog, GDF-9b/BMP-15, in human breast cancer.Ann Surg Oncol. 2007 Jul;14(7):2159-66. doi: 10.1245/s10434-007-9397-5. Epub 2007 Apr 24.
1188 Regulation of vimentin by SIP1 in human epithelial breast tumor cells.Oncogene. 2006 Aug 17;25(36):4975-85. doi: 10.1038/sj.onc.1209511. Epub 2006 Mar 27.
1189 RGS-GAIP-interacting protein controls breast cancer progression.Mol Cancer Res. 2010 Dec;8(12):1591-600. doi: 10.1158/1541-7786.MCR-10-0209. Epub 2010 Oct 27.
1190 Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer.Cell Rep. 2019 Oct 1;29(1):76-88.e7. doi: 10.1016/j.celrep.2019.08.076.
1191 The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis.Proc Natl Acad Sci U S A. 2006 May 23;103(21):8173-8. doi: 10.1073/pnas.0510254103. Epub 2006 May 16.
1192 A polymorphism in the G protein beta3-subunit gene is associated with bone metastasis risk in breast cancer patients.Breast Cancer Res Treat. 2008 Oct;111(3):449-52. doi: 10.1007/s10549-007-9808-0. Epub 2007 Nov 4.
1193 Cloning of a novel nucleolar guanosine 5'-triphosphate binding protein autoantigen from a breast tumor.Cell Growth Differ. 1996 Feb;7(2):271-80.
1194 Nucleostemin reveals a dichotomous nature of genome maintenance in mammary tumor progression.Oncogene. 2019 May;38(20):3919-3931. doi: 10.1038/s41388-019-0710-0. Epub 2019 Jan 28.
1195 3 Chains of type V collagen regulate breast tumour growth via glypican-1.Nat Commun. 2017 Jan 19;8:14351. doi: 10.1038/ncomms14351.
1196 PLD-Specific Small-Molecule Inhibitors Decrease Tumor-Associated Macrophages and Neutrophils Infiltration in Breast Tumors and Lung and Liver Metastases.PLoS One. 2016 Nov 16;11(11):e0166553. doi: 10.1371/journal.pone.0166553. eCollection 2016.
1197 G-protein-coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion.Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4191-6. doi: 10.1073/pnas.1320239111. Epub 2014 Mar 5.
1198 Gpx2 is an overexpressed gene in rat breast cancers induced by three different chemical carcinogens.Cancer Res. 2007 Dec 1;67(23):11353-8. doi: 10.1158/0008-5472.CAN-07-2226.
1199 Identification of a novel putative non-selenocysteine containing phospholipid hydroperoxide glutathione peroxidase (NPGPx) essential for alleviating oxidative stress generated from polyunsaturated fatty acids in breast cancer cells.J Biol Chem. 2004 Oct 15;279(42):43522-9. doi: 10.1074/jbc.M407141200. Epub 2004 Aug 4.
1200 Regulation of GREB1 transcription by estrogen receptor alpha through a multipartite enhancer spread over 20 kb of upstream flanking sequences.J Biol Chem. 2007 Jun 15;282(24):17335-9. doi: 10.1074/jbc.C700030200. Epub 2007 Apr 26.
1201 HYNIC and DOMA conjugated radiolabeled bombesin analogs as receptor-targeted probes for scintigraphic detection of breast tumor.EJNMMI Res. 2019 Mar 18;9(1):25. doi: 10.1186/s13550-019-0493-x.
1202 The DFNA5 gene, responsible for hearing loss and involved in cancer, encodes a novel apoptosis-inducing protein.Eur J Hum Genet. 2011 Sep;19(9):965-73. doi: 10.1038/ejhg.2011.63. Epub 2011 Apr 27.
1203 An InVivo Gain-of-Function Screen Identifies the Williams-Beuren Syndrome Gene GTF2IRD1 as a Mammary Tumor Promoter.Cell Rep. 2016 Jun 7;15(10):2089-2096. doi: 10.1016/j.celrep.2016.05.011. Epub 2016 May 26.
1204 Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression.Mol Syst Biol. 2008;4:188. doi: 10.1038/msb.2008.25. Epub 2008 Apr 15.
1205 Hexose-6-phosphate dehydrogenase controls cancer cell proliferation and migration through pleiotropic effects on the unfolded-protein response, calcium homeostasis, and redox balance.FASEB J. 2018 May;32(5):2690-2705. doi: 10.1096/fj.201700870RR. Epub 2018 Jan 2.
1206 Huntingtin-associated protein 1: a potential biomarker of breast cancer.Oncol Rep. 2013 May;29(5):1881-7. doi: 10.3892/or.2013.2303. Epub 2013 Feb 22.
1207 Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells.Int J Cancer. 2007 Jun 15;120(12):2557-67. doi: 10.1002/ijc.22550.
1208 Regulation of TIM-3 expression in a human T cell line by tumor-conditioned media and cyclic AMP-dependent signaling.Mol Immunol. 2019 Jan;105:224-232. doi: 10.1016/j.molimm.2018.12.006. Epub 2018 Dec 13.
1209 Hes-6, an inhibitor of Hes-1, is regulated by 17beta-estradiol and promotes breast cancer cell proliferation.Breast Cancer Res. 2009;11(6):R79. doi: 10.1186/bcr2446. Epub 2009 Nov 5.
1210 Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) interacts with PELP1 and activates MAPK.J Biol Chem. 2006 Feb 17;281(7):4395-403. doi: 10.1074/jbc.M510368200. Epub 2005 Dec 12.
1211 Proline-Rich Homeodomain protein (PRH/HHEX) is a suppressor of breast tumour growth.Oncogenesis. 2017 Jun 12;6(6):e346. doi: 10.1038/oncsis.2017.42.
1212 Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells.Cancer Cell. 2003 May;3(5):471-82. doi: 10.1016/s1535-6108(03)00107-7.
1213 HOXA1 binds RBCK1/HOIL-1 and TRAF2 and modulates the TNF/NF-B pathway in a transcription-independent manner.Nucleic Acids Res. 2016 Sep 6;44(15):7331-49. doi: 10.1093/nar/gkw606. Epub 2016 Jul 5.
1214 Endocrine disrupting chemical, bisphenol-A, induces breast cancer associated gene HOXB9 expression in vitro and in vivo. Gene. 2016 Sep 30;590(2):234-43. doi: 10.1016/j.gene.2016.05.009. Epub 2016 May 13.
1215 Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer.Sci Transl Med. 2014 Mar 26;6(229):229ra41. doi: 10.1126/scitranslmed.3008326.
1216 HOXC8 promotes breast tumorigenesis by transcriptionally facilitating cadherin-11 expression.Oncotarget. 2014 May 15;5(9):2596-607. doi: 10.18632/oncotarget.1841.
1217 Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion.J Biol Chem. 2010 Nov 19;285(47):36721-35. doi: 10.1074/jbc.M110.162305. Epub 2010 Sep 15.
1218 Identification of 20 genes aberrantly methylated in human breast cancers.Int J Cancer. 2005 Sep 1;116(3):407-14. doi: 10.1002/ijc.21054.
1219 HOXD13 methylation status is a prognostic indicator in breast cancer.Int J Clin Exp Pathol. 2015 Sep 1;8(9):10716-24. eCollection 2015.
1220 N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.Carcinogenesis. 2005 May;26(5):1000-7. doi: 10.1093/carcin/bgi038. Epub 2005 Feb 3.
1221 The trimeric coiled-coil HSBP1 protein promotes WASH complex assembly at centrosomes.EMBO J. 2018 Jul 2;37(13):e97706. doi: 10.15252/embj.201797706. Epub 2018 May 29.
1222 Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study.J Steroid Biochem Mol Biol. 2006 Oct;101(2-3):136-44. doi: 10.1016/j.jsbmb.2006.06.015. Epub 2006 Aug 22.
1223 Anti-breast tumor activity of Eclipta extract in-vitro and in-vivo: novel evidence of endoplasmic reticulum specific localization of Hsp60 during apoptosis.Sci Rep. 2015 Dec 17;5:18457. doi: 10.1038/srep18457.
1224 Evaluation of a panel of tumor-associated antigens in breast cancer.Cancer Biomark. 2020;27(2):207-211. doi: 10.3233/CBM-190708.
1225 Phosphorylation of Ser78 of Hsp27 correlated with HER-2/neu status and lymph node positivity in breast cancer.Mol Cancer. 2007 Aug 14;6:52. doi: 10.1186/1476-4598-6-52.
1226 HspBP1 levels are elevated in breast tumor tissue and inversely related to tumor aggressiveness.Cell Stress Chaperones. 2009 May;14(3):301-10. doi: 10.1007/s12192-008-0085-6. Epub 2008 Nov 6.
1227 HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.J Immunol. 2003 Oct 15;171(8):4054-61. doi: 10.4049/jimmunol.171.8.4054.
1228 [Proteinkinase MAK-V/Hunk as a possible dianostic and prognostic marker of human breast carcinoma].Arkh Patol. 2004 Sep-Oct;66(5):6-9.
1229 Radioiodination and preclinical evaluation of 4-benzyl-1-(3-[(125)I]-iodobenzylsulfonyl)piperidine as a breast tumor imaging tracer in mouse.Ann Nucl Med. 2017 May;31(4):335-346. doi: 10.1007/s12149-017-1161-8. Epub 2017 Mar 17.
1230 Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer.BMC Cancer. 2008 May 30;8:154. doi: 10.1186/1471-2407-8-154.
1231 A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells.Oncogene. 1998 Nov 19;17(20):2629-36. doi: 10.1038/sj.onc.1202206.
1232 IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer invivo by JAK/STAT-mediated induction of p21.Cancer Lett. 2017 Jul 28;399:29-43. doi: 10.1016/j.canlet.2017.04.005. Epub 2017 Apr 12.
1233 Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: a report from the Shanghai Breast Cancer Study.Breast Cancer Res Treat. 2007 Sep;104(3):309-19. doi: 10.1007/s10549-006-9420-8. Epub 2006 Oct 25.
1234 Epigenetic inactivation implies independent functions for insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes.Clin Cancer Res. 2007 Jul 15;13(14):4061-8. doi: 10.1158/1078-0432.CCR-06-3052.
1235 The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.Oncotarget. 2017 Dec 6;8(69):113360-113372. doi: 10.18632/oncotarget.23008. eCollection 2017 Dec 26.
1236 High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity.Oncotarget. 2017 Jul 25;8(30):49470-49483. doi: 10.18632/oncotarget.17713.
1237 Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer.Carcinogenesis. 2015 Feb;36(2):256-71. doi: 10.1093/carcin/bgu326. Epub 2015 Jan 13.
1238 Activin and estrogen crosstalk regulates transcription in human breast cancer cells.Endocr Relat Cancer. 2007 Sep;14(3):679-89. doi: 10.1677/ERC-07-0054.
1239 Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover.Carcinogenesis. 2008 Jan;29(1):25-34. doi: 10.1093/carcin/bgm213. Epub 2007 Sep 24.
1240 [Expression of early placenta insulin-like growth factor (EPIL) in breast cancer cells provides an autocrine loop with enhancement of predominantly HER-2-related invasivity].Verh Dtsch Ges Pathol. 2005;89:201-6.
1241 GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion.Nat Cell Biol. 2008 Jan;10(1):85-92. doi: 10.1038/ncb1672. Epub 2007 Dec 16.
1242 IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5(+) B- and T-cell trafficking to tumor-conditioned media.Immunol Cell Biol. 2015 May-Jun;93(5):486-99. doi: 10.1038/icb.2014.110. Epub 2014 Dec 23.
1243 ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth.Breast Cancer Res. 2018 Dec 13;20(1):151. doi: 10.1186/s13058-018-1080-1.
1244 #NAME?
1245 Integrin alpha9 (ITGA9) expression and epigenetic silencing in human breast tumors.Cell Adh Migr. 2011 Sep-Oct;5(5):395-401. doi: 10.4161/cam.5.5.17949.
1246 The NRIF3 family of transcriptional coregulators induces rapid and profound apoptosis in breast cancer cells.Mol Cell Biol. 2004 May;24(9):3838-48. doi: 10.1128/MCB.24.9.3838-3848.2004.
1247 The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.Oncogene. 2008 Jan 31;27(6):865-76. doi: 10.1038/sj.onc.1210669. Epub 2007 Jul 23.
1248 Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer.Ann Oncol. 2013 Nov;24(11):2780-5. doi: 10.1093/annonc/mdt290. Epub 2013 Jul 29.
1249 TIP60: an actor in acetylation of H3K4 and tumor development in breast cancer.Epigenomics. 2018 Nov;10(11):1415-1430. doi: 10.2217/epi-2018-0004. Epub 2018 Oct 16.
1250 Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability.Oncogene. 2012 Jul 5;31(27):3244-53. doi: 10.1038/onc.2011.502. Epub 2011 Nov 28.
1251 Effects of TPX2 gene on radiotherapy sensitization in breast cancer stem cells.Oncol Lett. 2017 Aug;14(2):1531-1535. doi: 10.3892/ol.2017.6277. Epub 2017 May 29.
1252 Up-regulation of kin17 is essential for proliferation of breast cancer.PLoS One. 2011;6(9):e25343. doi: 10.1371/journal.pone.0025343. Epub 2011 Sep 29.
1253 Discovery of Klotho peptide antagonists against Wnt3 and Wnt3a target proteins using combination of protein engineering, protein-protein docking, peptide docking and molecular dynamics simulations.J Enzyme Inhib Med Chem. 2017 Dec;32(1):84-98. doi: 10.1080/14756366.2016.1235569. Epub 2016 Oct 21.
1254 Differential gene expression of TGF beta inducible early gene (TIEG), Smad7, Smad2 and Bard1 in normal and malignant breast tissue.Breast Cancer Res Treat. 2004 Jul;86(1):75-88. doi: 10.1023/B:BREA.0000032926.74216.7d.
1255 Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer.Oncogene. 2012 Apr 12;31(15):1988-94. doi: 10.1038/onc.2011.387. Epub 2011 Sep 5.
1256 Mutations and Krppel-like factor 6 (KLF6) expression levels in breast cancer.Tumour Biol. 2014 Jun;35(6):5219-25. doi: 10.1007/s13277-014-1678-6. Epub 2014 Feb 12.
1257 Krppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion.Cancer Res. 2007 Aug 1;67(15):7184-93. doi: 10.1158/0008-5472.CAN-06-4729.
1258 Multifunctional lipid-coated calcium phosphate nanoplatforms for complete inhibition of large triple negative breast cancer via targeted combined therapy.Biomaterials. 2019 Sep;216:119232. doi: 10.1016/j.biomaterials.2019.119232. Epub 2019 May 31.
1259 Intracellular signaling pathways regulate hormone-dependent kallikrein gene expression.Tumour Biol. 2008;29(2):63-75. doi: 10.1159/000135686. Epub 2008 Jun 2.
1260 Human kallikrein-related peptidase 12 (KLK12) splice variants discriminate benign from cancerous breast tumors.Clin Biochem. 2018 Aug;58:78-85. doi: 10.1016/j.clinbiochem.2018.05.017. Epub 2018 May 25.
1261 Development of Chemical Tools to Monitor Human Kallikrein 13 (KLK13) Activity.Int J Mol Sci. 2019 Mar 28;20(7):1557. doi: 10.3390/ijms20071557.
1262 The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.Br J Cancer. 2002 Nov 18;87(11):1294-300. doi: 10.1038/sj.bjc.6600590.
1263 Somatic mutations of the mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers.Pathol Oncol Res. 2011 Jun;17(2):429-33. doi: 10.1007/s12253-010-9316-0. Epub 2010 Nov 30.
1264 Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.PLoS One. 2019 Apr 16;14(4):e0209134. doi: 10.1371/journal.pone.0209134. eCollection 2019.
1265 Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.Cancer Biol Ther. 2010 Mar 1;9(5):389-96. doi: 10.4161/cbt.9.5.10926. Epub 2010 Mar 11.
1266 Expression of a novel lacrimal gland gene lacritin in human breast tissues.J Cancer Res Clin Oncol. 2003 Dec;129(12):735-6. doi: 10.1007/s00432-003-0514-y. Epub 2003 Oct 22.
1267 SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors.Sci Signal. 2018 Jan 30;11(515):eaan0949. doi: 10.1126/scisignal.aan0949.
1268 Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.Clin Cancer Res. 2003 Dec 15;9(17):6389-94.
1269 Autocrine laminin-5 ligates alpha6beta4 integrin and activates RAC and NFkappaB to mediate anchorage-independent survival of mammary tumors.J Cell Biol. 2003 Dec 22;163(6):1397-407. doi: 10.1083/jcb.200302023.
1270 Hypoxic regulation and prognostic value of LAMP3 expression in breast cancer.Cancer. 2011 Aug 15;117(16):3670-81. doi: 10.1002/cncr.25938. Epub 2011 Feb 11.
1271 BAD-LAMP controls TLR9 trafficking and signalling in human plasmacytoid dendritic cells.Nat Commun. 2017 Oct 13;8(1):913. doi: 10.1038/s41467-017-00695-1.
1272 The novel lupus antigen related protein acheron enhances the development of human breast cancer.Int J Cancer. 2012 Feb 1;130(3):544-54. doi: 10.1002/ijc.26015. Epub 2011 May 9.
1273 Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.Clin Cancer Res. 2005 Feb 15;11(4):1380-5. doi: 10.1158/1078-0432.CCR-04-1773.
1274 A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression.Genes Dev. 2009 Aug 1;23(15):1737-42. doi: 10.1101/gad.1809309.
1275 Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a-LCOR axis.Nat Cell Biol. 2017 Jun;19(6):711-723. doi: 10.1038/ncb3533. Epub 2017 May 22.
1276 Lactate dehydrogenase-B is silenced by promoter methylation in a high frequency of human breast cancers. PLoS One. 2013;8(2):e57697. doi: 10.1371/journal.pone.0057697. Epub 2013 Feb 21.
1277 Wnt3a-dependent and -independent protein interaction networks of chromatin-bound -catenin in mouse embryonic stem cells.Mol Cell Proteomics. 2013 Jul;12(7):1980-94. doi: 10.1074/mcp.M112.026914. Epub 2013 Apr 15.
1278 The HCCR oncoprotein as a biomarker for human breast cancer.Clin Cancer Res. 2005 Nov 1;11(21):7700-8. doi: 10.1158/1078-0432.CCR-04-2609.
1279 Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer.Cancer Cell. 2012 May 15;21(5):626-641. doi: 10.1016/j.ccr.2012.03.041.
1280 The FEL (AF-4) protein donates transcriptional activation sequences to Hrx-Fel fusion proteins in leukemias containing T(4;11)(Q21;Q23) chromosomal translocations.Leuk Res. 1997 Oct;21(10):911-7. doi: 10.1016/s0145-2126(97)00012-x.
1281 Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer.PLoS One. 2016 Nov 30;11(11):e0166731. doi: 10.1371/journal.pone.0166731. eCollection 2016.
1282 Genetic polymorphisms in the DNA repair enzyme ERCC2 and breast tumour risk in a Chinese population.J Int Med Res. 2008 May-Jun;36(3):479-88. doi: 10.1177/147323000803600312.
1283 Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome.Mol Cancer. 2008 Sep 16;7:71. doi: 10.1186/1476-4598-7-71.
1284 Cell cycle regulated phosphorylation of LIMD1 in cell lines and expression in human breast cancers.Cancer Lett. 2008 Aug 18;267(1):55-66. doi: 10.1016/j.canlet.2008.03.015. Epub 2008 Apr 24.
1285 Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms.Cell. 2011 Nov 23;147(5):1066-79. doi: 10.1016/j.cell.2011.10.039.
1286 miR-218 and miR-129 regulate breast cancer progression by targeting Lamins.Biochem Biophys Res Commun. 2018 Feb 12;496(3):826-833. doi: 10.1016/j.bbrc.2018.01.146. Epub 2018 Jan 31.
1287 LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer.Oncotarget. 2017 Feb 14;8(7):11977-11989. doi: 10.18632/oncotarget.14450.
1288 Loss of LRIG1 locus increases risk of early and late relapse of stage I/II breast cancer.Cancer Res. 2014 Jun 1;74(11):2928-35. doi: 10.1158/0008-5472.CAN-13-2112.
1289 Silencing of LRRC49 and THAP10 genes by bidirectional promoter hypermethylation is a frequent event in breast cancer.Int J Oncol. 2008 Jul;33(1):25-31.
1290 Genome-wide association study identifies five new breast cancer susceptibility loci.Nat Genet. 2010 Jun;42(6):504-7. doi: 10.1038/ng.586. Epub 2010 May 9.
1291 TGF-beta1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival.Br J Cancer. 2008 Oct 21;99(8):1357-63. doi: 10.1038/sj.bjc.6604689. Epub 2008 Sep 30.
1292 Versican G1 and G3 domains are upregulated and latent transforming growth factor- binding protein-4 is downregulated in breast cancer stroma.Breast Cancer. 2012 Jan;19(1):46-53. doi: 10.1007/s12282-011-0264-7. Epub 2011 Apr 20.
1293 Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies.Breast Cancer Res. 2008;10(6):R98. doi: 10.1186/bcr2201. Epub 2008 Nov 26.
1294 Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells.Mol Endocrinol. 2006 Sep;20(9):2020-35. doi: 10.1210/me.2005-0063. Epub 2006 Apr 27.
1295 LncRNA MACC1-AS1 sponges multiple miRNAs and RNA-binding protein PTBP1.Oncogenesis. 2019 Dec 10;8(12):73. doi: 10.1038/s41389-019-0182-7.
1296 Expression and mutational analyses of the human MAD2L1 gene in breast cancer cells.Genes Chromosomes Cancer. 2000 Dec;29(4):356-62. doi: 10.1002/1098-2264(2000)9999:9999<::aid-gcc1044>3.0.co;2-n.
1297 Premature polyadenylation of MAGI3 produces a dominantly-acting oncogene in human breast cancer.Elife. 2016 May 20;5:e14730. doi: 10.7554/eLife.14730.
1298 Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Mol Cancer Res. 2009 Feb;7(2):199-209. doi: 10.1158/1541-7786.MCR-08-0314. Epub 2009 Feb 10.
1299 Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.Oncotarget. 2016 Dec 6;7(49):81357-81366. doi: 10.18632/oncotarget.12877.
1300 Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells.Cancer Res. 2009 Dec 1;69(23):8853-61. doi: 10.1158/0008-5472.CAN-09-1636. Epub 2009 Nov 17.
1301 Extracellular signal-regulated kinase 7, a regulator of hormone-dependent estrogen receptor destruction.Mol Cell Biol. 2003 Sep;23(17):5979-88. doi: 10.1128/MCB.23.17.5979-5988.2003.
1302 End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability.Protein Cell. 2014 Jun;5(6):469-79. doi: 10.1007/s13238-014-0053-0. Epub 2014 Apr 19.
1303 Investigation of two Wnt signalling pathway single nucleotide polymorphisms in a breast cancer-affected Australian population.Twin Res Hum Genet. 2011 Dec;14(6):562-7. doi: 10.1375/twin.14.6.562.
1304 Csk homologous kinase (CHK) and ErbB-2 interactions are directly coupled with CHK negative growth regulatory function in breast cancer.J Biol Chem. 2002 Sep 27;277(39):36465-70. doi: 10.1074/jbc.M206018200. Epub 2002 Jul 16.
1305 The Distinct Gene Regulatory Network of Myoglobin in Prostate and Breast Cancer.PLoS One. 2015 Nov 11;10(11):e0142662. doi: 10.1371/journal.pone.0142662. eCollection 2015.
1306 Muscleblind-like 1 suppresses breast cancer metastatic colonization and stabilizes metastasis suppressor transcripts.Genes Dev. 2016 Feb 15;30(4):386-98. doi: 10.1101/gad.270645.115.
1307 GANP protein encoded on human chromosome 21/mouse chromosome 10 is associated with resistance to mammary tumor development.Cancer Sci. 2016 Apr;107(4):469-77. doi: 10.1111/cas.12883. Epub 2016 Feb 9.
1308 Tumor suppressor MCPH1 regulates gene expression profiles related to malignant conversion and chromosomal assembly.Int J Cancer. 2019 Oct 15;145(8):2070-2081. doi: 10.1002/ijc.32234. Epub 2019 Mar 21.
1309 Coactivation of estrogen receptor alpha (ER alpha)/Sp1 by vitamin D receptor interacting protein 150 (DRIP150).Arch Biochem Biophys. 2007 May 15;461(2):200-10. doi: 10.1016/j.abb.2006.12.030. Epub 2007 Jan 23.
1310 TMEM25, REPS2 and Meis 1: favourable prognostic and predictive biomarkers for breast cancer.Tumour Biol. 2009;30(4):200-9. doi: 10.1159/000239795. Epub 2009 Sep 21.
1311 Hypermethylation of the GSTP1 promoter region in breast cancer is associated with prognostic clinicopathological parameters.Neoplasma. 2010;57(1):35-40. doi: 10.4149/neo_2010_01_035.
1312 CRISPR deletion of MIEN1 in breast cancer cells.PLoS One. 2018 Oct 4;13(10):e0204976. doi: 10.1371/journal.pone.0204976. eCollection 2018.
1313 Identification of the functional role of AF1Q in the progression of breast cancer.Breast Cancer Res Treat. 2008 Sep;111(1):65-78. doi: 10.1007/s10549-007-9761-y. Epub 2007 Oct 11.
1314 Calcium regulates tertiary structure and enzymatic activity of human endometase/matrilysin-2 and its role in promoting human breast cancer cell invasion.Biochem J. 2007 Apr 1;403(1):31-42. doi: 10.1042/BJ20061390.
1315 The human ROX gene: genomic structure and mutation analysis in human breast tumors.Genomics. 1998 Apr 15;49(2):275-82. doi: 10.1006/geno.1998.5241.
1316 A single point mutation responsible for c-mos polymorphism in cancer patients.Oncogene. 1987 May;1(2):235-7.
1317 Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex.Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2024-32. doi: 10.1158/1055-9965.EPI-07-0116.
1318 Delineating a new feature of constitutional mismatch repair deficiency (CMMRD) syndrome: breast cancer.Fam Cancer. 2019 Jan;18(1):105-108. doi: 10.1007/s10689-018-0088-0.
1319 Homeobox protein MSX1 inhibits the growth and metastasis of breast cancer cells and is frequently silenced by promoter methylation.Int J Mol Med. 2018 May;41(5):2986-2996. doi: 10.3892/ijmm.2018.3468. Epub 2018 Feb 7.
1320 Homeobox transcription factor muscle segment homeobox 2 (Msx2) correlates with good prognosis in breast cancer patients and induces apoptosis in vitro.Breast Cancer Res. 2010;12(4):R59. doi: 10.1186/bcr2621. Epub 2010 Aug 3.
1321 Absence of Metallothionein 3 Expression in Breast Cancer is a Rare, But Favorable Marker of Outcome that is Under Epigenetic Control. Toxicol Environ Chem. 2010 Oct;92(9):1673-1695. doi: 10.1080/02772241003711274.
1322 Emerging roles of MTA family members in human cancers.Semin Oncol. 2003 Oct;30(5 Suppl 16):30-7. doi: 10.1053/j.seminoncol.2003.08.005.
1323 Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis.Breast Cancer Res Treat. 2019 Feb;173(3):573-583. doi: 10.1007/s10549-018-5026-1. Epub 2018 Oct 27.
1324 Immunohistochemical analysis of MUC5B apomucin expression in breast cancer and non-malignant breast tissues.J Histochem Cytochem. 2006 Mar;54(3):289-99. doi: 10.1369/jhc.5A6763.2005. Epub 2005 Sep 7.
1325 In vitro and in vivo analysis of B-Myb in basal-like breast cancer.Oncogene. 2009 Feb 5;28(5):742-51. doi: 10.1038/onc.2008.430. Epub 2008 Dec 1.
1326 MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer.Int J Cancer. 2002 Dec 20;102(6):608-14. doi: 10.1002/ijc.10765.
1327 Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.Nat Genet. 2017 Aug;49(8):1219-1230. doi: 10.1038/ng.3905. Epub 2017 Jun 26.
1328 The breast tumour-associated epithelial mucins and the peanut lectin binding urinary mucins are coded by a single highly polymorphic gene locus 'PUM'.Dis Markers. 1988 Jul-Sep;6(3):185-94.
1329 Myoferlin depletion elevates focal adhesion kinase and paxillin phosphorylation and enhances cell-matrix adhesion in breast cancer cells.Am J Physiol Cell Physiol. 2015 Apr 15;308(8):C642-9. doi: 10.1152/ajpcell.00276.2014. Epub 2015 Jan 28.
1330 Release of transcriptional repression via ErbB2-induced, SUMO-directed phosphorylation of myeloid zinc finger-1 serine 27 activates lysosome redistribution and invasion.Oncogene. 2019 Apr;38(17):3170-3184. doi: 10.1038/s41388-018-0653-x. Epub 2019 Jan 8.
1331 Neuronal apoptosis inhibitory protein is overexpressed in patients with unfavorable prognostic factors in breast cancer.J Korean Med Sci. 2007 Sep;22 Suppl(Suppl):S17-23. doi: 10.3346/jkms.2007.22.S.S17.
1332 Methylation of NBPF1 as a novel marker for the detection of plasma cell-free DNA of breast cancer patients.Clin Chim Acta. 2018 Sep;484:81-86. doi: 10.1016/j.cca.2018.05.030. Epub 2018 May 15.
1333 Systematic tracking of dysregulated modules identifies novel genes in cancer.Bioinformatics. 2013 Jun 15;29(12):1553-61. doi: 10.1093/bioinformatics/btt191. Epub 2013 Apr 23.
1334 Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene.PLoS One. 2018 Nov 28;13(11):e0207776. doi: 10.1371/journal.pone.0207776. eCollection 2018.
1335 Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy.Mol Cancer. 2011 Feb 27;10:23. doi: 10.1186/1476-4598-10-23.
1336 Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer.Oncogene. 2015 Oct;34(43):5427-35. doi: 10.1038/onc.2014.470. Epub 2015 Feb 16.
1337 TBX2 interacts with heterochromatin protein 1 to recruit a novel repression complex to EGR1-targeted promoters to drive the proliferation of breast cancer cells.Oncogene. 2019 Aug;38(31):5971-5986. doi: 10.1038/s41388-019-0853-z. Epub 2019 Jun 28.
1338 Abundant NDRG2 Expression Is Associated with Aggressiveness and Unfavorable Patients' Outcome in Basal-Like Breast Cancer.PLoS One. 2016 Jul 11;11(7):e0159073. doi: 10.1371/journal.pone.0159073. eCollection 2016.
1339 Identification of a novel estrogen receptor-alpha variant and its upstream splicing regulator.Mol Endocrinol. 2010 May;24(5):914-22. doi: 10.1210/me.2009-0413. Epub 2010 Mar 19.
1340 HRPAP20: a novel calmodulin-binding protein that increases breast cancer cell invasion.Oncogene. 2007 Mar 15;26(12):1780-8. doi: 10.1038/sj.onc.1209980. Epub 2006 Sep 25.
1341 Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers.Mol Cancer. 2013 Jun 12;12:60. doi: 10.1186/1476-4598-12-60.
1342 Concerted transcriptional regulation by BRCA1 and COBRA1 in breast cancer cells.Int J Biol Sci. 2007 Nov 26;3(7):486-92. doi: 10.7150/ijbs.3.486.
1343 Stimulatory cross-talk between NFAT3 and estrogen receptor in breast cancer cells.J Biol Chem. 2005 Dec 30;280(52):43188-97. doi: 10.1074/jbc.M506598200. Epub 2005 Oct 11.
1344 NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia.Int J Cancer. 2005 Apr 20;114(4):585-9. doi: 10.1002/ijc.20765.
1345 Hypoxia regulates the expression of the neuromedin B receptor through a mechanism dependent on hypoxia-inducible factor-1.PLoS One. 2013 Dec 9;8(12):e82868. doi: 10.1371/journal.pone.0082868. eCollection 2013.
1346 Identification of a second human nm23 gene, nm23-H2.Cancer Res. 1991 Jan 1;51(1):445-9.
1347 Thermo- and pH-dual responsive polymeric micelles with upper critical solution temperature behavior for photoacoustic imaging-guided synergistic chemo-photothermal therapy against subcutaneous and metastatic breast tumors.Theranostics. 2018 Jul 16;8(15):4097-4115. doi: 10.7150/thno.26195. eCollection 2018.
1348 Incidental finding of a breast carcinoma on Ga-68-DOTA-1-Nal3-octreotide positron emission tomography/computed tomography performed for the evaluation of a pancreatic neuroendocrine tumor: A case report.Medicine (Baltimore). 2018 Sep;97(36):e11878. doi: 10.1097/MD.0000000000011878.
1349 The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome.Breast Cancer Res. 2008;10(2):R28. doi: 10.1186/bcr1985. Epub 2008 Mar 29.
1350 Oxidative stress specifically downregulates survivin to promote breast tumour formation.Br J Cancer. 2013 Mar 5;108(4):848-58. doi: 10.1038/bjc.2013.40. Epub 2013 Feb 12.
1351 Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk.Breast Cancer Res Treat. 2008 Feb;107(3):421-5. doi: 10.1007/s10549-007-9565-0. Epub 2007 Apr 24.
1352 A Novel Truncated Form of Nephronectin Is Present in Small Extracellular Vesicles Isolated from 66cl4 Cells.J Proteome Res. 2019 Mar 1;18(3):1237-1247. doi: 10.1021/acs.jproteome.8b00859. Epub 2019 Feb 13.
1353 Identification of novel tumor antigens with patient-derived immune-selected antibodies.Cancer Immunol Immunother. 2009 Feb;58(2):221-34. doi: 10.1007/s00262-008-0543-0. Epub 2008 Jun 21.
1354 5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines.Cancer Lett. 2014 May 28;347(1):139-50. doi: 10.1016/j.canlet.2014.02.001. Epub 2014 Feb 7.
1355 NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.Breast Cancer Res Treat. 2018 Nov;172(2):469-485. doi: 10.1007/s10549-018-4905-9. Epub 2018 Aug 20.
1356 An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul;24(7):809-19. doi: 10.1038/cr.2014.71. Epub 2014 May 30.
1357 Depletion of signal recognition particle 72kDa increases radiosensitivity.Cancer Biol Ther. 2017 Jun 3;18(6):425-432. doi: 10.1080/15384047.2017.1323587. Epub 2017 May 11.
1358 Netrin-4 induces lymphangiogenesis in vivo.Blood. 2010 Jul 1;115(26):5418-26. doi: 10.1182/blood-2009-11-252338. Epub 2010 Apr 20.
1359 Identification of Nucleobindin-2 as a Potential Biomarker for Breast Cancer Metastasis Using iTRAQ-based Quantitative Proteomic Analysis.J Cancer. 2017 Sep 2;8(15):3062-3069. doi: 10.7150/jca.19619. eCollection 2017.
1360 Enhanced expression of the 8-oxo-7,8-dihydrodeoxyguanosine triphosphatase gene in human breast tumor cells.Cancer Lett. 1998 Mar 13;125(1-2):123-30. doi: 10.1016/s0304-3835(97)00507-7.
1361 Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation. Int J Cancer. 2011 Apr 15;128(8):1770-82. doi: 10.1002/ijc.25505.
1362 Comprehensive analysis of NuMA variation in breast cancer.BMC Cancer. 2008 Mar 10;8:71. doi: 10.1186/1471-2407-8-71.
1363 NUMB controls p53 tumour suppressor activity.Nature. 2008 Jan 3;451(7174):76-80. doi: 10.1038/nature06412.
1364 High NUP43 expression might independently predict poor overall survival in luminal A and in HER2+ breast cancer.Future Oncol. 2018 Jun;14(15):1431-1442. doi: 10.2217/fon-2017-0690. Epub 2018 Feb 6.
1365 NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress.Curr Cancer Drug Targets. 2008 Aug;8(5):421-30. doi: 10.2174/156800908785133196.
1366 Comprehensive proteome quantification reveals NgBR as a new regulator for epithelial-mesenchymal transition of breast tumor cells.J Proteomics. 2015 Jan 1;112:38-52. doi: 10.1016/j.jprot.2014.08.007. Epub 2014 Aug 27.
1367 Depletion of mitochondrial protease OMA1 alters proliferative properties and promotes metastatic growth of breast cancer cells.Sci Rep. 2019 Oct 14;9(1):14746. doi: 10.1038/s41598-019-49327-2.
1368 Bone marrow stromal cell-derived growth inhibitor inhibits growth and migration of breast cancer cells via induction of cell cycle arrest and apoptosis.J Biol Chem. 2005 Feb 11;280(6):4374-82. doi: 10.1074/jbc.M408708200. Epub 2004 Nov 29.
1369 OVOL2 antagonizes TGF- signaling to regulate epithelial to mesenchymal transition during mammary tumor metastasis.Oncotarget. 2017 Jun 13;8(24):39401-39416. doi: 10.18632/oncotarget.17031.
1370 Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer.Mol Cell Proteomics. 2005 Nov;4(11):1686-96. doi: 10.1074/mcp.M400221-MCP200. Epub 2005 Jul 26.
1371 Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1.Cancer Lett. 2008 Jul 8;265(2):298-306. doi: 10.1016/j.canlet.2008.02.024. Epub 2008 Mar 19.
1372 Targeted H3R26 deimination specifically facilitates estrogen receptor binding by modifying nucleosome structure.PLoS Genet. 2014 Sep 11;10(9):e1004613. doi: 10.1371/journal.pgen.1004613. eCollection 2014 Sep.
1373 Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.Breast Cancer Res Treat. 2020 Feb;179(3):605-614. doi: 10.1007/s10549-019-05483-7. Epub 2019 Nov 25.
1374 PAX2 expression is correlated with better survival in tamoxifen-treated breast carcinoma patients.Tissue Cell. 2018 Jun;52:135-142. doi: 10.1016/j.tice.2018.05.005. Epub 2018 May 9.
1375 Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer.Mol Cancer Ther. 2017 Dec;16(12):2747-2758. doi: 10.1158/1535-7163.MCT-17-0717. Epub 2017 Oct 4.
1376 The 3'-untranslated region of p21WAF1 mRNA is a composite cis-acting sequence bound by RNA-binding proteins from breast cancer cells, including HuR and poly(C)-binding protein.J Biol Chem. 2003 Jan 31;278(5):2937-46. doi: 10.1074/jbc.M208439200. Epub 2002 Nov 12.
1377 Protocadherin 17 functions as a tumor suppressor suppressing Wnt/-catenin signaling and cell metastasis and is frequently methylated in breast cancer.Oncotarget. 2016 Aug 9;7(32):51720-51732. doi: 10.18632/oncotarget.10102.
1378 Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.J Natl Cancer Inst. 2019 Jun 1;111(6):609-619. doi: 10.1093/jnci/djy151.
1379 KIAA0101 interacts with BRCA1 and regulates centrosome number.Mol Cancer Res. 2011 Aug;9(8):1091-9. doi: 10.1158/1541-7786.MCR-10-0503. Epub 2011 Jun 14.
1380 MicroRNA-124-3p directly targets PDCD6 to inhibit metastasis in breast cancer.Oncol Lett. 2018 Jan;15(1):984-990. doi: 10.3892/ol.2017.7358. Epub 2017 Nov 8.
1381 Suppression of PDHX by microRNA-27b deregulates cell metabolism and promotes growth in breast cancer.Mol Cancer. 2018 Jul 16;17(1):100. doi: 10.1186/s12943-018-0851-8.
1382 Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin): a clinically useful predictor for axillary lymph node metastases.Breast Cancer Res Treat. 2008 Dec;112(3):503-11. doi: 10.1007/s10549-007-9875-2. Epub 2007 Dec 29.
1383 p38 limits the contribution of MAP17 to cancer progression in breast tumors.Oncogene. 2012 Oct 11;31(41):4447-59. doi: 10.1038/onc.2011.619. Epub 2012 Jan 23.
1384 Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer.Cancer Lett. 2015 Jan 28;356(2 Pt B):374-381. doi: 10.1016/j.canlet.2014.09.033. Epub 2014 Oct 7.
1385 PES1 promotes breast cancer by differentially regulating ER and ER.J Clin Invest. 2012 Aug;122(8):2857-70. doi: 10.1172/JCI62676. Epub 2012 Jul 23.
1386 Abnormal expression of PFDN4 in colorectal cancer: a novel marker for prognosis.Ann Surg Oncol. 2010 Nov;17(11):3030-6. doi: 10.1245/s10434-010-1138-5. Epub 2010 Jun 15.
1387 Profilin-1 deficiency leads to SMAD3 upregulation and impaired 3D outgrowth of breast cancer cells.Br J Cancer. 2018 Oct;119(9):1106-1117. doi: 10.1038/s41416-018-0284-6. Epub 2018 Oct 15.
1388 Investigating the Antiangiogenic, Anti-drug Resistance and Apoptotic Effects of Soy Isoflavone Extract Alone or in Combination with Docetaxel on Murine 4T1 Breast Tumor Model.Nutr Cancer. 2017 Oct;69(7):1036-1042. doi: 10.1080/01635581.2017.1359316. Epub 2017 Sep 22.
1389 Expression of a repressor of estrogen receptor activity in human breast tumors: relationship to some known prognostic markers.Cancer Res. 2000 Jun 1;60(11):2796-9.
1390 PHLDA1 expression is controlled by an estrogen receptor-NFB-miR-181 regulatory loop and is essential for formation of ER+ mammospheres.Oncogene. 2015 Apr 30;34(18):2309-16. doi: 10.1038/onc.2014.180. Epub 2014 Jun 23.
1391 Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.Oncogene. 2015 Jan 15;34(3):373-83. doi: 10.1038/onc.2013.562. Epub 2014 Jan 27.
1392 PIAS1 regulates breast tumorigenesis through selective epigenetic gene silencing.PLoS One. 2014 Feb 24;9(2):e89464. doi: 10.1371/journal.pone.0089464. eCollection 2014.
1393 PIBF (progesterone induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome.Int J Cancer. 2004 Oct 20;112(1):51-60. doi: 10.1002/ijc.20326.
1394 Class II phosphoinositide 3-kinase C2 regulates a novel signaling pathway involved in breast cancer progression.Oncotarget. 2016 Apr 5;7(14):18325-45. doi: 10.18632/oncotarget.7761.
1395 The evolutionarily conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor suppressor function.Autophagy. 2005 Apr;1(1):46-52. doi: 10.4161/auto.1.1.1542. Epub 2005 Apr 17.
1396 microRNA-155 positively regulates glucose metabolism via PIK3R1-FOXO3a-cMYC axis in breast cancer.Oncogene. 2018 May;37(22):2982-2991. doi: 10.1038/s41388-018-0124-4. Epub 2018 Mar 12.
1397 The diagnosis of a metastatic breast tumor from ovarian cancer by the succession of a p53 mutation: a case report.World J Surg Oncol. 2017 Jun 29;15(1):117. doi: 10.1186/s12957-017-1185-5.
1398 Low PIP4K2B expression in human breast tumors correlates with reduced patient survival: A role for PIP4K2B in the regulation of E-cadherin expression.Cancer Res. 2013 Dec 1;73(23):6913-25. doi: 10.1158/0008-5472.CAN-13-0424. Epub 2013 Oct 14.
1399 DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.Breast Cancer Res Treat. 2008 Oct;111(3):429-37. doi: 10.1007/s10549-007-9800-8. Epub 2007 Oct 28.
1400 The phosphorylation status of PIP5K1C at serine 448 can be predictive for invasive ductal carcinoma of the breast.Oncotarget. 2018 Nov 20;9(91):36358-36370. doi: 10.18632/oncotarget.26357. eCollection 2018 Nov 20.
1401 Characterization of the methylation-sensitive promoter of the imprinted ZAC gene supports its role in transient neonatal diabetes mellitus.J Biol Chem. 2001 Jun 1;276(22):18653-6. doi: 10.1074/jbc.C100095200. Epub 2001 Apr 10.
1402 Ectopic expression of PLC-2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.Mol Carcinog. 2019 May;58(5):708-721. doi: 10.1002/mc.22964. Epub 2019 Jan 16.
1403 Methylation of PLCD1 and adenovirus-mediated PLCD1 overexpression elicits a gene therapy effect on human breast cancer.Exp Cell Res. 2015 Mar 15;332(2):179-89. doi: 10.1016/j.yexcr.2015.01.017. Epub 2015 Feb 2.
1404 Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer.Cancer Res. 2008 Sep 1;68(17):7165-75. doi: 10.1158/0008-5472.CAN-08-1360.
1405 "Stem cell like" breast cancers-a model for the identification of new prognostic/predictive markers in endocrine responsive breast cancer exemplified by Plexin B1.Eur J Obstet Gynecol Reprod Biol. 2008 Jul;139(1):11-5. doi: 10.1016/j.ejogrb.2008.02.015. Epub 2008 Apr 15.
1406 Transforming growth factor-beta (TGF-beta)-inducible gene TMEPAI converts TGF-beta from a tumor suppressor to a tumor promoter in breast cancer.Cancer Res. 2010 Aug 1;70(15):6377-83. doi: 10.1158/0008-5472.CAN-10-1180. Epub 2010 Jul 7.
1407 Podocalyxin promotes proliferation and survival in mature B-cell non-Hodgkin lymphoma cells.Oncotarget. 2017 Sep 27;8(59):99722-99739. doi: 10.18632/oncotarget.21283. eCollection 2017 Nov 21.
1408 POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance.Genet Med. 2016 Apr;18(4):325-32. doi: 10.1038/gim.2015.75. Epub 2015 Jul 2.
1409 Altered DNA polymerase iota expression in breast cancer cells leads to a reduction in DNA replication fidelity and a higher rate of mutagenesis.Cancer Res. 2004 Aug 15;64(16):5597-607. doi: 10.1158/0008-5472.CAN-04-0603.
1410 Increased levels of alpha-class and pi-class glutathione S-transferases in cell lines resistant to 1-chloro-2,4-dinitrobenzene.Eur J Biochem. 1993 Oct 15;217(2):671-6. doi: 10.1111/j.1432-1033.1993.tb18292.x.
1411 Post-translational modification of OCT4 in breast cancer tumorigenesis.Cell Death Differ. 2018 Nov;25(10):1781-1795. doi: 10.1038/s41418-018-0079-6. Epub 2018 Mar 6.
1412 PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.Tumour Biol. 2017 Jul;39(7):1010428317713492. doi: 10.1177/1010428317713492.
1413 Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer.J Exp Clin Cancer Res. 2019 May 9;38(1):187. doi: 10.1186/s13046-019-1187-y.
1414 A regulated PNUTS mRNA to lncRNA splice switch mediates EMT and tumour progression.Nat Cell Biol. 2017 Sep;19(9):1105-1115. doi: 10.1038/ncb3595. Epub 2017 Aug 21.
1415 Mutation analysis of five candidate genes in familial breast cancer.Breast Cancer Res Treat. 2007 Nov;105(3):377-89. doi: 10.1007/s10549-006-9461-z. Epub 2006 Dec 23.
1416 Protein phosphatase PP6 is required for homology-directed repair of DNA double-strand breaks.Cell Cycle. 2011 May 1;10(9):1411-9. doi: 10.4161/cc.10.9.15479. Epub 2011 May 1.
1417 Suppressive effects of a proton beam on tumor growth and lung metastasis through the inhibition of metastatic gene expression in 4T1 orthotopic breast cancer model.Int J Oncol. 2016 Jul;49(1):336-42. doi: 10.3892/ijo.2016.3520. Epub 2016 May 13.
1418 Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.Breast Cancer Res. 2007;9(6):R76. doi: 10.1186/bcr1789.
1419 Rac signaling in breast cancer: a tale of GEFs and GAPs.Cell Signal. 2012 Feb;24(2):353-362. doi: 10.1016/j.cellsig.2011.08.011. Epub 2011 Aug 27.
1420 PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.Int J Oncol. 2009 Nov;35(5):1015-23. doi: 10.3892/ijo_00000416.
1421 PRMT2, a C-terminal splice variant of PRMT2, inhibits the growth of breast cancer cells.Oncol Rep. 2017 Aug;38(2):1303-1311. doi: 10.3892/or.2017.5786. Epub 2017 Jul 3.
1422 Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes.Endocr Relat Cancer. 2012 Jul 22;19(4):509-26. doi: 10.1530/ERC-12-0100. Print 2012 Aug.
1423 Epigenetic silencing of the candidate tumor suppressor gene PROX1 in sporadic breast cancer. Int J Cancer. 2007 Aug 1;121(3):547-54. doi: 10.1002/ijc.22705.
1424 SNEV overexpression extends the life span of human endothelial cells.Exp Cell Res. 2006 Apr 1;312(6):746-59. doi: 10.1016/j.yexcr.2005.11.025. Epub 2006 Jan 4.
1425 PRR5 encodes a conserved proline-rich protein predominant in kidney: analysis of genomic organization, expression, and mutation status in breast and colorectal carcinomas.Genomics. 2005 Mar;85(3):338-51. doi: 10.1016/j.ygeno.2004.11.002.
1426 TSP50, a possible protease in human testes, is activated in breast cancer epithelial cells.Cancer Res. 2002 Jan 1;62(1):290-4.
1427 Overexpression of h-prune in breast cancer is correlated with advanced disease status.Clin Cancer Res. 2005 Jan 1;11(1):199-205.
1428 GT198 Expression Defines Mutant Tumor Stroma in Human Breast Cancer.Am J Pathol. 2016 May;186(5):1340-50. doi: 10.1016/j.ajpath.2016.01.006. Epub 2016 Mar 18.
1429 Statistical modeling for selecting housekeeper genes.Genome Biol. 2004;5(8):R59. doi: 10.1186/gb-2004-5-8-r59. Epub 2004 Jul 29.
1430 Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer.Clin Cancer Res. 1999 Nov;5(11):3460-7.
1431 S14 protein in breast cancer cells: direct evidence of regulation by SREBP-1c, superinduction with progestin, and effects on cell growth.Exp Cell Res. 2006 Feb 1;312(3):278-88. doi: 10.1016/j.yexcr.2005.10.022. Epub 2005 Nov 21.
1432 Re-expression of SPR1 in breast cancer cells by phorbol 12-myristate 13-acetate (PMA) or UV irradiation is mediated by the AP-1 binding site in the SPR1 promoter.Mol Med. 1999 Aug;5(8):526-41.
1433 Integration of Distinct ShcA Signaling Complexes Promotes Breast Tumor Growth and Tyrosine Kinase Inhibitor Resistance.Mol Cancer Res. 2018 May;16(5):894-908. doi: 10.1158/1541-7786.MCR-17-0623. Epub 2018 Feb 16.
1434 Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.Mol Endocrinol. 2009 Feb;23(2):176-87. doi: 10.1210/me.2008-0211. Epub 2008 Dec 18.
1435 Glycogen synthase kinase-3beta (GSK3beta) negatively regulates PTTG1/human securin protein stability, and GSK3beta inactivation correlates with securin accumulation in breast tumors.J Biol Chem. 2011 Aug 26;286(34):30047-56. doi: 10.1074/jbc.M111.232330. Epub 2011 Jul 11.
1436 CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration.Life Sci. 2019 Aug 15;231:116543. doi: 10.1016/j.lfs.2019.116543. Epub 2019 Jun 6.
1437 Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.Life Sci. 2007 Jul 4;81(4):280-7. doi: 10.1016/j.lfs.2007.05.012. Epub 2007 May 25.
1438 Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/-catenin pathway.Oncogene. 2016 Sep 8;35(36):4787-97. doi: 10.1038/onc.2016.10. Epub 2016 Feb 15.
1439 Protein kinase A-dependent synergism between GATA factors and the nuclear receptor, liver receptor homolog-1, regulates human aromatase (CYP19) PII promoter activity in breast cancer cells.Endocrinology. 2005 Nov;146(11):4905-16. doi: 10.1210/en.2005-0187. Epub 2005 Aug 18.
1440 Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis.J Natl Cancer Inst. 2010 Jun 16;102(12):866-80. doi: 10.1093/jnci/djq153. Epub 2010 May 18.
1441 Inactivation of Rab27B-dependent signaling pathway by calycosin inhibits migration and invasion of ER-negative breast cancer cells.Gene. 2019 Aug 15;709:48-55. doi: 10.1016/j.gene.2019.04.005. Epub 2019 Apr 16.
1442 Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells.PLoS One. 2012;7(7):e39432. doi: 10.1371/journal.pone.0039432. Epub 2012 Jul 9.
1443 The Protease Activated Receptor2 Promotes Rab5a Mediated Generation of Pro-metastatic Microvesicles.Sci Rep. 2018 May 9;8(1):7357. doi: 10.1038/s41598-018-25725-w.
1444 Epigenetic regulation of WTH3 in primary and cultured drug-resistant breast cancer cells.Cancer Res. 2005 Nov 1;65(21):10024-31. doi: 10.1158/0008-5472.CAN-05-1944.
1445 Regulation of endocytosis via the oxygen-sensing pathway.Nat Med. 2009 Mar;15(3):319-24. doi: 10.1038/nm.1922. Epub 2009 Mar 1.
1446 FHIT alterations in breast cancer.Semin Cancer Biol. 2001 Oct;11(5):361-6. doi: 10.1006/scbi.2001.0391.
1447 Down-regulation of c9orf86 in human breast cancer cells inhibits cell proliferation, invasion and tumor growth and correlates with survival of breast cancer patients.PLoS One. 2013 Aug 14;8(8):e71764. doi: 10.1371/journal.pone.0071764. eCollection 2013.
1448 Evidence for distinct functions for human DNA repair factors hHR23A and hHR23B.FEBS Lett. 2006 Jun 12;580(14):3401-8. doi: 10.1016/j.febslet.2006.05.012. Epub 2006 May 11.
1449 A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1).Nat Genet. 2009 May;41(5):579-84. doi: 10.1038/ng.353. Epub 2009 Mar 29.
1450 Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.J Natl Cancer Inst. 2019 Dec 1;111(12):1332-1338. doi: 10.1093/jnci/djz045.
1451 The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutations.Int J Cancer. 2004 Jul 20;110(6):845-9. doi: 10.1002/ijc.20169.
1452 No association between a stop codon polymorphism in RAD52 and breast cancer risk.Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1138-9.
1453 Loss of heterozygosity in the RAD54B region is not predictive for breast carcinomas.Pol J Pathol. 2007;58(1):3-6.
1454 The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer.Cancer Res. 2005 Oct 1;65(19):8646-54. doi: 10.1158/0008-5472.CAN-04-4243.
1455 RanBPM interacts with psoriasin in vitro and their expression correlates with specific clinical features in vivo in breast cancer.BMC Cancer. 2002 Nov 6;2:28. doi: 10.1186/1471-2407-2-28.
1456 -Arrestin2 regulates lysophosphatidic acid-induced human breast tumor cell migration and invasion via Rap1 and IQGAP1.PLoS One. 2013;8(2):e56174. doi: 10.1371/journal.pone.0056174. Epub 2013 Feb 6.
1457 RASAL2 activates RAC1 to promote triple-negative breast cancer progression.J Clin Invest. 2014 Dec;124(12):5291-304. doi: 10.1172/JCI76711. Epub 2014 Nov 10.
1458 Mapping of a novel ocular and cutaneous malignant melanoma susceptibility locus to chromosome 9q21.32.J Natl Cancer Inst. 2005 Sep 21;97(18):1377-82. doi: 10.1093/jnci/dji280.
1459 Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.Int J Oncol. 2009 Feb;34(2):517-28.
1460 Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells. Mol Cell Biol. 2006 Apr;26(7):2501-10. doi: 10.1128/MCB.26.7.2501-2510.2006.
1461 Nucleosomes positioning around transcriptional start site of tumor suppressor (Rbl2/p130) gene in breast cancer.Mol Biol Rep. 2018 Apr;45(2):185-194. doi: 10.1007/s11033-018-4151-6. Epub 2018 Feb 7.
1462 The small variant of the apoptosis-associated X-chromosome RBM10 gene is co-expressed with caspase-3 in breast cancer.Cancer Genomics Proteomics. 2008 May-Aug;5(3-4):169-73.
1463 RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer.BMC Cancer. 2014 May 7;14:322. doi: 10.1186/1471-2407-14-322.
1464 Expression of RBM5-related factors in primary breast tissue.J Cell Biochem. 2007 Apr 15;100(6):1440-58. doi: 10.1002/jcb.21134.
1465 Positive correlation between the expression of X-chromosome RBM genes (RBMX, RBM3, RBM10) and the proapoptotic Bax gene in human breast cancer.J Cell Biochem. 2006 Apr 15;97(6):1275-82. doi: 10.1002/jcb.20725.
1466 Exome sequencing and case-control analyses identify RCC1 as a candidate breast cancer susceptibility gene.Int J Cancer. 2018 Jun 15;142(12):2512-2517. doi: 10.1002/ijc.31273. Epub 2018 Feb 5.
1467 Germline RECQL mutations are associated with breast cancer susceptibility.Nat Genet. 2015 Jun;47(6):643-6. doi: 10.1038/ng.3284. Epub 2015 Apr 27.
1468 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
1469 Expression of the RERG gene is gender-dependent in hepatocellular carcinoma and regulated by histone deacetyltransferases.J Korean Med Sci. 2006 Oct;21(5):891-6. doi: 10.3346/jkms.2006.21.5.891.
1470 The transcription factor REST is lost in aggressive breast cancer.PLoS Genet. 2010 Jun 10;6(6):e1000979. doi: 10.1371/journal.pgen.1000979.
1471 Alternative splicing variant of RHBDD2 is associated with cell stress response and breast cancer progression.Oncol Rep. 2018 Aug;40(2):909-915. doi: 10.3892/or.2018.6489. Epub 2018 Jun 14.
1472 Decreased expression of the DBC2 gene and its clinicopathological significance in breast cancer: correlation with aberrant DNA methylation.Biotechnol Lett. 2013 Aug;35(8):1175-81. doi: 10.1007/s10529-013-1190-x. Epub 2013 Apr 2.
1473 Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients.Breast Cancer Res Treat. 2008 Nov;112(1):141-7. doi: 10.1007/s10549-007-9833-z. Epub 2007 Dec 4.
1474 Expression of WRCH1 in human cancer and down-regulation of WRCH1 by beta-estradiol in MCF-7 cells.Int J Oncol. 2002 Apr;20(4):777-83.
1475 RIN1 is a breast tumor suppressor gene.Cancer Res. 2007 Dec 15;67(24):11510-6. doi: 10.1158/0008-5472.CAN-07-1147.
1476 Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy.Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23691-23697. doi: 10.1073/pnas.1910824116. Epub 2019 Nov 4.
1477 Genomic stability, anti-inflammatory phenotype, and up-regulation of the RNAseH2 in cells from centenarians.Cell Death Differ. 2019 Sep;26(9):1845-1858. doi: 10.1038/s41418-018-0255-8. Epub 2019 Jan 8.
1478 RNF11 is a multifunctional modulator of growth factor receptor signalling and transcriptional regulation.Eur J Cancer. 2005 Nov;41(16):2549-60. doi: 10.1016/j.ejca.2005.08.020. Epub 2005 Oct 13.
1479 RNF144A functions as a tumor suppressor in breast cancer through ubiquitin ligase activity-dependent regulation of stability and oncogenic functions of HSPA2.Cell Death Differ. 2020 Mar;27(3):1105-1118. doi: 10.1038/s41418-019-0400-z. Epub 2019 Aug 13.
1480 Identification of the protein Zibra, its genomic organization, regulation, and expression in breast cancer cells.Exp Cell Res. 2004 May 1;295(2):448-59. doi: 10.1016/j.yexcr.2004.01.019.
1481 Oligomerization of the Nrdp1 E3 ubiquitin ligase is necessary for efficient autoubiquitination but not ErbB3 ubiquitination.J Biol Chem. 2014 Mar 21;289(12):8570-8. doi: 10.1074/jbc.M113.527036. Epub 2014 Feb 11.
1482 Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer.Cancer Res. 2007 Sep 1;67(17):8172-9. doi: 10.1158/0008-5472.CAN-07-0045.
1483 SR protein expression and CD44 splicing pattern in human breast tumours.Breast Cancer Res Treat. 2003 May;79(1):75-82. doi: 10.1023/a:1023338718974.
1484 Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer.Clin Cancer Res. 2002 Mar;8(3):752-8.
1485 Proteomic analysis of BRCA1-depleted cell line reveals a putative role for replication protein A2 up-regulation in BRCA1 breast tumor development.Proteomics Clin Appl. 2010 May;4(5):489-98. doi: 10.1002/prca.200900107. Epub 2010 Jan 4.
1486 Exclusion of BBC1 and CMAR as candidate breast tumour-suppressor genes.Br J Cancer. 1997;76(12):1550-3. doi: 10.1038/bjc.1997.594.
1487 High-level expression of the ribosomal protein L19 in human breast tumors that overexpress erbB-2.Cancer Res. 1993 Mar 15;53(6):1403-8.
1488 Modulation of expression of ribosomal protein L7a (rpL7a) by ethanol in human breast cancer cells.Breast Cancer Res Treat. 2001 Sep;69(1):29-38. doi: 10.1023/a:1012293507534.
1489 RPN2 gene confers docetaxel resistance in breast cancer.Nat Med. 2008 Sep;14(9):939-48. doi: 10.1038/nm.1858.
1490 Methylation and gene silencing of the Ras-related GTPase gene in lung and breast cancers. Ann Surg Oncol. 2007 Apr;14(4):1397-404. doi: 10.1245/s10434-006-9089-6. Epub 2006 Dec 29.
1491 A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.Cancer Res. 2008 Dec 1;68(23):9799-808. doi: 10.1158/0008-5472.CAN-08-0247.
1492 Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis.PLoS Genet. 2007 Nov;3(11):e214. doi: 10.1371/journal.pgen.0030214. Epub 2007 Oct 16.
1493 Nucleolar repression facilitates initiation and maintenance of senescence.Cell Cycle. 2015;14(22):3613-23. doi: 10.1080/15384101.2015.1100777.
1494 Human TIP49b/RUVBL2 gene: genomic structure, expression pattern, physical link to the human CGB/LHB gene cluster on chromosome 19q13.3.Ann Genet. 2000 Apr-Jun;43(2):69-74. doi: 10.1016/s0003-3995(00)01016-9.
1495 Expression of calcium-binding protein S100A2 in breast lesions.Br J Cancer. 2000 Dec;83(11):1473-9. doi: 10.1054/bjoc.2000.1488.
1496 Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment.Breast Cancer Res. 2017 Jun 19;19(1):70. doi: 10.1186/s13058-017-0863-0.
1497 Scaffold attachment factors SAFB1 and SAFB2: Innocent bystanders or critical players in breast tumorigenesis?.J Cell Biochem. 2003 Nov 1;90(4):653-61. doi: 10.1002/jcb.10685.
1498 Functional and clinical significance of SALL4 in breast cancer.Tumour Biol. 2016 Sep;37(9):11701-11709. doi: 10.1007/s13277-016-5150-7. Epub 2016 Jul 21.
1499 SASH1: a candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer.Oncogene. 2003 May 15;22(19):2972-83. doi: 10.1038/sj.onc.1206474.
1500 Downregulation of SCARA5 may contribute to breast cancer via promoter hypermethylation.Gene. 2018 Oct 5;673:102-106. doi: 10.1016/j.gene.2018.06.036. Epub 2018 Jun 13.
1501 Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma.Cell. 2008 Nov 28;135(5):865-78. doi: 10.1016/j.cell.2008.09.045.
1502 Association of heparan sulfate proteoglycans SDC1 and SDC4 polymorphisms with breast cancer in an Australian Caucasian population.Tumour Biol. 2015 Mar;36(3):1731-8. doi: 10.1007/s13277-014-2774-3. Epub 2014 Nov 1.
1503 SEL1L expression decreases breast tumor cell aggressiveness in vivo and in vitro.Cancer Res. 2002 Jan 15;62(2):567-74.
1504 Correlation of MDR-1, nm23-H1 and H Sema E gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patients.Anticancer Res. 2002 Jul-Aug;22(4):2275-80.
1505 Suppression of tumor-derived Semaphorin7A and genetic ablation of host-derived Semaphorin7A impairs tumor progression in a murine model of advanced breast carcinoma.Int J Oncol. 2017 Nov;51(5):1395-1404. doi: 10.3892/ijo.2017.4144. Epub 2017 Oct 3.
1506 SEPT9_i1 regulates human breast cancer cell motility through cytoskeletal and RhoA/FAK signaling pathway regulation.Cell Death Dis. 2019 Sep 26;10(10):720. doi: 10.1038/s41419-019-1947-9.
1507 Kallistatin is a new inhibitor of angiogenesis and tumor growth.Blood. 2002 Nov 1;100(9):3245-52. doi: 10.1182/blood-2002-01-0185.
1508 Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.Thromb Res. 2007;120(5):753-62. doi: 10.1016/j.thromres.2006.12.016. Epub 2007 Jan 29.
1509 The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression.Cancer Res. 2009 Jul 15;69(14):5690-8. doi: 10.1158/0008-5472.CAN-08-4573. Epub 2009 Jul 7.
1510 Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.Nat Genet. 2015 Apr;47(4):373-80. doi: 10.1038/ng.3242. Epub 2015 Mar 9.
1511 Aberrant expression of SETD1A promotes survival and migration of estrogen receptor -positive breast cancer cells.Int J Cancer. 2018 Dec 1;143(11):2871-2883. doi: 10.1002/ijc.31853. Epub 2018 Oct 4.
1512 Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy.Cancer Biol Ther. 2008 Jun;7(6):958-65. doi: 10.4161/cbt.7.6.5966. Epub 2008 Mar 20.
1513 Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer.PLoS One. 2012;7(5):e37928. doi: 10.1371/journal.pone.0037928. Epub 2012 May 31.
1514 Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis.Carcinogenesis. 2008 May;29(5):991-8. doi: 10.1093/carcin/bgn076. Epub 2008 Mar 19.
1515 Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor.Oncoimmunology. 2018 Aug 1;7(10):e1484982. doi: 10.1080/2162402X.2018.1484982. eCollection 2018.
1516 AND-34/BCAR3 differs from other NSP homologs in induction of anti-estrogen resistance, cyclin D1 promoter activation and altered breast cancer cell morphology.J Cell Physiol. 2007 Sep;212(3):655-65. doi: 10.1002/jcp.21059.
1517 Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma.Ann Surg Oncol. 2008 Apr;15(4):1070-80. doi: 10.1245/s10434-007-9790-0. Epub 2008 Feb 1.
1518 CIN85, a Cbl-interacting protein, is a component of AMAP1-mediated breast cancer invasion machinery.EMBO J. 2007 Feb 7;26(3):647-56. doi: 10.1038/sj.emboj.7601534. Epub 2007 Jan 25.
1519 A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations.J Med Genet. 2010 Nov;47(11):771-4. doi: 10.1136/jmg.2010.078113. Epub 2010 Aug 30.
1520 Suppression of cell migration is promoted by miR-944 through targeting of SIAH1 and PTP4A1 in breast cancer cells.BMC Cancer. 2016 Jul 4;16:379. doi: 10.1186/s12885-016-2470-3.
1521 Gene therapy with p53 and a fragment of thrombospondin I inhibits human breast cancer in vivo.Mol Genet Metab. 1998 Feb;63(2):103-9. doi: 10.1006/mgme.1997.2654.
1522 Sin3b interacts with Myc and decreases Myc levels.J Biol Chem. 2014 Aug 8;289(32):22221-36. doi: 10.1074/jbc.M113.538744. Epub 2014 Jun 20.
1523 Altered sirtuin expression is associated with node-positive breast cancer.Br J Cancer. 2006 Oct 23;95(8):1056-61. doi: 10.1038/sj.bjc.6603384. Epub 2006 Sep 26.
1524 Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation.Cancer Res. 2008 Apr 1;68(7):2204-13. doi: 10.1158/0008-5472.CAN-07-3141.
1525 Expression profile of SIX family members correlates with clinic-pathological features and prognosis of breast cancer: A systematic review and meta-analysis.Medicine (Baltimore). 2016 Jul;95(27):e4085. doi: 10.1097/MD.0000000000004085.
1526 DNA methylation pattern of the SLC25A43 gene in breast cancer.Epigenetics. 2012 Mar;7(3):300-6. doi: 10.4161/epi.7.3.19064.
1527 SLITs suppress tumor growth in vivo by silencing Sdf1/Cxcr4 within breast epithelium.Cancer Res. 2008 Oct 1;68(19):7819-27. doi: 10.1158/0008-5472.CAN-08-1357.
1528 Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer.Eur J Surg Oncol. 2019 Oct;45(10):1835-1838. doi: 10.1016/j.ejso.2019.05.016. Epub 2019 May 16.
1529 Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.J Natl Cancer Inst. 2019 Apr 1;111(4):388-398. doi: 10.1093/jnci/djy110.
1530 The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation.Oncogene. 2018 Aug;37(34):4750-4768. doi: 10.1038/s41388-018-0281-5. Epub 2018 May 16.
1531 Sequential [(18)F]FDG-[(18)F]FMISO PET and Multiparametric MRI at 3T for Insights into Breast Cancer Heterogeneity and Correlation with Patient Outcomes: First Clinical Experience.Contrast Media Mol Imaging. 2019 Jan 8;2019:1307247. doi: 10.1155/2019/1307247. eCollection 2019.
1532 Altered Expression and Localization of Tumor Suppressive E3 Ubiquitin Ligase SMURF2 in Human Prostate and Breast Cancer.Cancers (Basel). 2019 Apr 18;11(4):556. doi: 10.3390/cancers11040556.
1533 SNAIL1 action in tumor cells influences macrophage polarization and metastasis in breast cancer through altered GM-CSF secretion.Oncogenesis. 2018 Mar 29;7(3):32. doi: 10.1038/s41389-018-0042-x.
1534 Sphingosine 1-phosphate signaling induces SNAI2 expression to promote cell invasion in breast cancer cells.FASEB J. 2019 Jun;33(6):7180-7191. doi: 10.1096/fj.201801635R. Epub 2019 Mar 7.
1535 The Snf1-related kinase, Hunk, is essential for mammary tumor metastasis.Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15855-60. doi: 10.1073/pnas.0906993106. Epub 2009 Aug 28.
1536 Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer.Ann Surg Oncol. 2007 Jun;14(6):1909-18. doi: 10.1245/s10434-007-9376-x. Epub 2007 Apr 4.
1537 Differential hypermethylation of SOCS genes in ovarian and breast carcinomas.Oncogene. 2004 Oct 7;23(46):7726-33. doi: 10.1038/sj.onc.1207787.
1538 Sos1 Regulates Macrophage Podosome Assembly and Macrophage Invasive Capacity.J Immunol. 2015 Nov 15;195(10):4900-12. doi: 10.4049/jimmunol.1500579. Epub 2015 Oct 7.
1539 Batwing versus Wise pattern mammoplasty for upper pole breast tumours: a detailed comparison of cosmetic outcome.World J Surg Oncol. 2017 Mar 14;15(1):60. doi: 10.1186/s12957-017-1124-5.
1540 Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth.Cancer Res. 2016 Jun 1;76(11):3224-35. doi: 10.1158/0008-5472.CAN-15-2249. Epub 2016 Apr 5.
1541 The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers.Cancer Res. 2015 Oct 15;75(20):4351-63. doi: 10.1158/0008-5472.CAN-14-3475. Epub 2015 Aug 21.
1542 Macrophage HIF-2 regulates tumor-suppressive Spint1 in the tumor microenvironment.Mol Carcinog. 2019 Nov;58(11):2127-2138. doi: 10.1002/mc.23103. Epub 2019 Aug 22.
1543 Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):550-8. doi: 10.1158/1078-0432.CCR-06-1266.
1544 Steroid receptor RNA activator protein (SRAP) expression as a prognostic factor in ER+ human breast tumors.J Cancer Res Clin Oncol. 2013 Oct;139(10):1637-47. doi: 10.1007/s00432-013-1485-2. Epub 2013 Aug 2.
1545 C1orf64 is a novel androgen receptor target gene and coregulator that interacts with 14-3-3 protein in breast cancer.Oncotarget. 2017 May 11;8(34):57907-57933. doi: 10.18632/oncotarget.17826. eCollection 2017 Aug 22.
1546 SNIP/p140Cap mRNA expression is an unfavourable prognostic factor in breast cancer and is not expressed in normal breast tissue.Br J Cancer. 2008 May 20;98(10):1641-5. doi: 10.1038/sj.bjc.6604365. Epub 2008 May 13.
1547 Increased expression of SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human breast cancer.Clin Chim Acta. 2007 Sep;384(1-2):69-74. doi: 10.1016/j.cca.2007.06.001. Epub 2007 Jun 15.
1548 ST18 is a breast cancer tumor suppressor gene at human chromosome 8q11.2.Oncogene. 2004 Dec 9;23(57):9295-302. doi: 10.1038/sj.onc.1208131.
1549 The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer.J Biol Chem. 2006 Feb 10;281(6):3586-94. doi: 10.1074/jbc.M511826200. Epub 2005 Nov 30.
1550 Identification and functional characterization of a human GalNAc [alpha]2,6-sialyltransferase with altered expression in breast cancer.Mol Med. 2002 Jan;8(1):42-55.
1551 Lack of mutations within ST7 gene in tumour-derived cell lines and primary epithelial tumours.Br J Cancer. 2002 Jul 15;87(2):208-11. doi: 10.1038/sj.bjc.6600418.
1552 Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype.Oncotarget. 2017 Jul 18;8(29):47454-47473. doi: 10.18632/oncotarget.17665.
1553 Regulation of FcepsilonRI-mediated signaling by an adaptor protein STAP-2/BSK in rat basophilic leukemia RBL-2H3 cells.Biochem Biophys Res Commun. 2003 Jul 4;306(3):767-73. doi: 10.1016/s0006-291x(03)01042-8.
1554 Expression of MLN64 influences cellular matrix adhesion of breast cancer cells, the role for focal adhesion kinase.Int J Mol Med. 2010 Apr;25(4):573-80.
1555 Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer.Int J Biochem Cell Biol. 2011 Oct;43(10):1417-21. doi: 10.1016/j.biocel.2011.06.007. Epub 2011 Jun 17.
1556 Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression.J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):93-103. doi: 10.1007/s10911-008-9062-z. Epub 2008 Jan 29.
1557 Four regions of allelic imbalance on 17q12-qter associated with high-grade breast tumors.Genes Chromosomes Cancer. 1997 Dec;20(4):354-62.
1558 Reflector-guided breast tumor localization versus wire localization for lumpectomies: A comparison of surgical outcomes.Clin Imaging. 2018 Jan-Feb;47:14-17. doi: 10.1016/j.clinimag.2017.07.020. Epub 2017 Aug 1.
1559 DRAK2 participates in a negative feedback loop to control TGF-/Smads signaling by binding to type I TGF- receptor.Cell Rep. 2012 Nov 29;2(5):1286-99. doi: 10.1016/j.celrep.2012.09.028. Epub 2012 Nov 2.
1560 MST3 promotes proliferation and tumorigenicity through the VAV2/Rac1 signal axis in breast cancer.Oncotarget. 2016 Mar 22;7(12):14586-604. doi: 10.18632/oncotarget.7542.
1561 Mammalian MST2 kinase and human Salvador activate and reduce estrogen receptor alpha in the absence of ligand.J Mol Med (Berl). 2011 Feb;89(2):181-91. doi: 10.1007/s00109-010-0698-y. Epub 2010 Nov 23.
1562 HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells.Cancer Res. 2011 Mar 15;71(6):2152-61. doi: 10.1158/0008-5472.CAN-10-3059. Epub 2011 Jan 25.
1563 Mitochondrial genome instability resulting from SUV3 haploinsufficiency leads to tumorigenesis and shortened lifespan.Oncogene. 2013 Feb 28;32(9):1193-201. doi: 10.1038/onc.2012.120. Epub 2012 May 7.
1564 SUSD2 promotes tumor-associated macrophage recruitment by increasing levels of MCP-1 in breast cancer.PLoS One. 2017 May 5;12(5):e0177089. doi: 10.1371/journal.pone.0177089. eCollection 2017.
1565 Estrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cells.Oncogene. 2015 Jan 15;34(3):323-33. doi: 10.1038/onc.2013.553. Epub 2014 Jan 13.
1566 Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells.Mol Cell. 2010 Sep 10;39(5):761-72. doi: 10.1016/j.molcel.2010.08.013.
1567 Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer.Sci Signal. 2015 Jan 20;8(360):ra7. doi: 10.1126/scisignal.2005537.
1568 SYNJ2BP promotes the degradation of PTEN through the lysosome-pathway and enhances breast tumor metastasis via PI3K/AKT/SNAI1 signaling.Oncotarget. 2017 Sep 19;8(52):89692-89706. doi: 10.18632/oncotarget.21058. eCollection 2017 Oct 27.
1569 Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.Oncogene. 2010 Aug 26;29(34):4814-25. doi: 10.1038/onc.2010.229. Epub 2010 Jun 14.
1570 Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression.Cancer Res. 2008 Mar 1;68(5):1462-70. doi: 10.1158/0008-5472.CAN-07-3094.
1571 Ada3 requirement for HAT recruitment to estrogen receptors and estrogen-dependent breast cancer cell proliferation.Cancer Res. 2007 Dec 15;67(24):11789-97. doi: 10.1158/0008-5472.CAN-07-2721.
1572 Downregulation of TAP1 and TAP2 in early stage breast cancer.PLoS One. 2017 Nov 1;12(11):e0187323. doi: 10.1371/journal.pone.0187323. eCollection 2017.
1573 Metastasis-suppressor transcript destabilization through TARBP2 binding of mRNA hairpins.Nature. 2014 Sep 11;513(7517):256-60. doi: 10.1038/nature13466. Epub 2014 Jul 9.
1574 Galectin-1 knockdown improves drug sensitivity of breast cancer by reducing P-glycoprotein expression through inhibiting the Raf-1/AP-1 signaling pathway.Oncotarget. 2017 Apr 11;8(15):25097-25106. doi: 10.18632/oncotarget.15341.
1575 The T-box transcription factors TBX2 and TBX3 in mammary gland development and breast cancer.J Mammary Gland Biol Neoplasia. 2013 Jun;18(2):143-7. doi: 10.1007/s10911-013-9282-8. Epub 2013 Apr 28.
1576 MITOSTATIN, a putative tumor suppressor on chromosome 12q24.1, is downregulated in human bladder and breast cancer.Oncogene. 2009 Jan 15;28(2):257-69. doi: 10.1038/onc.2008.381. Epub 2008 Oct 20.
1577 Transforming properties of TC-1 in human breast cancer: interaction with FGFR2 and beta-catenin signaling pathways.Int J Cancer. 2007 Sep 15;121(6):1265-73. doi: 10.1002/ijc.22831.
1578 Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications.Am J Pathol. 2010 May;176(5):2139-49. doi: 10.2353/ajpath.2010.090477. Epub 2010 Mar 12.
1579 Hypoxia Drives Breast Tumor Malignancy through a TET-TNF-p38-MAPK Signaling Axis.Cancer Res. 2015 Sep 15;75(18):3912-24. doi: 10.1158/0008-5472.CAN-14-3208. Epub 2015 Aug 20.
1580 Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.Clin Cancer Res. 2004 Nov 15;10(22):7621-8. doi: 10.1158/1078-0432.CCR-04-1061.
1581 Transcriptional factor EB regulates macrophage polarization in the tumor microenvironment.Oncoimmunology. 2017 Apr 20;6(5):e1312042. doi: 10.1080/2162402X.2017.1312042. eCollection 2017.
1582 Expression and motogenic activity of TFF2 in human breast cancer cells.Peptides. 2004 May;25(5):865-72. doi: 10.1016/j.peptides.2003.12.024.
1583 Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells.BMC Mol Biol. 2007 Dec 3;8:110. doi: 10.1186/1471-2199-8-110.
1584 Hic-5 remodeling of the stromal matrix promotes breast tumor progression.Oncogene. 2017 May 11;36(19):2693-2703. doi: 10.1038/onc.2016.422. Epub 2016 Nov 28.
1585 Genetic and epigenetic alterations in sentinel lymph nodes metastatic lesions compared to their corresponding primary breast tumors.Cancer Genet Cytogenet. 2003 Oct 1;146(1):33-40. doi: 10.1016/s0165-4608(03)00123-7.
1586 Knockdown of ICB-1 gene enhanced estrogen responsiveness of ovarian and breast cancer cells.Endocr Relat Cancer. 2010 Feb 18;17(1):147-57. doi: 10.1677/ERC-09-0095. Print 2010 Mar.
1587 Linking transcriptional elongation and messenger RNA export to metastatic breast cancers.Cancer Res. 2005 Apr 15;65(8):3011-6. doi: 10.1158/0008-5472.CAN-04-3624.
1588 IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3' untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR.Int J Cancer. 2005 Mar 1;113(6):911-9. doi: 10.1002/ijc.20675.
1589 Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.J Mol Endocrinol. 2007 Oct;39(4):305-18. doi: 10.1677/JME-07-0001.
1590 Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status.Exp Cell Res. 2012 Jun 10;318(10):1094-103. doi: 10.1016/j.yexcr.2012.03.009. Epub 2012 Mar 23.
1591 Molecular Characterization and In-Silico Analysis of the Tissue Inhibitor of Metalloproteinases-3 (TIMP-3) Gene of Canine Mammary Tumor.Comb Chem High Throughput Screen. 2017;20(6):539-546. doi: 10.2174/1386207320666170217150741.
1592 Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers.Clin Cancer Res. 2016 Sep 1;22(17):4491-504. doi: 10.1158/1078-0432.CCR-15-2461. Epub 2016 Mar 30.
1593 Enhanced tight junction function in human breast cancer cells by antioxidant, selenium and polyunsaturated lipid.J Cell Biochem. 2007 May 1;101(1):155-66. doi: 10.1002/jcb.21162.
1594 TLK1B is elevated with eIF4E overexpression in breast cancer.J Surg Res. 2004 Jan;116(1):98-103. doi: 10.1016/j.jss.2003.08.001.
1595 Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers.Nat Commun. 2016 Oct 3;7:12991. doi: 10.1038/ncomms12991.
1596 MicroRNA-206 inhibits metastasis of triple-negative breast cancer by targeting transmembrane 4 L6 family member 1.Cancer Manag Res. 2019 Jul 22;11:6755-6764. doi: 10.2147/CMAR.S199027. eCollection 2019.
1597 Knockdown of TM9SF4 boosts ER stress to trigger cell death of chemoresistant breast cancer cells.Oncogene. 2019 Jul;38(29):5778-5791. doi: 10.1038/s41388-019-0846-y. Epub 2019 Jun 27.
1598 Analysis of the candidate tumor suppressor Ris-1 in primary human breast carcinomas.Mutat Res. 2006 Feb 22;594(1-2):78-85. doi: 10.1016/j.mrfmmm.2005.07.017. Epub 2005 Nov 8.
1599 Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer.Breast Cancer Res. 2017 Feb 8;19(1):15. doi: 10.1186/s13058-016-0785-2.
1600 Hyaluronan preconditioning of monocytes/macrophages affects their angiogenic behavior and regulation of TSG-6 expression in a tumor type-specific manner.FEBS J. 2019 Sep;286(17):3433-3449. doi: 10.1111/febs.14871. Epub 2019 May 16.
1601 Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells.BMC Cancer. 2005 May 25;5:54. doi: 10.1186/1471-2407-5-54.
1602 Expression of AITR and AITR ligand in breast cancer patients.Oncol Rep. 2007 Nov;18(5):1189-94.
1603 Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients.Int J Cancer. 2008 Jun 1;122(11):2454-61. doi: 10.1002/ijc.23417.
1604 Profile of differentially expressed genes after transfer of chromosome 17 into the breast cancer cell line CAL51.Genes Chromosomes Cancer. 2005 Nov;44(3):233-46. doi: 10.1002/gcc.20240.
1605 Regulation of p53 by TopBP1: a potential mechanism for p53 inactivation in cancer.Mol Cell Biol. 2009 May;29(10):2673-93. doi: 10.1128/MCB.01140-08. Epub 2009 Mar 16.
1606 Silencing of ASPP2 promotes the proliferation, migration and invasion of triple-negative breast cancer cells via the PI3K/AKT pathway.Int J Oncol. 2018 Jun;52(6):2001-2010. doi: 10.3892/ijo.2018.4331. Epub 2018 Mar 20.
1607 Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52.Clin Cancer Res. 2008 Aug 15;14(16):5050-60. doi: 10.1158/1078-0432.CCR-07-4994.
1608 Definition of the tumor protein D52 (TPD52) gene family through cloning of D52 homologues in human (hD53) and mouse (mD52).Genomics. 1996 Aug 1;35(3):523-32. doi: 10.1006/geno.1996.0393.
1609 Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors.Oncogene. 2003 Sep 18;22(40):6194-203. doi: 10.1038/sj.onc.1206719.
1610 Deep Coverage of Global Protein Expression and Phosphorylation in Breast Tumor Cell Lines Using TMT 10-plex Isobaric Labeling.J Proteome Res. 2017 Mar 3;16(3):1121-1132. doi: 10.1021/acs.jproteome.6b00374. Epub 2017 Feb 3.
1611 Tumor necrosis factor receptor-associated death domain protein is involved in the neurotrophin receptor-mediated antiapoptotic activity of nerve growth factor in breast cancer cells.J Biol Chem. 2003 May 9;278(19):16952-6. doi: 10.1074/jbc.M300631200. Epub 2003 Feb 25.
1612 Identification and characterization of proteins interacting with Traf4, an enigmatic p53 target.Cancer Biol Ther. 2006 Sep;5(9):1228-35. doi: 10.4161/cbt.5.9.3295. Epub 2006 Sep 20.
1613 SK4 channels modulate Ca(2+) signalling and cell cycle progression in murine breast cancer.Mol Oncol. 2017 Sep;11(9):1172-1188. doi: 10.1002/1878-0261.12087. Epub 2017 Jun 26.
1614 Aberrantly upregulated TRAP1 is required for tumorigenesis of breast cancer.Oncotarget. 2015 Dec 29;6(42):44495-508. doi: 10.18632/oncotarget.6252.
1615 Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response.Breast Cancer Res. 2011 Aug 24;13(4):R82. doi: 10.1186/bcr2934.
1616 Estrogen-responsive RING finger protein controls breast cancer growth.J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):101-4. doi: 10.1016/s0960-0760(03)00209-7.
1617 The Breast Cancer Tumor Suppressor TRIM29 Is Expressed via ATM-dependent Signaling in Response to Hypoxia.J Biol Chem. 2016 Oct 7;291(41):21541-21552. doi: 10.1074/jbc.M116.730960. Epub 2016 Aug 17.
1618 DEAR1, a novel tumor suppressor that regulates cell polarity and epithelial plasticity.Cancer Res. 2014 Oct 15;74(20):5683-9. doi: 10.1158/0008-5472.CAN-14-1171. Epub 2014 Sep 26.
1619 Chromosome 8 BAC array comparative genomic hybridization and expression analysis identify amplification and overexpression of TRMT12 in breast cancer.Genes Chromosomes Cancer. 2007 Jul;46(7):694-707. doi: 10.1002/gcc.20454.
1620 TRPS1 regulates oestrogen receptor binding and histone acetylation at enhancers.Oncogene. 2018 Sep;37(39):5281-5291. doi: 10.1038/s41388-018-0312-2. Epub 2018 Jun 12.
1621 TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.Breast Cancer Res Treat. 2009 Jan;113(2):253-60. doi: 10.1007/s10549-008-9934-3. Epub 2008 Feb 26.
1622 Genomic structure of the human tetratricopeptide repeat-containing gene, TTC4, from chromosome region 1p31 and mutation analysis in breast cancers.Int J Mol Med. 2000 Feb;5(2):197-200.
1623 Intratumoral heterogeneity of ADAM23 promotes tumor growth and metastasis through LGI4 and nitric oxide signals.Oncogene. 2015 Mar 5;34(10):1270-9. doi: 10.1038/onc.2014.70. Epub 2014 Mar 24.
1624 Breast cancer antiestrogen resistance 3-p130(Cas) interactions promote adhesion disassembly and invasion in breast cancer cells.Oncogene. 2016 Nov 10;35(45):5850-5859. doi: 10.1038/onc.2016.123. Epub 2016 Apr 25.
1625 Transcriptional and translational modulation of KAI1 expression in ductal carcinoma of the breast and the prognostic significance.Int J Mol Med. 2009 Feb;23(2):273-8.
1626 Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic model.Carcinogenesis. 2018 Jan 12;39(1):47-55. doi: 10.1093/carcin/bgx097.
1627 miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.IUBMB Life. 2018 Jan;70(1):71-80. doi: 10.1002/iub.1705. Epub 2017 Dec 16.
1628 EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.Breast Cancer Res Treat. 2011 Jun;127(3):831-9. doi: 10.1007/s10549-011-1380-y. Epub 2011 Feb 15.
1629 SCF(FBXO22) targets HDM2 for degradation and modulates breast cancer cell invasion and metastasis.Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11754-11763. doi: 10.1073/pnas.1820990116. Epub 2019 May 28.
1630 HOXB7 promotes malignant progression by activating the TGF signaling pathway.Cancer Res. 2015 Feb 15;75(4):709-19. doi: 10.1158/0008-5472.CAN-14-3100. Epub 2014 Dec 26.
1631 Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells.BMC Cancer. 2015 Nov 11;15:896. doi: 10.1186/s12885-015-1907-4.
1632 Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer.Ann Oncol. 2009 Jun;20(6):1020-5. doi: 10.1093/annonc/mdn733. Epub 2009 Jan 15.
1633 The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer.Front Immunol. 2019 Jul 11;10:1594. doi: 10.3389/fimmu.2019.01594. eCollection 2019.
1634 Necdin is a breast cancer metastasis suppressor that regulates the transcription of c-Myc.Oncotarget. 2015 Oct 13;6(31):31557-68. doi: 10.18632/oncotarget.5230.
1635 RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.Epigenetics. 2014 Nov;9(11):1496-503. doi: 10.4161/15592294.2014.983361.
1636 Human REV3 DNA Polymerase Zeta Localizes to Mitochondria and Protects the Mitochondrial Genome.PLoS One. 2015 Oct 13;10(10):e0140409. doi: 10.1371/journal.pone.0140409. eCollection 2015.
1637 The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling.Nat Cell Biol. 2015 Jan;17(1):81-94. doi: 10.1038/ncb3082. Epub 2014 Dec 22.
1638 SRSF1-Regulated Alternative Splicing in Breast Cancer.Mol Cell. 2015 Oct 1;60(1):105-17. doi: 10.1016/j.molcel.2015.09.005.
1639 Regulation of the T-box transcription factor Tbx3 by the tumour suppressor microRNA-206 in breast cancer.Br J Cancer. 2016 May 10;114(10):1125-34. doi: 10.1038/bjc.2016.73. Epub 2016 Apr 21.